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Abstract 
 
This thesis is concerned with the synthesis and properties of racemic and enantiopure 
sulfoxides, compounds which have application as biologically active agents and are useful tools 
for chemical synthesis. Particular focus is placed on the sulfoxide Omeprazole, which is one of 
the world’s best selling pharmaceutical products, and the single isomer form of the drug  
(S)-Esomeprazole. 
Chapter one covers the fundamental aspects of sulfoxide chemistry, the synthesis of 
racemic sulfoxides, and describes various approaches to the production of chiral sulfoxides in 
optically pure form such as resolution, nucleophilic substitutions methodologies, and non-metal 
based oxidative processes which use either chiral catalysts or chiral oxidants.  Chapter two 
continues this review discussing stereoselective sulfide oxidations using metal catalysts.   
The discovery, mechanism of action, and large scale synthesis of Omeprazole, a 
biologically active sulfoxide used to treat ailments associated with excess stomach acid, is 
discussed in chapter three.  In addition, this chapter examines the developments of the single 
enantiomer drug (S)-Esomeprazole and the various synthetic strategies employed in the 
production of this chiral sulfoxide.    
The ensuing chapters describe my own work: chapter four contains work on the 
synthesis of a range of sulfides, racemic sulfoxides, and sulfones.  Following on from this the 
asymmetric synthesis of chiral sulfoxides, including (S)-Esomeprazole, using a modified Kagan 
type titanium tartrate catalyst system was investigated, with the achievement of sulfoxidation 
enantioselectivities of up to > 99.5% ee.   
In chapter five the development of a new method for the determination of enantiomeric 
excess of (S)-Esomeprazole by 1H NMR is examined.  Chiral tartrates were employed as chiral 
shift agents (CSA) and were found to provide efficient and accurate measurement of sulfoxide 
ee.  The choice of NMR solvent, the host:guest ratio, and the efficacy of the tartrates to act as 
CSA for a range of structurally diverse sulfoxides was also investigated.  
Chapter six covers three studies on the structures and reactivities of Omeprazole and 
related sulfoxides.  X-ray crystallographic diffraction (XRD) was employed to investigate the 
solid state structures and packing a range of sulfoxides. The effect of annular tautomerism was 
explored by 1H and 13C NMR for a series of benzimidazole based sulfoxide species, including 
Omeprazole. Finally, 1H NMR was employed to investigate the selective deuteration of 
sulfoxides such as Omeprazole, including the examination of H/D-exchange observed by NMR 
in DMSO-d6. 
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1 Introduction: Synthesis and application of sulfoxides 
 
1.1 Sulfoxides 
 
To the synthetic chemist the sulfoxide is a useful and versatile functional group, with uses as 
chiral auxiliaries and synthons for stereoselective carbon–carbon bond formation.1-9  
Furthermore, the sulfinyl functionality is regularly found in biologically active materials, both 
naturally occurring and manmade.10-12  Over the past century great efforts have been made to 
fully understand and exploit the utility of the sulfoxide, from the early debates over the nature of 
the bonding in the group right through to the challenges presented in the development of an 
asymmetric synthesis of the modern day “blockbuster” drug Esomeprazole (S)-1.1.13-16  The aim 
of this chapter is to present an overview of the occurrence, application, and synthesis of 
sulfoxides, with particular emphasis given to the formation of chiral sulfoxides. 
 
 
 
1.2 Biologically important sulfoxides 
 
The sulfoxide functional group is found in a large number of molecules of biological interest, 
many of which have application as pharmaceuticals for the treatment of a wide range of 
conditions.17  Modafinil 1.2 is a psychostimulant used to treat sleep disorders such as narcolepsy 
and sleep apnea.18-20  Although typically prescribed in the racemic form, the two enantiomers of 
Modafinil have been shown to have differing pharmacological effects, with the (S)-isomer being 
eliminated from the body at a rate three times faster than that of the (R)-isomer.21  The anti-
inflammatory drug Sulindac 1.3 is employed in the treatment of arthritic conditions and has, 
over the past ten years, gained interested as an anti-cancer treatment.22  Four neurokinin 
antagonists 1.4-1.7 have been investigated for their potential for use in treatments against 
depression, urinary incontinence and asthma.23   
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The efficacy of some medicinal therapies can be attributed to the sulfoxide metabolite of the 
administered drug.  One example of this is found in the treatment for neurocysticercosis where 
the active sulfoxide 1.8 is believed to be responsible for the anthelmintic properties of the 
antiparasitic drug Albendazole 1.9.24  (+)-Sparsomycin 1.10, a metabolite of Streptomyces 
sparsogenes and Streptomyces cuspidosporus, has been the subject of investigation for its 
activity against fungi, bacteria, viruses, and several tumor systems.  Other members of the 
pyrimidinylpropanamide family have also been investigated in the form of sulfoxides 1.11 and 
1.12.25  The anti-bacterial properties of the -lactam based Carpetimycin sulfoxide 1.13 have 
also been reported.26  The ustiloxin cyclic peptides, isolated from the fungus Ustilaginoidea 
virens, are known to exhibit antimitotic properties which cause inhibition in growth of several 
human cancer lines; sulfoxide 1.14 and 1.15 have been found to be particularly potent against 
breast and liver cancer.27, 28   
 
 
 
3 
 
1.3 Applications of sulfoxides  
 
Sulfoxides are versatile starting materials for a wide range of synthetic transformations.5, 7  In 
addition, they can be used as chiral auxiliaries and ligands for use in asymmetric synthesis and 
have been called “one of the most efficient and versatile chiral controllers in C–C and C–X 
bond formation”.29  The polarized S-O bond allows for co-ordination to both transition metals 
and Lewis acids, and the stable pyramidal configuration about sulfur gives rise to ordered and 
rigid transition state geometries.  The pyramidal inversion barrier for a typical sulfoxide is 
between 3543 kcal mol-1 hence sulfinyl groups are configurationally stable at room 
temperature and generally remain so up to 200C.17, 30-32  
 
Chiral sulfoxides are often exploited for their ability to transfer stereochemical information in 
reactions sites that can be proximal or more distant within the reacting molecule.3, 6  The 
efficacy in employing sulfoxides for the purpose of stereochemical control can be attributed to 
two factors.  Firstly the substituents on a sulfoxide sulfur, i.e. two different carbon ligands, a 
lone pair of electrons and an oxygen, provide a greatly contrasting steric and stereoelectronic 
environments in the diastereotopic faces of a reacting molecules.6, 33  Secondly, there is a great 
number of methods by which sulfoxides, particularly homochiral ones, may be obtained.  The 
great success in developing these methods, particularly over the past two decades, has given rise 
to the development of sulfoxide mediated reactions which include Diels-Alder cycloadditions, 
asymmetric hydrogenations of ketones and olefins, Pd-catalyzed enantioselective allylic 
alkylations, and stereoselective radical allylations to name but a few.22, 34, 35  Unfortunately it is 
not possible to do justice to the extensive application that sulfoxides have in modern synthesis; 
instead a number of interesting highlights are presented here. For examination of this area in 
greater detail there are a number of excellent books and reviews that may be consulted, in 
addition to those texts already referenced herein.36-50 
 
The sulfinyl group can act as an o-metalation group; when an optically pure sulfoxide species is 
used this reaction can occur in a diastereoselective manner, one such example was reported by 
Kagan and coworkers in the ortho-lithiation p-tolyl ferrocene species (SS)-1.16 which afforded 
sulfoxide (SP,SS)-1.17 (Scheme 1.1).
51  Subsequent lithium-zinc exchange with ZnCl2 gave 
(RP,SS)-1.18a which then underwent a Negishi coupling to introduce an aryl group.  
Alternatively the aryl group could be introduced via Suzuki coupling with the boronic 
intermediate (SP,SS)-1.18b, also generated from the lithiated species (SP,SS)-1.17.  
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Scheme 1.1 
 
Sulfoxide species with a -hydrogen are known to form olefins such as 1.20, and a sulfenic acid 
by way of a syn-elimination type reaction.52-54  Under pyrolysis conditions the reaction proceeds 
in a stereocontrolled manner via a cyclic transition state, as shown in Scheme 1.2.55 
 
 
Scheme 1.2 
 
Hauser and coworkers reported the use of a remote sulfoxide group to guide a stereospecific 
hydroxylation in an acyclic system (Scheme 1.3).56  The diastereomeric sulfoxide 1.21 was 
treated with osmium tetroxide in a catalytic amount (3-5 mol%) and trimethylamine N-oxide 
(TMAO) (3 equiv).  Acetylation gave the diacetate sulfone 1.22 as the sole product.  The 
stereoselectivity of the dihydroxylation was attributed to complexation between the osmium and 
the sulfinyl oxygen, with only a modest steric effect exerted by the chiral amide group. 
 
 
Scheme 1.3 
 
A sulfoxide directed asymmetric Michael addition was employed in the preparation of the  
2,2,3-cyclopentanone (S,S)-1.23 (Scheme 1.4).57-59  Addition of the naphthyl-Grignard reagent 
1.24 to sulfoxide (S)-1.25, followed by in situ C-methylation gave (S,S)-1.26 as a single 
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diastereomer.  The -sulfinylcyclopentanone (S,S)-1.26 was converted into the enolate  
(S,S)-1.27 via dimethylcopper lithium desulfurization.  Alkylation of the enolate ion was found 
to proceed in a regio- and stereospecific manner, with the addition of bromoacetate affording 
the 9,11-secosteroid (S,S)-1.23 with a yield of 89% from (S)-1.25 
 
 
Scheme 1.4 
 
Sulfoxides can also be used to control the diastereofacial selectivity in aldol type reactions.60, 61  
Solladié and coworkers reported an efficient synthesis of -hydroxyacids based around the 
condensation of carbonyl compounds with p-tolyl sulfinyl acetates such as 1.28 (Scheme 1.5).   
 
 
Scheme 1.5 
 
Diastereoselectivity was found to be high (85-95% ee) for the condensation reactions across a 
range of carbonyls.  The success of the methodology was attributed to the use of a Grignard 
reagents, such as tBuMgBr, as the base which allowed for a chelation controlled transition 
state.62  An empirical rule was proposed relating the absolute configuration of the afforded -
hydroxyester to that of the parent sulfoxide.  In subsequent studies an exception was noted in 
that the reactions of -unsaturated carbonyls such as trans crotonaldehyde gave the 
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condensation product 1.31 with the opposite configuration for the hydroxyl group compared to 
the products, such as 1.32, arising from the typical aldehydes (Scheme 1.6).63    
 
 
Scheme 1.6 
 
In the synthesis of the neolignan porosin 1.33 a sulfoxide-directed lactonization was employed 
by Marino et al. (Scheme 1.7).  This route provided efficient access to 3,4-disubstiuted  
-butyrolactones and allowed for complete control over the relative and absolute 
stereochemistry at the lactone C-3 and C-4 positions.64  A proposed mechanism for the 
lactonization step suggested acylation of the oxygen of sulfoxide 1.34 by the electrophilic 
ketene, generating the zwitterionic species 1.35.  A [3,3]-sigmatropic rearrangement would then 
give a Pummerer type intermediate 1.36 which, when trapped by the carboxylate anion, would 
produce the corresponding substituted lactone 1.37.  The successful application of this 
procedure saw the optically pure (3R,4S)-dichlorolactone 1.37 obtained in a yield of 76%.   
 
  
Scheme 1.7 
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1.4 Synthesis of sulfoxides 
 
The oxidative transformation from sulfide to sulfoxide affords a product with immense value 
and versatility in organic synthesis.  Although the addition of a single oxygen atom may, at least 
on paper, seem incredibly simple, there are many aspects which one may wish to consider when 
approaching the selective synthesize of a particular sulfoxide.  Considerations must be made 
with respects to the chemoselectivity of the oxidations process in order to avoid excessive 
production of unwanted sulfone.  In addition, there is an increasing need for the use of 
environmentally friendly reagents and improved “atom efficiency”, particularly for syntheses 
carried out on an industrial scale.65  The desire for the production of sulfoxide in stereoselective 
fashion brings about a further dimension of complexity; however there is an extensive library of 
techniques currently available to choose from.   
 
It must be noted that one of the ways by which a target sulfoxide may be reached is through the 
transformation of the appending functional groups of a pre-existing sulfoxide.  This, however, is 
beyond the scope of what can be covered here; instead we shall mainly focus of the generation 
of a sulfoxide species by ways of reactions that occur at the sulfur atom, such as oxidation or 
nucleophilic substitution, amongst others.  The exception to this lies in the discussion of kinetic 
resolution of racemic sulfoxides (Section 1.4.2.1.2). 
 
1.4.1 Racemic sulfoxides 
 
When there is no requirement for control of the stereochemical outcome there are numerous 
methods that can be used for the oxidation of sulfides to sulfoxides.66  Oxidizing agents 
applicable for this reaction include mCPBA, nitric acid, peracids, peresters, ozone, 
dinitrogentetraoxide, N-halosuccinimide, 1-chlorobenzotriazole, diazobicyclo-[2,2,2]-octane 
bromine complex, selenium dioxide, manganese dioxide, chromic acid, ceric ammonium nitrate, 
oxone, and ε-phthalimidoperhexanoic acid  (PPHA)67-70  Kowalski and coworkers have 
published a review covering S-oxidations using halogen derivatives such as molecular halogens, 
hyperchlorites, hypervalent iodine reagents and periodates.71  The same group has also reviewed 
method using hydrogen peroxide, giving consideration to the effects of solvents and range of 
metal, and non-metal based catalyst systems.72  The series of reviews by Rayner, and continued 
by Proctor, provide an overview of methods arising in the literature between 1994 and 2001.40, 
41, 73-76  
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In recent years advances have been made in the arena of metal based catalysts for use in 
sulfoxide synthesis.  Novel catalyst systems comprising of Ta(V) or Nb(V) chlorides or 
ethoxides have also been investigated, with the use of an aqueous H2O2 oxidant.
77  An oxidation 
system has been reported that makes use of oxygen from the air with oxidation of aryl methyl 
sulfides to sulfoxides promoted by HNO3 and FeBr3.
78  A mild and chemoselective oxidation of 
sulfides and methyl cysteine containing peptides using Sc(OTf)3 has also been published.
79  
Using a more common metal for S-oxidation, a Ti(IV) system has been reported by Luchini et 
al. with a C3-symmetric triphenolate amine ligand; the catalyst system was employed in 
loadings a low as 0.01 mol% for use with aqueous H2O2 as the oxidant.
80 
 
Recent developments in metal free approaches to the synthesis of racemic sulfoxides include the 
use of organocatalysts such as thiourea dioxide, flavins and tetrazole amide derivatives.81-84   
A number of novel oxidizing agents have been reported such as the use of an urea–hydrogen 
peroxide adduct.85  Oxaziridine-mediated and imine-catalyzed oxidations of sulfides have been 
included in a review by Adams et al.86  A 2010 review by Stingl et al. covers many additional 
aspects of metal free sulfoxidation.87 
 
Investigations into developing more environmentally friendly oxidations have included the use 
of ultrasound in assisting sulfoxide synthesis, photooxidations and solvent free procedures.
88-90
  
For environmentally friendly sulfide oxidations H2O2 is often the preferred oxidant.  A longer 
reaction time is typically associated with this reagent, however a number of methods have been 
reported that overcome this problem such as the use of additives like poly(ethyleneglycol) 
dimethylether (PEGDME500) or 1,3,5-triazo-2,4,6-triphosphorine-2,2,4,4,6,6-tetrachloride 
(TAPC) and the formation of oxidizing complexes such poly(N-vinylpyrrolidone)-H2O2 and 
poly(4-vinylpyridine)-H2O2.
88, 91-94 
 
1.4.2 Chiral sulfoxides 
 
In the synthesis of optically active sulfoxides there are four main approaches that may be 
considered, these are depicted in Figure 1.1.  The first method involves the separation and 
isolation of each enantiomers of a racemic sulfoxide, or a sulfoxide of low enantiopurity.  This 
resolution may be achieved through a physical method such as HPLC, or in the case of kinetic 
resolution through a chemical transformation.  The second method involves the transformation 
of a diastereomerically pure sulfinate to a chiral sulfoxide through nucleophilic displacement 
with an organometallic based reagent.  This reaction, pioneered by Andersen, typically proceeds 
with inversion of stereochemistry at sulfur.   
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Figure 1.1 
 
The third method involves the enantioselective oxidation of a prochiral sulfide and has become 
the most widely employed method for stereoselective synthesis of sulfoxides and can be 
separated into three categories: biological mediated oxidations, non-metal based oxidations, and 
metal-based oxidations.  Biological and non-metal based methods of S-oxidation shall be 
discussed in the rest of this chapter, however in order to cover the extensive topic metal-based 
asymmetric synthesis of chiral sulfoxides has been given its own dedicated chapter. 
 
The fourth method involves the transformation of a pre-existing, optically pure sulfoxide under 
non-racemizing conditions; this route is greatly dependent on sourcing a suitable chiral 
sulfoxide from the chiral pool or prior synthesis for starting material therefore, with a small 
number of exceptions, particularly when discussion kinetic resolution of sulfoxides (Section 
1.4.21.2), we shall limit discussion only to transformations that occur directly on sulfur, rather 
than further afield in the molecule. 
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1.4.2.1 Resolution of chiral sulfoxides 
 
Resolution is the oldest synthetic method for the production of enantiomerically pure 
materials.
95
  Several methods have been reported for the isolation of chiral sulfoxides, including 
classical resolution via diastereomers, chromatographic separation via the use of chiral 
stationary phases, and kinetic resolutions (both chemical and enzymic) amongst others.  Despite 
inherent limitations (i.e. a maximum yield of only 50% of the desired enantiomer if starting 
from a racemic mixture), separation of enantiomers via resolution remains a popular technique 
in the pharmaceutical industry.96  Where single enantiomer drugs are being assessed for in vivo 
testing for the first time, resolution allows for simple, rapid, and more cost efficient production 
of initial materials compared to the development of asymmetric synthesis method.15, 97   
 
1.4.2.1.1 Classical resolution 
 
Many sulfoxide species have been successfully resolved using classical resolution techniques 
i.e. the preparation of diastereomers which allow for separation based upon differing 
physiochemical properties.  In one of the earliest papers to address the structure and bonding of 
mixed sulfoxides (where R1  R2), Harrison and coworkers described the resolution of racemic 
4-aminophenyl p-tolyl sulfoxide by a process which involved the formation, recrystallization, 
and subsequent decomposition of diastereomeric camphorsulfonate salts.14  More recently, the 
enantiomers of sulfoxide ()-1.38 were resolved with mandelic acid (MA) in MeCN; both 
enantiomers were recovered in good yields (with respect to the resolving agent) and with 
excellent optical purity (> 99% ee) (Scheme 1.8).98 
 
 
Scheme 1.8 
 
Prisinzano et al. reported the resolution of modafinic acid ()-1.39, a carboxylic acid derivative 
of the psychostimulant Modafinil 1.2, using fractional crystallization of the salts formed with 
the resolving agent -methylbenzylamine.20  The same group subsequently reported an 
alternative methodology whereby adducts were formed between modafinic acid ()-1.39 and a 
chiral thiazolidinethione auxiliary (R)-1.40 (Scheme 1.9); this method allowed for separation of 
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the diastereomeric products via column chromatography as opposed to the crystallizations 
employed previously.99 
 
Scheme 1.9 Reagents and conditions: (i) DCC, DMAP, CH2Cl2; (ii) column chromatography;  
(iii) CHCl3–MeOH–NH4OH. 
 
The formation of diastereomeric adducts has also been employed in the resolution of racemic 
aryl dichloromethyl sulfoxides, via reversible Aldol-type reactions with (–)-menthone.100  The 
formation of complexes has also proved synthetically useful in the resolution of sulfoxides.  The 
treatment of (+)- or (–)-trans-dichloro(ethylene)(-methylbenzylamine)-platinum(II) with ethyl 
p-tolyl sulfoxide was reported to give rise to diastereomeric sulfoxide-amine-platinum 
complexes, via a slow displacement of ethylene, which were separable by crystallization.101   
 
Resolution via host-guest complexation is also well known; one advantage of this method is that 
is possible to resolve compounds which lack the acidic or basic functionalities required for 
classical resolutions involving the formation of diastereomeric salts.  -Cyclodextrins, which 
are natural oligosaccharides formed by seven glucose units and feature a hydrophobic cavity 
within a torus shaped molecule, have been employed in the direct resolution of a number of 
alkyl aryl and alkyl benzyl sulfoxides.102  Although the optical purities of the partially resolved 
sulfoxides were low (≯ 15% ee), they could be improved by recrystallization.103  Dehydrocholic 
acid 1.41, a bile acid derivative, has been successfully employed as a host molecule to form 
inclusion complexes with a range of aryl alkyl sulfoxides; guest sulfoxides were resolved with 
good to high optical purities (36-99% ee) in the final products.104  Complexation of sulfoxides 
with chiral hosts such as the tartaric acid derivative 1.42 or (R)-BINOL (R)-1.43 have also 
proved a simple and effective method for resolution.105, 106  Chiral host (2R,3R)-1.42, and its 
enantiomer were both reported to allow access to optically active alkyl pyridyl sulfoxides with 
very high enantiomeric excess (95-99.5% ee).105  The use of diol (R)-1.43 as a resolving agent 
for a number of aryl alkyl- and dialkyl sulfoxides gave sulfoxide products with either low (0-
25% ee) or excellent enantiopurity  (> 99.5% ee), revealing the importance of the sulfoxide 
molecular shape in the complexation process.106   
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Separation of enantiomers based on classical resolution typically relies on the formation of 
stable diastereomers which can be isolated through crystallization or normal phase 
chromatography.  Unfortunately these techniques cannot be applied universally; products may 
form oils, they may not be suitable for derivatization, or they may not be easily separable 
through crystallization or simple chromatography.   
 
1.4.2.1.2 Kinetic resolution 
 
Kinetic resolution occurs when two enantiomers of a racemate are subjected to a transformative 
process which occurs at different rates for each enantiomer.  If the kinetic resolution is efficient, 
one enantiomer is converted to a new species while the other remains unchanged but enriched in 
optical purity.
107, 108
 Oxidative kinetic resolution of racemic sulfoxides is the most common type 
of this reaction reported for the attainment of chiral sulfoxides; reactions of this type are 
discussed in subsequent sections of this thesis, within the context of the oxidative methodology.  
There are, however, a number of other transformations which may afford chiral sulfoxides by 
way of kinetic resolution, such as reduction of racemic sulfoxides and modification to sulfoxide 
side chains.   
 
Mikołajczyk and coworkers explored the preferential reduction of sulfoxide enantiomers by 
treating racemic methyl alkyl sulfoxides with o-ethyl phosphonothioic acid or o-ipropyl 
methylphosphonothioic acid.109  Enantioselectivity of the reductions was low yielding 
sulfoxides with 6% ee at most.  Optically active lithium aluminium hydride complexes were 
also employed for reduction kinetic resolution, but again only low optical purities were 
observed.110  Montanari et al. reported the selective reduction of mesityl p-tolyl sulfoxide in the 
presence of a chiral poly[N-(1-phenylethyl)iminoalane] tetramer.111  A mixture of 
enantioenriched sulfoxide was obtained in 78% ee alongside the corresponding sulfide.  
Reductive kinetic resolution has been reported by a number of groups using DMSO 
reductases.112, 113  One example from Abo et al. used Rhodobacter sphaeroides f.s. denitrificans, 
isolated from the waste water of a tofu factory, in the reduction of the S-enatiomer of racemic 
methyl phenyl sulfoxide to the corresponding sulfide.114  The (R)-enatiomer of this sulfoxide 
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was obtained in optical purities between 79-97% ee; expansion of the substrate scope for 
enantioselective deoxygenation saw a range of racemic alky aryl- and diaryl-sulfoxides resolved 
to give recovered sulfoxides in up to > 99% ee.   
 
Chemical transformations that occur beyond the sulfur atom of a sulfoxide are a common way 
to selectively transform one sulfoxide enantiomer during kinetic resolution.  Naso et al. 
employed the chiral base (+)-cinchonine 1.44 to effect a selective elimination reaction, 
stereoselectively converting racemic -halosulfoxides into enantioenriched vinyl sulfoxides 
(Scheme 1.10).115  Performing this reaction on p-tolyl -fluoroethyl sulfoxide (-1.45 gave 
vinyl sulfoxide (S)-1.46 in 23% ee, with the unreacted sulfoxide recovered with 24% ee.   
 
 
Scheme 1.10 
 
Kunieda and coworkers obtained partially resolved -ketosulfoxides with optical purities of up 
to 72% ee through the reaction of a menthyl ester with-sulfinyl carbanions such as (-1.47; 
enantioenrichment was also observed in the sulfoxide 1.48 derived from unreacted starting 
material (up to 13% ee) (Scheme 1.11).   
 
 
Scheme 1.11 
 
The dynamic kinetic resolution of allylic sulfoxides was reported by Dornan and coworkers.  By 
combining the Mislow [2,3]-sigmatropic rearrangement with catalytic asymmetric 
hydrogenation, sulfoxides with up to 88% ee were obtained, in yields between 53-84%.  A 
rhodium based catalyst system was employed using the chiral diphosphine ligand (S,S)-1.49 
(Scheme 1.12). 
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Scheme 1.12 
 
Lao et al. reported their investigations into the hydrogenative kinetic resolution of vinyl 
sulfoxides; isolation of both recovered and reduced sulfoxide products, in excellent yields and 
optical purity, was achieved (Scheme.1.13). 
 
 
Scheme 1.13 
 
An enzymatic kinetic resolution was reported by Ohta and coworkers; hydrolysis of racemic 
sulfinyl acetates and propionate was carried out using Corynebacterium equi IF 3730 to afford 
the recovered chiral sulfoxides in optical purities of up to 90% ee and yields between 30-43% 
(of a possible 50%).116  Burgess and Henderson performed biocatalytic resolution of sulfinyl 
acetates using Pseudomonas K-10, affording unreacted sulfoxide acetates and corresponding 
acids with excellent enantiopurities (Scheme 1.14).117   
 
 
Scheme 1.14 
 
Enzyme catalyzed hydrolysis was also employed by Kwiatkowska et al. to produce 
enantiomerically enriched acetoxymethyl aryl sulfoxides through kinetic resolution.
118
  Serreqi 
et al. examined hydrolase-catalyzed kinetic resolution of sulfoxides by hydrolysis of pendant 
acetoxy groups.119  Hydrolase screening identified cholesterol esterase to be the most effective 
enzyme for enantioselectivity; from the racemic sulfoxide (-1.51, (S)-2-
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(methylsulfinyl)phenyl acetate (S)-1.51  was obtained with > 99% ee, in a yield of 11% after 
one recrystallization (Scheme 1.15).   
 
 
Scheme 1.15 
 
Whole cells of Rhodococcus sp. ECU0066 were used to catalyze the resolution of racemic alkyl 
aryl sulfoxides.120  Sulfoxides were recovered in high ee (up to > 99% ee) in good yields for the 
method employed (up to 45% yield). 
 
A kinetic resolution in the solid state was reported by Toda et al.  Racemic sulfoxides were 
oxidised in the presence of the optically active host compound (-)-1,6-di(o-chlorophenyl)-l,6-
diphenylhexa-2,4-diynel,6-diol 1.52 (Scheme 1.16).121  Enantiopure methyl noctyl 1.53 was 
afforded through the combined process of enantioselective inclusion complexation and selective 
oxidation using mCPBA (Scheme 1.16).  
  
 
Scheme 1.16  
 
An alternative method used to obtain optically active sulfoxides is through enantioselective 
chromatography via the use of a chiral stationary phase (CSP); chromatographic resolution of 
enantiomers is also a highly valuable, and widely employed, tool for analysis.  For the 
resolution of sulfoxides via HPLC or LC there is a wide range of materials that have been 
successfully employed as CSPs.  Some of the most commonly encountered are based upon 
functionalised silica coated with polysaccharides such as amylose or cellulose.122-124  These 
polysaccharide based CSPs include the commercially available Daicel columns: Chiralpak AD 
and AS, Chiralcel OD and OJ, which are sometimes referred to as the “golden four” due to their 
popularity and applicability.125-128  CSPs of this type are commonly employed for resolution of 
sulfoxide enantiomers via supercritical-fluid chromatography (SFC). 129-131  Pirkle type CSPs for 
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HPLC and LC are also commercially available; these include a -acid based CSP containing the 
3,5-dinitrobenzoyl derivative of 1,2-diaminocyclohexane (DACH-DNB).132, 133  Pirkle and 
coworkers also reported the use of (R)-N-(3,5-dinitrobenzoyl)phenylglycine bound to 
aminopropyl silica as a successful CSP for enantioselective LC of sulfoxides and N-substituted 
sulfoximines.134  Nanoporous materials such as homochiral metal-organic frameworks have 
been applied as CSPs for HPLC.135, 136  Similarly, a recent publication reported the use a 
homochiral porous organic cage as a stationary phase for high resolution GC of a range of 
racemates, including sulfoxides.137  Other chiral stationary phases employed for sulfoxide 
resolution include those based upon macrocyclic glycopeptides, and bovine serum albumin 
(BSA), immobilized to HPLC-silica.138, 139  Cyclodextrins have been employed as chiral 
selectors for sulfoxide enantioseparation using HPLC, GC, and capillary electrophoresis.140-142 
 
1.4.2.1.3 Enantiomeric enrichment via achiral chromatography   
 
Occasionally the isolation of enantiomerically enriched sulfoxides can be achieved through 
achiral gravity driven or flash chromatography due to the rare phenomenon of self-
disproportionation of enantiomers (SDE).143-147  Kagan and coworkers described examples of 
atypical cases of fractionation of sulfoxide enantiomers by achiral flash chromatography.148  
Alerted by poor reproducibility of enantioselectivities during investigations of the asymmetric 
oxidation of methyl p-tolyl sulfide, it was found that the optical purity of the sulfoxide product 
(R)-1.48 depended strongly on which fraction was analyzed.  The possibility of partial 
racemisation was excluded after treating an enantiopure sample under the same conditions, with 
all fractions retaining the original 100% ee.  Pollution by contaminant was also ruled out.  
Further investigation showed that starting from sulfoxide (R)-1.48 (86% ee), enantioenrichment 
by during chromatography could be observed in the first fraction (99% ee, major enantiomer) 
with depletion occurring in the later fractions (73% ee, major enantiomer) (Table 1.1, entry 1).  
Similarly when starting from sulfoxide (R)-1.48 with a lower initial optical purity (20% ee) the 
same trend was observed, with high initial ee values that decreased to give the lowest values in 
the last fractions (37% ee and 18% ee, respectively) (Table 1.1, entry 2).  Increasing, or 
decreasing the amount of silica gel used did not improved the efficiency of enantiomeric 
enrichment (Table 1.1, entry 3 and 4, respectively).  The splitting of the enantiomeric excess 
was less pronounced when alumina was employed as the stationary phase (Table 1.1, entry 5) 
and the use reverse phase silica was found to only affect the speed of elution, not the 
fractionation of sulfoxide ee (Table 1.1, entry 6). 
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Entry Sulfoxide % eea First fraction, % ee Last fraction, % ee 
1 p-Tol-S(O)-Me (1.48)b 86.0 (R) 99.5 (R) 73.5 (R) 
2 p-Tol-S(O)-Me (1.48)b 20.0 (R) 37.0 (R) 18.0 (R) 
3 p-Tol-S(O)-Me (1.48)b,c 85.5 (R) 93.0 (R) 72.0 (R) 
4 p-Tol-S(O)-Me (1.48)b,d 85.5 (R) 89.5 (R) 80.0 (R) 
5 p-Tol-S(O)-Me (1.48)b,e 86.0 (R) 91.0 (R) 80.5 (R) 
6 p-Tol-S(O)-Me (1.48)b,f 91.0 (R) 99.5 (R) 73.0 (R) 
7 Bn-S(O)-tBu (1.54) 44.5 (S) 53.0 (S) 42.0 (S) 
8 Fc-S(O)-Me (1.55)g,h 90.5 (R) 99.5 (R) 82.0 (R) 
9 Fc-S(O)-Ph (1.56)i 65.0 (R) 79.0 (S) 94.0 (R) 
Table 1.1 Chromatography performed using ~10 g silica gel/mmol sulfoxide with elution by EtOAc, unless 
stated otherwise.  a) Initial sulfoxide % ee measured by HPLC on Chiralcel OD-H (Diacel); b) prepared by 
mixing of two enantiopure sulfoxides; c) 50 g silica gel/mmol sulfoxide; d) 4.5 g silica gel/mmol sulfoxide;  
e) flash chromatography on Al2O3; f) 20 g reverse phase silica gel/mmol sulfoxide; g) elution by 50%  
EtOAc–Et2O; h) Fc = ferrocenyl; i) elution by 50% EtOAc–cyclohexane 
 
Fractionation of enantiomeric excess during chromatography on silica was not unique to 
sulfoxide 1.48, a similar trend was observed also for benzyl tbutyl sulfoxide 1.54, methyl 
ferrocenyl sulfoxide 1.55 and phenyl ferrocenyl sulfoxide 1.56.  A change in the order of elution 
was observed with sulfoxide (R)-1.56 (65% ee) where the minor (S)-enantiomer was afforded in 
the first fraction (79% ee (S)), whereas the major enantiomer was eluted with the highest ee 
towards the end (94% ee (R)).  The enantiomeric modification was found not to be a general 
trend for all sulfoxides examined; no perturbation in optical purity was observed following 
chromatography of neither p-tolyl ferrocenyl sulfoxide nor tbutyl ferrocenyl sulfoxide.  Further 
to the work of Kagan, only a small number of additional sulfoxides have been reported as 
showing a similar behaviour during achiral chromatography, including methyl npentyl sulfoxide 
and an important class of prazole based species which include the blockbuster drug 
Esomeprazole (S)-1.1 (discussed further in chapter three).149, 150   
 
This remarkable physiochemical phenomenon of enantiomeric enrichment, or SDE, is thought 
to be attributed to intermolecular interactions, with auto-associations of the chiral species 
leading to formation of hetero- and/or homo- dimers.143, 151  These diastereomeric agglomerates 
may present with differing mobilities in the solution phase, or associate differently with the 
stationary phase, leading to fractionation of enantiomeric excesses.  In order to avoid 
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complications arising from aggregation of this type, consideration must be made during workup 
and isolation stages, typically achieved by combining sulfoxide fractions prior to analysis.152, 153   
 
1.4.2.2  Synthesis of chiral sulfoxides via nucleophilic displacement at sulfur 
1.4.2.2.1 The Andersen method 
 
In 1962 a new method for the synthesis of sulfoxides with high optical purities was reported by 
Andersen et al. which involved the addition of an organomagnesium halide Grignard reagent to 
an optically active sulfinate ester (Ss)-1.57. 
154  The resulting nucleophilic displacement of O-
menthyl was found to proceed via an SN2 mechanism with complete inversion of configuration 
at sulfur, affording (R)-ethyl p-tolyl sulfoxide 1.58 in a good yield (62%) (Scheme 1.17).155-157 
 
 
Scheme 1.17 
 
This methodology not only provided new access to enantiopure sulfoxides, which in turn could 
be used in further synthesis but, as a technique that could produce chiral sulfoxides in a 
stereospecific manner, it also provided important evidence for consideration in discussions, such 
as those by Mislow, concerning the assignment of absolute configuration of a number of sulfur 
containing species.4, 156-159  The Andersen method also circumvented many of the limitations in 
obtaining enantiopure sulfoxides found previously; there was no need for an acidic or basic 
handle for use in resolution by diasteomeric salt formation, and this method gave sulfoxides 
with higher enantiopurity than those achieved through asymmetric sulfoxidation by optically 
active peracids which had been recently reported by Maccioni.14, 160  To achieve sulfoxide 
products with high ee using the Andersen method the preparation of the menthyl sulfinate 
precursor in high optical purity is necessary. Although both diastereomers of p-tolyl sulfinate 
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ester 1.55 are now commercially available it was previously necessary to perform repeated 
crystallizations to separate the less soluble isomer (SS)-1.57 from its oily epimer. Solladie and 
Mioskowski reported a method whereby interconversion of the sulfoxide epimers was promoted 
by acidic conditions and in combination with crystallization from acetone, the desired sulfinate 
ester precursor could be obtained in high yields (80-90%) (Scheme1.18).161 
 
 
Scheme 1.18 
 
An alternative method for the preparation of a range of  menthyl sulfinate esters was reported by 
Sharpless who described a one step procedure involving the in situ reduction of sulfonyl 
chlorides by trimethyl phosphites in the presence of triethylamine.162 In addition, the synthesis 
and/or application of crystalline menthyl sulfinates such as 1-naphthyl, 1-(2-naphthyl), 
 1-(2-OMe-naphthyl), 4-bromophenyl have been reported in the literature.155, 158, 163, 164  
Alternative organometallic reagents have also been reported, with Harpp et al. disclosing the 
successful application of organocopper lithium reagents in place of the Grignard traditionally 
employed by the Andersen menthod.165 
 
Recently, Dorta et al. employed a classical Andersen approach in the synthesis of four bis-
sulfoxide ligands for use in Rh-catalyzed asymmetric transformations.153, 154 The four 
stereoisomers of the 1,1’-binaphthalene-2,2’-diyl-bis(p-tolylsulfoxide) ligand (p-tol-BINASO 
1.58 and 1.59), were created in one-step reactions from racemic commercially available starting 
material 1.60 (scheme 1.12).  Column chromatography separated the two atropisomers of the 
diastereomeric BINASO crude materials, and following the use of both epimers of the menthyl 
sulfinate ester four pure ligands were obtained in yields between 34-60% (Scheme 1.19).   
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Scheme 1.19 
 
1.4.2.2.2 Alternative sulfinylating agents  
 
The range of chiral sulfoxides that can be achieved by implementation of the Andersen 
methodology is generally restricted to alkyl aryl or diaryl sulfoxides due to the limited 
availability of appropriate menthyl sulfinate esters precursors.  For example, the oily nature of 
menthyl methyl sulfinates results in diastereomers which are difficult to separate and are 
unsuitable for use in this way.166  A solution to this problem lies in the replacement of menthyl 
with an alternative chiral alcohol, which allows for the formation of more easily separable 
sulfinate esters.  Andersen et al. published a procedure wherein cholesterol was employed in 
place of menthol for the formation of the diastereomeric sulfinate esters precursors.  Treatment 
of each epimer with a range of Grignard reagents afforded dialkyl sulfoxides; although yields 
were typically less than 50%, the optical purity of the sulfoxide products were high and 
generally in excess of 80% ee.   
 
The use of trans-2-phenylcyclohexanol 1.61 for the production of enantiomerically enriched 
sulfinate ester was reported by Whitesell et al.  Although more expensive than menthol, the 
chiral cyclohexanol auxiliary 1.61 allowed for production of sulfinate diastereomers that were 
readily separated by both chromatography and crystallization.  The synthesis of sulfinate ester 
was observed to occur with some kinetic diastereoselectivity (up to 10:1), and with both isomers 
of the auxiliary available there was equal and ready access to the desired sulfinate ester, and 
chiral sulfoxide derived there from (Scheme 1.20).167, 168 
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Scheme 1.20 
 
Ellman and coworkers evaluated a number a chiral acyl transfer catalysts for use in the 
preparation of sulfinate esters due to the similarities between sulfinyl and acyl transfer.  
Amongst them were the chiral (dimethylamino)pyridine derivative 1.63, the more electron rich 
ferrocene-derived acyl transfer catalyst 1.64, and the N-methylimidazole-containing peptide 
1.65. 
 
 
 
Subsequent work featured the use of more commercially available and inexpensive cinchona 
alkaloids such as quinidine 1.66 in catalytic amounts to afford butylsulfinate ester 1.67, and 
phenyl tbutyl-sulfoxide 1.68, with excellent enantioselectivity (Scheme 1.21).      
 
 
Scheme 1.21 
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Toru et al. reported a novel approach centered around a cinchona alkaloid/sulfinyl chloride 
combination, prepared in situ, which was found to act as a sulfinylating agent on an achiral 
alcohol.169 Aryl tbutyl sulfinates 1.69 were obtained in good yields (68-93%) with high 
enantioselectivity (83-99% ee); both enantiomers of the sulfinate esters could be obtained by 
using the alkaloid quinidine acetate (QDA 1.70) to afford one isomer, and hydroquinine acetate 
(HQA 1.71) to give the epimer (Scheme 1.22).  
 
 
Scheme 1.22 
 
A general sulfinylating process was reported by Senanayake et al. which allowed for the 
synthesis of sulfinate esters and their equivalent enantioenriched sulfoxides using the alkaloid 
quinine 1.72 and quinidine as chiral auxiliaries.170  The reaction was presumed to proceed via 
formation of a pseudo five-membered ring oxathiazolidine 1.73, featuring a noncovalent S-N 
bond, the displacement of which would be preferential over that of the S-O bond following 
addition of the tbutyl Grignard reagent (Scheme 1.23). 
 
 
Scheme 1.23 
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When complex 1.73 was treated with p-tolylmagnesium chloride, only the formation of a 
racemic disulfoxide occurred.  However, this was circumvented by employment of  
p-tolyldiethylaluminum, prepared in situ from diethylaluminium chloride and p-tolylmagnesium 
bromide (Scheme 1.24). 
 
 
Scheme 1.24 
 
The formation of diastereomeric sulfinamides also allows access to the formation of 
enantioenriched sulfoxides.  Auxiliaries, such as the oxazolidinones 1.78 and 1.79 reported by 
Evans, and sultam 1.80 reported by Oppolzer formed intermediate sulfonamides diastereomers 
which were easily separable by crystallization, and from which a range of sulfoxides were 
produced with excellent enantiopurity (up to > 99% ee).171, 172  The oxazolidinones 1.78 and 
1.79 were complimentary to each other as they afforded sulfoxides with opposite absolute 
configurations, and all three auxiliaries could be recovered and reused.  Chiral diamine 1.81 was 
investigated by Toru et al. in the enantioselective synthesis of chiral sulfinates by the reaction of 
p-tolysulfinyl chloride with achiral alcohols.173   
 
 
 
The application of carbohydrate auxiliaries for the preparation of diastereomeric sulfinate esters 
as precursors to chiral sulfoxides began with Ridley and Smal who, in 1981 reported the 
synthesis of a number of arenesulfinic esters of dicyclohexyl-D-glucofuranose (DCG, 1.82).174  
A decade later, Fernández et al. reported an efficient synthesis of both enantiomers of various 
methylsulfoxides using diacetone-D-glucose (DAG, 1.83) as the inducer of chirality (Scheme 
1.25).  Through the use of different amines it was possible to access either diastereomer of the 
sulfinate ester, with the utilization of diisopropylethylamine (DIPEA) giving the S- isomer and 
pyridine the R- epimer.  With the configuration at sulfur conveniently predetermined treatment 
with a variety of Grignard reagents transformed the diastereomerically pure sulfinates into 
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enantiomerically pure alkyl- or aryl-methyl sulfoxides (> 99.5% ee) in good to high yields (37-
90%) (Scheme 1.25).175-177 
 
 
Scheme 1.25 
 
Computational analysis of the DAG methodology suggested that the stereoselectivity and 
configurational outcome of the sulfinate ester synthesis was determined by firstly by a DKR  
mechanism of the sulfinyl chloride, and secondly by the bulkiness of the base used leading to 
differing pathways due to steric hindrance of the sulfinamindes formed in situ.178-180 Subsequent 
improvements to the DAG methodology led to the development of a DMAP catalyzed process, 
which was found to enhance both the enantioselectivity and rate of reaction, and led to the 
formation of a range of sulfoxides and sulfinamides.181 
 
1.4.2.2.3 Double nucleophilic displacement at sulfur 
 
To create enantiomerically pure sulfoxides a strategy may be used whereby nuclophilic 
substitution occurs twice at sulfur.  Here, the prochiral faces of thionyl chloride are 
differentiated through use of a bifunctional scaffold, which can be chiral diols or amino 
alcohols, to form diastereomeric sulfites or aminosulfites.  The presence of two leaving groups 
in the molecule allows for two sequential reactions with organometallic reagents, affording the 
desired chiral sulfoxide.  Kagan and coworkers investigated this approach and found it to be an 
efficient method for the synthesis of chiral sulfoxides, particularly tbutyl sulfoxides.182-184  
Cyclic sulfite 1.84 was obtained as a mixture of diastereomers from the reaction of starting 
thionyl chloride and diol 1.85, which in turn was produced easily in one step from (S)-ethyl 
lactate, a material which is inexpensive and readily available from the chiral pool.  
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Crystallization of sulfite 1.84 was followed by the formation of monosubstitued sulfinates 1.86 
or 1.87 following the addition of various Grignard reagents (Scheme 1.26). 
 
Scheme 1.26 
 
It was observed that when a hindered reagent, such as tBuMgBr or mesitylMgBr, was used  
(SS)-sulfinate 1.87 was predominantly obtained; the less hindered MeMgI afforded an excess of 
(RS)-sulfinate 1.86.  A range of chiral 
tbutyl sulfoxides were obtained using this approach in 
moderate to excellent yields (27-99%) and high enantiopurity (85-> 99.5% ee).   
 
Kagan et al. also reported the use of cyclic sulfites derived from C2-symmetric alcohols as 
precursors of sulfinates, where the diasterotopic oxygens of sulfite 1.88 had potential for 
differing reactivity towards attack by an achiral nucleophile.184  From dimenthyl sulfite 1.88, 
menthyl tbutylsulfinate 1.89 was prepared by the reaction of 1,2-dibromoethane and Mg in THF, 
followed by addition of tBuLi (2 equiv).  Sulfinate 1.89 was obtained in excellent yield (100%) 
as a mixture of diastereomers (70% de); transformation of 1.89 into (S)- phenyl tbutyl sulfoxide 
1.90 (70% ee) by addition of PhLi (2.1 equiv) was achieved in a quantitative yield (Scheme 
1.27).  Cyclic sulfites were also explored by Vallée et al., who found that C2-symmetric sulfites 
formed from mannitol derivatives could be utilized in the synthesis of tbutylsulfinates.185   
 
 
Scheme 1.27 
 
In 1972 Wudl and Lee reported the use of ephedrine as a chiral auxiliary in the pursuit of 
enantiomerically pure sulfoxides, thus pioneering the cyclic aminosulfite methodology (Scheme 
1.28).186  In subsequent work further application of the methodology and mechanistic detail was 
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discussed.187  In this process 1,2,3-oxathiazolidine-S-oxide diasteromers (SS)-1.91 and (RS)-1.91 
were obtained in a 72:28 ratio through reacting thionyl chloride with (–)-ephedrine 1.91 in the 
presence of the triethylamine.  Crystallization allowed for diastereomerically pure (SS)-1.91 to 
be collected, and acid mediated equilibriation allowed for further production of (SS)-1.91 from  
(RS)-1.91.  Treatment of optically pure (SS)-1.91 with alkyl or aryl lithium afforded 
hydroxysulfinamides 1.93 in good yield (60-90%) but only with an average of 50% ee at sulfur, 
with the low selectivity attributed to epimerization presumed to be due to a sulfinyl-transfer 
mechanism.  Further transformation of the sulfonamides via reaction with organolithium 
reagents gave sulfoxides in good yield and high optical purity (70-75%, 85-86% ee); the use of 
MeMgBr produced optically pure methyl p-tolyl sulfoxide 1.48, but only in 25% yield.  This 
disparity was thought to be due to the difficulty in breaking the S-N bond, with racemisation 
potentially occurring.6 
 
 
Scheme 1.28 
 
By 1991 Synder and Benson had development a number of improvements to Wudl and Lee’s 
aminosulfite methodology.188  Firstly, by allowing the diastereomers 1.91 to equilibriate at 0C 
in the presence of triethylammonium diastereoselectivity was increased in favour of (SS)-1.91 to 
80% which could then be isolated by crystallization in a 70% yield.  Secondly, the 
transformation of 1.91 into sulfinamide 1.93 was carried out using various freshly prepared 
Grignard reagents in toluene, as opposed to organolithium reagents in THF used by Wudl et al.  
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Hydroxysulfinamides 1.93 were obtained in yields from 50 to 94%, and with diasteroselectivity 
ranging from 30 to > 99% ee (Scheme 1.28).  
 
The choice of Grignards reagents over organolithiums was thought to avoid epimerization at 
sulfur during the first displacement step, and also prevented the formation of symmetric 
sulfoxides due to double displacement. Finally, for the second displacement step, it was found 
that addition of AlMe3 to the intermediate sulfinamide prior to addition of the Grignard reagent 
gave the desired sulfoxides in good yields and excellent enantioselectivities (> 99% ee).  The 
improvement in both yield and optical purity of the sulfoxide products was attributed to the 
formation of the dimethylaluminiumalkoxide complex 1.94.  With this approach, chiral alkyl 
aryl and dialkyl sulfoxides could be prepared, with access to both enantiomers by simply 
reversing the order of nucleophilic displacement or by using the commercially available 
(1S,2R)-(+)-ephedrine enantiomer as the chiral auxiliary.  Despite the numerous improvements, 
this methodology still suffered limitations, for example it was not possible to produce and 
sulfinamide intermediate where R=Ph in an acceptable yield due to formation of diphenyl 
sulfoxides.  No tbutyl sulfoxides could be produced either, due to the unreactive nature of the 
tbutyl sulfinamide, however these could easily be accessed via Kagan’s cyclic sulfite 
methodology.    
 
Further improvements to the aminosulfite methodology came from Senanayake et al.   
N-sulfonyl (1R,2S)-aminoindanol 1.95 was used as a chiral auxiliary in place of ephedrine.189 
The electron withdrawing group on nitrogen allowed for preferential cleavage of the N-S bond 
by an organometallic agent, reversing the selectivity of the initial nucleophilic displacement step 
(Scheme 1.29).  This procedure was used by Senanayake et al. to generate a range of chiral 
sulfinamides 1.96 with excellent recovery of the chiral auxiliary.  Production of the enantiopure 
endo 1.97 intermediate was achieved on kilogram scale.   
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Scheme 1.29 
 
Soon after, Senanayake et al. reported the use of cis-aminoindanol 1.95 in the synthesis of 
optically active sulfoxides. It was demonstrated that simply changing the base could 
dramatically change the facial selectivity of the reaction between thionyl chloride and indanol 
1.95 (Scheme 1.30).190, 191  (S)- and (R)-butyl isopropyl sulfoxide 1.98 were prepared via the 
sulfinates 1.99 using this procedure in good yield (98% and 89% respectively) with excellent 
enantioselectivity (99% ee for each epimer).   
 
 
Scheme 1.30 
 
Senanayake et al. also described their work in finding a less expensive alternative to N-sulfonyl 
(1R,2S)-aminoindanol 1.95.  Here, the readily available amino alcohol N-tosylnorephedrine 
1.100 was used to prepare N-tosyl-1,2,3-oxathiazolidine-2-oxide 1.101, from which chiral 
sulfoxides could be prepared in a one-pot synthesis; the auxiliary 1.100 could be easily 
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recovered and recycled from the final reaction mixture (Scheme 1.31).  A wide range of 
optically active sulfoxides were furnish from this procedure in high yield (63-97%) and with 
excellent enantioselectivities (90-> 99% ee).  The one-pot methodology was employed in the 
preparative-scale synthesis of (R)- methyl p-tolyl sufoxide 1.48, for use in the preparation of a 
drug intermediate without isolation of the sulfoxide during the process.192  
 
 
Scheme 1.31 
 
García Ruano et al. prepared enantiomerically enriched sulfoxides starting from norephedrine-
derived N-benzyloxycarbonylsulfinamide 1.104.193  After a one-pot reaction of 1.104 with an 
organometalic reagents, then HBF4, and then a final organometallic reagent, a variety of 
sulfoxides were obtained with optical purities typically greater than 93% ee, and yields between 
50-78% (Scheme 1.32).  A similar methodology to this was applied by Qin et al. in the 
synthesis of chiral sulfinamides.194   
   
 
Scheme 1.32 
 
1.4.2.3 Non-metal based oxidation of prochiral sulfides 
1.4.2.3.1 Oxidations performed using a chiral oxidant 
 
Peracids 
Some of the earliest work in the field of asymmetric synthesis of chiral sulfoxides involved the 
use of peracids to oxidize prochiral sulfides.  A number of research groups investigated a range 
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of peracids for this application; results however were generally poor, with reported 
enantioselectivities typically less than 10% ee.66, 157, 159, 160, 195-197   
 
Chiral peroxides 
In 2001 Aoki and Seebach investigated the use of the chiral hydroperoxy alcohol TADOOH 
1.105, a derivative of tetraaryl-1,3-dioxolane-4,5-dimethanol (TADDOL), in asymmetric sulfide 
oxidations (Scheme 1.33).198  Using this reagent as the oxidant methyl phenyl sulfoxide was 
obtained as the (S)-enantiomer in a yield of 73% and enantioselectivity of 86% ee; some 
overoxidation to the sulfone was also observed.   
 
 
Scheme 1.33 
 
Colonna et al. reported a catalytic asymmetric sulfoxidation using a dioxirane generated in situ 
from potassium peroxymonosulfate (Oxone) and fructose derived ketone 1.106.  The product 
from monooxidation of di-tbutyl disulfide was achieved to give the corresponding sulfoxide in 
78% ee, with a yield of > 98% (Scheme 1.34).199  Dieva et al. performed similar investigations 
using an in situ generated dioxirane producing benzyl methyl sulfoxide in a 46% yield, with low 
enantioselectivity (26% ee).200   
 
 
Scheme 1.34 
 
Caprolactams 
Sato et al. reported the enantioselective oxidation of sulfides using chiral halogencaprolactam 
(+)-N-chloro-7-isopropyl-4-methyl-2-oxohexamethyleneimine 1.107.  (R)-Aryl alkyl sulfoxides 
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were obtained in very low ee (< 3% ee).201  Previous work by Sato et al. had discussed the 
oxidation of sulfides by N-bromo--caprolactam 1.108 in the presence of an optically active 
alcohol.  Using this method, with (R)-menthol as the chiral alcohol, (R)-benzyl  
p-tolyl sulfoxide was produced in 56% ee but in low yield (4%).
202
   
 
 
 
Oxaziridines 
Oxaziridines are a class of heterocyclic compounds featuring a three-membered C-N-O ring 
which can act as aprotic, neutral oxidizing agents in a number of different reactions, one of 
which is sulfoxidation.203-205  Davies et al. conducted extensive research into oxaziridines, and 
developed a number of reagents that could be used for asymmetric sulfide oxidations, the four 
main types of which are shown below.205, 206  
 
 
 
When N-sulfonyloxaziridines 1.109 were first reported in 1978 they represented a new class of 
oxaziridines as they were the first example of these compounds to have a substituent other than 
carbon or hydrogen attached to the nitrogen atom.205  The electrophilic oxygen was reported to 
be highly selective, oxidizing sulfides to sulfoxides with no overoxidation to sulfones.207  Using 
a stoichiometric amount of the oxaziridine oxidizing agents 1.113 and 1.114 sulfoxides were 
afforded in good to high yields.  A catalytic version of this reaction was reported a number of 
years later.208  
 
 
 
The following year Davis and coworkers reported the development of an oxaziridine reagent 
capable of asymmetric induction during the sulfoxidation process.209  2-[(–)-Camphor-10-
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ylsulphonyl]-3-nitropheny1) oxaziridines 1.115 and 1.116 were produced as a mixture of 
diastereomers; crystallizations of these gave 1.115 and 1.116 in 33% optical purity, and 1.115 in 
68% optical purity.    
 
 
 
Oxidations performed on three sulfide substrates using the optically enriched oxaziridines gave 
sulfoxides with optical purities of up to 14% ee (Scheme 1.35); sulfonamides 1.117 and 1.118 
could be recovered (> 90% yield) and recycled.  Although enantioselectivities of these reactions 
were low, they represented values 1.3-2.0 times better than optical purities reported thus far 
using peroxy acids.209  
 
 
Scheme 1.35 
 
The mechanism of oxygen transfer from oxaziridine was believed to be by nucleophilic attack 
by the sulfide substrate on the electrophilic oxaziridine oxygen.  Asymmetric induction was 
believed to be made possible by the incorporation of the active site oxygen into a rigid chiral 
environment, with the enantioselectivity of the sulfoxidation reaction determined largely by the 
steric demands of both the sulfide substrate and the oxaziridine oxidizing agent.210  The 
configuration of the oxaziridine’s three-membered ring was thought to control the configuration 
of the sulfoxide product, leading Davis et al. to develop a model from which the stereochemical 
outcome of the reaction could be predicted.  Improvements to the oxaziridine based oxidation 
led to increased enantioselectivity, by 1982 Davis and coworkers had greatly increased the 
optical purities of the sulfoxides, the best result being 46% ee, with the use of diastereomeric 
mixtures of oxaziridines such as 1.119 and 1.120 and their respective epimers (Scheme 1.36).210  
Davis et al. also reported a kinetic resolution of p-tolyl methyl sulfoxide using oxaziridines 
(R,R)-1.120, with the recovered sulfoxide isolated in up to 28% ee.211          
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Scheme 1.36 
 
Davis and coworkers reported the use of the chiral sulfamyloxaziridine 1.121, which afforded 
ipropyl p-tolyl- and methyl 9-anthryl sulfoxides in 65 and 68% ee respectively, representing the 
highest optical purities reported for a chemical asymmetric sulfoxidation at that time (Scheme 
1.37).212  The sulfamyloxaziridines offered numerous practical advantages over the 
sulfonyloxaziridines, including improved chromatographic stability, making them easier to 
purify, and greater ease in the structure could be varied.  Further refinements to the 
sulfamyloxaziridine oxidizing agents saw (S)-alkyl aryl sulfoxides being produced in up to 91% 
ee; these results were comparable, and in some cases better than those being reported at that 
time by Kagan who employed a Ti-based modified Sharpless catalyst system. 213    
 
 
Scheme 1.37 
 
Davis et al. also investigated the synthesis and properties of optically active 
(camphorsulfonyl)oxaziridines, such as 1.122-1.124.214  Although these oxaziridines were used 
in high optical purity, the enantioselectivity they displayed in sulfoxidations were inferior to 
those obtained using N-sulfamyloxaziridines. Methyl 9-anthryl- and nbutyl p-tolyl- sulfoxide 
were both achieved in 75% ee using oxaziridines 1.124 (Scheme 1.38).215   
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Scheme 1.38 
 
A third class of oxaziridine was reported by Davis et al. in 1993.  N-sulfonyloxaziridines, such 
as dichlorocamphorylsulfonyloxaziridine 1.125 were used in enantiomerically pure form, 
allowing access to sulfoxides in optical purities of 65 to > 95% ee (Scheme 1.39).216, 217  
Oxaziridines such as these were also shown to be highly effective in the asymmetric synthesis 
of chiral selenoxides.218   
 
 
Scheme 1.39 
 
Oxaziridines 1.125 was employed by Schwan and Pippert for the oxidation of a number of aryl 
and alkyl 2-(trimethylsilyl)ethyl sulfides (Scheme 1.40).219  The results from a number 
oxaziridine based oxidations were compared to those performed using various titanium based 
catalyst systems, and for four out a possible five sulfide substrates oxidized, the sulfoxides 
produced using the oxaziridine were higher in both yield and enantiopurity.    
 
 
Scheme 1.40 
 
Nishi et al. reported the use of oxaziridines 1.125 and 1.126 for the asymmetric synthesis of  
(S)-1.127, a key intermediate for the synthesis of a biologically active sulfoxide.98  A number of 
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metal based catalyst systems were also employed, and the results from which were compared 
with those from the oxaziridines.  Both oxaziridines performed well, giving high yields and 
enantioselectivities; 1.126 gave the sulfoxide product in the highest optical and chemical yield 
of all the systems studied (95%, 96% ee) (Scheme 1.41). 
 
 
Scheme 1.41 
 
Oxaziridine mediated oxidations on sulfides in the solid state were examined by Colombo et 
al.220  In the oxidation of two sulfides mounted on solid support resins, oxaziridine 1.125 
outperformed the Ti-tartrate based catalyst systems of Kagan and Modena in regard to yield and 
enantioselectivity.  Sulfoxides 1.128 and 1.129 were both obtained in high yield and 
enantioselectivities (Scheme 1.42).  
 
 
Scheme 1.42 
 
Davis et al. also investigated sulfonyloxaziridines derived from benzothiazole, such as 1.130, 
but found them to be less effective than oxaziridines reported previously, with the  
(2S,3R)-1.130 isomer generally performing better than its epimer.221  Using these oxaziridines 
methyl 9-anthryl- and nbutyl p-tolyl sulfoxides were afforded in up to 53% and 19% ee, 
respectively.  Davis and coworkers also investigated the preparation and utilization of exo-
camphorylsulfonyloxaziridines such as 1.131, however they were found to give sulfoxides with 
low optical purities (5-17% ee). 222 
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Meladinis et al. prepared a series of oxaziridines from 8-camphorsulfonic acid, including 1.132, 
and applied them in asymmetric oxidations of prochiral sulfides.  (S)-Methyl phenyl sulfoxide 
1.106 was afforded in high yield and optical purity (Scheme 1.43).   
 
 
Scheme 1.43 
 
Page et al. was the first to report the catalytic enantioselective oxidation of sulfides using an 
imine derived oxidizing agent that was generated in situ.223  This methodology involved the 
employment of an enantiomerically pure camphorsulfonylimine under basic conditions, with the 
generation of a highly oxidiative species from H2O2 and the imine derivative.  Oxidations were 
performed in the presence of an organic base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU), which prevented any non-enantioselective oxidation of the sulfide substrate by the 
peroxide.  Initial investigations of this system saw oxidations giving sulfoxides in moderate to 
high yields but modest enantioselectivities (Scheme 1.44).  
 
37 
 
 
Scheme 1.44 
 
Further investigations by Page et al. found that the catalysts produced from H2O2 and imines 
1.134 and 1.135 gave sulfoxide products with high enantioselectivity (82 and 85% ee, 
respectively) (Scheme 1.45).9  
 
 
Scheme 1.45 
 
The sense of enantioselectivity observed using this system was initially observed to be the 
opposite of that obtained when using the oxaziridine 1.122 prepared from 1.136.  Page et al. 
surmised from this that the active oxidizing agent generated must be the -hydroperoxyamine 
1.137, and that the sulfide oxidation must travel via pathway A, rather than via pathway B 
which involved oxidation by the in situ derived oxaziridines 1.122 (Scheme 1.46).9, 224   
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Scheme 1.46 
 
Subsequent studies compared the action of the catalyst system of imine 1.134 with that of the 
derived oxaziridine 1.138 and, in contrast to previous reports, found that they gave sulfoxides 
with the same sense of chirality, suggesting that they should have a similar reactive 
intermediate.225 224   
 
 
 
Like Davis et al. Page and coworkers explored benzisothiazole based structure for use in 
asymmetric sulfoxidation.226  The catalyst generated from H2O2 and imines 1.139-1.143 gave 
sulfoxides of low optical purities (up to 38% ee).  Using the oxaziridine derived 1.143 
oxidations were performed on a range of sulfides and dithianes, from which the monooxidation 
products of 2-phenyl-1,3-dithiane was afforded in 83% ee.  Comparison of the 
enantioselectivity of the oxidations using the oxaziridine and those which used the imines 
showed a similar sense of asymmetric induction between the two methods.226   
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Schoumacker et al. reported a new and easily accessible chiral N-alkyloxaziridine such as 1.144 
and 1.145, which could be activated by protons or by a Lewis acid, specifically ZnCl2. Alkyl 
aryl sulfoxides were generated in moderate to good optical and chemical yields through the use 
of 1.2 equivalents of both oxaziridine and ZnCl2; the best result came from the oxidation of 
methyl naphthyl sulfide by oxaziridine 1.145 which gave the corresponding sulfoxide in 60% 
yield and 63% ee.    
 
 
 
Oxaziridine salts 
In 1988 Hanquet et al. reported the successful development of acid promoted oxygen transfer 
catalyst, allowing selective oxidation of sulfides to racemic sulfoxides. 227  This system was 
later developed for asymmetric sulfoxidation.  Chiral oxaziridinium salts were prepared from 
(1S,2R)-norephedrine and could be in a stoichiometric or substoichiometric amounts to effect 
oxidation of sulfides.  Oxidation of methyl p-tolyl sulfide was performed by use of 
oxaziridinium 1.146, or the neutral form 1.147, affording the sulfoxide product in 32% and 43% 
ee, respectively.228, 229   
 
 
 
Hanquet et al. also developed N-alkyl binaphthyl derived oxaziridines, such as 1.148, for use in 
acid promoted sulfoxidations of dialkyl or alkyl aryl sulfides.230  Good yields were achieved, 
with no formation of the sulfone overoxidation products observed.  Enantioselectivities of 
between 20-88% ee were achieved, with the configuration of the sulfoxides dependent on the 
structure of the sulfide substrate.  Enantiomerically pure imines, arising from oxygen transfer 
from the oxaziridine, could be recovered in yield up to 90%, and reused.   
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The novel oxaziridine salt 1.149, derived from cholesterol was employed by Bohé et al. as an 
oxidizing agent in the enantioselective oxidation of sulfides with impressive results.231  
Sulfoxides were obtained in good yields and high optical purities, with (R)-methyl p-tolyl 
sulfoxide afforded in 88% yield and > 99% ee; (R)-benzimidazole sulfoxide was obtained also 
in high enantioselectivity (98% ee), but in a lower yield (57%) (Scheme 1.47).  
 
 
Scheme 1.47 
 
Isoquinolinium salts 
The isoquinolium salt 1.150 was prepared by Rozwadowska et al. and applied in the 
enantioselective oxidation of methyl p-tolyl sulfide to the corresponding (R)-sulfoxide.  
Examining a range of reaction conditions, sulfoxide 1.48 was obtained in moderate to high 
yields and low to moderate optical purity (Scheme 1.48).  The use of mCPBA as the oxidant 
lead to racemic sulfoxides, or products with very low enantiopurity.   
 
 
Scheme 1.48 
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N-phosphinoyloxaziridines 
Boyd et al. reported the use of N-phosphinoyloxaziridines 1.151 and 1.152 in the asymmetric 
oxidation of methyl p-tolyl sulfide and alkyl 9-anthryl sulfides.232  Sulfoxides with moderate to 
high optical purities were obtained, with the (S)-nbutyl 9-anthryl sulfoxide afforded by 1.152 
with the highest enantioselectivity (70% ee).  The configuration of the sulfoxide products was 
observed to be dependent on the oxaziridines configuration, with 1.151 giving (R)-sulfoxides, 
whilst 1.152 gave (S)-sulfoxides; the configuration at phosphorus was determined not to exert 
any influence on the enantioselectivity of the oxidation reactions.  
 
 
 
Hypervalent iodine compounds 
The oxidation of sulfides by iodine, or iodine based compound has been known since the 
1960s.233  Imamoto reported the application of the trivalent chiral iodine reagent 1.153, 
generated by the reaction between iodosylbenzene with a derivative of L-tartaric anhydride, in 
the asymmetric oxidation of sulfides.
234
  Moderate enantioselectivity was observed for the 
oxidation of aryl methyl sulfides (up to 53% ee) but aliphatic sulfoxides were furnished in poor 
optical purities. 
  
 
 
Tohma et al. employed the hypervalent iodine(V) reagent iodosybenzene (PhIO2) in a cationic 
reversed micellar system suitable for sulfide oxidations.235  Aryl alkyl (S)-sulfoxides were 
achieved in high yields and moderate to good enantioselectivities, with the addition of catalytic 
amounts of cetyltrimethylammonium bromide (CTAB) and the chiral tartaric acid 1.154 
indispensible for enhancement of optical and chemical yields, the former especially for its 
ability to solubilize and activate PhIO2.  Quideau and Ozanne-Beaudenon used similar 
conditions for the oxidation of methyl p-tolyl sulfide, using a stabilized version of 2-
iodoxybenzoic acid (IBX) called SIBX, composed of IBX (49%), benzoic acid (22%), and 
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isophthalic acid (29%).  Using 1.154 as the source of chirality, methyl p-tolyl sulfoxide was 
obtained in 81% yield, 50% ee (Scheme 1.49).236   
 
 
Scheme 1.49 
 
Tohma et al. also developed a new catalytic enantioselective sulfoxidation that could be 
conducted in water using MgBr2 and (+)-dibenzoyl-tartaric acid, both in substoichiometric 
amounts.237  (R)-Sulfoxides were obtained in high yield but moderate optical purities (Scheme 
1.50), complementing the stereoselectivity of the catalyst system previously developed.      
 
 
Scheme 1.50 
 
Zhdankin et al. also developed a number of iodine based oxidizing agents for sulfoxidation 
reactions.238, 239  The novel amino acid derived benziodazole oxides 1.156-1.159 were amongst 
the first to be developed, and were analogous to the Dess-Martin periodinane (DMP) 1.160 and 
IBX 1.161.  Compounds 1.156-1.159 offered a better safety profile and greater solubility in 
non-polar organic solvents compared to oxidizing agents 1.160 and 1.161, and could easily be 
prepared from commercially available precursors.  Employment of the oxidizing agents 1.156-
1.158 saw methyl phenyl sulfoxide achieved in high yield (90-92%) but low enantioselectivity 
(11-16% ee); the configuration of the afforded sulfoxide was not discussed.240   
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Zhdankin later developed a chiral pseudo-benziodoxazine derivative prepared from  
(S)-proline.  N-(2-Iodyl-phenyl)-acylamide 1.162 was found to oxidize p-tolyl methyl sulfide to 
give sulfoxide 1.48 in high yield, but low enantioselectivity (Scheme 1.51).241  
 
 
Scheme 1.51 
 
1.4.2.3.2 Oxidations performed in presence of a chiral catalyst 
 
Cyclodextrins  
Cyclodextrins (CDs) are supramolecular cage molecules created from the enzymic degradation 
of starch.242  These oligosaccharides are formed from 6, 7,or 8 glucose units (-, -, and -CD 
respectively) and feature a hydrophobic cavity that can encapsulate other molecules.102, 242  The 
use of cyclodextrins to mediate asymmetric sulfoxidations was first reported by Czarnik in 
1984.243  Using mCPBA the oxidation of sulfide 1.163 was carried out in the presence of -CD, 
giving sulfoxide 1.164 in 34% ee (Scheme 1.52), which at the time was comparable to the 
highest asymmetric induction reported for a chemical sulfoxidation reaction.210 Drabowicz and 
Mikołajczyk also reported the synthesis of optical enriched sulfoxides using -cyclodextrins, 
with H2O2 as the oxidant, achieving enantioselectivities up to 30% ee.
244   
 
 
Scheme 1.52  
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Surendra investigated enantioselective sulfoxidations using N-bromosuccinimide in the 
presence of -CD.245  Good chemical yields were obtained but asymmetric induction was poor  
(< 10% ee).  Mojr et al. employed flavin-cyclodextrin conjugates such as 1.165 and 1.166 to 
catalyze sulfoxidations of methyl aryl sulfides with H2O2.
246, 247
  Catalyst loadings as low as 0.2 
mol% were employed, with high conversions and modest to high enantioselectivities achieved 
(up to 80% ee).  
 
 
 
Flavins 
A number of flavin-based species have been involved in asymmetric sulfoxidation reactions.248  
In 1988, Toda reported flavin mediated synthesis of enantioenriched sulfoxides using the chiral 
flavin 1.167, which acted as an asymmetric autorecycling oxygenation catalyst.249   
 
 
 
The catalyst was capable of performing up to eight turnovers, producing methyl aryl sulfoxides 
in modest to good enantioselectivities, the highest of which was 65% ee for (R)- methyl p-tolyl 
sulfoxide.  A structurally related capped flavin 1.168 was prepared by Murahashi, which was 
used to prepare the naphthyl sulfoxide 1.169 in 72% ee (Scheme 1.53).250 
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Scheme 1.53 
 
More recently, Jurok et al. have reported their use of non bridged chiral flavinium salts 1.170 to 
mediate the oxidation of a range of sulfide substrates; methyl 2-naphthyl sulfoxide 1.169 was 
produced in 54% ee using this approach.251, 252  Yashima and coworkers prepared the novel 
optically active riboflavin polymer 1.171, and used it to catalyze three model sulfide substrates.  
Methyl p-tolyl sulfoxide was obtained in 60% ee, representing the highest enantioselectivity 
reported for the catalyst; this result was most favourable compared to the monomeric flavin 
counterpart, which only achieved a maximum enantioselectivity of 30% ee.   
   
 
 
Chiral phosphoric acid derivatives  
List and coworkers investigated a series of “confined” Brønsted acids for application in 
asymmetric sulfoxidations.253  The use of imidodiphosphoric acids catalysts 1.172-1.174 in the 
oxidation of thioanisole produced sulfoxides in optical purities up to 98% ee, in some cases in 
quantitative yields.  The efficiency of the reaction was improved by the addition of MgSO4 to 
removed water, shortening the reaction time from 24 h to 2.  A variety of aryl alkyl and dialkyl 
sulfides were oxidized using this system, affording the sulfoxides in high yield and 
enantioselectivity (Scheme 1.54).  The synthetic value of this approach was demonstrated by 
carrying out the key oxidation step in the asymmetric synthesis of Sulindac 1.3, giving the target 
sulfoxide in 95% yield and 98% ee.    
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Scheme 1.54 
 
Asymmetric sulfoxidations catalyzed by BINOL derived phosphoric acids were also reported by 
Liu et al.254  Through screening a range of BINOL derived catalysts 1.175 was found to be the 
most efficient in the oxidation of thioanisole, giving (S)-methyl phenyl sulfoxide in 65% yield, 
78% ee.  Oxidation of a range of sulfides gave the sulfoxides in modest to high yield and good 
to high enantioselectivity, with benzyl phenyl sulfoxide afforded in the highest optical purity 
(82% ee, 68% yield) (Scheme 1.55).   
 
 
Scheme 1.55 
 
Jindal and Sunoj reported oxidations of thioanisole performed in the presence of axial chiral 
BINOL derived phosphoric acid catalysts 1.176-1.178 (Scheme 1.55).255  The sulfoxide product 
obtained using catalysts 1.176 and 1.177 had enantiopurites of 16 and 56% ee respectively 
whereas excellent enantioselectivity was achieved using catalyst 1.178 (98% ee) (Scheme 1.56).  
Tsogoeva and coworkers examined similar BINOL based catalysts for use in the oxidation of 
thioanisole and p-nitro thioanisole.256  Enantioselectivies achieved were modest, with the 
highest achieved being 59% ee.   
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Scheme 1.56 
 
Electrochemical asymmetric oxidation 
In 1976 Firth and Miller reported their attempts at using modified chiral electrodes in order to 
perform enantioselective sulfide oxidations.  The enantioselectivities from these early 
investigation of this method were poor (< 2% ee).257  In the decade following, Komori and 
Nonanka had greater success with electrochemical based sulfoxidations.  Poly(L-valine) coated 
platinum electrodes were used to oxidize phenyl cyclohexyl sulfide, giving the sulfoxide with 
an optical purity of 54% ee and in a 31% yield.258  Subsequent work investigated a range of 
poly(amino acid) coated Pt/graphite electrodes and found poly(valine) to be the most effective 
at mediating this type of reactions.  tButyl phenyl sulfoxide was produced using this method in 
high optical purity (93% ee), a result which compared favourably to those published by Kagan 
and Modena at the time.259   
 
Solid state catalysis 
Taghizadeh performed enantioselective sulfide oxidations using a solid state catalyst system in 
order to synthesis a library of sulfoxide-based Modafinil analogues.260  The catalyst system, 
comprising of functionalised silica-based mesoporous MCM-41 with chiral amino oxazoline, 
Cu(MeCN)4 (10 mol%), and H2O2, was found to afford sulfoxides in enantioselectivities no 
greater than 37% ee.     
 
1.4.2.3.3 Biological asymmetric sulfide oxidations  
 
Biocatalysis provides an alternative to chemical synthesis for the production of enantiomerically 
enriched sulfoxides.  It allows access to the target products in one step, often with high 
enantioselectivity.261  There is little call for reactions to occur under high pressure, or 
temperature, and with water as a common solvent the reaction conditions are typically 
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environmentally benign.4, 262  Biologically mediated sulfide oxidation can be carried out using 
whole cells or through isolated enzyme systems.  A number of reviews with discussions on this 
topic have been published.4, 6, 66, 263, 264  
 
1.4.2.3.3.1 Oxidations using whole cells 
 
The use of whole cells for asymmetric sulfoxidation avoids a number of problems associated 
with the isolation and use of complex enzyme systems.22  Whole microbial cells can be used in a 
resting state, or in an actively growing one.   
 
Fungi 
One of the earliest documentation of whole cell oxidation of a sulfide came from Wright et al. 
who, in 1954, reported the use of Aspergillus niger to convert biotin to the corresponding  
(–)-sulfoxide.  In the decade following, Dodson and Tsuchiya successfully prepared benzyl 
phenyl sulfoxide in 18% ee by oxidation of the sulfide by fermentation with fungus A. niger.265  
Boyd and coworkers reported the production of optically active sulfoxides through treatment of 
various sulfides under aerobic conditions with growing A. niger, or with the material obtained 
by extracing A. niger with acetone.266  Yields of the afforded sulfoxide were generally modest 
(up to 65%) with optical purities of 4-99.5% ee (Scheme 1.57).  It was observed that sulfoxides 
with bulky side group were produced with greater enantioselectivity than those that were less 
sterically demanding ( Scheme 1.56).    
 
 
Scheme 1.57 
 
Biocatalysts found in the fungus Mortierella isabellina ATCC 42613 were observed by Holland 
et al. to mediate the production of a variety of sulfoxide in very high enantiomeric excess.267, 268 
This group also extensively reported investigations into the activity of the fungus 
Helminothosporium sp. NRRL 4671 toward asymmetric sulfoxidation.268-274  Fusarium 
oxysporum and Helminothosporium were employed in the enantioselective oxidation of five 
vinyl sulfides.275  Four sulfoxides were obtained in good to high optical purity (66- 98% ee), 
with the biological oxidation of the sulfides giving better results with regard to 
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enantioselectivity than for oxidations carried out using an oxaziridine reagent or a Kagan type 
titanium based catalyst system. 
 
Filamentous fungi Botrytis cinerea, Eutypa lata, and Trichoderma viride were employed to 
carry out a series of biooxidations of a series of substituted sulfides.  Sulfoxides were produced 
with medium to high enantioselectivity, with the formation of (R)-enantiomers preferentially 
produced by T. Viride and E. Lata, whilst B. cinerea gave sulfoxides with the opposite sense of 
chirality. 276  White rot basidiomycetes were found to promote oxidation of aromatic sulfides, 
producing sulfoxides with good optical purities and only minimal amounts of sulfone. 277  
Basisiomycetes, Irpex lacteus, Pycnoporus sanguineus, Trichaptum byssogenum, Trametes 
rigida, Trametes versicolor and Trametes villosa, all gave exceptionally high enantioselectivity 
(> 99% ee) in the oxidation of phenyl propyl sulfide.  
 
Barth et al. employed fungi Nigrospora sphaerica, Papulaspora immera Hotson, and Mucor 
rouxii in the production of an enantiomerically enriched metabolite of the drug Albendazole 1.9 
(Scheme 1.58).  A study of the effects of pH on the fungi saw the sulfoxide (R)-1.8 produced by 
M. rouxii in 90% ee after 96h of incubation at pH 5.278 
 
 
Scheme 1.58 
 
Bacteria 
The oxidation of antibiotics clindamycin and linomycin by Streptomyces in 1969 was the first 
evidence of bacterial cells being able to perform the biotransofrmation of converting sulfides to 
sulfoxides.279, 280  Adams et al. prepared a number of aryl alkyl sulfoxides using the 
commercially available topsoil bacterium Pseudomonas frederiksbergensis.281  Sulfoxide with 
high enantiomeric excess were achieved (70-99% ee), including methyl p-tolyl sulfoxide which 
was produced in a quantitative yield and high optical purity (> 99% ee). Enantiopure nbutyl 
phenyl sulfoxide was obtained by Ohta et al. using the bacteria Corynebacterium equi IFO 
3730, alongside a variety of other alkyl and allyl aryl sulfoxides with high optical purities (75-
99% ee). 
282-284
  The bioconversion of alkyl aryl sulfides to give sulfoxides with up to 95% ee 
using Gordonia terrae IEGM 136 was reported by Kylosova et al.285  Cells of this bacterium 
were immobilized into a cryogel of polyvinyl alcohol, which reduced the biotransformation time 
from 144h to 12h, in comparison to using free cells.  (R)-sulfoxides were produced using this 
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methodology, with high enantioselectivity (77-95% ee).262  Kylosova et al. also reported their 
use of the bacterium Rhodococcus rhodochrous IEGM 66, which allowed access to 
enantiocomplementary (S)-sulfoxides in up to 89% ee.285   
 
Chen and coworkers used the resting cells of Pseudomonas monteilii CCTCC M2013683, 
isolated from soil samples, to produce chiral sulfoxides, of (R)-configuration, in yield of 54-
99% and enantioselectivities of 63-99%.  (R)-Methyl phenyl sulfoxide was produceding high 
yield and optical purity (99%, 90% ee) using the ethane grown Micrococcus sp. M90C.286  The 
fungus Beauveria bassiana ATCC-7159 was used in the production of 1.181, a key intermediate 
in the synthesis of Modafinil 1.2.  The (S)-sulfinyl carboxylic acid 1.181 was produced in 
enantiopure form and excellent yield 89%; subsequently the sulfoxide was subjected to 
transformation by the bacterium Bacillus niger to convert it to the final amide form, giving 
Modafinil 1.2 in 68% ee, in a quantitative yield (Scheme 1.59). 287 
 
 
Scheme 1.59 
 
Algae 
Microalgae have also proven valuable for their application in asymmetric sulfoxidation.  Whole 
cells of Chlorella sorokiniana were used to oxidise a range of alkyl aryl and dialkyl sulfides, 
resulting in modest yields (up to 67% conversion) and moderate optical purities (up to 58% 
ee).288  The dialkyl sulfoxide products were found to be in the (S)-configurations, while the 
opposite enantiomer was favoured in the alkyl aryls oxidations.   
 
Yeasts 
Yeasts, such as Saccharomyces cerevisiae have been successfully used for the oxidation of 
sulfides to optically active sulfoxides. The low cost and abundance of these microbial species 
make them ideal for application in biotransformation.289  Beecher et al. reported that  
S. cerevisea NCYC 73 and commercially available Allinsons yeast were both active for the 
oxidation of methyl phenyl- and methyl p-tolyl sulfide, but not for 
t
butyl methyl sulfide.
289, 290
  
Both strains of yeast produced the (R)-sulfoxide, complimenting the oxidations performed by 
Beecher et al. on the same sulfide substrates by one or more of the Baeyer Villiger 
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Monooxygenase (BMVO) enzymes present in Psuedimonas putuda NCIMB 10007, which 
afforded sulfoxides in the (S)-configuration.291  
 
1.4.2.3.3.2 Oxidations using isolated enzymes 
 
Peroxidases 
The use of isolated enzymes to catalyze asymmetric sulfide oxidations has attracted 
considerable attention.292-295  Chloroperoxidase (CPO), from the marine fungus Caldariomyces 
fumago, is one of the most versatile of all the peroxidases, and is active towards asymmetric 
sulfoxidation. 292, 296  Early applications of this enzyme gave poor results, as reported by 
Kobyashi et al. with the oxidation of thioanisole by H2O2 occurring to give the corresponding 
sulfoxide in just 13% ee.297  Subsequent research by Colonna and coworkers saw greater 
success; (R)-p-tolyl methyl sulfoxide was obtained in 83% ee using tbutyl hydrogen peroxide 
(TBHP), whereas oxidation by H2O2 resulted in a sulfoxide with an enantiopurity of 37% ee.
42, 47  
Using TBHP to test the generality of C. fumago oxidation, a series of alkyl aryl and dialkyl 
sulfides were examined.  Sulfoxide yields ranging from 7-100% were achieved, with optical 
purities from 19-92% ee.  It was determined that the enantioselectivity of the reaction was 
largely dictated by the steric demands of the sulfide substrate.  Colonna et al. later showed the 
importance of experimental parameters, including the choice of oxidant, for the attainment of 
sulfoxides in high ee and demonstrated the optimized methodology with the oxidation of methyl 
2-pyridyl sulfide, gaining the sulfoxide product in enantiopure form.298  Dialkyl sulfoxides were 
also produced with high conversion and in excellent enantioselectivities; these results were 
comparable to those reported at that time for the oxidation of dialkyl species by Kagan and 
Modena.299  Further optimization to the CPO sulfoxidation methodology was reported by 
Sheldon et al. who obtained excellent optical purities for sulfide oxidations carried out in 
tBuOH–water mixtures.294, 300  High enantioselectivities were reported by Vargas et al. for a 
series of -carbonyl sulfoxides produced using CPO.301   
 
The first asymmetric electroenzymatic oxidation was carried out using electrochemically 
generated H2O2 and catalyzed by CPO from C. fumago.  Using this method, thioanisole was 
oxidised to give the sulfoxide with 99% ee.302  A biphasic system using supercritical carbon 
dioxide was employed as a reaction medium for CPO mediated sulfoxidation.303  Oxidations 
mediated by CPO using H2O2 took place in the aqueous phase, utilizing the oxidant generated in 
situ from H2 and O2 using a Pd-catalyst in the scCO2 phase.  Sulfoxides were achieved in high 
ee (up to 94% ee) albeit in modest yield (up to 34%).  Hollmann et al. reported the light driven, 
in situ production of H2O2 to be used in CPO oxidations of sulfides, involving a flavine 
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photocatalyst and using EDTA as a sacrificial electron donor.304  Methyl phenyl sulfoxide was 
obtained in quantitative yield and 99% ee using this procedure; the use of formate in place of 
EDTA, in order to make the reaction less environmentally damaging, led to a decrease in 
enantioselectivity (78% ee).  Nanobiocatalysts consisting of CPO-coated magnetic nanoparticles 
were utilized by Wang et al. to achieve the asymmetric oxidation of thioanisole to afford the 
(R)-sulfoxide with excellent enantioselectivity (99% ee). 305 
 
Lactoperoxidase was employed for asymmetric sulfoxidation reactions by Tuynman et al.  The 
oxidation of thioanisole took place giving the (R)-sulfoxide in 85% yield and 80% ee.306  The 
performance of the enzyme was reported to improve when the oxidant was added continuously, 
rather than in discrete aliquots. 
 
Studies by Colonna et al. using horse radish peroxidase (HRP) gave sulfoxides with optical 
purities of up to 68% ee.  These results were later improved upon by Ozaki et al. with 
engineered biocatalysts, where one of the amino acids in the HRP enzyme, phenylalanine, was 
replaced with leucine.307, 308  This resulted in a major improvement in enzyme performance, with 
alkyl aryl sulfoxides afforded in > 90% ee in comparison to a maximum of 77% ee when using 
the native enzyme.  A mutant enzyme produced by replacing phenylalanine with threonine gave 
poorer enantioselectivities, with 44% ee being the maximum achieved.   
 
Myeloperoxidase (MPO) and manganese peroxidase (MnP) were examined by Tuynman for 
their application in sulfoxidation reactions.309  Oxidations of thioanisole that were performed 
using H2O2 catalyzed by MPO occurred with low enantioselectivity (23% ee at pH 5, 32% ee at 
pH 6) and gave the sulfoxide product as the (R)-enantiomer.  Conversely, oxidations performed 
using MnP afforded the (S)-sulfoxide in low yields (18-36%) but with high enantioselectivity 
(91% ee at pH 5 and 87% ee at pH 7).  Coprinus cinereus peroxidise was reported to catalyze 
the formation of (S)-methyl phenyl sulfoxide in 84% yield with 73% ee.306   
 
Vanadium haloperoxidases have been well studied and are known to be highly active towards 
asymmetric sulfoxidation and kinetic resolution of racemic sulfoxides.310, 311  Vanadium 
bromoperoxidase (VBrPO) show great stability towards high temperature and the presence of 
organic cosolvents.312, 313  Andersson and Allenmark investigated the catalytic effect of VBrPO 
from the algae Corallina officinalis in the H2O2 oxidation of prochiral sulfides.
314, 315  Their 
initial finding showed the preferential oxidation of a series of rigid, bicyclic sulfides to the (S)-
enantiomer of the corresponding sulfoxides, which was in contrast to the enantioselectivity 
exhibited for the oxidations performed using CPO.316  High activity was displayed by VBrPO, 
with 2,3-dihydrobenzo[b]thiophene oxidized quantitatively with 98% ee; substrates with a cis-
53 
 
positioned carboxyl group were rapidly oxidized, with sulfoxide obtained with > 95% ee.  Loss 
of enantioselectivity was observed in the presence of bromide ions, suggesting a competing 
reaction involving the oxidation of bromine.  Wever et al. showed that haloperoxidases slowly 
mediated the oxidation of methyl and p-tolyl phenyl sulfide, as well as 4-methoxy thioanisole to 
the corresponding sulfoxides.311  VBrPO from brown seaweed Ascophyllum nodosum was used 
to obtain (R)-methyl phenyl sulfoxide in 88% ee. In contrast, when VBrPO from red seaweed 
Corallina pilulifera was employed the enantioselectivity was reversed, and (S)-methyl phenyl 
sulfoxide was afforded in 55% ee; CPO from Curvularia inaequalis employed for the same 
reaction gave only a racemic mixture.311   
 
 Monooxygenases 
A number of Baeyer Villiger monooxygenases (BVMOs) have been to act as catalysts for 
asymmetric sulfide oxidations.317-320 4-Hydroxyacetophenone monooxygenase (HAPMO), a 
novel BVMO from P. Fluorescens ACB was found convert phenyl and benzyl sulfides to the 
corresponding (S)-sulfoxides with excellent optical purities (up to 99% ee) and conversions up 
to 97%; allyl and vinyl sulfoxide were obtained in conversions close to 70% with 98% ee.  The 
high levels of optical purity was reported to be solely due to the asymmetric oxidation process, 
with no additional kinetic resolution of the afforded sulfoxides.317  BVMO oxidations of 
heteroatom sulfides, using HAPMO, phenylacetone monooxygenase (PAMO), or a PAMO-
mutant (M-PAMO) were reported by Gotor et al.320  HAPMO gave the best results, with 
excellent enantioselectivity (> 99% ee) but with great variation in conversions (11-99%). 
Borderwick et al. tested eight variants of Yarrowia monooxygenase for efficiency in 
sulfoxidation and found that optical purities of up to 99% ee were achievable for the oxidation 
of methyl p-tolyl sulfide and methyl phenyl sulfide.318  Some variants however showed no 
reactivity towards the sulfides substrates at all.  Recently, a BVMO has been successfully 
employed in the manufacture of a chiral sulfoxide drug intermediate on a kilogram scale.319     
 
Cyclohexanone monooxygenase (CMO) from Acinetobacter is another enzyme line that has 
been well studied with respect to enantioselective oxidation of sulfides321-323  Colonna et al. 
studied the sulfoxidation of numerous alkyl aryl and alkyl sulfides and found that CMO produce 
a mixture of (S)- and (R)-sulfoxides in extremely high optical purities, with moderate to high 
yields.324  (R)-methyl phenyl sulfoxide was produced in 99% while using the same enzyme 
produced (S)-ethyl p-fluorophenyl in 93% ee.  Subsequent studies extended the substrate scope 
to include sulfides with alkyl chains substituted with CN, Cl, vinyl, or hydroxyl groups.  Optical 
purities of up to 99% ee were found, with yields of up to 95%.321, 325  From the results of 
oxidations of over 30 sulfide substrates Colonna and coworkers developed an active site model 
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to explain and predict the enantioselectivity of sulfoxidation reactions mediated by CMO from 
Acinetobacter NCIB 9871.322   
 
A cytocrome P450 monooxygenase from Rhodococcus sp. ECU0066 was used by Zhang et al. 
the the oxidation of ranage of aryl alkyl sulfides, producing (S)-sulfoxides with good to high 
enantiomeric excesses (64-99% ee).326  Subsequent investigations improved the methodology 
with the use of a biphasic organic–aqueous solvent system; (S)-phenyl methyl sulfoxide was 
achieved with 99% ee using this system which showed a marked improvement on the 
enatioselectivity of the single phase system which gave the sulfoxide in 60% ee.327   
 
Studies by Brand et al. showed that naphthalene dioxygenase (NDO) from Pseudomonas sp. 
NCIB 9816-4 produced sulfoxides in the (S)-configuration from the asymmetric oxidation of 
alkyl aryl sulfides.328 In contrast, toluene dioxygenase (TDO) from Pseudomonas pudita F1 
produced sulfoxide of varying enantioselectivity and absolute configuration, which seemed to 
be dependent on the p-substituent on the aromatic ring system.  This study showed that the 
dioxygenase component of NDO and TDO could function as sulfoxidases, whereas previously 
asymmetric sulfoxidations has only been inspected using intact cells of different bacteria 
expressing NDO and TDO.  Extensive studies on NDO and TDO have also been reported by 
Boyd and coworkers, who employed P. pudita UV4 and NCIMB 8859, producing sulfoxides in 
enantioselectivities of > 98% ee.328-332 
 
Tyrosinase 
Colonna and coworkers found that mushroom tyrosinase Agaricus bisporus was active in 
sulfoxidations reactions; with the use of a catechol as the reducing agent, the oxidation of 
thioansole was catalyzed by tyrosinase to give the (R)-sulfoxide with high ee (> 80% ee), albeit 
in low yield (< 20%).  The low yield was believed to be due to the catechol competing with the 
sulfide in the oxidation reaction.333 334    
 
1.4.2.3.3.3 Oxidations in the presence of bovine serum albumin  
 
Sugimoto reported the oxidation of aromatic sulfides performed by sodium metaperiodate in the 
presence of bovine serum albumin (BSA), a carrier protein in biological systems.335  Sulfoxides 
were obtained in good yield and high enantioselectivity, with the highest optical purity achieved 
for the oxidation of sulfide 1.182, giving (R)-1.183 in 81% ee (Scheme 1.60).       
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Scheme 1.60 
 
Monooxidation of di-p-tolyl dithioacetal 1.184 was reported by Ogura; sodium periodate was 
used a the oxidant in the presence of BSA, with a two phase aqueous–organic solvent system in 
employment.336  The (S)-sulfoxide 1.185 was obtained in good ee but only modest yield (30%, 
60% ee) (Scheme 1.561).  Expansion of the substrate scope to include alkyl aryl sulfides saw 
ipropyl phenyl sulfoxide 1.183 produced with similar enantioselectivity (60% ee) but in greater 
yield (76%).   
 
 
Scheme 1.61 
 
Under similar conditions to those used by Sugimoto, Colonna et al. performed BSA catalyzed 
oxidations on a range of aryl alkyl sulfides featuring carbonyl groups on the alkyl chain.  BSA 
was used in a catalytic amount (5 mol%) alongside two equivalents of the oxidant to furnish 
sulfoxides with enantioselectivities of up to 70% (Scheme 1.62).  Interestingly, when H2O2 was 
used in place of NaIO4 the (S)-enantiomer of ester 1.186 was obtained instead of the (R)-
enantiomer previously given.   
 
 
Scheme 1.62 
 
Colonna and coworkers also reported on the oxidations of aryl alkyl sulfides using in situ 
generated dioxiranes, catalyzed by BSA.  Sulfoxides were achieved in enantioselectivities up to 
89% ee and with good yields.337  Subsequent oxidations of prochiral keto sulfide, where the 
carbonyl functional group served as the dioxirane precursor, gave (S)-sulfoxides in up to 84% 
ee.338   
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1.5 Summary 
 
Sulfoxides are an important and useful functional group for many synthesis processes.  
Biologically active sulfoxides are found in a number of natural products and pharmaceuticals.  
As such a great deal of interest has been directed toward the development of new methods for 
the synthesis of sulfoxides, particularly those in high optical purity.  Anyone wishing to pursue 
the asymmetric synthesis of a chosen sulfoxide would have a wide range of methods to do so 
by, each with its own inherent advantages and disadvantages. 
 
Resolution of racemic enantiomers can be simple and rapid, but can also be wasteful and low 
yielding unless the undesired enantiomer can be reused or epimerized.  Chromatographic 
methods can provide materials in high enantiopurity but are unsuitable on a larger scale and can 
be wasteful in terms of solvent use.   
 
Alongside resolution techniques, there are a wide range of chemical methodologies for the 
synthesis of chiral sulfoxides.  One of the most effective methods is enantioselective oxidation; 
in this chapter a variety of non-metal based processes have been presented.  Biological 
oxidations are known to produce sulfoxides in excellent enantiopurity but can be highly 
substrate specific.  Enantiomerically enriched sulfoxides have been successfully produced using 
chiral oxidants such as chiral hydroperoxides, oxaziridines and oxaziridinium salts, and 
hypervalent iodine compounds amongst others.   
 
Catalytic methods, using non-metal based reagents have also been utilized for the synthesis of 
chiral sulfoxides.  Cyclodextrins, flavins, and derivatives of phosphoric acid have been used in 
tandem with oxidants such as mCPBA and hydrogen peroxides to afford sulfoxides in high 
enantiopurity.  Although these methods have proved useful in the formation of enantiomerically 
enriched sulfoxides, most require additional steps for the initial synthesis of the chiral oxidant or 
chiral catalyst.   
 
Chiral auxiliaries have been employed to produce optically enriched sulfoxides for well over 50 
years.  This method build of the pioneering work of Andersen et al. and allows for separation of 
diastereomeric sulfinates and sulfinamides which can then be transformed to single enantiomer 
sulfoxides through reaction with various Grignard reagents.  Despite the success of this method 
there is a reliance on the ability to create and separate the diastereomeric intermediates 
 
Despite the great amount of interest in the production and utilization of sulfoxides, particularly 
over the past three decades, there still remain a number of challenges in this area.  Many of the 
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current methods employing non-metal based reagents require stoichiometric amounts of the 
auxiliary.  It is likely that future developments in the synthesis of sulfoxides, particularly in the 
single enantiomer form, will look toward greener and more sustainable methodologies.   
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2 Introduction: Metal-catalyzed asymmetric sulfide oxidation 
2.1 Titanium-catalyzed S-oxidations 
 
Sharpless asymmetric epoxidation (SAE): The origin of Ti/tartrate mediated asymmetric 
sulfoxidation 
In 1980 a major breakthrough in the area of asymmetric oxidation occurred when Sharpless and 
Katsuki reported a new chiral epoxidation system.339-341  A chiral titanium complex prepared 
from Ti(OiPr)4 and optically pure diethyl tartrate (DET) in a 1:1 ratio was employed to effect the 
asymmetric epoxidation of allylic alcohol using tbutyl hydroperoxide (TBHP).  This system was 
found to give uniformly high asymmetric induction in a range of allylic alcohol substrates  
(> 90% ee), with consistent enantiofacial selectivity depending on the choice of (–)-(S,S)- or  
(+)-(R,R)-DET (Scheme 2.1). 
 
 
Scheme 2.1 
 
For the epoxidation of less reactive substrates one equivalent of both Ti(OiPr)4 and tartrate were 
required to achieve reasonable reaction rates.  However, for more reactive substrates sub-
stoichiometric amounts (e.g. 0.1 equiv) of both Ti(OiPr)4  and DET were sufficient.  The use of 
anhydrous TBHP was an important requirement in order to achieve high enantiomeric purity, 
and was achieved by the use of molecular sieves.342  The asymmetric epoxidation product of 
(E)--phenylcinnamyl alcohol was afforded in 99% ee.  In contrast, the addition of one 
equivalent of water resulted in only 48% ee being obtained.342  The mechanism of the SAE has 
been widely studied, particularly with respect to the structure of the active catalyst species.343, 344  
Although an unexpected diversity in the binding modes of the tartrate ester ligands and 
titanium(IV) was observed, the dominant complex species arising from Ti(OiPr)4 and the dialkyl 
tartrate esters was shown to be [Ti(tartrate)(OR)2]2, for which a number of structures, such as 
2.1-2.3,  were proposed.  On the basis of solid state studies on similar binuclear vanadyl tartrate 
complexes structure 2.2, with five-coordinate Ti atoms, was originally thought to be the correct 
Ti-tartrate structure.345  However, as a result of X-ray structure analysis of analogous Ti-
tartramide species it was decided that conformation 2.3 was a truer representation of the active 
catalyst species.346-348 
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The [Ti(tartrate)(OR)2]2 catalyst species is formed via addition of the chiral tartrate resulting in 
the displacement of four molecules of iPrOH (Scheme 2.2).  The bidentate tartrate diol has a 
higher binding constant for titanium in comparison to the individual isopropanol ligands; 
therefore the equilibrium of the reversible displacement reaction lies far to the right.  The use of 
a 10 mol% excess of tartrate to Ti(IV) alkoxide is also important in promoting the desired 
reaction equilibrium and is vital in order to achieve the highest possible enantioselectivity. 
 
 
Scheme 2.2  
 
The oxidizing agent and allylic alcohol coordinate to the same Ti centre, displacing a further 
two iPrOH molecules, and forming the loaded catalyst.  The hydroxyl group on the substrate 
provides a handle, directing the enantiofacial selectivity of the oxygen delivery to the lower face 
of the alkene as drawn (Scheme 2.3).349, 350   
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Scheme 2.3  
 
The Kagan and the Modena Sulfoxidation Methodologies 
Following the success of the SAE methodology, the application of chiral titanium(IV) tartrate 
complexes to the asymmetric oxidation of sulfides has been extensively studied.341  In 1984 
Kagan et al. reported that employment of the classical Sharpless reagent in the oxidation of 
methyl p-tolyl sulfide led to the racemic sulfoxide 1.48 (41%) and respective sulfone (17%); the 
addition of one equivalent of water dramatically increased the enantioselectivity of the 
sulfoxidation reaction to 84% ee; the use of a second equivalent of tartrate was found to further 
improve the optical purity of the afforded sulfoxide (90% ee) (Scheme 2.4).347  It was proposed 
that the addition of water to the classical Sharpless reagent (1:1 Ti(OiPr)4:tartrate) induced a 
change in the structure of the active catalyst species.  As titanium alcoholates are known to 
hydrolyze to give TiO2 species, via the formation of Ti-OH, it was thought it was unlikely that 
water was acting as a ligand, instead the addition of water led to hydrolysis of a Ti-OiPr bond 
with formation of a -oxo bridge between dimers (Ti-O-Ti); the possible formation of 
oligomeric species containing multiple -oxo bridges was also hypothesized.347, 351 347  
 
In the same year, the Modena group independently reported the use of 1:4 ratio of 
Ti(OiPr)4:(R,R)-DET to obtain sulfoxides in satisfactory chemical yields (41-99%) and moderate 
to good enantioselectivity (14-88% ee) (Scheme 2.4).352, 353  Investigation of the Modena 
catalyst system by Kagan et al. revealed that under strictly anhydrous conditions a 1:4 ratio of 
Ti(OiPr)4:(R,R)-DET afforded nearly racemic sulfoxides, which indicated the additional 
equivalents of tartrate employed by the Modena group may have inadvertently introduced water 
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to the system and it was proposed that both groups were in fact investigating the same 1:2:1 
Ti(OiPr)4:(R,R)-DET:H2O composition in their sulfoxidation reactions.
36, 354   
 
 
Scheme 2.4 
 
Subsequent studies by the Kagan group found their modified Sharpless reagent to be applicable 
in the asymmetric oxidation of a wide range of sulfides with consistent enantiofacial 
selectivity.47, 354  A relationship between the absolute configuration of the chiral tartrate and that 
of the product sulfoxide was established with the stereochemical outcome of such reactions 
attributed to the steric effects of the substituents on the sulfide (Scheme 2.5).   
 
 
Scheme 2.5 [L] = large, [S] = small 
 
A tentative mechanism for the asymmetric oxidation of sulfides with the water modified 
titanium reagent was proposed (Scheme 2.6) based on electron spectroscopy for chemical 
analysis (ESCA) studies on a solution of Ti(OiPr)4 in isolation or with various other components 
of the catalyst system (DET, H2O, TBHP).  The ESCA studies revealed an immediate change in 
the coordination geometry of the Ti(OiPr)4, which is tetrahedral, to an octahedral Ti species after 
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addition of DET; the octahedral structure of such a species may be accounted for by DET acting 
as a tridentate ligand similar to that shown in Figure 2.1.  Vicinal titaniums, which may be 
expected from a Ti2O2 cores were not detected indicating an open or highly mobile complex 
structure.183  
 
 
Scheme 2.6  Note: possible coordination between ester groups and the titanium centre have been omitted for 
clarity 
 
A transition state model for the asymmetric oxidation of methyl p-tolyl sulfide was proposed, 
consisting of a dimeric titanium-tartrate complex, proposing a bimetallic complex with the 
assumption that one tartrate acts as a tridentate ligand, and with the sulfide nucleophile 
attacking along the O-O bond of the coordinated peroxide (Figure 2.1).  
 
 
Figure 2.1 
 
Attempts to apply the Kagan reagent in substoichiometric amounts, with respect to the sulfide 
substrate, yielded sulfoxides in poor optical purity which was attributed to the inhibitory effect 
of the product sulfoxide which are known to be good ligands for titanium alcoholates.351  
However, the use of cumene hydroperoxide (CHP) as the oxidant allowed the titanium-tartrate 
complex to be used in a reduced amount (20-50 mol%) without loss of enantioselectivity.355  A 
further reduction in catalyst loading, to 10 mol%, was achieved when iPrOH was used in place 
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of water in the preparation of the Kagan Ti-tartrate complex, with the addition of molecular 
sieves, thought to regulate the amount of water present in the system. An optimized ratio of 
1:4:4 of Ti(OiPr)4:(R,R)-DET:
iPrOH with 4Å MS led to the formation of methyl p-tolyl 
sulfoxide in 77% chemical yield and 96% ee.  The application of a water and iPrOH free reagent 
comprising of Ti(OiPr)4 and (R,R)-DET (1:2 equiv with respect to the substrate, 10 mol% 
catalyst loading)  was found to afford the sulfoxide product with 7% ee.355  A modified catalytic 
cycle was proposed for the oxidation of sulfides with the new iPrOH modified Kagan reagent 
(Scheme 2.7).355  The active catalyst complex was proposed to be the monomeric titanium 
species 2.4, formed from the dimeric species 2.5 in the presence of iPrOH (Scheme 2.7).  The 
addition of iPrOH in the reaction mixture was believed to permit catalyst turnover by 
displacement of the sulfoxide in 2.6 to reform 2.4, thus enabling the use of the modified  
Ti-tartrate reagent in substoichiometric amounts.  This reaction mechanism however remains a 
matter of debate, as does the structure of the active catalyst species most likely due to the 
complex mixtures of equilibrating species involved.356, 357 
 
 
Scheme 2.7  
 
Applications of Titanium/Tartrate Catalyzed S-Oxidation 
Titanium tartrate catalyst systems are a popular choice for the asymmetric oxidation of sulfides.  
The components of the system are inexpensive and readily available, with a range of alkyl 
tartrates to choose from and the option of either enantiomer of the ligand to enable to production 
of the sulfoxide isomer of choice.  There is also the opportunity for fine tuning the system 
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through the variation of reagent ratios and/or the use of additives.  This methodology is popular 
for the preparation of pharmaceutical ingredients, from discovery stage through to a multi 
kilogram scale.  The blockbuster drug Esomeprazole (S)-1.1 is prepared by a modified Kagan 
protocol developed by von Unge et al. using a catalyst system of Ti(OiPr)4:(S,S)-DET:H2O in 
ratios of 0.3:0.6:0.1 equiv with respect to sulfide.  Cumene hydroperoxide (CHP) was employed 
as the oxidant; the base diisopropylethylamine (DIPEA) as an additive was found to be 
necessary for attainment of high enantioselectivity.  This catalyst system and the synthesis of 
Esomeprazole (S)-1.1 shall be discussed further in subsequent chapters.   
 
 
 
Kagan et al. used a titanium-tartrate catalyst system in the synthesis of RP73163 (S)-2.7, a 
metabolite of the potent ACAT inhibitor 2.8; of the two possible sulfoxide enantiomers only the 
(S)-isomer was found to exhibit bioactivity hence the requirement for an asymmetric synthesis 
suitable for potential scale up.358  Direct oxidation of imidazole sulfide 2.8 using a 
stoichiometric amount of the catalyst system Ti(OiPr)4:(S,S)-DET:H2O (1:2:1 equiv with respect 
to the sulfide substrate) gave sulfoxide 2.7 in good yield but as a racemic mixture.  An 
alternative route to (S)-2.7was found which involved asymmetric oxidation of the p-methoxy 
benzyl- (PMB) protected sulfide 2.9, followed by transformation of sulfoxide (S)-2.10, 
exploiting the acidic nature of the protons - to the newly formed sulfoxide centre (Scheme 
2.8). 
 
 
Scheme 2.8 
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S-oxidation was found to proceed efficiently using the original catalyst conditions 
(Ti(OiPr)4:(S,S)-DET:H2O 1:2:1) to give sulfoxide (S)-2.10 in 71% yield, with excellent 
enantiopurity (98-99% ee).  In order to minimize the use of the (then) expensive unnatural (S,S)- 
form of the tartrate ligand the conditions were optimized and catalysis of the oxidation was 
achieved using modified, anhydrous conditions of 0.5 mol equiv of Ti(OiPr)4 and 1 mol equiv 
(S,S)-DET  to afford the sulfoxide (S)-2.10 in high ee (98-99% ee) and high yield (75%) after 
one recrystallization and requiring no chromatography.  Subsequent reactions allowed target 
sulfoxide RP73163 (S)-2.7 to be eventually achieved in > 99% ee.  Having been successfully 
scaled up to a multikilogram scale, the synthesis of RP 73163 (S)-2.7 represents one of the 
earliest examples of a large scale asymmetric sulfoxidation.   
 
Sulindac 1.3 has been prepared in both enantiomeric formed by Maguire et al. using Kagan 
procedure.359  Asymmetric oxidation of sulfide 2.11 was carried out with CHP in the presence of 
Ti(OiPr)4:DET:H2O 1:2:1 at -30C for 12h.  Using (R,R)- or (S,S)-DET as the chiral ligand 
afforded sulfoxide 2.12 in 89% and 90% ee respectively (yields 54-56%) (Scheme 2.9).   
 
 
Scheme 2.9 
 
Senanayake and coworkers screened a range of S-oxidation catalyst conditions as part of a 
program toward developing a scalable synthesis of dihydropyrimidines bearing chiral sulfoxide 
groups (Scheme 2.10).360  Methodologies developed by Kagan and by Modena were 
investigated (entries 1 and 2, Table 2), as well as those reported by von Unge for the 
asymmetric synthesis of blockbuster drug Esomeprazole (entry 3).125  Of the Ti-tartrate catalyst 
systems examined, the Kagan protocol gave the target sulfoxide in excellent yield, with the 
highest enantioselectivity (73% ee).   
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Scheme 2.10 
 
entry 
Ti(OiPr)4:(S,S)-DET / 
equiv 
Additive  
(equiv) 
CHP / 
equiv solvent 
T (C) / 
time (h) 
Isolated 
yield (%) 
%ee 
(config) 
1 1:2 H2O (1) 2 CH2Cl2 -20 / 24 99 73 (S) 
2 1:4 - 2 CH2Cl2 -20 / 24 99 31 (S) 
3 0.3:0.6 
H2O (0.1) 
DIPEA (0.3) 
1 toluene 35 / 24 90 1 (S) 
Table 2.1 DIPEA = diisopropylethylamine 
 
The asymmetric synthesis of the selective estrogen receptor modulator 2.15, with the 
stereoselective formation of key intermediate 2.16 was carried out via a modified Kagan 
oxidation of vinyl sulfide 2.17.361  Ligand screening showed that diisopropyl tartrate (DIPT) was 
best for induction of asymmetry with sulfoxide 2.16 afforded in 38% ee; this figure was 
significantly improved with further optimization, with great increase in ee values upon addition 
of diisopropylethylamine (DIPEA) to the catalyst mixture. The catalyst was used in a 
substoichiometric loading (15 mol%) with Ti(OiPr)4:DIPT:H2O:DIPEA ratios of 1:2:1:2. The 
order of addition of reagent held significant importance with respect to efficacy of the catalyst 
system, and reproducibility of the ee.  Optimal conditions saw addition of Ti(OiPr)4 to a solution 
of the tartrate ligand, DIPEA, and water in THF; aging of the catalyst system overnight was 
followed by addition of the sulfide 2.17, and finally addition of CHP.  This procedure was 
carried out on a multikilogram scale, with sulfoxide 2.16 formed in 92% ee; crystallization 
directly from the reaction mixture gave a product with an optical purity of 99% ee (86% yield) 
and avoided many difficulties typically encountered when dealing with titanium and tartrate 
ester residues in reactions of this type (Scheme 2.11).   
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Scheme 2.11 
 
A number of other biologically active sulfoxides have been synthesized using Kagan, or 
modified Kagan methodologies. Makino et al. recently published work on vasopressin 
receptors, detailing the optimization process leading to the synthesis of N-benzoyl-1,5-
benzothiazepine sulfoxide 2.18.  High enantioselectivity was observed for catalyst loadings as 
low as 10%, with the benzothiazepine S-oxide derivative produced in 97% ee (94% yield).362  
The atypical antipsychotic agent 2.19, which was in development for the treatment of 
schizophrenia, was required in > 99% ee, as the epimer was shown to have undesirable effects 
on the central nervous system.363  Hogan et al. reported their use of factorial design to examine 
13 variables involved in the asymmetric oxidation process, and found increased sulfoxide ee 
was attained at lower charge ranges of DET and Ti(OiPr)4; improvement in the 
enantioselectivity  was reported from 60% ee (discovery method) up to 92% ee following 
optimization of the catalyst system and reaction protocol, with a final achievement of > 99.5% 
ee (73% isolated yield) after sulfoxide crystallization.     
 
 
 
Asymmetric oxidation sulfide 2.20, by Moseley and coworkers, formed part of the synthesis of 
the neurokinin antagonist ZD2249 1.5.364  Sulfoxide intermediate 2.21 was provided in 94% ee 
using Kagan’s conditions (Scheme 2.12); the temperature of the reaction was a result of a 
compromise between enantioselectivity and reaction rate, and the almost stoichiometric use of 
69 
 
CHP (1.05 equiv) minimized the unacceptable production of the corresponding sulfone 
byproduct whilst allowing for an acceptable reaction time.   
 
 
Scheme 2.12 
 
The titanium/tartrate catalyst system has also been show to a useful tool in the kinetic resolution 
of racemic sulfoxides.  Lattanzia et al. demonstrated that using the oxidative conditions reported 
by Modena, i.e. Ti(OiPr)4:(R,R)-DET (0.5:2 equiv) with CHP (0.65 equiv) as the oxidant, 
enantioselective oxidation of a racemic sulfoxides 2.22 to the sulfones 2.23 occurred, allowing 
for unreacted starting material to be recovered in enantioenriched form.365  Recovered 
sulfoxides were found to have ee values between 9-94% ee with low yields (18-40% - typical of 
a resolution process) (Scheme 2.13); the absolute configurations of the afforded enantioenriched 
sulfoxide were not disclosed. 
 
 
Scheme 2.13 
 
Alternative Chiral Ligands for Use in Ti-Catalyzed S-Oxidations 
In addition to research on titanium-tartrate type catalyst systems, many investigations have 
focused on the use of alternative chiral ligands for Ti-mediated asymmetric oxidations of 
sulfides. 
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Diols and related ligands 
Uemura et al. reported the use of (R)-BINOL 1.43 as a catalyst ligand in the synthesis of chiral 
sulfoxides.366-368  Although enantiopure BINOL species had previously been found ineffective 
for employment in Sharpless asymmetric epoxidation reactions, initial publications on 
sulfoxidation reactions were more positive.  Oxidations performed in the presence of catalyst 
species formed in situ from Ti(OiPr)4 and (R)-BINOL, in a 1:2 ratio, gave rise to methyl p-tolyl 
sulfoxide 1.48 in good enantioselectivity (73% ee) and high yield (88%) when a 10 mol% 
catalyst loading was used (Scheme 2.14).366  The presences of one equivalent of water (with 
respect to sulfide substrate) or more was found to be essential for attainment of high 
enantioselectivity of the reaction, and for extended catalyst turnover and lifespan.367   
 
 
Scheme 2.14 
 
Subsequent optimization saw ee values of up to 96% achieved, using 2.5 mol% catalyst loading 
with TBHP as the oxidant, as it was proposed that the enantioselectivities were as a result of an 
initial asymmetric oxidation to the chiral sulfoxide (ca 50% ee) followed by kinetic resolution 
of the sulfoxide.  Standalone kinetic resolution experiments saw methyl p-tolyl-, p-bromo, and 
p-nitro-sulfoxides isolated in > 99% ee (24-26% yield).368   
 
In addition to Uemura’s work, a number of other groups have investigated sulfoxidation 
reactions catalyzed by titanium complexes of BINOL, or derivatives of BINOL.369, 370  Pescitelli 
et al. postulated (BINOLate)6Ti4(OH)4 as the catalyst precursor species arising from Uemura’s 
protocol of 1:0.5:10 BINOL/Ti(OiPr)4/H2O mixture.
371  An immobilized chiral Ti-BINOL 
complex was employed by Sahoo and coworkers to obtain alkyl aryl sulfoxides in excellent ee 
(77-> 99% ee), and good yields (54-63%).372  Bolm and Dabard demonstrated that the 
bissteroidal diols 2.24 could act as efficient ligand in asymmetric sulfoxidation, achieving  
(S)-sulfoxide 1.48 in 90% ee and 80% yield from a catalyst system with a Ti:ligand ratio of 1:2, 
in a 10 mol% catalyst loading.373  Martyn et al. investigated catalytic asymmetric sulfoxidation 
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using F8BINOL 2.25 as the auxiliary in the chiral titanium catalyst, and found that the use of the 
fluorinated BINOL derivative gave better enantioselectivity than when BINOL was used, but 
also afforded sulfoxides with the opposite absolute configuration.374, 375   
 
 
 
The chiral titanium complex produced from Ti(OiPr)4 and optically active diol 2.26 was 
employed by Imamoto and Yamanoi to perform oxidation on methyl p-tolyl sulfide using TBHP 
at 20 C.376  Initial results were disappointing, with only 10% ee observed (70% yield), but 
optimization of reaction conditions saw this increase to 95% ee, with a sulfide:Ti(OiPr)4:2.26 
ratio of 10:5:1 used, CHP (2 equiv) employed as the oxidant and inclusion of 4Å MS in the 
reaction mixture.  This system was applied to the oxidation of a range of alkyl aryl sulfides, 
affording sulfoxides in modest to high yield (36-92%) and up to 95% ee (Scheme 2.15); 
significant production of the corresponding sulfone was also observed which the authors 
attributed to a kinetic resolution of sulfoxides following the initial oxidation process.  
 
 
Scheme 2.15 
 
Optically active diols 2.27 and 2.27 were used in the Ti-mediated synthesis of chiral alkyl aryls 
sulfoxides.377  High enantiopurities (up to 84% ee), with moderate yields (21-79%).were 
achieved in a range of sulfoxides through oxidations catalyzed by the chiral Ti-1,4-diol 
complexes formed in situ.   
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Rosini et al. examined the use of hydrobenzoin type ligands in Ti-mediated sulfoxidation 
reactions.378-380  Using ligand 2.29, a range of aryl alkyl- and aryl benzyl sulfoxides were 
produced in good yields (55-74%) and moderate to high optical purities (22-99% ee).  
Subsequent work examined the use of a range of p-substituted hydrobenzoin species and found 
that the tBu-derivative 2.30 gave rise to (S)-p-tolyl methyl sulfoxide 1.48 with the highest 
enantioselectivity (90% ee), in high yield (70%) (Scheme 2.16).  Capozzi and Cardellicchio also 
employed hydrobenzoin type diol ligands in catalytic asymmetric sulfoxidations, including the 
synthesis of chiral sulfoxide precursors to Sulindac 1.3.381-383 
 
 
Scheme 2.16 
 
Zeng et al. reported the use a 2,10-campanediol derived titanium complex catalyst in the 
asymmetric formation of sulfoxide 1.106.384  When TBHP was used as the oxygen source the 
(S)-sulfoxide was always the predominant product; however the use of CHP gave varied results, 
depending on how much of the oxidant was employed.  When less than 1.2 quiv of CHP was 
used, the (R)-sulfoxide was formed as the major enantiomer, conversely the (S)-sulfoxide was 
formed in excess when > 1.6 equiv of CHP was used (Scheme 2.17).  The greatest 
enantioselectivity (99%, 11% yield) was observed when CHP (2 equiv) was used with a 10 
mol% catalyst loading of Ti(OiPr)4:2.30:H2O (1:2:5).  An accompanying kinetic resolution 
process alongside the asymmetric oxidation was indicated by increased sulfone production with 
longer reaction times, with similarly increasing ee values and reduction in sulfoxide yield.  
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Scheme 2.17 
 
The chiral tetradentate ligand 2.31 was created by Corey et al. which outperformed Kagan type 
oxidations for the asymmetric oxidation of a number of sulfides.356  
 
 
 
The 8-quinoline-based ligand 2.32, developed by Bhadra et al., formed part of a binuclear 
titanium catalyst that was reported to give high levels of stereoselectivity in sulfoxidations of -
hydroxypropyl sulfides.385  Using a 10 mol% catalyst loading, with a Ti(OiPr)4:ligand ratio of 
2:1, chiral -hydroxyproyl sulfoxide were obtained in high yield (72-83%) and high optical 
purities (90-95% ee) (Scheme 2.18).  
 
 
Scheme 2.18 
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Salen and Salan ligands 
Numerous reports of the use of Ti-salen complexes in asymmetric sulfoxidation have been 
published.386-388  Fujita et al. reported the first Ti-salen based catalyst for asymmetric 
sulfoxidation.389  Using the binuclear N,N′-disalicylidene-(R,R)-1,2-cyclohexanediamine-
titanium(IV) complex 2.33, methyl phenyl sulfide was oxidized by trityl hydroperoxide (THP) 
with enantioselectivities up to 53% ee.  
 
 
 
Katsuki and coworkers conducted extensive studies of new salen complexes for Ti-mediated 
sulfide oxidation, taking inspiration from a second generation (salen) manganese (III) complex 
developed within the group which performed well in oxidation of alkyl aryl sulfides.390-393  
Application of (salen) titanium(IV) complex (R)-2.34 (4 mol%) saw poor performance, giving 
an enantioselectivity of only 10 % ee for the oxidation of thioanisole.  Complex 2.34 was 
converted to the corresponding di--oxo (salen) titanium complex 2.35 (Scheme 2.19), which 
gave improved sulfoxidation enantioselectivity (76% ee); when oxidation was performed with a 
urea-hydrogen peroxide adduct (UHP) a considerably improved ee of 94% was achieved.  The 
asymmetric sulfoxidation of a range of aryl sulfides was carried out using 2 mol% of complex 
2.35, with high yields (78-93%) and excellent enantiopurities (92-99% ee) obtained.   
 
 
Scheme 2.19 
 
Bryliakov and Talsi reported titanium-salan complexes capable of catalyzing stereoselective 
sulfoxidations with H2O2, with accompanying kinetic resolution of the sulfoxides.
29, 387, 394, 395   
A number of tetradentate ligand were synthesized and the Ti-salan catalyst complexes formed in 
situ were evaluated for efficacy and enantioselectivity, using a catalyst loading of 2 mol% and a 
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slight excess of oxidant (1.1 equiv); optical purities of 43-64% ee were obtained, with sulfoxide 
yields of 63-68%.   
 
 
Scheme 2.20 
 
The corresponding di--oxo titanium salen complexes 2.41-2.45 were prepared and evaluated 
for their use with a 1 mol% catalyst loading; oxidation of a range of alkyl aryl and alkyl benzyl 
sulfides proceeded with improved enantioselectivity, with the exception of 2.45.  Optimization 
of the system saw phenyl benzyl sulfoxide 2.46 produced in 97% ee (64-65% yield) using the 
preformed complex 2.44, again with a significant amount of overoxidized product obtained 
(35% yield) (Scheme 2.21).   
 
 
Scheme 2.21 
 
Trialkanolamine ligands  
In 1994 Nugent and Harlow first documented the synthesis of complexes formed between 
Ti(OiPr)4 and homochiral trialkanolamine ligands 2.47.
396  Complexes of this type were 
subsequently investigated for use in asymmetric sulfoxidation by Nugent, in collaborations with 
Modena et al.397-403 Initial studies examined the reactivity and enantioselectivity of catalyst 
complexes 2.50 and 2.51, formed in situ from Ti(OiPr)4 and enantiopure trialkanolamines 2.47 
and 2.48 (Scheme 2.22). Claims made by the authors suggest the development of an effective 
catalyst capable of high turnover numbers (1-2 mol% catalyst loading) and enantiomeric 
excesses of afforded sulfoxides in the range of 40-84% ee, however these figures relate to only a 
small percentage of the results published; in general only moderate asymmetric induction was 
observed during the oxidation process (3-36% ee), with the highest enantioselectivity exhibited 
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when ligand 2.48 was employed, with CHP used as the oxidant.  The optical purity of product 
sulfoxides was attributed to a combination of both an asymmetric oxidation process and kinetic 
resolution of the corresponding sulfoxide.   
 
 
Scheme 2.22 Reagents and conditions: a) stoichiometric Ti(O
i
Pr)4, CHCl3, 20C; b) oxidant (TBHP or CHP);  
c) 
i
PrOH; d) Ti(O
i
Pr)4 (0.75 equiv.), CH2Cl2, 20C followed by solvent removal; e) excess of ligand 
 
Numerous reports since then have discussed the structures of the various complexes involved, 
including the polynuclear aggregate obtained with a substoichiometric amount of Ti(OiPr)4 was 
added to the ligand, and the reaction mechanism of the titanium-trialkanolamine mediated 
sulfoxidations.398, 399  It was proposed that addition of cumyl hydroperoxide to complexes 2.50-
2.52 afforded an active catalyst species with a biphilic nature, behaving as an electrophile 
towards sulfides while at the same time the kinetic resolution pathway saw a dominating 
nucleophilic behavior toward the oxidation of sulfoxides.  Modena et al. have more recently 
reinvestigated the stereoselective oxidation of a range sulfides, catalyzed by the complex 
(R,R,R)-2.53 (10 mol% catalyst loading), with modest to good enantioselectivities observed (45-
71% ee) (Scheme 2.23).403 
 
 
Scheme 2.23 
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Schiff base ligands 
Brylaikov and Talsi reported the used of tridentate Schiff base ligand, derived from chiral 
aminoalcohols, for use in titanium catalyzed sulfoxidation reactions.404  Screening of the ligands 
in the oxidation of benzyl phenyl sulfide showed that the best enantioselectivity was achieved 
through use of 2.54, in a catalyst loading of 5 mol% with Ti(OiPr)4:ligand ratio of 1:1.5.  
Sulfoxide (S)-2.46 was afforded in modest enantiopurity (60% ee) (Scheme 2.24). 
 
 
Scheme 2.24 
 
Bera et al. investigated a range of diphenyl Schiff bases (2.55-2.57) for use in the oxidation of 
thioanisole.405 A catalyst loading of 2.5 mol % was employed, with a Ti(OiPr)4:ligand ratio of 
1:1.2.  Hydrogen peroxide (1.1 equiv) was used as the oxidant giving methyl p-tolyl sulfoxide 
1.48 in moderate to high enantioselectivities (30-98% ee).   
 
 
 
Miscellaneous ligands 
A range of oxazolines with diverse substituents were synthesized by Chen et al. and explored as 
chiral ligands in asymmetric sulfoxidation of a number of alkyl aryl sulfides.406  The highest ee 
value was achieved under optimized conditions using oxazoline 2.58.  Titanium isopropoxide 
and oxazoline were employed in ratios of 1:2 respectively, with a catalyst loading of 5 mol %.  
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The sulfoxide products were afforded in enantiopurities ranging from 21-96% ee, and in low 
yields (27-50%) (Scheme 2.25); high production of the over-oxidized sulfone products supports 
the authors proposal that the highest enantioselectivity observed was due to the concomitant 
processes of sulfide oxidation and kinetic resolution of the generated sulfoxide.   
 
 
Scheme 2.25 
 
A practical method for the synthesis of platelet adhesion inhibitor OPC-29030 2.59 was 
established utilizing the asymmetric oxidation of sulfide 2.60 to (S)-2.61 employing a chiral 
titanium-mandelic acid complex catalyst system.407  Application of Kagan’s sulfoxidation 
protocol to 2.60 gave sulfoxide (S)-2.61 in only 54% ee (78% yield), although recrystallization 
could raise this figure to > 99.5% ee.  Screening of Kagan type Ti-based catalyst systems were 
carried out, examining various mono-, bi-, and tridentate ligands in place of the usual tartrate 
esters.  (R)-Mandelic acid was found to provide the best conditions for high enantioselectivity, 
and oxidative conditions of Ti(OiPr)4:(R)-Mandelic acid:CHP (1:2:1 with respect to sulfide 
2.60) gave (S)-2.61 in 74% yield, and 76% ee i.e. higher enantiopurity than the original  
Ti-tartrate system.  The large scale synthesis of 2.59 was performed using the optimized 
conditions of Ti(OiPr)4:(R)-Mandelic acid:CHP (0.4:0.6:1 equiv), which saw the production 
sulfoxide (S)-2.61 in 99.7% ee (55% yield) after one recrystallization (Scheme 2.26).   
 
79 
 
 
Scheme 2.26 
 
Titanium-Catalyzed S-Oxidations with Optically Active Peroxides  
Although the majority of research on Ti-mediated synthesis of optically active sulfoxides has 
focused on the chiral ligand used, a number of groups have published work investigating the use 
of chiral peroxides in partnership with Ti(OiPr)4.  Adams et al. reported the Ti-catalyzed 
asymmetric oxidation of alkyl aryl sulfides by optically active hydroperoxide 2.62 (> 99% 
ee).408 The oxygen transfer to methyl p-tolyl sulfide, from (S)-1-phenylethyl hydroperoxide (S)-
2.62, gave sulfoxide 1.48 (74% ee) but with much overoxidation to the corresponding sulfone 
(Scheme 2.27); mechanistic studies showed that enantioselectivity arose from a combination of 
asymmetric induction in the oxidation and a kinetic resolution of the sulfoxide.  Oxidation of 
further p-tolyl sulfides afforded sulfoxides in high ee (up to 80% ee) but once again higher 
optical purities came at the expense of greater sulfone production.  
 
 
Scheme 2.27 
 
Lanttanzi, Scretti, and coworkers investigated the employment of furyl hydroperoxides as 
oxidants, gaining access to chiral sulfoxides through a modified Modena procedure.353, 409-417  
Methyl aryl- and methyl alkyl-sulfides underwent asymmetric oxidation using tertiary furyl 
hydroperoxide 1.253 and Ti(OiPr4):(R,R)-DET (in ratios 1:4 with respect to sulfide substrate), 
giving (R)-sulfoxides in good yields (53-79%) and enantioselectivities (74-91% ee).  Secondary 
furyl hydroperoxides were employed in the oxidation of methyl p-tolyl sulfide, with two equiv 
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of chiral peroxide species 1.254, and Ti(OiPr)4:(R,R)-DIPT (1:4), giving sulfoxide 1.48 in 
excellent enantioselectivity (75% yield, 95% ee), with the observation that the asymmetric 
oxidation involved a kinetic resolution of the racemic hydroperoxide (Scheme 2.28).  Kinetic 
resolution of()-1.48 using this system provided enantioenriched (R)-1.48 in > 95% ee but only 
38% yield.     
 
 
Scheme 2.28 
 
It was postulated that the attainment of chiral sulfoxides through Ti-catalyzed oxidation with 
furyl hydroperoxides such as 2.63 and 2.64 was achieved though enantioconvergent oxidation 
of sulfides and kinetic resolution of the sulfoxides.353, 413-416  Similar investigations were carried 
out using the steroidal peroxide species 2.65, affording aryl alkyl sulfoxides in moderate to 
good yield (58-74%), and high optical purity (84-> 95% ee); hydroperoxide 2.65 allowed for 
reduced reaction times compared to 2.64, but at the expense of product ee.415 
 
 
 
Various enantiopure camphor hydroperoxides (2.66-2.69) were synthesizes  by Lattanzi et al. 
for use in Ti-mediated asymmetric S-oxidation reactions.418  In these investigations no 
additional chiral source, such as a tartrate, was deemed necessary; instead it was proposed that 
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asymmetric induction was brought about by steric interactions between the sulfide substrate and 
the camphor derived oxidant to result in the preferential formation of one sulfoxide enantiomer.  
An interesting feature of the work lies in the ability to regenerate the hydroperoxide; as the 
asymmetric oxidation occurs the peroxides were reduced to alcohols, these could then be 
recycled back to their corresponding peroxide using H2O2. Overall enantioselectivity of the S-
oxidations performed using these peroxides in the presence of Ti(OiPr)4 was only moderate; 
methyl p-methoxy-sulfoxide was obtained in 53% ee (yield 31%), representing the highest ee 
value achieved, with peroxide 2.67 as the oxygen source.  Kinetic resolution of racemic 
sulfoxide ()-1.48 using 2.69 afforded enantioenriched (R)-1.48 in only 34% ee and 27% yield.  
A review by Lattanzi and Scretti, describe these investigations in greater depth.416  
 
2.2 Vanadium-catalyzed S-oxidations 
 
After titanium, vanadium is one of the most popular metals used in catalyst systems for 
asymmetric sulfoxidation reactions.419-422 Early investigations by Modena examined the 
mechanism of sulfide oxidation catalyzed by vanadyl acetylacetonates in the presences of 
optically active alcohols based solvents.423  Phenyl methyl- and p-tolyl methyl- sulfide were 
oxidized by TBHP, however asymmetric induction was low, with optical purities no greater 
than 10% ee achieved.   
 
Vanadium catalyst with Schiff base type ligands have been widely researched and reported in 
the literature, with great diversity in structure and efficacy.424-441  It is beyond the scope of this 
thesis to discuss this type of catalyst in great detail, however a general overview shall instead be 
provided.  Imine based ligands 2.70-2.74 were employed by Bolm and coworkers who were the 
first to report high levels of enantioselectivity for vanadium mediated sulfoxidation reactions.442 
 
 
 
Oxidations were carried out using safe and inexpensive H2O2, and the vanadium-Schiff base 
catalyst system was reported to be simple to use, i.e. room temperature reaction conditions with 
exclusion of air and humidity unnecessary.  The catalyst system was found to be highly efficient 
at concentrations as low as 0.01 mol% of the complex.  Methyl phenyl sulfoxide 1.106 was 
obtained in 94% yield with 70% ee when ligand 2.71 was employed (Scheme 2.29).     
82 
 
 
 
Scheme 2.29 
 
Very little over oxidation of sulfoxides to the sulfone products was observed suggesting the 
high enantioselectivities were as a result of the asymmetric oxidation process alone, without any 
associated kinetic resolution.  Bolm et al. subsequently applied their methodology to the 
enantioselective oxidations of dithioacetals and dithioketals to give the corresponding 
monosulfoxides with ee values up to 85%.443 
 
Ellman and coworkers employed the Bolm catalyst system for the preparation of synthetic 
intermediate 2.75 by way of the asymmetric oxidation of tbutyl disulfide 2.76.444-446  
Thiosulfinate 2.75 was achieved in excellent yield and enantioselectivity (98%, 91% ee) 
(Scheme 2.30).  Subsequent optimization of this process allowed the reaction to be carried out 
successfully on a kilogram scale with only minor loss of enantioselectivity (86% ee).447  
 
 
Scheme 2.30 
 
A tandem catalytic approach was used by Jackson et al. after examining asymmetric oxidations 
and kinetic resolutions using the 3,5-diido ligand (S)-2.74.448  (R)-methyl p-tolyl was obtained in 
41% yield (out of a possible 50%) and 98% ee from kinetic resolution of the racemic sulfoxide 
carried out in chloroform at 0C; these conditions were subsequently used for asymmetric 
oxidations on a range or alkyl aryl sulfides.  Enantioselectivities of up to  
> 99.5% ee were achieved, with the corresponding sulfones observed indicating that some 
kinetic resolution had taken place in addition to the oxidation process.  Similar studies were 
carried out by Maguire and coworkers in the oxidation and kinetic resolution of benzyl aryl 
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sulfoxides, also using the 3,5-diido ligand (S)-2.74.449, 450  Zeng et al. reported their use of 
preformed chiral vanadium-Schiff base complexes 2.77 a-e, and their application in asymmetric 
oxidation and accompanying kinetic resolution.430, 431  Enantioselectivities of up to 99% were 
achieved in the oxidation of methyl phenyl sulfide.   
 
 
Scheme 2.31 
 
Berkessel and Vetter examined a number of diastereomeric Schiff base ligands in order to 
determine the optimal conditions for the enantioselective oxidation of thioanisole and  
o-bromothioanisole.451  Reactions were performed using a ratio of 1:1.5:100:110 of 
VO(acac)2:ligand:substrate:H2O2.  Using ligand 2.78, methyl phenyl sulfoxide was obtained in 
92% yield and 78% ee; ligand 2.79 afforded the same sulfoxide in similar yield (91%) but with 
slightly lower enantioselectivity (70% ee).  The oxidation of o-bromothioanisole, when carried 
out using ligand 2.79, afforded the corresponding sulfoxide in 78% ee and 97% yield.  
 
 
 
Katsuki et al. developed the ligand 2.80 for use in vanadium based enantioselective 
sulfoxidation.  Oxidations carried out on a range of alkyl aryl sulfides using the chiral vanadium 
complex prepared in situ from VO(acac)2 and ligand 2.80 afforded sulfoxides in high yields and 
moderate to high optical purities (Scheme 2.32).  A small amount of methanol added to the 
reaction flask was found to be advantageous in regards to improving the enantioselectivity of 
the reaction due to the positive effect on the equilibriation between peroxovanadium species.  
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Scheme 2.32 
 
Li et al. achieved excellent results from the asymmetric oxidations catalyzed by the vanadium-
Schiff base complex featuring the diastereomeric ligand 2.81, derived from a -amino alcohol.  
High yields and exceptional enantioselectivity was observed for enantioselective synthesis of 
alkyl aryl sulfoxides (Scheme 2.33).  
 
 
Scheme 2.33 
 
High levels of asymmetric were also observed in the sulfoxide products reported by Wang et al. 
who disclosed the use of chiral Schiff bases derived from halogen functionalized 
hydroxynaphthaldehydes.  A two step procedure was developed whereby an initial oxidation 
step was followed by further addition of oxidant to promoted oxidation of any remaining 
sulfide, and to effect kinetic resolution of the sulfoxide already formed.  Ligand 2.82-2.84 were 
found to be the most effective, with enantioselectivities of 92 - 99% ee achieved, albeit with 
moderate yields (51-67%) (Scheme 2.34). 
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Scheme 2.34 
 
Suresh et al. synthesized as series of trimeric variants of well known chiral vanadium-Schiff 
base catalysts.  Examination of the catalytic activity showed that the C3-symmetric ligands 2.85 
and 2.86, featuring a (1R,2S)-aminoindanol type Schiff base, were most effective in terms of 
activity and asymmetric induction.452  The use of complexes formed in situ from 2.85 and 
VO(acac)2 for asymmetric oxidation of various alkyl aryl and benzyl aryl sulfide afforded 
sulfoxides in moderate to high ee and high yields (54-86% ee and 82-98% yield). Ligand 2.86 
performed equally well, affording sulfoxides in yields ranging from 81-94% with 
enantioselectivities between 67- 89% ee.   
 
 
 
Ruffo and coworkers examined a series of Schiff bases with carbohydrate structures in 
vanadium mediated asymmetric sulfoxidation reactions.453 The catalyst system featuring ligand 
2.87 was found to be the most efficacious in the oxidation of methyl phenyl sulfide, affording 
the corresponding sulfoxide in high yield (97%) but only modest enantioselectivity (60% ee).  
Chuo and coworkers examined twenty substitutionally and electronically diverse (1R)-camphor 
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based Schiff base ligands; the vanadium complex with ligand 2.88 performed exceptionally well 
in the oxidation of ethyl 2-naphthyl sulfide at catalyst loadings of 1 mol%,  affording the 
sulfoxide in excellent enantioselectivity and in good yield (> 99% ee, 72% yield).454  Various 
alkyl aryl sulfoxides were produced in high ee and good yields (85-97% ee, 60-74% yield) with 
the high levels of enantioselectivity attributed to a combination of asymmetric oxidation and 
subsequent kinetic resolution of the afforded sulfoxide.   
 
 
 
Liu et al. reported the synthesis and application of a rigid tetrahydroquinoline ligand 2.89; 
asymmetric oxidations catalyzed by vanadium complexes featuring Liu gave sulfoxides in good 
to high yield (80-95%), with enantioselectivities up to 77% ee.455  Chiral norephidrine based -
amino alcohol based ligands were employed by Aydin.456  Schiff bases 2.90 and their reduced 
counterparts 2.91 were examined in vanadium mediated sulfide oxidations alongside their 
respective epimers.  Sulfoxides were afforded with high optical purities (92-99% ee) in 
moderate to high yields (60-89%), with the observation that the reduced Schiff base ligands 
2.91 gave sulfoxides lower enantioselectivities than ligand 2.90.  
 
Vanadium Schiff base complexes immobilized on mesoporous materials have been reported, 
although asymmetric induction for sulfoxidation reactions have generally been low (< 31% 
ee).440, 457  Barbarini et al. investigated polymer supported chiral Schiff base ligands, and 
reported sulfoxidation enantioselectivities of up to 61% ee.  The most successful solid supported 
Schiff base ligands were developed by Jackson and coworkers.458, 459  Although initial studies 
from this group reported low enantioselectivities for sulfoxidation (11% ee being the highest), 
subsequent work focused on the rapid generation of libraries of simple chiral Schiff bases 
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mounted on Merrifield solid support resins.  Ligand 2.74 and 2.92 were identified as the most 
effective, with optical purities of up to 97% ee achieved over a range of sulfoxides.    
 
 
 
Salen type ligand have also been successfully applies in vanadium mediated sulfide oxidations.   
Fujita and coworkers were early pioneers of vanadium catalysts for sulfoxidation; (R,R)-2.93 
was used to catalyze the oxidation of methyl phenyl sulfide using a catalyst loading of 10 mol%, 
the corresponding sulfoxide was afforded  in high yield (96%) but with only moderate 
enantioselectivity (40% ee) (Scheme 2.35).  Subsequent studies by Fujita and coworkers 
examined oxovanadium(V) complexes with Schiff bases, derived from L-amino acids and 
salicylaldehyde, however the enantioselectivity of these catalyst systems were poor, providing 
sulfoxide with optical purities of up to a maximum of 14% ee.    
 
 
Scheme 2.35 
 
High sulfoxide enantioselectivities were reported by Sun et al. with the use of vanadium-salan 
complex formed in situ from VO(acac)2 and ligand 2.94.
152  Oxidation of a range of alkyl aryl 
and benzyl aryl sulfides afforded sulfoxides in high yields (71-86%) and moderate to high 
enantioselectivities (51-95% ee) (Scheme 2.36).  Kinetic resolutions of a range of racemic 
sulfoxides using this catalyst system gave enantiomerically enriched sulfoxides with 
enantioselectivities ranging from 78-98% ee.   
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Scheme 2.36 
 
2.3 Manganese-catalyzed S-oxidations 
 
One of the earliest reports of a manganese based catalyst for use in asymmetric sulfoxidation 
reactions came from Halterman et al. who carried out sulfide oxidations in the presence of the 
D4-symmetrical manganese-tetraphenylporphyrin complex 2.95.
460  Iodosylbenzene was 
employed as the oxidant, and with the use of a 0.25 mol% catalyst loading (with respect to 
sulfide) a range of sulfoxides were obtained in modest enantioselectivity (40-68% ee).  
Simmonneaux and coworkers used a similar manganese complex in their investigations into 
asymmetric sulfide oxidations using hydrogen peroxide, with sulfoxidation enantioselectivities 
of up to 80% ee achieved. 461  Complex 2.96 was employed in the enantioselective synthesis of 
Sulindac 1.3, affording the target molecule in low ee (27% ee).      
 
 
 
Jacobsen and coworkers reported their work on enantioselective sulfide oxidations, using chiral 
(salen)Mn(III)Cl complexes.462  (R,R)-2.97, and its epimer were used in the production of a 
range of optically active sulfoxides with modest ee (up to 68% ee) in high yields (80-95%) 
(Scheme 2.37). 
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Scheme 2.37 
 
Katsuki et al. had greater success with their (salen)Mn(III)Cl complexes, with complex 2.98 
affording methyl aryl sulfoxides with up to 90% ee and yields up to 76%.465463-465 Subsequent 
work within the Katsuki group saw the development of the second generation Mn(salen) 
complex 2.99, which exhibited improved enantioselectivity over complex 2.98 whilst retaining 
efficiency (Scheme 2.38).  Sulfoxides with generally high optical purities (up to 96% ee) and 
good to high yields (up to 98%) were produced with complex 2.99, using PhIO as the 
oxidant.466, 467  Performing the oxidations in the presence of 4-phenylpyridine N-oxide (4-
PPNO) was found to increase enantioselectivity in a number of cases.  
 
 
Scheme 2.38  
 
Dai et al. have used a porphyrin-inspired complex, formed in situ from Mn(OTf)2 and ligand 
2.100, to catalyze a wide variety of sulfides oxidations by hydrogen peroxide.  Optically active 
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alkyl aryl sulfoxides were produced in high yields (up to 92%) with excellent enantioselectivity 
(91 to > 99% ee) (Scheme 2.39).468  Further work has continued the development of this catalyst 
system, including recent adaptation for use under continuous-flow microreactor conditions, 
which enabled the direct scaling of enantioselective sulfoxidation reactions to a multi-gram 
scale, with the desired sulfoxide product afforded within 20 minutes.469, 470   
 
 
Scheme 2.39 
 
Schoumacker et al. isolated a number of manganese(II) complexes from solutions of Mn(ClO4)2 
or Mn(acac)2 and ligand 2.101 and evaluated their efficacy as catalyst in the oxidation of 
prochiral sulfides.471  The alkyl aryl sulfoxides afforded from oxidation carried out in the 
presence of [Mn(2.101)(ClO4)2] were found to have low optical purity (5-12% ee) with the (S)- 
enantiomer in excess.  In contrast, when [Mn(2.101)(acac)2] was employed (R)-sulfoxides were 
obtained, with moderate enantioselectivities (20-62% ee).  Gao and coworkers reported the use 
of the chiral salen-manganese complexes 2.102 featuring a pyrrolidine backbone.472  Optically 
active sulfoxides were obtained in low to modest ee (3-42% ee).    
 
 
 
Hirotsu et al. prepared dimanganese(III) complexes of salen-type ligands anchored by 9,9-
dimethylxanthene-4,5-diyl spacers and evaluated their abilities as catalyst for asymmetric 
sulfoxidation.
473
  Complex 2.103 afforded sulfoxides with the best enantioselectivities, ranging 
from 5-39% ee (Scheme 2.40).  Performing the oxidations in the presence of  
4-(dimethylamino)pyridine (DMAP) was found to enhance enantioselectivity.   
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Scheme 2.40 
 
Mukaiyama et al. achieved the synthesis of optically active sulfoxides using pivaldehyde in the 
presence of a chiral-oxo aldiminatomanganese(III) catalyst complex.474, 475  Alkyl aryl 
sulfoxides were produced in moderate to high yields (44-93%) and modest to good 
enantioselectivities (24-72% ee).  Alcon and coworkers employed manganese complexes with 
tetradentate C2-symmetrical ligands encapsulated in zeolites; sulfoxidation proceeded with low 
asymmetric induction giving products with up to 27% ee.476  Zhang et al. used triply 
immobilized salen ligands for Mn-mediated sulfoxidation, achieving excellent results.477  
Sulfoxides with enantioselectivities up to 92% ee were obtained.   
 
Enantioselectivity due to hydrogen bonding was explored by Bach et al. with their use of a the 
chiral Mn(salen) complex 2.104.478  The asymmetric oxidation of the sulfide containing lactam 
2.105 proceeded smoothly, delivering the corresponding sulfoxide 2.106 with 47% ee, whereas 
oxidation of the N-methylated analogue 2.107 resulted in a racemic sulfoxide 2.108, supporting 
the hypothesis of H-bonding driven stereoselectivity (Scheme 2.41).  A range of cyclic 
sulfoxides were obtained using this catalyst system, with yields of 64-91% and 
enantioselectivities from 13 to 67% ee.   
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Scheme 2.41 
 
2.4 Iron-catalyzed S-oxidations 
 
In 1990 Groves and Viski reported the use of the chiral vaulted binaphthyl porphyrin 2.109 in a 
number of different Fe(III)-catalyzed asymmetric transformations, amongst them was the 
oxidation of prochiral sulfides.479  Alkyl aryl sulfoxides were produced via oxidation by 
iodosylbenzene in the presence of a 0.1 mol% catalyst loading of 2.109-Fe(III)Cl, with high 
yields achieved (67-88%) but modest enantioselectivities (14-48% ee).   
 
 
Figure 2.2 Left:  Vaulted binaphthyl porphyrin 2.109; image reproduced with permission from ref.
479
     
Centre and right:  C2 symmetric “twin coronet” porphyrin catalyst 2.110; image reproduced with permission 
from ref.
480
 
 
Naruta et al. also reported modest enantioselectivities when using iron complexes of “twin 
coronet” porphyrin 2.110 to catalyst asymmetric sulfoxidations.  Aryl sulfoxides were achieved 
in low ee (17-31% ee) (Scheme 2.42), however enantioselectivity was improved by the 
inclusion of 1-methylimidazole (1-MeIm) in the reaction mixture, which was believed to 
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coordinated to the active metal centre and enhance the asymmetric induction by altering the 
porphyrin structure around iron and prevent catalyst decomposition.480, 481   
 
 
Scheme 2.42 
 
Iron porphyrin catalysts derived from the antipodes of a C2-chiral 1,4-xylyene-strapped 
porphyrin were created by Inoue et al. and utilized in the asymmetric oxidation of a number of 
alkyl aryl sulfides.482  Enantioselectivity was initially poor, with enantioselectivities between  
0-36% obtained, however the addition of imidazole resulted in improved enantiomeric excesses 
of the afforded sulfoxides (18-71% ee).482  Low optical purities (up to 40% ee) were also 
reported by Fontcave and coworkers following their investigation of sulfide oxidations 
catalyzed by the iron complex [Fe2O(pb)4(H2O)2](ClO4)4] (pb=(–)-4,5-pinene-2,2’-
bipyridine).483  
 
Tsogoeva et al. screened a range of iron(III) Schiff base complexes for use as catalyst in 
hydrogen peroxide oxidations of thioanisole.  Results were modest, with enantioselectivities of 
up to 54% achieved.439  Bolm et al. were more successful in their endeavors to develop an iron 
based catalyst system for asymmetric sulfoxidation reactions.484, 485  A 2003 publication 
demonstrated the use of various iron complexes, formed in situ from [Fe(acac)3] and Schiff 
bases 2.71, 2.74, and 2.111-2.113, to allow access to optically active sulfoxides with up to 90% 
ee.486  The oxidations were carried out with simple conditions (stirring at RT in a capped 
vessel), and could be performed in the presence of air and moisture with no effect on 
enantioselectivity.  Initial investigations revealed that ligand 2.113 performed best in the 
oxidation of thioanisole; expansion if the substrate scope saw oxidation of a number of alkyl 
aryl sulfoxides achieved in moderate to high ee (59-90% ee) but with only modest yields (21-
44%) (Scheme 2.43).  Little to no sulfone by product was observed indicating that high 
enantiopurities were achieved through asymmetric oxidation alone, without any additional 
kinetic resolution of the sulfoxides.   
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Scheme 2.43 
 
Subsequent work by Bolm and coworkers found that the addition of various carboxylic acids 
and their derivatives improved yields at no detriment to the enantioselectivity of the oxidations; 
enantioselectivities of up to 96% ee were reported, with improved yields (up to 78%).487  The 
asymmetric oxidation of key intermediates in the synthesis of Sulindac 1.3 was published using 
the Bolm Fe-catalyst system.488  Under the original 2003 oxidation protocol published by Bolm, 
the sulfoxide 2.12 was afforded in moderate enantioselectivity (58% ee, 53% yield); carrying 
out the oxidation in the presence of 4-methoxybenzoic acid, or its lithium derivative resulted in 
enhanced enantioselectivity (92% ee) and yield (71 or 69% respectively) (Scheme 2.44).  
 
 
Scheme 2.44 
 
Katsuki and Egami reported a water compatible Fe(salan) catalyst system which carried out 
asymmetric sulfoxidations with high enantioselectivity and sulfoxide selectivity.489, 490  
Fe(salan) 2.115 was used in a 0.2 mol % catalyst loading, with aq. H2O2 as the oxidant, 
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affording a range of methyl aryl- and methyl alkyl- sulfoxides in yields of 88-98% and 
enantiopurities of 87-96% ee (Scheme 2.45).  
 
 
Scheme 2.45 
 
An iodosylbenzene(salen)iron complex was identified by Bryliakov and Talsi as the active 
intermediate in a (salen)iron(III)-catalyzed asymmetric sulfide oxidation.491, 492  Modest 
enantioselectivities were reported with the use of complex 2.116 for a range of methyl aryl- and 
phenyl benzyl-sulfoxides (20-62% ee) (Scheme 2.46).   
 
 
Scheme 2.46 
 
 
A dipeptide ligand was used as the source of chirality in the Fe-mediated synthesis of  
(R)-Modafinil 1.2 reported by Tsogoeva and coworkers.256 Using a relatively high catalyst 
loading of 20 mol% the biologically active sulfoxide was obtained in good yield (75%) but with 
only 22% ee (Scheme 2.47).   
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Scheme 2.47 
 
2.5 Molybdenum-catalyzed S-oxidations 
 
Attempts at using molybdenum based catalyst systems with Schiff base type ligands have 
shown low asymmetric induction for sulfoxidation reactions, with enantioselectivities of < 17% 
ee reported.493, 494  Conversely, Tan and coworkers have produced excellent results employing a 
chiral bisguandinium dinuclear oxodiperoxomolybdosulfate ion pair catalyst for asymmetric 
sulfide oxidations. 495  The ion pair catalyst [2.118]2+[-SO4)Mo2O2(-O2)2(O2)2]
2-, which was 
isolatable or generated in situ, enabled the production of sulfoxides with a wide range of 
structural characteristics to be obtained in high yields (79-99%), with ee values of 37-96% ee 
(Scheme 2.48).  
 
 
Scheme 2.48 
 
Binchio et al. reported the enantioselective oxidation of thioanisole by hydrogen peroxide in the 
presence of a catalytic amount of Na2MoO4 and functionalised -cyclodextrin (-CD) based 
ligands such as 2.119.496  The active oxidant oxodiperoxomolybdenum complex MoO(O2)2L 
(where L= ) was employed in a 4.5% catalyst loading, affording methyl phenyl sulfoxide 
in fair to good yields (62-98%) with enantioselectivities in the range of 17-60% ee (Scheme 
2.49); no overoxidation to the corresponding sulfone was observed. 
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Scheme 2.49 
 
A chiral bis hydroxamic acid (BHA)-molybdenum complex was employed by Yamamoto and 
coworkers to achieve the oxidation of sulfides and disulfides with yields up to 83% and optical 
purities of up to 86% ee.497, 498  Kinetic resolution of racemic methyl phenyl sulfoxide using 
BHA ligand 2.121 afforded the (S)-sulfoxide with 68-75% ee.  A combination of asymmetric 
oxidation and kinetic resolution of the sulfoxide was performed using 1.5-1.75 equivalents of 
either CHP or THP giving enhanced enantioselectivity of the produced sulfoxides (92-99% ee) 
(Scheme 2.50). 
 
 
Scheme 2.50 
 
Galindo performed Mo-catalyzed asymmetric oxidations of prochiral sulfides with H2O2 in the 
presence of [MoO(O2)2(H2O)n] and the chiral imidazolium based carboxylate ligand 2.122.
499  
Modest enantioselectivity was achieved in the oxidation of thioanisole (up to 42% ee at 93% 
conversion to sulfoxide) with the use of a 2.5 mol% catalyst loading and 1 equiv of H2O2 
(Scheme 2.51); when 1.6 equiv of the oxidant was used optical purities up to 83% ee (40% 
yield) were achieved through concomitant asymmetric oxidation and oxidative kinetic 
resolution of the sulfoxide.   
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Scheme 2.51 
 
2.6 Ruthenium-catalyzed S-oxidations 
 
Katsuki et al. employed the Ru-salen complex 2.123 for the aerobic sulfoxidation of methyl aryl 
sulfides under visible light irradiation.153, 393  Using a 5 mol% catalyst loading excellent 
enantioselectivities were achieved (84-98% ee), with yields from 18-98% (Scheme 2.52).  
 
 
Scheme 2.52 
  
Fontcave et al. reported the oxidation of several simple alkyl aryl sulfides using both the  and 
-enantiomers of the “chiral at metal” complexes cis-[Ru(dmp)2(MeCN)2][PF6]2 (dmp = 2,9-
dimethyl-1,10-phenanthroline) 2.124.500  Enantiomeric excesses of the afforded sulfoxides were 
poor, with a maximum ee of 18% achieved for methyl p-bromophenyl sulfoxide. 
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A “chiral at metal” Ru-complex was used by Li et al. for the synthesis of enantiopure Modafinil 
acid 1.181 and its analogues (2.131 and 2.132).501  The use of both enantiomers of the Ru-
complex allowed for both enantiomers of chiral Modafinil acids to be obtained in excellent ee 
(> 98% ee) and high yields (Scheme 2.53). 
 
 
Scheme 2.53 
 
2.7 Copper-catalyzed S-oxidations 
 
Many attempts at designing an efficient copper based catalyst for asymmetric sulfoxidation 
reactions have met with little or no success.476, 502-505  Reports from the Maguire group however 
show that they are an exception, with initial studies employing a catalyst complex produced 
from copper(II)acetylacetonate (acac) and a Schiff base ligand providing sulfoxides with 
moderate ee (up to 81% ee), albeit in low yields (20-30%) (Scheme 2.54).30, 506  These results 
were in agreement with previous reports of low reactivity of copper towards sulfoxidation, and 
were indicative of catalyst inhibition, presumably through complexation of the sulfoxide to the 
metal centre.476, 505   
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Scheme 2.54 
 
The Cu-mediated oxidation worked best for sterically hindered aryl benzyl sulfides, with little 
sulfone observed.  Oxidations were performed on a number of sulfides with ligand 2.113 in the 
presences of additives such as dimethyl sulfoxide (DMSO), 4-methylmorpholine-N-oxide 
(NMO) or an ionic liquid which resulted in improvements in both yield and enantioselectivity 
for nearly all cases.  Similar sulfoxidation protocols have been reported by Bolm et al. using 
vanadium or iron Schiff complexes, but interestingly the analogous copper based reactions 
afford the sulfoxide product with the opposite asymmetric induction.  Maguire et al. later 
published work expanding upon their early investigation into Cu-mediated sulfoxidations, 
demonstrating the optimization of reaction conditions, the result of which gave improved yields 
whilst retaining good enantioselectivity.507  Inhibition of the catalyst by sulfoxide coordination 
was overcome by the use of a hexane–methanol mix as the solvent. It was determined that 
substrate steric effects were more significant than electronic effects when it came to the 
enantioselectivity of sulfide oxidation.  In 2013 the group reported the best enantioselectivity so 
far for a sulfoxide produced using the Maguire catalyst system, 2-napthyl benzyl sulfoxide was 
achieved in 97% ee, however the yield was only 32%.508   
 
2.8 Aluminium-catalyzed S-oxidations 
 
Katsuki et al. reported the development of water compatible aluminium (salalen) catalyst 
complexes for use in asymmetric sulfide oxidation reactions, with aqueous hydrogen peroxide 
as the oxidant.393, 422, 509, 510  Oxidation of thioanisole in the presence of Al(salanen) complex 
2.133 was only moderately selective, poorly reproducible and afforded methyl phenyl sulfoxide 
in enantioselectivities ranging from 20-60% ee (40-60% yield).  In contrast, complexes 2.134 
and 2.135, containing a binol based salalen ligand, performed better, with much higher levels of 
asymmetric induction and selectivity for sulfoxide production. 
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Using complex 2.135 (2 mol%) in MeOH, in the presence of a phosphate buffer, various alkyl 
aryl sulfoxide were obtained with excellent enantioselectivity and yield (97-99% ee, 81-91%) 
(Scheme 2.55).  Oxidation of racemic methyl phenyl sulfoxide revealed that the  
(R)-enantiomer was preferentially oxidized to the sulfoxide, and it was concluded that a 
synergistic kinetic resolution process accompanied an initial asymmetric oxidation to allow the 
sulfoxide products to be obtained in such high optical purities.  
 
 
Scheme 2.55 
 
2.9 Zirconium-catalyzed S-oxidations 
 
In 1999 Modena and coworkers reported the use of polydentate ligand 2.136 in both Ti(IV)- and 
Zr(IV)- catalyst systems for asymmetric sulfoxidation using alkyl hydroperoxides.397, 402, 511  
While the titanium based system was reported to be an effective catalyst with regard to high 
turnover numbers (1-2 mol% catalyst loading) and enantiomeric excesses of afforded sulfoxides 
in the range of 40-84% ee, it was reported that a partially hydrolyzed zirconium catalyst bearing 
the ligand 2.136 could perform equally well, if not better.  Stereoselective sulfoxidations 
performed using the Zr-based system with low catalyst loadings (2 mol %) gave high 
enantioselectivity (80-91% ee), with the product sulfoxides afforded with opposite absolute 
configurations to those if the Ti-system had been used (Scheme 2.56). In addition, sulfinyl 
compounds with poor steric differentiation between substituents flanking sulfur, such as  
benzyl-, tbutyl-, nbutyl-, or ipropyl aryl sulfoxides, could be obtained with high 
enantioselectivities.  One of the limitations of the Zr-based catalysis was high production of the 
over-oxidized to the sulfone products, which indicated that a second oxidative process was 
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occurring and that high ee values were as a result of both the asymmetric oxidation and a kinetic 
resolution, both leading to high amounts of the same sulfoxide enantiomer, albeit in low yield.     
 
 
Scheme 2.56 
 
2.10 Tungsten-catalyzed S-oxidations 
 
Tan et al. reported a highly efficient system for enantioselective sulfoxidations using a catalytic 
amount of silver tungstate in the presence of a chiral dicationic bisguanidinium 2.137.365 
Using this system benzimidazole benzyl sulfoxide was obtained with 88% ee, in a yield of 83%; 
a number of other heterocyclic systems, such as benzothiazole, pyridine, and thiophene 
sulfoxides were produced, alongside various phenyl sulfoxides, in yields of 53-99% and high to 
excellent optical purities (80-99% ee) (Scheme 2.57).    
 
 
Scheme 2.57 
 
Thankur and Sudalai reported the application of a heterogeneous catalyst system based on WO3 
(5 mol%) and various chiral cinchona alkaloids (10 mol%), such as hydroquinidine-2,5-
diphenyl-4,6-pyrimidinediyl diether [(DHQD)2-PYR] 2.138, in the asymmetric oxidation of 
aryl alkyl sulfides. Using 30% H2O2 (1.1 equiv) as the oxidant sulfoxides were isolated in good 
yields (62-90%) with up to 65% ee, representing the first successful application of a tungsten-
catalyzed sulfoxidation system.512  WO3 could be recovered and reused up to five times with no 
ill effect upon conversion and enantioselectivity of sulfoxide production.  WO3-catalyzed 
kinetic resolutions of various racemic sulfoxides was also reported using (DHQD)2-PYR 2.138 
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as the ligand, affording optically active sulfoxides with 44-90% ee in yields between 25-44% 
along with the corresponding sulfones.  Other tungsten based sulfoxidation processes have been 
reported, such as the ionic liquid-based system comprised of chiral anions 2.139 and 2.140.513 
 
 
 
2.11 Platinum-catalyzed S-oxidations 
 
The stereoselective oxidation of prochiral aryl alkyl sulfides mediated by a chiral platinum 
diphosphine complex 2.141 was reported in 2005 by Scarso and Strukul.514  A dimeric platinum 
complex [[(R)-BINAP]Pt(-OH)2(BF4)3] was used with low loading (1 mol%) at room 
temperature to activate 35% H2O2 towards sulfides in a water–surfactant solution.  This system 
was reported to be the first to carry out an asymmetric catalytic oxidation performed in water.  
Chiral sulfoxides were afforded with optical purities ranging from moderate to good (22-88% 
ee), in good to high yields (63-99%) and with highly favourable sulfoxide/sulfone selectivity.      
 
 
 
2.12 Osmium-catalyzed S-oxidations 
 
An osmium catalyst supported on layered double hydroxides (LDH) was reported by Kantam et 
al.515  Oxidations performed on methyl phenyl sulfide using N-methylmorpholine N-oxide 
(NMO) co-oxidant and a cinchona alkaloid as a chiral ligand afforded the sulfoxide 1.106 in 
good yields with moderate enantioselectivities (up to 51% ee) (Scheme 2.58).  These oxidations 
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were performed using a catalyst loading of 1% and osmium:ligand ratios from 1:1 to 1:10.  
When (R,R)-diisopropyl tartrate and (R,R)-DET were employed as chiral ligand 
enantioselectivity was low (24% and 26% ee respectively).  The authors included discussions on 
the effects of solvent, and the reusability of the LDH-OsO4 catalyst which showed that although 
recovery of the catalyst was possible, it did not perform well when reused.   
 
Scheme 2.58 
 
2.13 Niobium-catalyzed S-oxidations 
 
Katsuki and Miyazaki reported a niobium(salen) complex that was found to be an effective 
catalyst for sulfoxidation of various sulfides using urea-hydrogen peroxide (UHP) as the 
oxidant.339  The catalyst complex was created from niobium chloride dimethoxyethane (dme) 
[NbCl3(dme)] and salen 2.142 which, following screening of a range of salen ligands and a 
Schiff base, was found to produce the greatest asymmetric induction during the oxidation of 
thioanisole.  A 1:1 ratio of NbCl3(dme):salen ligand was employed and using a catalyst loading 
of 5 mol% methyl phenyl sulfoxide 1.106 was afforded in 59% yield, with 68% ee. 
  
 
 
Investigations of reaction time and temperature were discussed by the authors, as was the effect 
of the NbCl3(dme):salen ratio on the optical purity of the afforded sulfoxides.  Optimized 
catalyst conditions were then employed in the asymmetric oxidation of various sulfides, with 
the respective sulfoxides produced in good to high yields (58-94%), and with high optical 
purities (77-86% ee) (Scheme 2.59). 
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Scheme 2.59 
 
Bolm and coworkers also investigate the use of niobium in a catalyst system for asymmetric 
sulfoxidation. 310  During investigation of vanadium based catalysts the oxidation of thioanisole 
was carried out with an analogous niobium based system, however, despite high yield (86%), 
poor enantioselectivity was observed (7% ee). 
 
2.14 Bismuth-catalyzed S-oxidations 
 
In 2012 the first asymmetric oxidation of sulfides by a bismuth based catalyst system was 
reported by Chakraborty and Malik.516  Initial trials saw a range of Bi(III) compounds, such as 
Bi2O3, Bi(NO3)3·5H2O, BiCl3 and BiBr3, screened for catalytic activity towards oxidation of 
sulfides by TBHP (70% in water, 3 equiv).  The most efficacious catalyst in terms of sulfide to 
sulfoxide conversion was found to be Bi2O3 used in a loading of 10 mol%.  (S)-BINOL was 
employed as the chiral ligand (1 mol%) and when the catalyst system was used against a various 
aryl alkyl- and aryl benzyl- sulfides, the afforded (S)-sulfoxides were isolated in both high 
yields (81-90%)  and enantiopurities (78-98% ee) (Scheme 2.60); using this system no 
overoxidation to the respective sulfones was observed.     
 
 
Scheme 2.60 
 
2.15 Summary 
 
Asymmetric sulfide oxidation using metal based catalyst is one of the most studied methods for 
the production of chiral sulfoxides.  A number of biologically active sulfoxides such as 
Esomeprazole (S)-1.1, Modafinil 1.2, Sulindac 1.3 have been produced in single enantiomer 
forms using this method. 
 
One of the great advantages of this method is the versatility and range of catalyst systems 
available, with access to both enantiomers of the sulfoxide product made possible by the choice 
of the chiral ligand and its configuration.  Alongside the choice of metal to base the catalyst 
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system on there is also great potential for modification of a catalyst with the choice of ligand, 
oxidant, and through the use of additives in the reaction mixture. 
 
Great progress has been made in the area of metal catalyst sulfide oxidation since the 
groundbreaking work of Kagan in the 1980s.  Titanium based catalyst systems remain one of 
the most popular choices, whilst Vanadium based catalysts developed by Bolm are also 
effective however many require a number of steps to produce the Schiff base or salen type 
ligands. There are limitations however to these methods; the titanium-tartrate catalyst system 
developed by Kagan suffers from poor catalyst turnover numbers, and so is wasteful when 
carried out at a larger scale.  The use of vanadium catalysts is undesirable as it is believed to be 
hazardous to the environment.517 
 
Manganese, aluminium, ruthenium, copper, iron, zirconium, niobium, and bismuth based 
systems amongst others have been reported as successful catalysts for asymmetric sulfoxidation.  
In addition to sulfoxidation reactions, numerous examples of oxidative kinetic resolution using 
metal based catalyst systems have also been discussed.  
 
 Future developments in this area are likely to be directed towards more sustainable methods, 
using environmentally friendly reagents and lower catalyst loadings.  This last matter is 
particularly relevant in the application of Kagan type titanium tartrate catalyst systems; 
elucidation of the reaction mechanism and a greater understanding of the catalytic process 
involved would be a significant step towards improving the catalytic turnover and improving the 
efficiency of the asymmetric sulfoxidation reaction. 
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3 Introduction: Omeprazole and Esomeprazole 
 
3.1 Omeprazole: A Proton Pump Inhibitor  
 
Since its development in the late 1970s Omeprazole (Losec, Prilosec) ()-1.1 has become one of 
the world’s best selling drugs, with over 800 million patients treated and peak annual sales 
exceeding $6 billion.518-520  The revenue generated from this single drug in 2000 was reported to 
be greater than the total cash intake from the top five grossing films up to that time (Jurassic 
Park, Titanic, Independence Day and two Star Wars movies), as well as the combined value of 
all the most well known paintings of the top ten-grossing artists (Picasso, Monet, Renoir, Degas, 
Cézanne, Chagall, Matisse, Pissaro, van Gogh, and Modigliani).16 
 
 
 
Omeprazole belongs to a class of drugs named proton pump inhibitors (PPIs), which inhibit the 
molecular engine driving the generation of gastric acid secretion in the stomach.
521, 522  
Acid 
limiting drugs such as Omeprazole have been called “one of the most important advances in 
gastroenterology” and are part of the core treatments for the safe and effective management of 
gastric acid related diseases and injuries such as esophagitis, gastroesophageal reflux disease 
(GERD), peptic ulcer disease (PUD), and Zollinger-Ellison syndrome.523-525  Additional uses 
include prevention of non-steroidal anti-inflammatory drugs (NSAID) associated ulcers, and in 
combination with antibiotics are an integral part of eradication therapy for Helicobacter 
 pylori.526, 527  Heartburn and acid reflux are the most common minor symptoms treatable by 
administration of drugs such as Omeprazole, with 25-40% of the population in industrialized 
countries reporting these symptoms weekly.528, 529  PPIs have had a dramatic impact on the 
occurrence of life threatening conditions, such as perforated ulcers, and have allowed 
management of gastric disease to change from a largely surgical path, to one that is now 
treatable by a family physician or GP.530, 531   
 
Omeprazole has an excellent safety profile and is prescribed to women during pregnancy and 
those breastfeeding, as well as infants under one, and children.532, 533  It is also on the WHO 
essential medicines lists for both adults and children.534  Given the extent to which Omeprazole 
has been prescribed it is a well established and well observed pharmaceutical.  Long term PPI 
use has been investigated in regard to the effects of acid suppression and the resulting extended 
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pH increase in the gastric system, which may affect absorption of Fe, Ca, Mg, and vitamin B12 
since their absorption in the body is facilitated by acid.  There are conflicting reports, with some 
sources suggesting that this may lead to problems such as increased risks of fractures and risk of 
food sensitization; other reports indicate that long term PPI use is not problematic at all.526, 528, 
535, 536  Omeprazole does however have its limitations such as a short plasma half life, which can 
lead to the reoccurrence of symptoms especially at night.526  Omeprazole has also been found to 
increase the bioavailability of certain drugs with acid dependent absorption, and is known to 
increase the plasma half life of diazepam.526, 530, 537, 538 
 
In addition to its activity as a gastric acid inhibitor, Omeprazole and the single enantiomer form 
Esomeprazole have been investigated for a number of additional uses such as a treatment for 
preeclampsia, smoke induced lung injury, and as an inhibitor of atrial fibrillation.539-541  The 
antiprotozoal activity of Omeprazole has been considered with research conducted into its 
potential against the parasites Trichomonas vaginalis, Giardia intestinalis, Entamoeba 
histolytica, Schistosoma mansoni, and diseases such as Leishmaniasis.542-544  Omeprazole has 
also been investigated for its antioxidant properties, and has been a lead molecule for a number 
of drug discovery routes.545-547  There have also been reports of Omeprazole being used in the 
spectrophotometric determination of Ni(II) and the voltammetric determination of Cu.548, 549 
 
3.2 Development of Omeprazole 
 
Omeprazole, developed by Astra Pharmaceuticals in Sweden (later to become AstraZeneca), 
was the first of its class of substituted benzimidazole compounds, specifically developed to 
target the H+, K+ -adenosine triphosphatase (ATPase) gastric acid pump.  A number of other 
PPIs have been marketed by different companies, with Lansoprazole, Pantoprazole and 
Rabeprazole (3.1-3.3) featuring the same 2-pyridylmethylsulfinyl benzimidazole core structure;  
tenatoprazole 3.4 which features an imidazo-pyridine structure has been developed as a next 
generation PPI but not yet granted FDA approval.550  Although these drugs share a similar target 
and mechanism of action, the subtle differences between them affect the precise mechanism and 
location by which they inhibit the pump, resulting in slight clinical differences in their 
effectiveness.520, 551  Omeprazole 1.1 and Lansoprazole 3.1 are also marketed in their single 
enantiomer forms, Esomeprazole (S)-1.1, and Dexlansoprazole (R)-3.1.552  The development and 
manufacturing of the single enantiomer form of Omeprazole shall be discussed further in 
subsequent sections.   
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The inhibition of stomach acid production has long been a pharmaceutical target; the first drug 
recognized to inhibit gastric secretions was an extract of belladonna, the active agent of which 
was atropine- a potent but non selective muscarinic agent which inhibited the vagal stimulation 
of acid production.530  PPI predecessors such as Cimetadine and Ranitidine (Zantac) were the 
original blockbuster drugs, the former being the first drug ever to earn >$1 billion in a year.521, 
553  These drugs, developed in the late 70s and early 80s, acted as H2-histamine receptor 
antagonists, mediating the basal rate of production of acid.530, 554  Despite their great success 
they suffered from a short duration of action and it was found that patients developed a 
tolerance toward them in as little as seven days, reducing the efficacy of these drugs by as much 
as 50%.555  H2-histamine receptor blockers were quickly surpassed by PPIs upon the 
introduction of Omeprazole in Europe in 1988 and in the USA in 1990.518, 520, 526, 531 
 
The synthetic development of Omeprazole began in 1966, with research to find a gastric acid 
secretion blocker, initiated with the observation that some local anesthetics, such as Lidocaine, 
reduced acid production when given orally to man; this project ended in 1970 when compound 
3.5, which had been a highly effective antisecretory agent in rats, was found to have no effect in 
humans.556  From 1972 testing continued with the pyridylthioacetamide 3.6 (CMN131) as the 
lead compound, however hepatic toxicity issues due to the thioamide group saw this group 
replaced with other sulfur contained moieties to give compounds such as 3.7 and 3.8.  The latter 
of these two compounds was the starting point for investigations into compounds featuring two 
heterocyclic ring systems joined by a connecting chain from which compound 3.9 was 
generated and was found to exhibit  very good antisecretory activity. After H 124/26 3.9 was 
identified, it was discovered that it was already covered by a Hungarian patent which described 
the drug as a treatment for tuberculosis; the sulfoxide metabolite of 3.9 however was not 
covered and this metabolite, later to be name Timoprazole 3.10, was found to be an even more 
110 
 
potent antisecretory agent than its parent sulfide.531  Unfortunately both the sulfide and 
sulfoxide were found to be toxic, affecting the iodine recapture of the thyroid gland.553 
 
 
 
A literature search showed that some substituted mercapto-benzimidazoles did not affect the 
thyroid, leading to the introduction of such substitutions to the Timoprazole structure.  These 
substitutions eliminated the toxic effects without reducing the acid inhibition, and lead to the 
development of Picoprazole 3.11 in 1976.557  The following year, at a symposium on hydrogen 
ion transport George Sachs and coworkers presented data on the enzyme H+, K+ -ATPase, newly 
discovered by Ganser and Forte, showing it to be the final step in a common pathway for all 
types of acid secretion.530, 554, 556, 558  These findings raised the idea that the benzimidazole agents 
could be inhibitors of the H+, K+-ATPase, and the biochemical and synthetic research was 
continued in parallel.  Optimization of the substituted benzimidazole agents was carried out 
with the aim of finding a more potent agent than Picoprazole.  It was found that increasing the 
pyridyl pKa through addition of electron donating substituents on the pyridine ring increased the 
potency of the drug as an acid inhibitor.  The best analogue created was compound H 168/68, 
later to be named Omeprazole 1.1.  
 
 
 
The methoxy substituent on the benzimidazole ring was found to offer greater stability to the 
drug at neutral pH than for example, the benzimidazolyl substitution pattern of picoprazole 
3.11.557  It was found that the two methyl groups on the pyridine ring forced the methoxy group 
out of the plane of the ring, reducing the electron donating abilities and in turn the pKa; 
however this arrangement  was found to be the most potent of all, giving in vivo activity higher 
than any other combination of methyl and methoxy substitution patterns.556  By 1980, after more 
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than a decade of research a compound had been developed that had the optimal safety and 
pharmacological profile, however Omeprazole presented a number of challenges with regard to 
shelf life and stability.  A significant step toward solving these problems was the discovery that 
alkali salts of Omeprazole showed greater resistance to chemical instability and 
decomposition.557   
 
3.3 Mechanism of Action 
 
The parietal cells of the stomach secrete gastric acid in response to stimuli such as the sight, 
smell, taste, or thought of food, or the presence of food in the stomach or intestine.  The result 
of such stimuli is the activation of histamine, acetylcholine, or gastrin receptors (the H2, M3, and 
CCK2 receptors respectively), located in the basolateral membrane of the parietal cell, which 
initiate signal transduction pathways that all result in the activation of the H+,K+-ATPase 
(Figure 3.1).531  One of the great advantages of PPIs over other acid-inhibiting drugs lie in their 
mechanism of action; inhibition of the H+,K+-ATPase by Omeprazole will reduce acid secretion 
independently of how the secretion was stimulated.  This is in contrast to pharmacological 
agents such as the H2 receptor blockers Ranitidine and Cimetidine where their acid blocking 
effects can be overcome by food induced stimulation of acid production by acetylcholine or 
gastrin receptors.   
 
Omeprazole, like other PPIs, is a prodrug which is converted to the active agent via an acid 
catalyzed rearrangement in the parietal cells of the stomach.  Absorbed in the small bowel 
Omeprazole exists at physiological pH as a membrane permeable weak base, with a pKa of ~ 4 
corresponding to the pyridine nitrogen.552, 556  It is transported to the parietal cells, of which 
there are over one billion of, where it selectively accumulates in the acidic seceretory canaliculi 
which is the only space in the human body with a pH below 4.530  With secretion of gastric acid 
the extracellular lumen of the canaliculus achieved a pH as low as 1, resulting in a 1000-fold 
increase in concentration of Omeprazole compared to the plasma concentration.559  Omeprazole 
has a half life of approximately 2 minutes at pH 1 so rapidly undergoes activation by 
protonation and is converted to the achiral sulfenic acid and sulfenamide active forms, which 
are permanent cations making the molecules relatively membrane impermeable.530  These active 
forms are highly reactive and thiophilic and covalently bind to luminally accessible cysteine 
residues on the H+,K+-ATPase irreversible inhibiting acid secretion until replacement pumps can 
be created, which can take up to 36 hours.560  The covalent binding involved in the H+,K+-
ATPase inhibition results in a duration of action that typically outlasts the plasma half life of 
Omeprazole.   
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Figure 3.1 Representation of the parietal cell of the stomach; Image used with permission from ref
531
 
 
It is estimated that only 70% of proton pumps are inhibited at anytime as not all gastric acid 
pumps are active to produce the acid required to convert Omeprazole into its active form.  It 
takes 26-96 hours for a steady state of acid inhibition to be achieved, and for long term relief 
from acid related symptoms the patient must take regular, that is at least daily, doses of the drug 
with pre-breakfast administration found to be most effective.552, 554 
 
As Omeprazole is acid labile, measures must be taken to protect it from exposure to the acidic 
environment of the stomach en route to the small bowel where the drug is absorbed into the 
bloodstream.526  There are a variety of delivery systems available which prevent absorption until 
an environmental pH greater than 5, such as enteric coated tablets, gelatin capsules, or coated 
granules which are supplied as powder for suspensions.520, 561  Some forms are packaged in 
combination with bicarbonate to provide pH neutralization, and some PPIs are available as IV 
preparations.520, 526   
 
The mechanism by which Omeprazole rearrangement occurs has been well studied.556, 560, 562-566  
Under acid conditions Omeprazole is transformed to the spiro intermediate 3.12 which arises as 
a result nucleophilic attack of the pyridine nitrogen on the C2-position of the protonated 
benzimidazole 3.13 (Scheme 3.1).  Aromatization to the sulfenic acid 3.14 is followed by 
dehydration to the tetracyclic sulfenamide 3.15 which reacts with the target enzyme and 
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deactivates it via formation of the disulfide complex 3.16.  Initially it was believed that the 
substituents on the pyridine ring were the main influence on the rate of reaction of conversion of 
Omeprazole and other PPIs to their active forms.  Subsequent studies however showed that the 
reaction rate is influence by the protonation of the benzimidazole and the nucelophilicity of the 
unprotonated pyridine.562    
 
 
Scheme 3.1 
 
3.4 Synthesis of Omeprazole  
3.4.1 Structure and nomenclature of Omeprazole 
 
Omeprazole can exist in two tautomeric forms, either the 5-methoxy or the 6-methoxy 
benzimidazole form.567, 568  Conventionally Omeprazole has been represented in the literature as 
the 5-methoxy isomer; however studies have shown that the 6-methoxy species may be the 
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more common form in both the solid state and in solution.569, 570  Crystallographic data 
published on samples of racemic Omeprazole have clearly shown the 6-OMe form, however in 
more than one instance the molecule has been erroneously named as the 5-OMe 
benzimidazole.571, 572   
 
 
 
For the sake of accuracy, and in keeping with the solid state structures observed by the X-ray 
diffraction studies discussed in chapter 6, Omeprazole has been represented as the 6-OMe 
tautomer throughout this body of work, and by analogy this structural convention has continued 
for other methoxy benzimidazole contined species.   
 
3.4.2 Synthesis of Omeprazole 
 
Omeprazole can be obtained through oxidation of the sulfide Pyrmetazole 3.17 which in turn is 
created through the reaction of benzimidazole thiol 3.18 and pyridine salt 3.19 in the presence 
of a base (Scheme 3.2).573  The thiol and the pyridine salt are commercially available to 
purchase in mutigram amounts, however that was not always the case leading to the 
development of a number of synthetic routes for the preparation of Omeprazole and its 
precursors.      
 
 
Scheme 3.2 
 
Branstrom et al., who developed Omeprazole at Astra Pharmaceuticals, disclosed their method 
for the preparation of the tetrasubstituted pyridyl species 3.20 for use en route to Omeprazole 
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1.1 (Scheme 3.3).556, 574  Oxidation of trimethyl pyridine 3.21 was performed by hydrogen 
peroxide in acetic acid to give N-oxide 3.22, followed by nitration giving the 4-nitro pyridine 
derivative 3.23.  Methoxy substitution of 3.23 displaced the nitro group to give the 4-methoxy 
pyridyl species 3.24 of which subsequent treatment with acetic anhydride gave the 2-
pyridylmethyl acetate 3.25.575  The corresponding alcohol derivative 3.26 was afforded through 
treatment of 3.25 with base, followed by reaction with thionyl chloride to displace the hydroxyl 
group with chloride giving the target pyridine 3.20.  Omeprazole 1.1 was obtained through 
reaction of thiol 3.18 with the pyridine 3.20 in the presence of NaOH; oxidation of Pyrmetazole 
sulfide with mCPBA gave 1.1 as a racemic mixture.53  
 
 
Scheme 3.3 
 
Numerous patents have been granted for alternative methods for the synthesis of Omeprazole 
and its precursors; Al Badr gives an overview of ten of these patented synthetic routes in a book 
chapter dedicated to Omeprazole.576  Large scale oxidations from the pharmaceutical industry 
giving Omeprazole 1.1 from Pyrmetazole 3.17 have been reported which use inorganic oxidants 
such as sodium perborate, sodium hydrochlorite or sodium percarbonate in the presence of Mo 
catalysts (Scheme 3.4).91 
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Scheme 3.4 
 
Bhalero and coworkers reported a novel synthetic route to Omeprazole 1.1, via the formation of 
the benzimidazole ester 3.29 and subsequent in situ reaction with the pyridyl Gringard 
intermediate 3.30 (Scheme 3.5).577  Omeprazole was obtained in a yield of 30%. 
 
 
Scheme 3.5 
 
3.5 Esomeprazole: A single enantiomer proton pump inhibitor 
3.5.1 Development of a new proton pump inhibitor 
 
Following the global success of Omeprazole the development team at Astra began the hunt for a 
successor.  Despite its excellent acid inhibitory ability Omeprazole was found not to be equally 
effective throughout the population, with some patients experiencing uncontrolled symptoms 
and requiring additional dosages to sufficiently control their acid production.  By 1987 the 
search for the next proton pump inhibitor was underway, with the aim to find a compound 
which offered improved pharmacokinetics and metabolic profile, which would reduce 
interpatient variability with regard to acid control.557     
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A variety of analogues were produced based on the chemical and mechanistic knowledge  
gained from studying Omeprazole and its target enzyme, with over 30 scientists creating and 
screening hundreds of compounds.  Only a small number of analogues were found to satisfy the 
preclinical goals from which four compounds, including sulfoxides H 259/31 3.31 and  
H 326/07 3.32, were chosen for human testing after passing rigorous preclinical testing.   
 
Assessment of the key parameters of pharmacokinetic properties, acid inhibition ability, and 
safety revealed that only one species proved superior to Omeprazole – H 199/18, the (S)-
enantiomer of Omeprazole (S)-1.1, or Esomeprazole as it became known. 
 
 
 
The finding that Esomeprazole performed better than its racemate Omeprazole was surprising 
for the development team.  Given the knowledge that the mechanism of acid inhibition occurred 
via an achiral sulfenamide intermediate it was assumed that both enantiomers would have an 
identical effect.  Supporting this theory were the findings from in vitro testing on isolated 
gastric glands which had shown identical dose-response curved for acid inhibition for both 
enantiomers.  The possibility was raised however that the disparity in efficacy between the 
racemic Omeprazole and the single enantiomer form of the sulfoxide may be attributed to 
differences in metabolism; subsequent testing showed this hypothesis to be correct.578-582 
 
Proton pump inhibitors, including Omeprazole, undergo hepatic metabolism via the cytochrome 
P450 system via the isoforms CYP2C19 and CYP3A4.559, 583  The CYP 2C19 enzyme 
metabolizes Omeprazole to the hydroxyl and 5-O desmethyl metabolites, while the CYP3A4 
converts it to the sulfone559, 584  The two enantiomers undergo the same transformations but 
there are quantitative differences in the relative dependence on the two enzymes.  Hydroxylation 
via CYP2C19 is responsible for 98% of the total intrinsic clearance of the R-enantiomer, but 
only for 70% of the S-enantiomer.  In addition the CYP3A4 is responsible for 2% of clearance 
of the R-enantiomer, but 30% for Esomeprazole.580, 584-587  Metabolism by CYP3A4 occurs at a 
slower rate than by CYP2C19, and as a result Esomeprazole has a lower total intrinsic clearance 
than the R-enantiomer and its first-pass metabolism is decreased compared with the racemate, 
leading to higher plasma levels of the drug when Esomeprazole is used in the single enantiomer 
form.529, 557, 584, 585  As a result of the higher metabolic stability and improved bioavailability 
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afforded by Esomeprazole a more effective control of acid inhibition is achieved compared to 
the racemate at the same dosage.585-587   
 
Testing of Esomeprazole also revealed improved performance towards interindividual 
variability compared with the racemate Omeprazole.  Genetic polymorphism affects the 
metabolism of PPIs and therefore influences the extent of acid control between individuals.  The 
CYP 2C19 enzyme is expressed polymorphically meaning that some individuals do not express 
this enzyme.41, 43 This leads to variation within the population with respect to how efficiently 
metabolism of Omeprazole occurs, with poor metabolizers making up 3% of the Caucasian 
population, and 15-20% in Asian populations.559, 583, 588  The pharmacokinetic differences for 
Esomeprazole compared to Omeprazole means that the significant difference in the relative 
dependence on CYP2C19 and CYP3A4 leads to a lower impact of the polymorphic metabolism 
in vivo.  For the majority of the patient population (extensive metabolizers), the improved 
pharmacokinetics of Esomeprazole results in higher bioavailability, while for those considered 
poor metabolizers exposure is limited due to the greater involvement of the CYP3A4 enzyme in 
metabolizing the (S)-enantiomer.  Overall the use of Esomeprazole was found to gives a more 
consistent interpatient response in regards to acid inhibition.559, 583     
 
3.5.2 The Chiral Switch 
 
In the pharmaceutical industry a chiral switch is defined as when a chiral drug that has 
previously been claimed, approved, and marketed as a racemate, or mixture of diastereomers, is 
subsequently redeveloped as a single enantiomer drug.589  The development of Esomeprazole is 
one of the most well known examples of a drug undergoing a “chiral switch”, and as well as 
being one of the most successful it may also possible one of the most controversial.590-592  The 
development of a single enantiomer form of a drug can offer a number of therapeutic 
advantages, such as reducing metabolic load on the body, increasing potency of a drug, and 
reducing side effects.  This is particularly relevant when one enantiomer of a drug is ineffective 
or has adverse effects associated with it.587, 591, 593-595   
 
In the case of Esomeprazole there have been questions raised as to whether or not a single 
enantiomer form actually offers any significant advantage over the original racemate.590, 596, 592  
One of the sources of doubt comes from publication of clinical trials which claim to show 
Esomeprazole superiority over Omeprazole and other PPIs but which compared non equivalent 
dosages of the drugs under inspection.582  It is worth noting that the recommended daily dose of 
Esomeprazole is 40 mg, whilst that of Omeprazole is only 20 mg, leading some to suggest that 
the effectiveness of Esomeprazole is simply due to an increased dosage of the medication.597, 598  
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There are also those critics who suggest that chiral switches are simply one way of extending a 
patent franchise and to protect against competitions from generic racemates.591, 599  The 
development of single enantiomer drugs has also been criticized for placing an unfair financial 
burden on the patient, one which outweighs the therapeutic advantages of the single enantiomer 
drugs, for example Esomeprazole can cost up to 10 time as much as the racemic drug 
Omeprazole.590  Despite these criticisms, Esomeprazole has gone on to be a blockbuster drug in 
its own right, marketed in the form of the magnesium salt as Nexium, with peak global sales of 
$8.1 billion in 2011.588   
 
3.5.3 Asymmetric synthesis of Esomeprazole  
3.5.3.1 Industrial Process Development of Esomeprazole 
 
The preparations of the chiral sulfoxide Esomeprazole (S)-1.1 typically involve asymmetric 
oxidation of Pyrmetazole 3.17, or resolution of the derivatized racemate.  Both of these methods 
were employed by Federsel and Larsson who have written about the process of developing 
Esomeprazole and how they successfully developed a method for synthesis of Esomeprazole 
from gram scale to multi ton per annum production.15, 519, 600  The first approach that was taken 
by Astra was resolution of racemic Omeprazole. 
 
The identification of Esomeprazole as a potential successor to Omeprazole raised the issue of 
how to obtain sufficient amounts of the single enantiomer sulfoxide for in vivo testing. With 
unlimited access to an abundant amount of the racemic sulfoxide it was felt that it would be 
logical to pursue a resolution type procedure.  Analytical and semi-preparative separation of the 
enantiomers of Omeprazole had been achieved on a milligram scale using chiral 
chromatography, but a larger scale resolution was required as 500 g of material had been 
requested for the first batch of the separated enantiomers.139, 601  Derivatization of Omeprazole 
for resolution was not straightforward due to its sensitivity towards acid, however a procedure 
was developed enabling the covalent attachment of a chiral handle prior to diastereomeric 
separation (Scheme 3.6).  Racemic Omeprazole was reacted with formaldehyde to give 3.33 via 
substitution on the benzimidazole nitrogen with a hydroxylmethyl group.  Chloro-
dehydroxylation by thionyl chloride to give compound 3.34 was followed by O-alkylation with 
(S)-mandelic acid to give a diastereomeric mixture of the esters 3.35.  Production of the 
mandeloyl derived esters was labour intensive, taking almost 300 man-hours over a period of 40 
days.  Starting from 40 kg of the racemic Omeprazole the three step procedure afforded 5.3 kg 
of the material in a purity of 93% pure, equating to a yield of approximately 9%. 
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Scheme 3.6 
 
The next step was the separation of the derivatized diastereomers 3.35 by chromatography; this 
procedure was also labour and resource intensive, requiring 10 m3 of eluents for less than 1 kg 
of each enantiomer of the sulfoxide, and complicated by the necessity of a rapid work up of the 
collected fractions due to the potential for decomposition and racemisation of the Omeprazole 
derivatives.  Nevertheless separation was achieved, giving a chromatographic yield of 65% for 
each diastereomer.  Conversion under basic conditions gave around 900 g each of the target 
sulfoxide enantiomers, in optical purities of 96% ee, representing an overall yield of 4.5% based 
on 40 kg of the racemic starting material.  The formation of the sodium salts not only improved 
the stability of the Omeprazole enantiomers but also converted the oily neutral forms into the 
crystalline solids of the salt form.  Further loss of material during salt formation left just enough 
of each enantiomer to fulfil the original order of 500 g.  Whilst the first attempt to scale up the 
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production of the Omeprazole enantiomers had achieved its original goal, another order was on 
its way but this time for 5 kg, ten times the amount that had just been produced.   
 
Optimization of the resolution strategy was able to greatly improve the yield for certain steps.  
For example, production of the chloromethyl species 3.34 was enhanced by isolation of the 
CH2OH adduct 3.33 prior to chloro-dehydroxlyation resulting in an increase in the yield of 3.34 
to 60-70%.  Improvements such as this however were not enough and other methodologies were 
considered for the large scale production of Esomeprazole.  Biological strategies, such as kinetic 
resolution through bioreduction of racemic Omeprazole, or oxidation of the Omeprazole sulfide 
using various microorganisms were found to be workable but were not carried forward.  New 
advances in the field of asymmetric sulfoxidation gave the best hope for the development of a 
new synthetic direction.   
 
Asymmetric oxidation via the use of Davis oxaziridines was conducted, affording Esomeprazole 
(S)-1.1 in 40% ee.  As Omeprazole crystallizes as a racemate therefore it was possible to raise 
the optical purity of Esomeprazole to 94% ee by a crystallization process, leaving behind 
enantiomerically enriched Esomeprazole in the mother liquor.  Despite the ability to obtain 
Esomeprazole in high enantiopurity this methodology was not feasible on a large scale due to 
the cost involved in the use of the oxidizing agents in stoichiometric amounts. 
 
The titanium tartrate catalyst systems developed by Kagan for asymmetric sulfoxidation were 
tested but initial examination of the process gave disappointing results, affording the target 
sulfoxide in just 5% ee.  It was soon discovered however that the addition of a base to the 
reaction mixture had a substantial impact upon improving the enantioselectivity of the catalyst 
system, allowing for the development of a successful methodology in which Esomeprazole 
could be produced in high enantiomeric purity on a large scale.   
 
In 2000, ten years after the original patent on the procedure was filed, a paper was published by 
von Unge et al. which reported the asymmetric synthesis of Esomeprazole as developed by 
AstraZeneca.125  Using cumene hydroperoxide (CHP) as the oxidant, the Omeprazole sulfide 
Pyrmetazole 3.17 was stereoselectively oxidized in the presence of a titanium-diethyl tartrate 
(DET) catalyst to give Esomeprazole (S)-1.1 in over 94% ee; formation of the sodium salt 
(S)-3.36 gave the sulfoxide in an enantiomeric excess of > 99.5% in a yield of 55% (Scheme 
3.7).  This protocol was employed on a multikilogram scale to produce 3.83 kg of sodium 
Esomeprazole (S)-3.36.  This methodology was also employed for the enantioselective synthesis 
of seven Omeprazole analogues, with the optical purities of the obtained crude sulfoxides close 
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to or above 90% ee; the synthesis of the proton pump inhibitor Dexlansoprazole has also been 
reported using similar conditions602 
 
 
Scheme 3.7 
 
The attainment of Esomeprazole in high optical purity was achieved by three modifications to 
the original Kagan type oxidation protocol.  Firstly, preparation of the catalyst, comprising of 
Ti(OiPr)4, (S,S)-DET and water was performed in the presence of the sulfide 3.17, with care 
taken over the precise order of reagent addition.  Secondly, aging of the catalyst was performed 
by allowing the components of the catalyst and the sulfide to be stirred at an elevated 
temperature to allow for equilibration of the catalyst complex.  Thirdly, the oxidation was 
performed in the presence of the base N,N-diisopropylethylamine (DIPEA), also known as 
Hünig’s base.125 
 
An optimized ratio of Ti(OiPr)4:DET:H2O of 0.3:0.6:0.1 equiv (with respect to sulfide substrate) 
was employed, equating to a catalyst loading of 30 mol%.  Enantioselectivity in the oxidation 
process was observed when a catalyst loading of 4 mol% was used, with Esomeprazole obtained 
in 91% ee.  It was, however reported that the use of catalyst loadings lower that 30 mol% had a 
detrimental effect on the reproducibility of the reaction enantioselectivity.  The role of the base 
DIPEA in the reaction remains unclear, although it has been suggested that the inclusion of the 
base helped stabilize the acid sensitive sulfoxide product.22  von Unge and coworkers reported 
that using other bases, such as triethylamine and 4-methylmorpholine was possible but gave the 
product sulfoxide 1.1 with lower enantiopurity.  When stronger bases, such as  
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1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were used the enantioselective of the reaction 
decreased dramatically, suggesting that the role of the base was more than just as an agent to 
abstract the benzimidazole NH proton.  Additionally, it was observed that using a stronger base 
led to the predominant formation of the (R)-enantiomer of Omeprazole, despite the continued 
use of (S,S)-DET as the chirality source.125  The importance of the benzimidazole NH in the 
sulfide substrate, with respect to the reaction enantioselectivity, was highlighted by the fact that 
sulfoxidation of N-alkylated benzimidazole species proceeded to give only racemic products.  
This was also the case for sulfide substrates lacking an imidazole or benzimidazole type group.  
From these findings it was hypothesized that the NH group of the benzimidazole and/or the base 
DIPEA may participate in the chiral titanium catalyst complex.   
 
3.5.3.2 Alternative syntheses of Esomeprazole 
 
A number of alternative strategies for the asymmetric synthesis of Esomeprazole have been 
published.  These include metal and non metal based oxidations of the prochiral sulfide 
Pyrmetazole 3.17, resolutions of the racemic sulfoxide Omeprazole 1.1, and chromatographic 
separations.     
 
3.5.3.2.1 Resolution of racemic Omeprazole 
 
Chromatographic resolution 
Esomeprazole (S)-1.1 was resolved for the first time analytically in 1984 using an affinity 
chromatographic technique with immobilized bovine serum albumin.139  In 1990 the 
semipreparative resolution of Omeprazole enantiomers was achieved on a 
trisphenylcarbamoylcellulose-based stationary phase.601  Since that time there have been a 
number of reports published covering many aspects of the analytical separation of Omeprazole 
by HPLC methods.126, 127, 603-607  Supercritical fluid chromatography has been employed for the 
analytic, semipreparative and preparative resolution of Omeprazole enantiomers.130, 608-611      
 
The phenomenon of self-disproportionation of enantiomers (SDE) was observed for 
Omeprazole by Song et al.150  It was observed that when non racemic mixtures of the sulfoxide 
were eluted under achiral column chromatography conditions, using a silica stationary phase, 
enrichment in the optical purity of the first fractions occurred, while depletion was observed in 
the final fractions.  Across a range of solvents and solvent mixtures the differences in ee (ee) 
between the first and the last were measured.  Starting from a sample of Esomeprazole (76% ee) 
ees of up to 39% were observed, with the largest effect seen when a 2:1 mixture of EtOAc–
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CH2Cl2 was employed as the eluent; it was also observed that some decomposition occurred 
under these conditions.  When racemic Omeprazole (0% ee) or pure Esomeprazole (100% ee) 
was examined no change in optical purity was observed between the first and last fraction when 
methyl isobutyl ketone was used as the solvent.  It was proposed that the formation of 
heterochiral dimers of Omeprazole was the reason for the observed SDE during achiral gravity 
driven chromatography.   
 
Classical resolution 
Reddy et al. described the process for the separation of Esomeprazole from the racemic 
sulfoxide, affording (S)-1.1 in an optical purity of > 99.5% ee (Scheme 3.8).612-614   
 
 
Scheme 3.8 
 
Omeprazole 1.1 was treated with sodium hydroxide to afford the sodium salt 3.36.  Ti(OiPr)4 
and (S,S)-DET and triethylamine were added to a solution of 3.36, followed by the addition of 
(S)-mandelic acid.  The mandelic acid salt of Esomeprazole precipitate was collected and 
neutralized to give Esomeprazole (S)-1.1 with an optical purity of > 99.5%.   
 
Deng et al. reported the resolution of both enantiomers of Omeprazole via inclusion 
complexation with the chiral host BINOL 1.43.571  Recrystallisation of the inclusion complex 
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followed by separation of the species by column chromatography gave Esomeprazole (S)-1.1 in 
98% ee.  Similarly using (R)-BINOL 1.43, the (R)-enantiomer of Omeprazole was obtained in  
> 99% ee.  Although it was not possible to grow crystals suitable for analysis of the inclusion 
complex by X-ray crystallography, IR analysis indicated the sulfinyl group did not contribute to 
the H-bonding within the inclusion complex  
 
 
 
3.5.3.2.2 Non-metal based oxidations 
 
Oxidations by oxaziridines and oxaziridinium salts 
Esomeprazole-sodium (S)-3.36 was obtained in 67% yield and 99% ee using a stoichiometric 
amount of (1R)-(-)-(10-camphorsulfonyl) oxaziridine (1R)-1.122, with the base DBU added to 
the reaction mixture to facilitate the reaction by activation of the prochiral sulfide 3.17 (Scheme 
3.9).
615
  The sodium salt was prepared directly from the crude material of the reaction.   
(R)-Rabeprazole (R)-3.3 was prepared in a similar fashion, using the (1S)-enantiomer of the 
oxaziridine 1.122; the target sulfoxide was afforded in 76% ee which was increased to 97% ee 
after transformation to the sodium salt.  Delsarte et al. recently described a similar process 
which employed oxaziridine (1R-1.122) and the base DBU in the asymmetric synthesis of 
Esomeprazole.616  The final product was the potassium salt of Esomeprazole (S)-3.38 which was 
achieved in 80-85% and 75% ee.     
 
 
Scheme 3.9 
 
The asymmetric synthesis of the Esomeprazole analogue (S)-Lansoprazole from the sulfide 3.39 
using the chiral oxaziridinium salt 1.149 was reported by del Bohé et al.  Sufoxide (S)-3.1 was 
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afforded in 97% ee using a stoichiometric amount of the oxaziridinium oxidizing agent (Scheme 
3.10). 
 
 
Scheme 3.10 
 
Biologically mediated synthesis of Esomeprazole  
Babiak et al. reported the oxidation of Pyrmetazole 3.17 by the gram positive bacterium 
Lysinibacillus sp. B71, isolated from soil polluted with elemental sulfur.  Esomeprazole 
obtained in enantiopure form, in a conversion of 77%.617  A Baeyer-Villiger monooxygenase 
(BVMO) mediated oxidation affording Esomeprazole (S)-1.1 has been reported, as has the 
production of the same sulfoxide from isolated and modified cyclohexane monooxygenases 
(CHMOs) from Acinetobacter calcoaceticus NCIMB9871.
618-620
  Microbial oxidation of 
Rabeprazole sulfide by the mold Cunninghamella echinulata MK40 has been reported, with the 
(S)-sulfoxide afforded in > 99% ee.621 
  
3.5.3.2.3 Metal based oxidations 
 
Titanium mediated synthesis of Esomeprazole  
Federsel et al. employed a modified von Unge protocol for the synthesis of Esomeprazole 1.1, 
altering the order of addition of the reagents.622  (S,S)-DET and water (0.6 and 0.1 equiv 
respectively) were added to sulfide 3.17 the mixture heated at 50 C for a 15 min; subsequently 
Ti(OiPr)4  (0.3 equiv) was added and warming continued for a further 45 minutes. Following 
addition of DIPEA (0.3 equiv) and CHP (1.0 equiv) the temperature of the reaction mixture was 
adjusted to 35 C, and stirring continued for 2 hours.  Esomeprazole was obtained in the form of 
the potassium salt (S)-3.38 (78% yield), with an optical purity of 97% ee (Scheme 3.11).  
  
Follow up investigations described investigation of the catalyst active species via atmospheric 
pressure chemical ionization-mass spectrometry (APCI/MS), from which it was hypothesized 
that addition of water to the catalyst reaction mixture facilitated the formation of mononuclear 
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titanium species believed to be the active catalyst intermediates.623  NMR studies were also used 
to investigate the reactions, from which it was concluded that under catalytic conditions the 
amine DIPEA was able to coordinate to the titanium metal centre and dissociate the coordinated 
substrate, in this case an imidazole species.     
 
 
Scheme 3.11 
 
Guoyong et al. used a tartramide as the chiral ligand in the Ti-mediated oxidation of 
Pyrmetazole 3.17 to give Esomeprazole (S)-1.1 in high yield and enantioselectivity (92%, 95% 
ee) (Scheme 3.12).624  Ti(OiPr)4 and the ligand 3.40 were added to a solution of the sulfide and 
heated for one hour, after which time water was added.  With this methodology no additional 
base was required in order to achieve high enantioselectivity.   
  
 
Scheme 3.12 
 
The (S)-enantiomers of the PPIs Lansoprazole, Pantoprazole and rabebprazole (S)-3.1-3.3 were 
all obtained in high yield and enantiopurity under this protocol (85-89%, 94-96% ee). 
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The asymmetric oxidation of Pyrmetazole 3.17 using the preformed titanium salalen complex 
3.41, prepared from Ti(OiPr)4 and ligand 3.42(Scheme 3.13), was reported by Bryliakov and 
coworkers.387, 422, 625, 626  Despite the authors repeatedly discussing the synthesis of Esomeprazole 
(S)-1.1 their results instead state that they obtained the (R)-enantiomer of Omeprazole.  
Nevertheless, the sulfoxide (R)-1.1 was obtained in high yield and optical purity (96%, 96% ee) 
using a catalyst loading of 1 %.  It is presumed that using the opposite enantiomer of the chiral 
ligand would afford the (S)-enantiomer of the sulfoxide.  Aqueous H2O2 (1.05 equiv) was 
employed as the oxidant, rendering it necessary for a two phase solvent system to be employed.  
(R)-Lansoprazole 3.1 was also obtained using this system, with the employment of the chiral 
ligand 3.43 to prepare the Ti-salalen complex 3.44.   
 
 
Scheme 3.13 
 
A titanium catalyst system formed in situ from Ti(OiPr)4 and the hexa-aza-triphenolic 
macrocycle ligand 3.45 was found to afford Esomeprazole as the sodium salt (S)-3.36  in 
excellent enantioselectivity and high yield (72% yield, > 99.5% ee) (Scheme 3.14).627  
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Scheme 3.14 
 
For this reaction Ti(OiPr)4 and water was added to a solution of macrocycle 3.45 in toluene then, 
after stirring for one hour at 25 C, the sulfide substrate 3.17 was added followed by heating to 
50 C for a further 60 minutes.  CHP (1.3 equiv) was employed as the oxidant and a base such 
as DIPEA was necessary for high enantioselectivity of the sulfoxidation reaction.  A ratio of 
1:2:2 for the ligand 3.45:H2O:DIPEA was established as optimal for the achievement of high 
sulfoxidation enantioselectivity.  Examining the effect of catalyst loading on the reaction 
showed that the use of a Ti(OiPr)4:3.45 ratio of 47:13 (mol%) gave Esomeprazole in excellent 
optical purity (> 99.5% ee), although a ratio of 66:13 also afforded the sulfoxide in high 
enantioselectivity (99% ee); it is unclear from the published data whether these figures relate to 
the sulfoxide product as the free base or as the final sodium salt form.   

Jiang et al. developed a sulfoxidation procedure for the synthesis of Esomeprazole using the 
catalyst complex formed in situ from Ti(OiPr)4 and th e hydrobenzoin type ligand 3.46.
628  In 
relative ratios of 1:2:10 Ti(OiPr)4:3.46:H2O a catalyst loading of 5 mol% was employed, 
affording Esomeprazole (S)-1.1 in high yield and enantiopurity (92%, 96% ee) (Scheme 3.15).  
The reaction was performed on a multigram scale and gave the sulfoxide in > 99% ee, obtained 
as the sodium salt (S)-3.36 (70% yield).  Using this catalyst system the (S)-enantiomers of the 
PPIs Lansoprazole, Pantoprazole and Rabeprazole (S)-3.1-3.3 were also obtained in high yields 
and enantioselectivity (81-90%, 82-92% ee).  
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Scheme 3.15 
 
Sun et al. employed the chiral diol 3.47 in the Ti-mediated asymmetric sulfoxidation of 
Pyrmetazole 3.17.377  The catalyst complex was formed in situ from Ti(OiPr)4 and the diol, 
which were employed in a ratio of 0.10:0.15 (mol%) which equates to a catalyst loading of 10 
mol%.  Esomeprazole (S)-1.1 was obtained in good yield and enantioselectivity (72%, 76% ee) 
(Scheme 3.16).  
 
 
Scheme 3.16 
 
Khomenko and coworkers developed a method for the synthesis of Esomeprazole which 
mimicked the conditions used by von Unge et al. however instead of using DIPEA the chiral 
amine (R)-N,N-dimethyl-1-phenylethanamine was used instead.629  The catalyst complex formed 
in situ comprised of Ti(OiPr)4, (S,S)-DET and H2O in a ratio of 46:70:30 (mol%), and was 
prepared in the presence of the sulfide 3.17.  Amine (R)-3.48 (49 mol%) was added prior to 
addition of the oxidant CHP (0.95 equiv).  Esomeprazole was obtained in 82% with an optical 
purity of 79% ee; conversion to the Na-salt (S)-3.36 afforded the sulfoxide in 57% yields, with 
> 99.5% ee (Scheme 3.17).   
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Scheme 3.17 
 
The use of the opposite enantiomer of the amine in an analogous procedure gave Esomeprazole 
(S)-1.1 in similar yield but higher enantioselectivity (82%, 84% ee); transformation to the Na-
salt (S)-3.36 occurred giving an overall yield of 64% and optical purity of > 99.5% ee.  It was 
proposed by the authors that the chiral amine acted as a second chiral ligand in the active 
catalyst complex as the change in absolute configuration of the amine had been observed to 
have an effect on the overall enantioselectivity of the reaction.  
 
Kagan et al. examined the enantioselectivity of a range of asymmetric sulfoxidation reactions in 
order to identify the best procedure for the synthesis of Esomeprazole analogue  
(S)-Tenatoprazole (S)-3.4.630  Employment of Bolm’s vanadium catalyzed asymmetric 
sulfoxidation method, using a catalyst complex formed from VO(acac)2 and a chiral Schiff base 
derivative saw (S)-Tenatoprazole (S)-3.4 obtained in 80% ee, which was raised to 99% ee after 
two recrystallizations.442  A tungsten mediated synthesis using a (WO)3-cinchona alkaloid 
catalyst system, which had also been employed for the synthesis of (S)-Lansoprazole (S)-3.1, 
was also investigated in for the synthesis of (S)-Tenatoprazole, giving the sulfoxide (S)-3.4 in 
good yield by only moderate enantioselectivity (75%, 41% ee).512  Under conditions similar to 
the von Unge Esomeprazole synthesis, including the use of the base DIPEA, the  
(S)-Tenatoprazole (S)-3.4 was afforded in 63% ee and 73% yield.  The best methodology found 
was a titanium mediated sulfoxidation which gave the target sulfoxide in the high yield and 
enantioselectivity (90%, > 99% ee) with (1R,2S)-cis 1-amino-2-indanol (1R,2S)-3.49 used as the 
source of chirality (Scheme 3.18). 
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Scheme 3.18 
 
A ratio of < 1:2 for Ti(OiPr)4:ligand was found to give the best results, and it was found that the 
addition of water to the reaction mixture had a deleterious effect on the chemical and optical 
yield of the sulfoxide.  Ageing of the catalyst mixture was also found to be unfavourable.  Other 
additives such as iPrOH and DIPEA were found to have no effect upon the reaction outcome. 
The cis configuration of the -amino alcohol was found to be crucial in ensuring a good 
enantiomeric outcome, and it was concluded that both the primary amine and hydroxyl group 
were important for good enantioselectivity.  Curiously the reaction procedure sees the addition 
of the catalyst reagents and the oxidant carried out twice.  Ti(OiPr)4 and the chiral ligand were 
added to the sulfide (in a ratio of 0.25:0.50 equiv) followed by 1.16 equiv of CHP.  After 
stirring at 0 C for 6 hours this process was repeated using the same amounts of each reagent.  
No explanation was included as to why the reaction was carried out in this manner. 
 
Vanadium mediated synthesis of Esomeprazole  
The silica supported vandium complex 3.50 was employed by Shen et al. as a heterogeneous 
catalyst for the asymmetric sulfoxidation of Pyrmetazole 3.17.631  Using H2O2 as the oxidant 
Esomeprazole (S)-1.1 was obtained in high yield and good enantioselectivity (92%, 68% ee) 
(Scheme 3.19).   
 
 
Scheme 3.19 
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An oxidative kinetic resolution of racemic Omeprazole was reported by Khomento et al.632  The 
active catalyst complex was formed in situ from VO(acac)2 and the chiral ligand 3.51; the base 
DIPEA was added to the catalyst complex solution prior to addition of the racemic sulfoxide 
which was then followed by addition of the oxidant (CHP, 1 equiv).  A 1 mol% catalyst loading 
was employed, with a reagent ratio of 1.0:1.5:1.0 for VO(acac)2:3.51:DIPEA.  Enantioselective 
oxidation of the racemic sulfoxide gave Esomeprazole in 50% ee (Scheme 3.20).  When DIPEA 
was excluded from the reaction mixture a complex mixture of products was obtained which was 
found to contain no sulfoxide.  Using the catalyst system for the asymmetric oxidation of 
Pyrmetazole 3.17 gave Esomeprazole (S)-1.1 in an optical yield of only 31% ee.  
 
 
Scheme 3.20 
 
Manganese mediated synthesis of Esomeprazole  
A gram scale asymmetric synthesis of Esomeprazole (S)-1.1 was performed by Dai et al. using a 
porphyrin-inspired manganese catalyst complex which was formed in situ from Mn(OTf)2 and 
the chiral ligand 2.100.468  Esomeprazole (S)-1.1 was obtained in a yield of 90% with an optical 
purity of 82% ee (Scheme 3.21).   
 
 
Scheme 3.21 
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Kinetic resolution of the racemic sulfoxide Omeprazole ()-1.1 was also performed with this 
catalyst system; using 1 equiv of the oxidant and a catalyst loading of 1 mol%; Esomeprazole 
(S)-1.1 was achieved in 89% ee, with a yield of 39%.   
 
The synthesis of Esomeprazole was performed by Choi and coworkers using the manganese-
salen catalyst complex 3.52 in a 10 mol% catalyst loading.  The target sulfoxide was obtained in 
70% ee with a yield of 59% (Scheme 3.22).633    
 
 
Scheme 3.22 
 
3.6 Summary 
 
Omeprazole (-1.1 is one of the most widely prescribed pharmaceuticals of all time.  Used for 
the treatment of a number of stomach acid related conditions this drug is composed of a 
methylsulfinyl group flanked by a methoxy benzimidazole group on one side and a substituted 
pyridine on the other.  Omeprazole (-1.1 is a prodrug which is converted to the active form in 
situ and acts on the H+K+-ATPase pump which is the source of gastric secretions.     
 
The single enantiomer drug Esomeprazole (S)-1.1, the (S)-enantiomer of Omeprazole (-1.1, 
was found to be superior to the original racemic sulfoxide in terms of efficacy and was found to 
reduce interpatient variability in acid inhibition.  The synthetic approach to producing the chiral 
sulfoxide Esomeprazole (S)-1.1 is typically via the enantioselective oxidation of the prochiral 
sulfide Pyrmetazole 3.17, although procedures have also been reported for the isolation of 
Esomeprazole (S)-1.1 via resolution of the racemic sulfoxide.   
 
Oxidations have been reported which use biological agents and non-metal based reagents, such 
as oxaziridines.  Metal based catalyst systems are a popular choice for the asymmetric synthesis 
of Esomeprazole (S)-1.1.  Both vanadium and manganese based catalyst systems have been 
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reported to facilitate the oxidation of Pyrmetazole 3.17, to give Esomeprazole in high 
enantioselectivity.  Titanium based catalyst systems are the most commonly employed, with a 
range of different ligands explored, however relatively high catalyst loadings are required in 
order to obtain the target sulfoxide in high enantioselectivity.  
 
The development history of Omeprazole and Esomeprazole is described by Federsel, and 
Lindberg and Carlsson. 15, 519, 556, 557, 600  Federsel provides insight into the processes involved in 
taking the production of the single enantiomer sulfoxide Esomeprazole (S)-1.1 from mg scale to 
a multikilogram scale suitable for the industrial synthesis of the drug.  The large scale synthesis, 
which was reported by von Unge et al., employs a titanium-tartrate based catalyst system for the 
asymmetric oxidation of the Omeprazole sulfide Pyrmetazole 3.17 using the oxidant cumene 
hydroperoxide.125  Catalyst equilibration and ageing steps, as well as the addition of the base 
DIPEA, are reported to be essential for the achievement of high enantioselectivity.   
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4 Results and Discussion: Asymmetric synthesis of 
Esomeprazole 
4.1 Project aims 
 
The asymmetric synthesis of the blockbuster drug Esomeprazole (S)-1.1 is one of the great 
successes of the pharmaceutical industry (Scheme 4.1).  Although a method has been developed 
which enables the asymmetric formation of Esomeprazole (S)-1.1 in high optical purity, the 
high level of catalyst loading remains problematic.  In the large scale synthesis, 2.35 kg of 
tartrate, 1.6 kg of Ti(OiPr)4, and 3.3 kg of oxidant (cumene hydroperoxide, CHP) are required in 
order to produce 3.83 kg of pure product.125  Although the industrial process is likely to be more 
efficient there is still potential for improvement in terms of a reduction of catalyst loadings and 
simplification of the process.  These modifications would not only lower costs in terms of 
starting materials but also reduce the amount of by-product waste, which may require specialist 
disposal considerations.   
 
In addition to the low catalyst turnover, the process also affords the target sulfoxide in only 
moderate yields.  For the two steps from sulfide 3.17 to sodium salt (S)-3.36, von Unge et al. 
report an overall yield of only 56% when using a 30 mol% catalyst loading (Scheme 4.1).  In 
the same paper the authors report that upon completion of the S-oxidation reaction that the ratio 
of sulfoxide:sulfone in the crude material was 76:1 and that the conversion of the sulfide 
starting materials was 92%.  It is apparent that a substantial amount of material is lost in the 
course of the workup procedure and/or during formation of the Na-salt.   
 
 
Scheme 4.1  Reagents and conditions: (i) Ti(O
i
Pr)4:(S,S)-DET:H2O (0.3:0.6:0.1 equiv relative to sulfide 3.17), 
toluene, 54C, 50 min; (ii) DIPEA:CHP (0.3:1), 30C, 1h; (iii) NaOH (0.7), MIBK; (iv) crystallization from 
methyl isobutyl ketone and MeCN 
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The primary objective of our studies was to gain insight into the Ti-tartrate mediated  
S-oxidation involved in the synthesis of Esomeprazole.  It was our expectation that by studying 
the processes in detail we could achieve a greater understanding of some of the basic 
mechanistic features such as the effect of additives (e.g. water and amines), reaction times and 
temperatures and the effect of solvent choice, and to ascertain more information on the 
mechanism of asymmetric induction and identify the active catalyst species.  In the course of 
this process we hoped to identify some of the limitations of the current methodology, and it was 
our long term goal to develop methods by which we could overcome these issues, potentially 
improving catalyst efficacy and/or developing a novel catalyst system.   
 
4.2 Preparation of racemic Omeprazole and related compounds 
 
To enable a detailed investigation into the Ti-mediated asymmetric synthesis of Esomeprazole 
(S)-1.1 it was first necessary to prepare the sulfide precursor Pyrmetazole 3.17, the racemic 
sulfoxide Omeprazole (-1.1, and the corresponding sulfone 4.1 in order to gather 
spectroscopic data on the different species, and in the case of the sulfide to produce materials 
for use in the asymmetric sulfoxidation reactions.   
 
 
 
Thiol 3.18 and the pyridine salt 3.19 were reacted in the presence of two equiv of NaOH to give 
sulfide 3.17 in yields up to 89% (Scheme 4.2).  This reaction was carried out on a scale of up to 
30 g.  The sulfide product was afforded as a colourless gum, which proved difficult to 
manipulate.  Purification was achieved via column chromatography followed by trituration with 
diethyl ether which converted the material to a powder, allowing for greater ease of handling. 
The structure of Pyrmetazole 3.17 was confirmed by X-ray crystallography (discussed further in 
section 6.1).  
 
 
Scheme 4.2 
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The racemic sulfoxide Omeprazole (-1.1 was obtained via mCPBA oxidation of Pyrmetazole 
3.17.  The use of a two phase solvent system was found to be necessary due to the sensitivity of 
the sulfoxide product to acid; using a system that had previously been employed within our 
research group one equiv of the oxidant was added dropwise to the sulfide in CH2Cl2 in the 
presence of NaHCO3 (sat. aq.) which neutralised the benzoic acid by product of the sulfide 
oxidation.69  This reaction was performed on a multigram scale, affording the sulfoxide product 
in conversions up to 97% from the sulfide (as measured by 1H NMR analysis of the crude 
materials) in yields up to 75% (Scheme 4.3). The structure of the afforded sulfoxide was 
confirmed by X-ray crystallographic analysis.  Over oxidation to the corresponding sulfone was 
minimized by slow addition of the oxidant under high dilution conditions.  
 
 
Scheme 4.3 
 
Omeprazole was found to be challenging to work with and a great amount of time and effort 
was required to understand the properties of this compound in order to allow successful 
synthesis, isolation, and handling of the sulfoxide in both the racemic and single enantiomer 
form.  Column chromatography was found not to be a viable method of purification due to the 
limited solubility of the racemic Omeprazole crude materials in the eluents which gave the best 
separation of the sulfide, sulfoxide and sulfone materials arising from the oxidation.  Visible 
degradation of the sulfoxide was observed during attempts at column chromatography, with the 
colourless sulfoxide degrading to give materials purple in colour with an associated significant 
loss of material on the column.  Purification of the crude racemic sulfoxide was eventually 
achieved through crystallization from CH2Cl2 by addition of diethyl ether which acted as an 
antisolvent.  
 
In addition to instability towards acidic conditions it is also known to be heat, light and moisture 
sensitive.634  When stored at rt for a number of weeks in a sealed glass container a significant 
change of colour was observed in the material, from colourless to light brown/purple.  There 
was however very little difference found in the 1H NMR spectra of the discoloured sulfoxide 
material compared to freshly produced Omeprazole, suggesting that the discolouration comes 
from the formation of a very small amount of highly coloured impurities; repurification of 
discoloured Omeprazole was achieved easily by dissolution in dichloromethane, treatment with 
activated charcoal and MgSO4 followed by addition of diethyl ether to induce crystallization.  
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Synthesis of the Omeprazole sulfone was also carried out by oxidation of the sulfide 3.17 using 
mCPBA (2.0-2.5 equiv), again using the two phase solvent system of dichloromethane and 
NaHCO3, affording the sulfone 4.1 in yields of up to 59% (Scheme 4.4).  
 
 
Scheme 4.4 
 
The improved stability of the sulfone 4.1 compared to the sulfoxide 1.1 allowed for purification 
via column chromatography.  Although recrystallization was possible it was found that any 
sulfone material recovered was in the form of the solvate of the recrystallization solvent; x-ray 
crystallography found the sulfone as the MeOH solvate.  The N-oxide 4.2 was a common side 
product of this reaction, and could be easily identified by 1H NMR by the characteristic singlet 
peak at 5.35 ppm corresponding to the CH2 protons, compared to the sulfone which gave a 
singlet at 5.02 ppm for the same protons.635  The analogous sulfoxide N-oxide 4.3 was identified 
in crude materials from the synthesis of Omeprazole 1.1 by mCPBA oxidation but not isolated.  
The formation of this species occurred in amounts typically less than 2% of the sulfoxide yield 
and could be identified by 1H NMR from a singlet occurring at 4.81 ppm corresponding the CH2 
protons.635   
 
 
 
The alkali metal salts of Omeprazole are known to have increase stability compared to the 
neutral form.557  Sodium Omeprazole ()-3.36 was obtained via treatment of the racemic 
sulfoxide 1.1 with sodium hydroxide (0.7-1.0 equiv, ~ 50% w/w aqueous solution) (Scheme 
4.5).  Precipitation of the Omeprazole salt from MeCN was at times spontaneous, or could be 
induced by concentration of the solution under vacuum and/or seeding or scratching the flask.  
Crystallization could also be invoked by dropwise addition of the diethyl ether antisolvent.  The 
potassium salt of Omeprazole was also synthesized using a similar methodology as the sodium 
salt is believed to produce crystals that are too small for analysis by single crystal X-ray 
diffraction (XRD).636  Crystals obtained of the K-salt ()-3.38 were found to be sufficient for 
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analysis by XRD; further discussion of the crystal structures of Omeprazole 1.1 and related 
species can be found in section 6.1. 
 
 
Scheme 4.5 
 
4.2.1 Spectroscopic and chromatographic analysis of Omeprazole and related 
compounds 
 
1H NMR spectroscopy was used to determine the level of oxidation of the products arising from 
the oxidation of sulfide Pyrmetazole 3.17.  Figure 4.1 shows the 1H NMR spectra obtained using 
DMSO-d6 whilst Figure 4.2 shows the spectra obtained using CDCl3.   
 
 
Figure 4.1 
1
H NMR spectra of Pyrmetazole 3.17, Omeprazole 1.1, and Omeprazole sulfone 4.1 in DMSO d6 
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Figure 4.2 
1
H NMR spectra of Pyrmetazole 3.17, Omeprazole 1.1, and Omeprazole sulfone 4.1 in CDCl3 
 
Characteristic AB signals were observed for the diastereotopic CH2 protons of the racemic 
sulfoxide 1.1 with DMSO-d6 as the NMR solvent; when CDCl3 was employed as the solvent the 
AB pattern of the diastereotopic protons was less pronounced.  The methylene protons of the 
corresponding sulfone 4.1 and sulfide 3.17 were observed as singlets, with enhanced 
deshielding observed going from sulfide to sulfoxide to sulfone (Figures 4.1 and 4.2).  The 
opposite effect was observed for the signal corresponding to the pyridine 6''-H, which was 
observed at a lower frequency for the sulfone 4.1 in comparison to the Omeprazole 1.1 and 
Pyrmetazole 3.17.   
 
Tautomerization of the benzimidazole heterocycle was observed as broadening of the aromatic 
proton signals, and was observed to a greater extent in samples using CDCl3 as the NMR 
solvent.  Tautomerism of Omeprazole will be discussed further in section 6.2.  Interestingly the 
signal for the pyridyl 3''-Me was observed at a lower frequency than the 5''-Me for the sulfoxide, 
whereas for the sulfide or sulfone it is the 5''-Me protons which are observed further upfield.  
This may be due to the anisotropic effect of the S=O group on the protons of the  
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3''-Me group, or due to aggregation of the sulfoxide in solution, with the formation of 
heterochiral dimers altering the chemical shift of the pyridyl 3''-Me protons.637, 638  
 
The relative ratios of sulfide:sulfoxide:sulfone in a crude product could be determined from the 
signals of the CH2 protons.  These signals easily distinguished from each other in the 
1H NMR 
spectra when CDCl3 was used as the solvent (Figure 4.2), however an overlap between the 
sulfide and sulfoxide CH2 proton signals was found when DMSO-d6 was used, which was often 
necessary for NMR comparison with compounds insoluble in CDCl3.  Where this was the case 
the relative ratios of the species could be determined by assessing each half of the sulfoxide AB 
signal separately and calculating the difference in peak integration arising from the overlapping 
sulfide signal (Figure 4.3).   
 
 
Figure 4.3 Partial 
1
H NMR spectra of a mixture of Pyrmetazole 3.17, Omeprazole 1.1, and Omeprazole sulfone 
4.1 in DMSO-d6 illustrating how relative ratios of each species can be deduced from integration of 
characteristic proton signals  
 
The formation of Na-Omeprazole 3.36 gave rise to a distinct change in the appearance of the 
CH2 protons compared to the neutral sulfoxide 1.1 (Figure 4.4).  An accompanying upfield shift 
was observed for the benzimidazole protons of the Na-salt 3.36.   
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Figure 4.4 
1
H NMR spectra of Na-Omeprazole 3.36 and Omeprazole 1.1, both in DMSO-d6 
 
It was often found that the CH2 protons of Na-Omeprazole 3.36 were depleted or indeed absent 
from the 1H NMR spectra; this phenomena was attributed to H/D exchange of the acidic protons 
with the NMR solvent (DMSO d6), this shall be discussed further in section 6.3. 
 
The enantiomeric purity of Esomeprazole (S)-1.1 was determined by chiral HPLC, using a 
Chiracel OD-H column.  The chromatographs for racemic Omeprazole ()-1.1 and 
enantioenriched Esomeprazole (S)-1.1 (90% ee) are illustrated in Figure 4.5 and 4.6 
respectively.  
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Figure 4.5 Chromatograph of racemic Omeprazole 1.1; tR (Senantiomer) = 35.5 min, tR (Renantiomer) = 41.4 min 
[Chiracel OD-H; flow rate 1.0 mL min
-1
; 5% ethanolhexane; 20 C] 
 
 
Figure 4.6 Chromatograph of Esomeprazole (S)-1.1 (90% ee); tR (Smajor) = 35.0 min, tR (Rminor) = 45.0 min 
[Chiracel OD-H; flow rate 1.0 mL min
-1
; 5% ethanolhexane; 20 C] 
 
The absolute configuration of the enantioenriched sulfoxide 1.1 was determined by comparison 
with the NMR data reported by Redondo et al. who used (S)-BINOL (S)-1.43 as a chiral shift 
reagent for the determination of enantiomeric purity of Esomeprazole (S)-1.1.  As part of our 
work, enantiomerically pure tartrates, such as (S,S)-diethyl tartrate, (S,S)-diisopropyl tartrate 
and (R,R)-dimethyl tartrate, were identified as alternative, inexpensive chiral shift reagents for 
enantiomeric determination of sulfoxides such as Esomeprazole (S)-1.1; this work is reported in 
chapter five. 
 
4.2.2 1H NMR characterization of Omeprazole vs. Esomeprazole  
 
During the course of this research it was observed that solutions of Omeprazole and 
Esomeprazole in CDCl3 gave significantly different 
1H NMR spectra.  As the enantiopurity of 
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the sulfoxide substrate 1.1 increased from 0% ee to 100% ee it was found that the pyridyl 
methoxy group showed a downfield shift of 0.08 ppm, whereas the benzimidazolyl methoxy 
group shifted upfield by less than 0.01 ppm (Figure 4.7).  Similarly the 3''-Me group on the 
pyridine ring moved down field by 0.08 ppm as the enantiopurity of the sulfoxide increased 
from 0 to 100%, however the 5''-Me group was observed to be barely affected with a change of 
less than 0.01 ppm upfield.   
 
 
 
Figure 4.7 
1
H NMR (CDCl3) of Esomeprazole from 0% ee to 100% ee 
 
These findings are consistent with work reported by Albert et al. who investigated this 
phenomena through 1H NMR monitoring of the online titration of the Omeprazole solutions 
from 100% (R)-enantiomer through to 100% (S)-enantiomer.
637
  In addition to the reported 
findings of Albert et al. we observed distinct changes to the appearance of the CH2 protons and 
certain protons of the benzimidazole group.  With increasing % ee of the sulfoxide solution the 
CH2 group coalesces to give a singlet at 4.80 ppm, in contrast to the characteristic AB system 
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observed for the racemic sample of the sulfoxide (Figure 4.8).  In addition, the chemical shifts 
of the broad signals corresponding to the benzimidazole 4-H and 7-H protons are also observed 
to change, with the Benz 7-H proton undergoing a downfield shift of up to 0.15 ppm as the 
optical purity of the sulfoxide was increased. 
 
Figure 4.8 
1
H NMR (CDCl3) of Esomeprazole from 0% ee to 100% ee 
 
Albert and coworkers proposed that the origin of the differences in chemical shifts observed for 
racemic Omeprazole compared to the single enantiomer form (either (R)- or (S)- enantiomer) 
may be due to the formation of heterochiral dimers in solution, such as that shown in Figure 
4.10.  Dimerization takes place over the SO-H-N bonds generating a 10 membered chair 
conformation with - stacking of the heterocyclic rings stabilizing the structure.  In an 
aggregation of this type the methoxy and 3''-Me group of the pyridine ring would be subject to 
the ring current effects, whereas the benzimidazole methoxy group, and the pyridyl 5''-Me 
would be less affected.  This proposed structure is identical to that reported for the crystal 
structure of racemic Omeprazole in the solid state, and the crystal structure obtained from XRD 
analysis of Omeprazole obtained during this work (Figure 4.9).572  Further discussion of the 
solid state structure of Omeprazole and related compounds can be found in section 6.1. 
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Figure 4.9 Crystal structure of Omeprazole showing the structure of the heterochiral dimer; displacement of 
ellipsoids are at the 50% probability level and hydrogen atoms are omitted for clarity 
 
Comparison of the structures of the heterochiral dimer and the two possible homochiral dimers 
of omeprazole reveals the importance of the orientation of the sulfinyl group with respect to the 
formation of hydrogen bonds.  Whereas the heterochiral dimer is able to form two hydrogen 
bonding between the sulfoxide molecules, in the homochiral dimers the orientation of the 
sulfinyl groups allows for only one H-bond to form, thus reducing the stability of the overall 
intermolecular interactions.   
 
 
Figure 4.10  Heterochiral (left) and homochiral dimers (centre and right) of Omeprazole 1.1 
 
4.3 The Asymmetric synthesis of Esomeprazole  
 
Early attempts to study the titanium tartrate mediated asymmetric synthesis of Esomeprazole 
(S)-1.1 gave disappointing results.  Using a scaled down version of the literature procedure 
published by von Unge et al. the target sulfoxide was afforded in low optical and chemical 
yields, with poor reproducibility.125  In addition isolation and purification of the reaction 
products was extremely difficult. The work up procedure involved quenching of the reaction 
using aqueous ammonium hydroxide, separation of the phases, then acidification of the aqueous 
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phase and extraction of the sulfoxide; during the quenching process large amounts of insoluble 
titanium salts were produced which made separation of the phases extremely difficult.  Attempts 
to remove the titanium dioxide via filtration through a number of different media did not work, 
and on occasion was found to exacerbate the problem.  Although 1H NMR analysis of the crude 
products indicated the presence of the desired sulfoxide, large amounts of tartrate and cumyl 
alcohol were also identified. Unfortunately it was believed that purification via column 
chromatography was not feasible for Esomeprazole (S)-1.1 as attempts at chromatography of the 
racemic sulfoxide had led to decomposition of the material on the column.  Chiral HPLC 
analysis performed on the crude materials showed the presence of many unidentifiable species, 
suggested that decomposition of the sulfoxide was occurring during, or prior to HPLC analysis.   
 
Although the synthesis, isolation, and subsequent handling of Esomeprazole were initially found 
to be more difficult than anticipated, through greater understanding of the properties of 
Omeprazole and Esomeprazole many of these issues were eventually resolved.  Improvements 
were made to the work up procedure which allowed for greater ease in isolating the target 
sulfoxide; quenching of the reaction, by addition of aqueous ammonium hydroxide, was 
followed by vigorous stirring of the mixture, after which the mixture was allowed to settle.  This 
process improved the efficiency in the removal of the insoluble titanium dioxide, achieved via 
filtration through a pad of Celite, and as a result allowed for better subsequent phase separation.  
The crude materials afforded from this work up process were found to contain less tartrate 
material, presumably due to hydrolysis during the extended quenching process.  
 
In contrast to the racemic sulfoxide Omeprazole, which was obtained as fine colourless 
crystalline platelets, Esomeprazole (S)-1.1 was obtained as a colourless oil that dried to a glassy 
foam under vacuum.  The enantioenriched sulfoxide was found to be more soluble in a range of 
solvents compared to the racemate, and this improved solubility allowed for column 
chromatography to be used for purification as the sulfoxide material was able to pass through 
the stationary phase at a more rapid pace.  The contrast between the physical forms of the 
racemic sulfoxide and enantioenriched Esomeprazole is in agreement with the models proposed 
in Figure 4.9, with the formation of heterochiral dimers held together by two hydrogen bonds 
leading to a crystalline product for racemic Omeprazole, whereas the enantioenriched sulfoxide, 
unable to form such stable dimers was obtained in the form of a glassy oil with greater solubility 
properties compared to the racemate.  
 
Esomeprazole (S)-1.1 is known to undergo self-disproportionation of enantiomers during 
chromatography, where the process of achiral gravity driven or flash chromatography can cause 
aggregation of enantiomers and lead to fractionation of the enantiomerically enriched sulfoxide 
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which for Esomeprazole would be observed as enrichment of ee in early fractions, and depletion 
of ee in later ones.150  In order to avoid errors in determining the enantioselective outcome of the 
Ti-mediated asymmetric sulfoxidation process chromatography of the sulfoxide products was 
conducted with care to combine all fractions of the sulfoxide prior to chiral HPLC or 1H NMR 
analysis for the determination of enantioselective excess.  
 
Optimization of the chiral HPLC conditions was the most critical factor in allowing 
investigation into the asymmetric synthesis of Esomeprazole (S)-1.1.  Reevaluation of the 
HPLC conditions used previously revealed that the poor results previously encountered with 
respect to enantioselectivity and reproducibility were not due to the reaction itself, but were an 
artifact of the HPLC conditions, in particular the use of a reversed phase column and the solvent 
system required for separation on that column, which were causing decomposition of the 
sulfoxide during analysis.  Using a normal phased column for chiral HPLC allowed for the use 
of a solvent system and conditions under which no sulfoxide decomposition was observed 
during analysis and thankfully accurate measurement of product ee was achieved.  In addition to 
withstanding the modified HPLC conditions, sulfoxide (S)-1.1 was actually found to be more 
robust than previously assumed, with degradation occurring over a much longer time period, 
and to a lesser extent than previously thought; this extended to the crude reaction materials 
which had not yet been subjected to purification.  
1
H NMR of these crude materials showed 
very little degradation after 10 days, whereas previously it was thought possible that 
decomposition may have been occurring, in a much shorter time frame, before HPLC analysis 
could be performed  on the samples.  Esomeprazole material acquired following column 
chromatography could be stored in a sealed glass container at rt for a number of days with very 
little degradation observed by 1H NMR or by any observable change in colour typically 
associated with decomposition of this sulfoxide.   
 
An additional factor that aided in the analysis of products afforded by the Ti-mediated synthesis 
of Esomeprazole (S)-1.1 was the development of a new NMR method for the measurement of 
enantiomeric excess (discussed in chapter five).  It was found the chiral tartrates, such as the 
(S,S)-diethyl tartrate (DET) employed in the asymmetric oxidation reaction as a ligand, could be 
used as a chiral shift reagents for Esomeprazole.  The ability to use 1H NMR for the 
determination of enantiomeric excess greatly increased the speed and simplicity of % ee 
determination, with the convenience of an inexpensive chiral shift reagent that was readily at 
hand having already been used as a ligand in the asymmetric oxidation process.   
 
The synthesis of Esomeprazole was achieved following a smaller scale version of the literature 
procedure; Ti(OiPr)4, (S,S)-(DET), and water were added to a suspension or solution of the 
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sulfide 3.17; employing a 30 mol% catalyst loading equated to the use of Ti(OiPr)4:(S,S)-
DET:H2O in a ratio of 0.3:0.6:0.1 equiv. with respect to the sulfide substrate.  After heating the 
mixture at 54 C for 45 minutes it was allowed to cool to 35 C whereupon 
diisopropylethylamine (DIPEA) (0.3 equiv.) and cumene hydroperoxide (CHP, 80% in cumene) 
(1.0 equiv.) were added and the mixture stirred for one hour.  As mentioned previously 
quenching of the reaction was achieved by addition of aqueous ammonium hydroxide, phases 
separation followed by acidification and extraction of the aqueous phase; whereas methyl 
isobutyl ketone was employed in the workup procedure reported in the literature we used 
dichloromethane which aided the separation of phases during the extraction processes.  Column 
chromatography was employed for purification of the crude materials to give Esomeprazole  
(S)-1.1 (Scheme 4.6 and Table 4.1). 
 
 
Scheme 4.6 
entry 
Catalyst 
loading  
/ mol % 
solvent 
Recovered 
S:SO:SO2  / %
a 
Isolated 
yield / % 
Ee  
/ %b 
Sulfoxide 
configuration 
1 30 toluene 0:90:10 30 93 (S) 
2 4 toluene 0:97:3 56 88 (S) 
3 1 toluene 3:94:3 0d 72e, f (S) 
4 30 toluene 0:99:1 64g >99.5 (S) 
5 30 CHCl3 0:95:5 71 93 (S) 
6 30 CHCl3 0:93:7 62 91 (S) 
7 30 CHCl3 10:88:2
h 48 92 (S) 
8 4 CHCl3 0:96:4 58 88 (S) 
9 1 CHCl3 4:92:4 20 14
f (S) 
10 30i CHCl3 12:72:16 10 84
f (S) 
11 30j CHCl3 33:54:13 7 82
f (R) 
Table 4.1 a) ratio of sulfide, sulfoxide and sulfone present in crude material as determined by 
1
H NMR; b) % 
ee determination performed on sulfoxide following column chromatography; c) proposed configuration based 
on 
1
H NMR experiments using (S)-BINOL as a chiral shift reagent according to ref 639; d) material lost 
during purification; e)% ee determined by 
1
H NMR using (S,S)-DET as a chiral shift reagent; f) % ee from the 
crude sulfoxide; g) obtained as the Na-salt (S)-3.36; h) reaction quenched using NaHCO3;  i) (S,S)-DIPT used 
as the chiral ligand; j) (R,R)-DMT used as the chiral ligand. 
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During development of the industrial scale process used by AstraZeneca it was found that the 
oxidation ran well in a broad range of solvents including EtOAc, methyl isobutyl ketone and 
toluene.15  The latter solvent was employed for the asymmetric oxidation for the large scale 
synthesis of Esomeprazole (S)-1.1; the industrial preparation of the Pyrmetazole 3.17 afforded 
the sulfide precursor as a toluene solution, therefore conducting the asymmetric sulfoxidation in 
the same solvent allowed the first process to be fed directly into the next. In order to replicate 
the process described by von Unge et al. we also employed toluene as a solvent.125 Although the 
sulfide starting material was found not to be fully soluble in toluene, once the catalyst reagents 
were added a homogenous mixture was obtained.  Titanium catalyzed oxidation were performed 
using catalyst loadings of 30 and 4 mol%, affording Esomeprazole (S)-1.1 in 93 and 88% ee 
respectively  (Table 4.1, entries 1 and 2), in close agreement with the reported results for this 
reaction of over 94% ee (30 mol% loading) and 91% ee (4 mol% loading).  Reducing the 
catalyst loading to 1 mol% resulted in production of Esomeprazole with decreased 
enantioselectivity (72% ee, Table 4.1, entry 3).  Yields of the reactions performed in toluene 
were moderate to low, although the literature procedure reports only a 56% yield of the 
sulfoxide after conversion to the sodium salt (S)-3.36.  Analysis of the crude materials by  
1H NMR indicated high conversions to the sulfoxide.  Some overoxidation to the Omeprazole 
sulfone 4.1 was observed, with the greatest amount (10%) afforded from use of a 30 mol% 
catalyst loading of the titanium catalyst.  When the reaction was carried out using a catalyst 
loading of 1 mol% an increased amount of unreacted sulfide starting material was recovered in 
the crude material in addition to a small amount of sulfone (Table 4.1, entry 3).  Isolation of the 
product sulfoxide in enantiopure form and moderate yield was achieved by the formation of as 
the Na-salt (S)-3.36 from the crude material following the work up procedure (Table 4.1, entry 
4).     
 
Chloroform was employed as an alternative solvent for the asymmetric synthesis of 
Esomeprazole (S)-1.1 as chlorinated solvents are known to be suitable solvents in metal-
catalyzed asymmetric sulfoxidation reactions.640  Additionally, sulfide 3.17 was found to be 
fully soluble in this solvent, in contrast to the use of toluene in which it formed a suspension.  
The use of catalyst loadings of 30 and 4 mol% gave Esomeprazole (S)-1.1 in high 
enantioselectivity (93 and 88% ee respectively) in good to high yields (Table 4.1, entries 5 and 
8) which for the 30 mol% catalyst loading reaction yielded the sulfoxide product in an amount 
twice that of the analogous reaction performed in toluene.  Using a 1 mol% loading in CHCl3 
resulted in a greatly reduced enantioselectivity compared to the reaction in toluene (Table 4.1, 
entries 9 and 3).  Reproducibility of the reaction was tested (Table 4.1, entries 5 and 6) with 
repetition of the oxidation performed using a 30 mol% catalyst loading; although comparable 
results were achieved for the enantiopurity of the  afforded sulfoxide a disparity was observed in 
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the yield which may be related to loss of material during the workup procedure.  Using sat. aq. 
NaHCO3 during the quenching stage of the work up procedure dramatically change the profile 
of products found in the crude materials suggesting a change in the species being carried 
through the work up procedure; the optical purity of the sulfoxide product was not affected 
(Table 4.1, entry 7).   
 
Alternative tartrates to (S,S)-DET were examined as chiral ligands. Reactions where (S,S)-
diisopropyl tartrate (DIPT) and (R,R)-dimethyl tartrate (DMT) were employed were found to 
afford Esomeprazole (S)-1.1 in good enantioselectivity but very low yields (Table 4.1, entries 
10 and 11).  A distinct colour change in the reaction mixture, from pale yellow to dark purple, 
was observed during the reaction which suggested possible decomposition of the sulfoxide 
which was reflected in the ratios of the species recovered.  Using a tartrate of the opposite 
chirality gave the (R)-sulfoxide (determined by 1H NMR using (R,R)-DMT as a chiral shift 
reagent) 
 
4.4 Enhancement of optical purity by crystallization 
 
The enhancement of the optical purity of Esomeprazole (S)-1.1 by crystallization was examined.  
Formation of the Na-salt (S)-3.36 using 1 equiv. of  NaOH(aq) afforded the salt (S)-3.36 in yields 
of 64-65% and was found to give enantiopure sulfoxide from (S)-1.1 with an enantiopurity of 91 
or 93% ee (Table 4.1, method A).  Method B exploited the fact that Omeprazole is known to 
crystallize as the racemate; a solution of Esomeprazole (S)-1.1 (80% ee) in dichloromethane was 
treated with diethyl ether, with dropwise addition, to initiate the formation of the Omeprazole 
racemate.  Removal of the racemic material left behind an optically enriched solution of 
Esomeprazole with 98% ee, and a yield of 78%.  Interestingly it was found that precipitation of 
the Omeprazole racemate occurred from a simple solution of Esomeprazole in acetonitrile 
(Table 4.2, method C).  Esomeprazole (80% ee) in acetonitrile was stirred for 10 minutes at rt, 
after which time racemic Omeprazole crystallized out of solution and was removed by filtration; 
removal of solvent from the filtrate gave enantiomerically enriched Esomeprazole (97% ee, 
79%).  
  
 
Scheme 4.7 
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Esomeprazole 
ee / % 
Product ee / % 
Sulfoxide 
product 
Yield / % Method 
91 > 99.5 (S)-3.36 65 A 
93 > 99.5 (S)-3.36 64 A 
80 98 (S)-1.1 78 B 
80 97 (S)-1.1 79 C 
Table 4.2 Method A: Optical enrichment via formation and preferential crystallization of (S)-3.36 via addition 
of 1 equiv of aq. NaOH to sulfoxide 1.1; Method B: Formation and removal of the crystalline Omeprazole 
racemate, leaving behind optically enriched Esomeprazole (S)-1.1 in solution via addition of Et2O antisolvent 
to a solution of Esomeprazole in CH2Cl2; Method C: Formation and removal of the crystalline Omeprazole 
racemate from a solution in MeCN, leaving behind optically enriched Esomeprazole (S)-1.1 in solution 
 
Isolation of Esomeprazole as the Na-salt (S)-3.36 using method A allows for the sulfoxide 
product to be obtained in exceedingly high optical purity; in addition, formation of the product 
in the form of the Na-salt is known to confer greater stability to the sulfoxide species, however 
this process suffers from loss of material with yields of 64-65% obtained in this work, and a 
yield of 55% reported in the literature.125, 557  While methods B and C afford both Esomeprazole 
in high ee and yield it is yet to be discovered whether or not these methods could be employed 
as part of the work up process following a Ti-mediated sulfoxidation reaction, and it may be that 
the presence of other species in the crude material such as residual tartrate or cumyl alcohol may 
prevent adequate crystallization of the racemate out of solution that is needed in order to leave 
optically enriched material behind following filtration. Modification and/or simplification of the 
procedure required to isolate Esomeprazole (S)-1.1 in high yield and ee following asymmetric 
sulfoxidation is one area of great interest going forward, testing these methods may provide a 
fruitful line of enquiry to follow.            
 
4.5 Synthesis of sulfides, sulfoxides, and sulfones analogous to the Omeprazole 
series 
 
To further the study of the Ti-meditated synthesis of Esomeprazole we synthesized a range of 
sulfides featuring structural similarities to Pyrmetazole 3.17, in order to understand how the 
heterocyclic motifs affected outcome of the asymmetric oxidations.  Seenivasaperumal et al. 
have reported on the importance of the benzimidazole NH with respect to its stereodirecting 
influence in Ti-tartrate mediated sulfoxidation reactions; in a similar manner we wanted to 
examine whether or not the pyridyl functional group contributed to the stereoselectivity of the 
asymmetric oxidation.  Additionally the synthesis and subsequent oxidation of Pyrmetazole-like 
sulfides would allow for examination of various properties of the Omeprazole analogues but 
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without the possibility of rearrangement that occurs when both the benzimidazole and pyridine 
rings are present in a sulfinyl compound such as Omeprazole.    
 
4.5.1 Synthesis of sulfides 
 
Sulfides 4.4 and 4.5 were synthesized by in situ formation of the sodium thiolates of thiol 3.18 
or p-tolyl thiol 4.6 followed by addition of benzyl bromide (Scheme 4.8).  Purification of sulfide 
4.4 was achieved by recrystallisation of the crude materials from ethyl acetate with hexane used 
as an anti solvent.  Sulfide 4.5 required purification by column chromatography prior to 
recrystallisation from aqueous ethanol.  Both sulfides were obtained in high yield.   
 
 
Scheme 4.8 
 
Sulfide 4.7 was prepared via methylation of 6(5)-methoxy-benzimidazole thiol 3.18 according 
to the procedure reported by Sachs et al. (Scheme 4.9).  Sulfide 4.7 was afforded in a yield of 
70% following recrystallisation from chloroform with hexane used as an antisolvent; the 
structure of this sulfide (as the 6-OMe tautomer) in the solid state was confirmed by X-ray 
diffraction analysis on a suitable crystal of sulfide 4.7. 
 
 
Scheme 4.9 
 
Sulfide 4.8 was obtained in 81% yield from p-tolyl thiol 4.6 and the pyridine salt 3.19 using a 
process analogous to that employed for the synthesis of Pyrmetazole sulfide 3.17 (Scheme 
4.10).  Column chromatography followed by recrystallisation was used for the purification of 
sulfide 4.8.  Sulfides 4.4, 4.5 and 4.8 were all produced in up to 100 mmol scale reactions and 
sulfide 4.7 was produced on a 50 mmol scale.  
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Scheme 4.10 
 
4.5.2 Synthesis of racemic sulfoxides 
 
Following the process used for the synthesis of Omeprazole -1.1 a range of racemic 
sulfoxides were prepared from sulfides 4.4-4.8 (Scheme 4.11).  The synthesis of methyl p-tolyl 
sulfoxide 1.48 was also undertaken, using methyl p-tolyl sulfide 4.9 purchased from Sigma 
Aldrich.  A two phase solvent system of dichloromethane and sat. aq. NaHCO3 was employed in 
order to minimize the benzoic acid byproduct of the oxidation reaction and avoid any potential 
decomposition of sulfoxide products under acidic conditions.  
 
 
Scheme 4.11 
Sulfide Ar R Sulfoxide Yield / % 
4.4 
 
 
4.9 78 
4.5 
  
4.10 91 
4.6 
 
Me 4.11 70 
4.7 
 
 
4.12 96 
4.8 
 
Me 1.48 91 
Table 4.3 
 
Racemic sulfoxides 4.9-4.12, and 1.48 were obtained in high to excellent yields following 
column chromatography and crystallization or trituration (Table 4.1).  The structures of 4.10, 
4.11, and 4.12 were confirmed by single crystal X-ray diffraction.  The synthesis of each 
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sulfoxide was carried out on a multigram scale, and in contrast to Omeprazole ()-1.1 all 
sulfoxides were found to be stable at rt indefinitely.   
 
4.5.3 Synthesis of sulfones 
 
In order to provide reference material for use in analyzing the products of Ti-mediated 
sulfoxidation reactions samples of sulfones were prepared by oxidation of sulfides  
4.4–4.8 using 2.2-2.5 equivalents of mCPBA (Scheme 4.12).  A two phase solvent system of 
dichloromethane and sat. aq. NaHCO3 was employed to neutralize the benzoic acid byproduct 
of the oxidation.  Purification was achieved by column chromatography of the crude sulfones, 
followed by recrystallization with the exception of sulfone 4.17 where chromatography was 
followed by trituration to afford a colourless amorphous solid.  Sulfones 4.13-4.17 were 
obtained in moderate to high yields (Table 4.4).  Single X-ray diffraction confirmed the 
structure of sulfone 4.13. 
 
 
Scheme 4.12 
Sulfide Ar R Sulfone Yield / % 
4.4 
 
 
4.13 79 
4.5 
  
4.14 40 
4.6 
 
Me 4.15 70 
4.7 
 
 
4.16 55 
4.8 
 
Me 4.17 40 
Table 4.4 
 
As with the synthesis of Omeprazole 1.1 and the corresponding sulfone 4.1 it was possible to 
identify the level of sulfide oxidation in the synthesis of sulfoxides 4.9-4.12, and 1.48, and 
sulfones 4.13-4.17 by the use of 1H NMR spectroscopy.  For sulfoxides 4.9, 4.10, and 4.12 
characteristic signals were observed at 4.58, 4.12, and 4.27 ppm respectively which correspond 
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to the diastereotopic CH2 adjacent to the sulfinyl group.  Oxidation to the sulfones resulted in 
the enhanced deshielding of the CH2 protons of compounds 4.13, 4.14, and 4.16 which were 
observed as singlets at 4.94, 4.62 and 4.71 ppm respectively.   
 
For the oxidation products of sulfides 4.6 and 4.8, which do not contain diastereotopic CH2 
groups, the protons signals from the methyl adjacent to the sulfinyl group are sufficient to 
identify to level of oxidation due to the deshielding that is observed going from sulfide to 
sulfoxide, and the on to the overoxidized sulfone.  For example, oxidation of sulfide 4.6 
afforded either the sulfoxide 4.11 or sulfone 4.15; the SOCH3 protons signals for these species 
were observed at 2.67, 3.08 and 3.46 ppm respectively and are sufficiently separated to allow 
for identification and quantification if each of these components were present in a crude product 
mixture (Figure 4.10).  A similar trend is observed for the methyl groups in the 1H NMR spectra 
of sulfide 4.8 and the corresponding sulfoxides 1.48 and sulfone 4.17, again allowing for 
identification and quantification of the species in a crude product mixture.     
 
 
Figure 4.11 
1
H NMR (DMSO-d6) spectra of sulfide 4.6, racemic sulfoxide 4.11 and sulfone 4.15 
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4.6 Titanium mediated asymmetric synthesis of chiral sulfoxides 
 
The titanium tartrate mediated asymmetric oxidation of sulfides 4.4-4.8 was performed 
following the procedure employed for the asymmetric synthesis of Esomeprazole (S)-1.1 
(Scheme 4.13).  Reactions were performed in toluene using a 30 mol% catalyst loading with 
catalyst equilibration and ageing performed in the presence of the sulfide substrates; following 
the addition of the oxidant (CHP) the reaction mixtures were stirred at 35 C for the time 
specified in Table 4.5.  
 
 
Scheme 4.13 
Sulfide Ar R Sulfoxide 
time /  
h 
S:SO:SO2  / 
%a 
Yield / %b Ee / %b 
3.17 
  
1.1 1 0:95:5 32 95  
4.4 
 
 
4.9 4 0:68:32 29 95 
4.5 
  
4.10 2 15:65:20 40 (24)
c 16 (19)c 
4.6 
 
Me 4.11 4 0:85:15 60 95 
4.7 
 
 
4.12 2 3:85:12 60 (40)
c 20 (27)c 
4.8 
 
Me 1.48 2 7:70:23 63 6  
Table 4.5 a) from the crude reaction products; b) after purification via column chromatography; c) following 
recrystallization 
 
For sulfoxides 4.9 and 4.11, which feature the benzimidazole hetereocycle the reaction was 
quench with aqueous ammonium chloride and was followed by an acid/base extraction process 
160 
 
in order to isolate the crude product, analogous to the process employed for the isolation of 
Esomeprazole (S)-1.1. For the remaining sulfoxides the quenching of the reaction was achieved 
using water, and the crude product was obtained through separation and extraction of the 
phases.  The absolute configuration of sulfoxides 1.48 and 4.10 are both presumed to be (S)-
enantiomer based on HPLC analysis and comparison of the order of elution with literature 
sources.449, 507  Based on the precedent set by the absolute configuration of these sulfoxides and 
the synthesis Esomeprazole (S)-1.1 it was presumed that sulfoxides 4.9, 4.10 and 4.12 were also 
afforded with the (S)-enantiomer as the major product. Determination of the enantiomeric 
excess of all sulfoxides was performed following column chromatography where all fractions 
containing sulfoxide material were combined prior to HPLC analysis in order to avoid any 
enhancement of ee via self disproportion of enantiomers, as discussed in sections 1.4.2.1.3.  
 
Sulfoxides were afforded in high enantiomeric excess (95% ee) from asymmetric oxidation of 
the sulfides containing a benzimidazole heterocycle, whilst low enantioselectivity was observed 
in the absence of this structural feature. This finding was in agreement with those of 
Seenivasaperumal et al. who reported the importance of the benzimidazole NH group for high 
enantioselectivity in the asymmetric synthesis of heterocyclic sulfoxides. It is unlikely that the 
pyridine nitrogen contributes to stereodirection in the oxidation process as indicated by the low 
optical purity of the product afforded from the Ti-mediated sulfoxidation of sulfide 4.7.  Overall 
the yields of the asymmetric oxidations were low to moderate, which may be due to the 
difficulties associated with work up procedure and removal of the insoluble titanium dioxide.  
From 1H NMR analysis of the crude products of the reactions it was found that significant 
overoxidation occurred, with the sulfone side product accounting for up to 32% of the species 
present in the crude products, in contrast to the synthesis of Esomeprazole (S)-1.1 which saw the 
formation of the sulfone 4.1 accounting for 5% of the crude material.  In addition, in the 
synthesis of the p-tolyl sulfoxides 4.10, 4.12, and 1.48 unreacted starting materials were 
recovered in the crude materials which may be due to the use of a different work up procedure 
to sulfoxides 1.1, 4.9, and 4.11, or due to differing interaction with the active catalyst species in 
the absence of a stereodirecting handle such as the benzimidazole NH leading to reduced 
efficacy of the oxidation process.   
 
4.7 Improving the understanding if the Ti-tartrate asymmetric S-oxidation 
reaction: NMR studies of the catalyst components 
 
The asymmetric synthesis of Esomeprazole (S)-1.1 is carried out using a high catalyst loading of 
30 mol%, which reflects the poor efficiency and low catalyst turnover of this system in 
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sulfoxidation processes.  Unfortunately using a lower catalyst loading increases the inefficiency 
of the reaction and is reported to be associated with loss of reproducibility, an important factor 
in the industrial scale production of pharmaceuticals. In order understand the relationship 
between catalyst loading and reaction enantioselectivity NMR studies were performed with the 
aim to develop a model for the in situ formation of the catalytically active Ti-complex.    
 
4.7.1 NMR studies of the catalyst components: Ti(OiPr)4 + Pyrmetazole sulfide 
 
During the asymmetric synthesis of Esomeprazole (S)-1.1, via the oxidation of Pyrmetazole 
3.17, the titanium based catalyst is formed in situ with importance placed on the order of 
addition of the reagents; Ti(OiPr)4 is added to a solution or suspension of sulfide 3.17, followed 
by addition of the chiral tartrate ligand and water.  For the attainment of high enantioselectivity 
it is then necessary to perform the equilibration and ageing of the catalyst in the presence of the 
sulfide.  In order to develop a model of the processes occurring during these steps we first 
investigated the interactions between the sulfide substrate and Ti(OiPr)4 in solution. 
 
 
Figure 4.12 Partial 
1
H NMR spectra of Pyrmetazole sulfide 3.17 in CDCl3 with the addition of varying 
amounts of Ti(O
i
Pr)4 added 
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1H NMR characterization performed on solutions comprised of Pyrmetazole 3.17 and Ti(OiPr)4 
in ratios of 1:0 to 1:1 equiv respectively (Figure 4.12).  Interestingly it was observed that 
addition of Ti(OiPr)4  induced a broadening of the benzimidazole 4-H and 7-H proton signals, 
and at ratios of sulfide:Ti(OiPr)4 above 1:0.8 these signals split.  The broadening of the signals 
attributed to the 4-H and 7-H protons, both of which are adjacent to the imidazole ring, implies 
the occurrence of exchange induced by the presence of the titanium reagent, with coordination 
of the benzimidazole to the metal centre resulting in two different tautomeric complexes 
(Scheme 4.14).  Further discussion of the effects of annular tautomerism of compound such as 
Pyrmetazole 3.17 may be found in section 6.2.  The formation of coordination complexes such 
as these is consistent with the observed structural requirements for the induction of high 
sulfoxidation enantioselectivity i.e. the need for a (benz)imidazole group in the sulfide substrate.  
 
 
Scheme 4.14 
 
It is also possible that the broadening effect may arise from Ti(OiPr)4 acting as a desiccant, 
removing residual water from the CDCl3 NMR solvent; when no Ti(O
i
Pr)4 is present the small 
amount of water in the solvent may be enough to allow for prototropic tautomerization to occur 
for the benzimidazole ring of the sulfide, the result of which is that the benzimidazole 4-H and  
7-H are seen on the NMR timescale as averages of the two possible isomeric forms. The 
reduction in water that may occur with the addition of increasing amounts of Ti(OiPr)4 may 
result in slowing the prototropic exchange sufficiently to allow for the benzimidazole 4-H and  
7-H protons to be seen in their two different tautomeric environments according to the 5-OMe 
or the 6-OMe isomers.    
 
4.7.2 NMR studies of the catalyst components: Ti(OiPr)4  
4.7.2.1 Ti(OiPr)4 concentration studies 
 
During the 1H NMR investigation of solutions of Ti(OiPr)4 and Pyrmetazole sulfide 3.17  it was 
found that Ti(OiPr)4 by itself displayed some notable concentration dependent behavior in 
solution, with large amounts of isopropyl alcohol liberated from the metal complex at low 
concentrations.  We examined the concentration dependent behavior of Ti(OiPr)4 in solution 
further in order to determine the possible effects this may have on catalyst formation and 
turnover during asymmetric sulfoxidation.  1H NMR characterization was performed on 
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solutions of Ti(OiPr)4 over a concentration range of 0.01-0.3 mol L
-1, simulating the conditions 
which may be associated with the use of differing catalyst loadings in a fixed volume of 
reaction solvent.  Solutions in both CDCl3 and Tol-d8 were assessed, with integration values of 
the methine proton signals of the bound isopropoxide ligand (4.91 ppm CDCl3, 4.54 ppm  
Tol-d8) and 
iPrOH (4.04 ppm CDCl3, 3.68 ppm Tol-d8) used to determine the relative quantities 
of Ti(OiPr)4 and free IPA in solution (Table 4.6).  For the solutions of Ti(O
iPr)4 in CDCl3, 
characterization was performed after 2h at room temperature in order to allow the equilibrium to 
be achieved, mimicking the catalyst ageing step in the Esomeprazole process.  Samples 
prepared using Tol-d8 as the solvent were also analyzed after a 2 hour period at rt.  The 
1H NMR 
spectra of Ti(OiPr)4 in CDCl3 at different concentrations is shown in Figure 4.13. 
 
 
Figure 4.13  
1
H NMR spectra of Ti(O
i
Pr)4 at varying concentrations in CDCl3 
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 CDCl3 Toluene d8 
[Ti(OiPr)4]  
/ mol L-1 
% bound 
 alkoxide  
% free  
alcohol  
% bound  
alkoxide  
% free  
alcohol  
0.30 95 5 93 7 
0.25 95 5 93 7 
0.20 95 5 92 8 
0.15 93 7 90 10 
0.10 91 9 90 10 
0.05 81 19 76 24 
0.025 65 35 61 39 
0.01 40 60 35 65 
Table 4.6 % based on integration of methane proton peaks of the bound alkoxide of Ti(O
i
Pr)4 and the of the 
free alcohol 
i
PrOH observed by 
1
H NMR for solutions of Ti(O
i
Pr)4 in CDCl3 or Tol-d8 
 
At the highest concentration examined in both solvents, 0.30 M, the predominant species in 
solution was the Ti-alkoxide, accounting for 93-95 % of the total methine signals, with only 
small amounts of iPrOH observed (5-7 %) (Table 4.6).  When the Ti(OiPr)4 concentration was 
varied, the ratio of bound alkoxide:free alcohol was found the change, with disproportionately 
high levels of alcohol observed at lower concentrations, accompanied by a depletion in 
Ti(OiPr)4.  The increase in 
iPrOH content for samples of low Ti(OiPr)4 concentration indicated 
that there must be a source of protons to allow formation of the alcohol from the alkoxide.  
Ti(OiPr)4 was purchased as a 97% solution, it is presumed that the reagent is 97% Ti(O
iPr)4 in 
iPrOH, and was used with no prior treatment in order to mimic the process for the synthesis of 
Esomeprazole reported by von Unge which details no special measurements taken such as the 
requirement for anhydrous conditions.125   
 
A number of theories have been considered to explain why such a disproportionately high 
amount of free alcohol is observed in solutions of low concentrations (i.e. < 0.1M Ti(OiPr)4).  
Aggregation of the metal-alkoxide species, to form dimers, trimers and oligomers of higher 
molecular complexities with multiple -oxo bridging groups, would be expected to be 
accompanied by the liberation of iPrOH from the displacement of alkoxide ligands.  A number 
of Ti-alkoxides have been reported to display concentration dependent variations in molecular 
weight.  Barraclough et al. found that for the normal alkoxides in dioxane, as the concentration 
was increased, the molecular weight increased, with no limiting value of increased molecular 
complexity up to the measured concentration of 0.5M.641  This type of concentration dependent 
behavior is likely to result in detection of relatively high amounts of free alcohol and decreased 
alkoxide signals at higher concentrations, in contrast with the observed behavior of Ti(OiPr)4. 
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Furthermore, Ti(OiPr)4 was been reported by Bradley et al. as showing an average molecular 
association of 1.4 (in refluxing benzene), with a subsequent value of 1.1 (±0.01) reported over a 
decade later for a range of concentrations from 3.39 × 10-3  to 16.29 × 10-3 M.642  Amyloxide, 
secondary and tertiary alkoxides of titanium are reported to be typically monomeric due to 
effective shielding of the metal core by the bulky substituents, which prevent aggregation.643-646  
Molecular weight determinations performed by Sharpless and coworkers confirmed the 
monomeric nature of Ti(OiPr)4, measuring a degree of association equal to 1 for a 0.22M 
solution in CH2Cl2.
647  It is therefore unlikely that the observed behavior of Ti(OiPr)4 is due to 
aggregation of the metal alkoxide under the different concentration conditions.  For further 
clarification of this, analogous studies may be carried out on Ti-alkoxides which are known to 
vary in molecular complexity with concentration and the results compared with those discussed 
here. 
 
The formation of dimeric species is known to occur in the presence of water.  Hydrolysis of the 
Ti-alkoxide bonds, to form Ti-OH and liberate iPrOH, may enable the formation of dimeric 
complexes through the relief of the steric shielding around the metal centre, thus allowing 
subsequent attack on the electropositive Ti (Scheme 4.15).351, 648 
 
 
Scheme 4.15  
 
Ti(OiPr)4 is known to undergo hydrolysis in the presence of water in quantities as low as 0.3 
H2O molecules per Ti atom.  The addition of dilute solutions of H2O (3% w/w) in 
iPrOH to the 
isopropoxide was reported to give a solid with a molecular composition corresponding to 
TiO2(O
iPr)6.
648  The formation of complex such this would result in a bound alkoxide:free 
alcohol ratio of 3:1, compared an assumed ratio of 4:0 for Ti(OiPr)4, and may account for the 
unexpectedly high proportions of free alcohol at lower concentrations.   
 
The impact of solution concentration on the observed alkoxide:alcohol ratios was most 
significant below 0.1 M, where the relative ratios of bound alkoxide:free alcohol dropped from 
81:19 (0.05 M) to 40:60 (0.01 M) (CDCl3).  A similar trend was observed in Tol-d8.  From these 
findings it is clear that at lower Ti(OiPr)4 concentrations, 
iPrOH is liberated at the expense of the 
parent Ti-alkoxide (Figure 4.14) 
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Figure 4.14 Percentage ratio of methine protons of bound alkoxide and free alcohol observed by 
1
H NMR in 
solutions of Ti(OiPr)4 against solution concentration. 
 
Quantification of the species in solution was based on three assumptions: i) excluding solvent, 
only Ti(OiPr)4 and 
iPrOH were present in solution, ii) the Ti-alkoxide complex was monomeric, 
and iii) four alkoxide methine protons equate to one Ti(OiPr)4 molecule, giving a 0.25:1 
stoichiometry for the protons assigned as bound alkoxide and free alcohol.  The calculated 
quantities of Ti(OiPr)4 and 
iPrOH are given in Table 4.7.   
 
 CDCl3 Toluene d8 
[Ti(OiPr)4] 
/ mol L-1 
% 
bound 
alkoxide 
% free 
alcohol  
Ti(OiPr)4  
/ mola 
iPrOH / 
mola 
% 
bound 
alkoxide  
% free 
alcohol  
Ti(OiPr)4  
/ mola 
iPrOH / 
mola 
0.30 95 5 214 45 93 7 209 63 
0.25 95 5 178 38 93 7 174 53 
0.20 95 5 143 30 92 8 138 48 
0.15 93 7 105 32 90 10 101 45 
0.10 91 9 68 27 90 10 68 30 
0.05 81 19 30 29 76 24 29 36 
0.025 65 35 12 26 61 39 11 29 
0.01 40 60 3 18 35 65 3 20 
Table 4.7 Percentage ratio of methine protons observed for bound isopropoxide ligand and free alcohol, 
i
PrOH, in solutions of Ti(O
i
Pr)4 determined from integrals of methine proton peaks observed by 
1
H NMR; 
assuming monomeric, tetra-coordinated Ti-alkoxide, giving a 1:4 alkoxide:free alcohol stoichiometry 
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Figure 4.15 illustrates the relationship between amount of Ti(OiPr)4 and 
iPrOH in CDCl3; the 
results for samples prepared in Tol-d8 were found to be in close approximation.  In contrast to 
the trend observed for Ti(OiPr)4 which shows a steady, linear increase, the effect of increasing 
concentrations appears to have a less significant effect on the amount of free alcohol in solution.  
While there is a 200 × difference in the molar quantity of Ti(OiPr)4 between high and low 
concentrations (0.01-0.3M) only a threefold difference in the amount of free alcohol across the 
concentration range was observed.  This observation may be indicative of Ti(OiPr)4 acting as a 
scavenger for water in the deuterated solvents.  As the amount of free alcohol observed in 
samples of a constant volume (and therefore constant water content) does not appear to vary as 
significantly as Ti(OiPr)4 bound alkoxide quantity, it may be that the traces of water present are 
a limiting reagent in the formation of alternative Ti-complexes.   
 
 
Figure 4.15 Calculated quantities of Ti(O  
 
Although only small relative quantities of water are required for the hydrolysis of Ti(OiPr)4, the 
amount of water present in the prepared NMR samples is believed to be too low to have a 
significant effect.  In addition the formation of solid material was not observed.  Karl Fischer 
titrations were carried out on solvents that had been treated under similar conditions to those 
used for the NMR studies; CDCl3 was passed through a plug of alumina and stored over 4Å MS, 
while Tol-d8 was taken straight from a newly opened bottle with no additional drying steps.  
The water content of CDCl3 and Tol-d8 was found to be 1.9 ppm and 50 ppm respectively.  In 
NMR samples containing 0.75 mL of the deuterated solvents the water content of the solvent 
alone would be 18 ×10-3 mol H2O in CDCl3 and 353 ×10
-3 mol H2O in Tol-d8.  These 
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quantities of water may be too small to cause the liberation of iPrOH on the scale observed here, 
suggesting that additional reactions may be occurring, or that there are additional sources of 
water causing these effects, such as incompletely dried glassware or if the prepared solutions 
were hygroscopic in nature.   
 
Further investigation of the effect of water on the alkoxide:alcohol ratio could be conducted 
using solvents with varying water content.  As the amount of free alcohol observed in samples 
of a constant volume (and therefore constant water content) does not appear to vary as 
significantly as Ti(OiPr)4, it may be that the traces of water present are a limiting reagent in the 
formation of alternative Ti-complexes.  An analogous study would therefore be performed 
whereby the concentration of Ti(OiPr)4 is varied through the use of different solvent volumes, 
which should provide varying levels of moisture. 
 
4.7.2.2 Implications for the Ti-mediated synthesis of Esomeprazole 
 
Although further work is required to understand the apparent concentration dependent behavior 
of Ti(OiPr)4, there are clear implication for the in situ formation of the active catalyst species 
based on these findings.  Kagan et al. reported that, in the absence of water, a iPrOH modified 
reagent (1:2:4 or 1:4:4 Ti(O
i
Pr)4:DET:
i
PrOH) could be employed in the asymmetric oxidation of 
p-tolyl methyl sulfide, affording the sulfoxide in high ee (83 and 93% ee respectively).  Higher 
proportions of iPrOH were found to be detrimental to the enantioselectivity and strict regulation 
of reaction conditions were required to maintain high enantiomeric excess of the sulfoxide 
product.355  The undesired presence of iPrOH at low reagent concentrations, in addition to water, 
may decrease efficiency of the catalyst system, due to competition for coordination sites on the 
metal centre.  It has been proposed that the inclusion of iPrOH in the catalyst system aids 
catalyst turnover by displacement of the sulfoxide product from the active catalyst complex, it is 
likely therefore that the amount of this alcohol in the catalyst system requires careful regulation 
in order to achieve maximum efficacy. 
 
If lowering of the catalyst loading was to be achieved by way of decreasing the quantities of the 
catalyst precursors added to solution then the in situ formation of the active catalyst may be 
compromised.  The relatively low amounts of Ti(OiPr)4 observed in solutions of low 
concentrations may result in perturbations of the optimized catalyst reagent stoichiometry.  In 
the AstraZeneca procedures described by von Unge et al., the synthesis of (S)-1.1 using a 30 
mol% catalyst loading was performed using an initial Ti(OiPr)4 concentration of 0.224 M (in 
toluene), whereas for the lower catalyst loading reaction (4 mol%), it was 0.042 M suggesting 
that the differences in enantioselectivity may partly be attributed to a variation in reagent 
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concentration.  From the results of the NMR studies performed in Tol-d8 it can be estimated 
from Figure 4.12 that by lowering the Ti(OiPr)4 concentration from 0.224 M to 0.042 M, the 
alkoxide:free alcohol ratio would change from 92:8 to 72:28, resulting in a significant difference 
in the amount of Ti(OiPr)4 and 
iPrOH present in the reaction mixture. 
 
Subsequently other reagents present in the catalyst preparation/ageing step would effectively be 
present in an excess to the optimized ratio, and therefore may alter the efficacy of an active 
catalyst species.  A reduction in the amount of Ti(OiPr)4, due to concentration dependent 
behavior, may contribute to a poor formation or destruction (e.g. through hydrolysis in the 
presence of excess water) of the active catalyst species, thus effectively lowing the catalyst 
loading.  Disturbance in the reaction equilibria may occur, with preferential formation of 
potentially inactive or competing catalysts species such as 4.18.  The formation of 
coordinatively saturated complexes such as 4.19 would reduce or prevent catalytic turnover 
(Scheme 4.16). 
 
 
Scheme 4.16 Preferential formation of an undesired Ti-complex due to an excess of DET with respect to 
Ti(O
i
Pr)4 
 
4.7.3 NMR studies of the catalyst components: Ti(OiPr)4 + DET + H2O 
 
Further NMR studies were conducted investigating the combination of Ti(OiPr)4 and DET, with 
and without the presence of water (Figure 4.16).  With the addition of water a complex mixture 
of signals occurring between 3.8-5.6 ppm was observed.   The peaks at 4.32 and 4.55 ppm are 
due an excess of DET in solution, however the appearance of signals at higher chemical shifts 
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may be indicative of the formation of low concentrations of complexes between DET and 
titanium, formed only in the presence of the water. 
  
 
Figure 4.16 Partial 
1
H NMR (CDCl3) spectra of Ti(O
i
Pr)4 and diethyl tartrate (DET) in a 1:2 ratio with and 
without the addition of 1 equiv of H2O 
 
The sulfoxidation catalyst reagents employed by Kagan, Modena and von Unge were examined 
by NMR (Figure 4.17).125, 347, 352  Once again, in addition to signals attributed to an excess of 
DET in solution, the formation of a complex mixture of species was observed.  Although further 
investigation is required to gain more information of the Ti-based complexes formed between 
these reagents it can be seen that the Modena catalyst system of 1:4:0 Ti(OiPr)4:DET:H2O 
produces a mixture of components almost identical to that formed by the Kagan system which 
features the addition of less tartrate but one equivalent of water.  It has been proposed that the 
addition of 4 equivalents of the hygroscopic tartrate in the Modena sulfoxidation system 
inadvertently introduces water into the catalyst mixture, and that the active catalysts 
investigated by Kagan and Modena were in fact the same 1:2:1 Ti(OiPr)4:DET:H2O.
36, 354  
Comparison of the 
1
H NMR spectra of the Kagan and Modena reagents supports this 
hypothesis.  
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Figure 4.17 Partial 
1
H NMR (CDCl3) spectra of the Kagan, Modena, and von Unge catalyst systems 
comprising of Ti(O
i
Pr)4, diethyl tartrate (DET), and H2O in various ratios 
 
4.8 Conclusions and future direction 
 
In pursuing investigations into the Ti-mediated asymmetric synthesis of Esomeprazole a number 
of unexpected challenges were faced, and thankfully most were overcome.  Esomeprazole and 
Omeprazole proved to be demanding compounds to synthesize and manipulate; as well as 
decomposing under acidic conditions, they also are known to be sensitive to light, moisture, and 
heat. Racemic Omeprazole was found to be unsuitable for purification by column 
chromatography due to poor solubility and decomposition on the column, and the workup 
procedure for the Ti-based sulfoxidation process was difficult and precarious.  Early attempts to 
quantify the enantioselectivity of products from the asymmetric sulfoxidation by chiral 
chromatography saw the decomposition of materials on the column, which had also been 
observed when during purification of Omeprazole by column chromatography.  The possibility 
was also raised that the sulfoxide was too unstable, and decomposition was occurring prior to 
analysis.  Through time and experience, however, we found suitable ways to isolate and analyze 
these sulfoxides.  Synthetic methodologies were developed for the production and isolation of 
Pyrmetazole 3.17, the sulfide precursor to Esomeprazole (S)-1.1, Omeprazole ()-1.1 the 
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racemic form of the sulfoxide, and the corresponding sulfone 4.1, all of which were achieved in 
good to high yield.   
 
Using a titanium-tartrate based catalyst system, developed by Kagan and subsequently modified 
by von Unge et al. the synthesis of Esomeprazole (S)-1.1 was achieved in good yields (up to 
71%) and high enantioselectivity (up to 93% ee); conversion of the sulfoxide product to the Na-
salt resulted in optical enrichment allowing for Na-Esomeprazole (S)-3.36 to be isolated in near 
optically pure form (> 99.5% ee).  The asymmetric sulfoxidation process was performed on a 
range of structurally diverse sulfides, some of which featured the heterocyclic motifs found in 
Esomeprazole.  It was found that the presence of the benzimidazole NH group was of great 
importance with respect to the stereoselectivity of the reaction, and that species without a 
benzimidazole ring were afforded in low ee.  Although further work is required to gain the 
desired insight into the processes involved in the Ti-mediated asymmetric synthesis of 
Esomeprazole (S)-1.1, in carrying out the work that is laid out here a great amount of worthy 
information was gathered on these compounds which would be of benefit to anyone continuing 
this vein of research.    
 
Omeprazole and Esomeprazole were found to exhibit differences in their physical and 
spectroscopic characteristics, arising from heterochiral dimer formation of the racemic 
sulfoxide.  Importantly, it was realized that while Omeprazole ()-1.1 required purification via 
crystallization and crystallized as the racemate, Esomeprazole (S)-1.1 however, was found to 
exist as an oil that would dry to a glassy solid under vacuum, and most importantly could 
withstand chromatography due to increase solubility over the racemic sulfoxide.   
 
With the knowledge gained during this body of work there are a number of paths that could be 
followed in its continuation.  It would be highly desirable to improve efficacy of the Ti-
mediated sulfoxidation, particularly with respect to the synthesis of Esomeprazole.  Alterations 
to the reaction process might involve the pre-formation of the active catalyst species.  
Alternatively one may wish to investigate the importance of catalyst loading during the different 
stages of the reactions, during the catalyst aging step or during the oxidation.  If it was found 
that a high catalyst loading was more important during the catalyst preparation and ageing step 
then the addition of further amounts of sulfide following catalyst ageing would result in the 
oxidation stage, and overall reaction occurring at an effectively lower catalyst loading.  
Simplification and/or improvements made to the work up procedure for the Ti-tartrate based 
sulfoxidation reaction may allow for greater recovery of material, and therefore greater reaction 
economy.  Further analysis of the conditions that afford Esomeprazole or Na-Esomeprazole in 
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high enantiopurity and higher yields may also allow for improvements in the reaction 
methodology. 
 
In this work we have identified that the concentration at which the catalyst reagents are used 
may have importance with respect to why lower catalyst loadings lead to a reduction in 
enantioselectivity.  Performing the asymmetric synthesis of Esomeprazole at varying 
concentrations may provide greater information on this matter.  Further studies could be 
performed using NMR, and other analytical means, to gather information on the nature of the 
active catalyst species, investigating the aspects of the sulfoxidation reaction protocol such as 
the importance placed on the order of addition of catalyst components, or on the role played by 
water, or additives such as DIPEA.   
 
Modifications to the current methodology may also be of interest to study, such as the 
application of a range of more structurally diverse chiral tartrates, or tartramide, based ligands.  
Future work may look at developing alternative methodologies for the asymmetric synthesis of 
Esomeprazole (S)-1.1, and may begin by assessing processes that are currently available for the 
asymmetric oxidation of sulfides, but have not yet been applied or adapted for use in the 
oxidation of Pyrmetazole.  Alternatively, it may be possible to adapt the current Ti-tartrate 
based oxidation process for the production of alternative chiral sulfoxide, though modification 
of the current protocol. 
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5 Evaluation of chiral tartrates for use as chiral solvating agents 
5.1.1 NMR spectroscopy as a tool for quantitative stereochemical analysis 
 
With the development of new methodologies in the field of asymmetric synthesis it is important 
to also develop new strategies for the measurement of enantiomeric purity.  Despite its relative 
low sensitivity compared to other techniques such as chiral HPLC or GC, NMR spectroscopy is 
nonetheless an attractive option by which enantiomeric excess determination can be achieved 
quickly and simply.102  The measurement of enantiomeric purity of a chosen solute can be 
achieved in a number of ways.649-652  A recent development in the utility of NMR for 
enantiodiscrimination is the use of chiral liquid crystals (CLC) as a solvent or as an orientating 
medium.653-658  Here the induction of a magnetic field orientates the CLC and in doing so has an 
aligning effect upon the enantiomeric solute.  The orientation of the solute is different between 
the two enantiomeric forms, thus all other sensitive NMR interactions, such as chemical shift 
anisotropies and dipolar coupling, are also different.  As this technique is based on shape 
recognition it is applicable to substrates such as chiral alkanes which lack a functional group 
required for derivitisation or complexation.659  Unfortunately this technique is still in its infancy 
and has been reported to suffer from poor sensitivity to chirality.660  The requirement of 
specialized reagents in the CLCs is also limiting in the widespread application thus far. 
 
A more classic approach is with the use of chiral derivitisation agents (CDAs).  These reagents 
are used prior to NMR analysis to form covalent bonds to the molecules of the mixture of 
enantiomers under investigation, thus producing diastereomers measureable under NMR 
conditions.661  In a simple achiral medium it is not possible to distinguish enantiomers by NMR 
as the resonances of enantiotopic nuclei are isochronous.  In contrast, diastereomeric species are 
distinguishable due to the anisochronous nature of certain diastereomeric nuclei.  The magnetic 
nonequivalence arising from this is reflected in the chemical shifts of the related stereogenic 
centers.  With sufficient resolution of the appropriate signals, this phenomenon, which was first 
noted by Cram over half a century ago, gives the relative ratios of diastereomers present by 
simple measurement of the signal integration values.651  There are a wide range of CDAs 
available, such as the acids developed by Mosher 5.1, and Mislow 5.2, camphanic acid 5.3, and 
the diamine 5.4 (Figure 5.1).651, 662-665  As a covalent bond forming reaction must take place it is 
important to select the appropriate CDA with respect to the functional groups available within 
the sample under investigation.  Great care must also be taken to ensure racemisation or kinetic 
resolution does not occur during the preparation of the derivatized materials in order to render 
accurate results from the subsequent spectroscopic analysis. 
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Figure 5.1 
 
A third method, and the one which shall be the focus from here on in, is the use of chiral 
solvating agents, also referred to as chiral shift agents (CSAs).  These reagents are used to form 
diastereomeric association complexes in solution which produce different chemical shifts.  
Additionally, the association constants of the complexes may differ in the formation of 
complexes between the CSA and the two enantiomers under scrutiny, giving rise to different 
time averaged solvation environments, contributing to the recognition of individual chiral 
species.666, 667  Hydrogen bonds, van der Waals forces and - interactions are often reported as 
the driving forces behind the formation of complexes in solution.639  There have been a wide 
range of CSAs reported in the literature.  Host-guest interactions between cyclodextrins (CDs) 
or crown ethers and chiral substrates are well known.649, 668  Derivatised CDs were found to be 
appropriate for enantiopurity determination of Selegiline 5.5, an anti-Parkinson’s drug for which 
only the (R)- enantiomer is active, and analogous phenylamines 5.6 and 5.7 (Figure 5.2).  
Functionalised crown ether 5.8 was shown to display enantiodiscrimination towards cis-
aminoindanol, with the crown cavity acting as a host towards ammonium salts which formed 
upon reaction of the carboxylic groups and the amine of the substrate. 669, 670  
 
 
Figure 5.2 
 
Lanthanides shift reagents, such as Eu(hfc)3 (hfc = heptafluoropropylhydroxymethylene)-(+)-
camphorate) 5.9, are widely used and commercially available.  Lewis-acid type complexation 
between the studied solute and the paramagnetic metal core of the shift reagent give rise to 
strong shielding or deshielding effects observed in the spectra of the solute.671  In addition there 
can be changes in chemical shift arising from interactions such as transfer of electron spin 
density (contact shift) or by the magnetic effect of unpaired electron magnetic moment (pseudo 
contact shift).672-676  Shift reagents of this kind usually require their gradual addition in small 
177 
 
amounts to the sample under scrutiny in order to achieve sufficient resolution.  One 
disadvantage to CSAs of this type is that signal line broadening, often due to proton-electron 
dipolar relaxation, can occur.  These reagents are also relatively expensive; Sigma-Aldrich 
currently quotes prices of £56-166 per g for Eu(hfc)3 and £23-151 per g for Eu(fod)3.
677, 678 
 
Simple, small chiral molecules are often effective as CSAs.  Chiral aryltrifluoromethylcarbinols, 
such 5.10 and 5.11, developed by Pirkle et al. are widely used, commercially available, simple 
to employ and in contrast to lanthanide type reagents do not suffer from line broadening.679 680  
The asymmetric synthesis of the antitumor alkaloid ()-Crispine A 5.12, and the determination 
of enantiopurity by 1H NMR was recently reported, with ()-(R)-t-butylphenylphosphinothioic 
5.13 successfully employed as a CSA.681  The phosphinopthioic acid 5.13 however, is not 
commercially available; for their own research on the synthesis of the chiral alkaloid 5.12, 
Yuste et al. reported that, due to limitations in the exportation of certain phosphorus compounds 
in their country (Mexico), the synthesis of the acid was not a viable option.  Instead they 
employed (S)-1,1-binaphthyl-2,2-diol ((S)-BINOL) 1.43 as a CSA, reporting that the use of  
five equivalents of the diol gave sufficient enantioresolution for accurate and reliable 
measurement of alkaloid enantiopurity.682  The cost of reagents such as can vary dramatically, 
for example 1 g of Pirkle’s alcohol 5.11 currently costs over £500 per g whereas (S)-BINOL 
1.43 is available for £13-33 per g.683, 684 
 
 
Figure 5.3  
 
5.1.2 CSA for the enantiodiscrimination of chiral sulfoxides 
 
There is a wide choice of CSA available for the enantiodetermination of chiral sulfoxides, 
including lanthanide- and macrocyclic- based reagents.637, 685-688  The larger aromatic group of 
alcohol 5.11, compared with 5.10, give a chiral shift agent with greatly increased shielding 
ability, with the 9-anthryl species giving up to 5 times greater chemical shift nonequivalence in 
comparison to phenyl analogue.689  The benzamide reagent 5.14, developed by Kagan et al. was 
reported to successfully resolve all four enantiomers in samples of Mesoridazine 5.15, a 
sulfoxide metabolite of the antipsychotic drug Thioridazine, thus allowing for the quantification 
of the diastereomeric ratios (Figure 5.4).  The enantiorecognition of reagents such as Pirkle’s 
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alcohols and Kagan’s amide is attributed to the H-bonding interactions between the sulfinyl 
group of the chiral solutes and the OH- and NH-groups of the respective CSAs.690 
 
 
Figure 5.4 
 
(S)--Methoxyphenyl and (S)--methoxy-2-naphthyl acetic acids ((S)-MPA 5.16 and (S)-NMA 
5.17 respectively) were reported to be good CSAs for dialkyl sulfoxide species such as 5.18.691  
The success of the methodology was attributed to the fact that these reagents were more acidic 
than those of Pirkle and Kagan, allowing for complexation with the basic sulfinyl oxygen of the 
target substrates at more dilute concentrations.  In subsequent studies on dialkyl sulfoxide 5.18 
(S)-Ibuprofen 5.19 and (S)-Naproxen 5.20 were employed because of their structural similarity 
to MPA and NMA, and greatly reduced price.
692
 
 
5.2 NMR enantiodiscrimination of Omeprazole, Esomeprazole, and related PPIs 
 
Whilst there are numerous papers on HPLC methods for the determination of enantiomeric 
purity of Esomeprazole and analogous PPIs, reports of using NMR as a tool are very limited.  
This is not surprising given the challenges present when handling these sulfoxides; water 
soluble or acid based CSAs are unsuitable due to the poor solubility and stability of 
Esomeprazole in neutral or acidic conditions, and a lack of appropriate functionalities means 
that the use of derivitisation agents is very limited.   
 
Cyclodextrins have been employed as CSAs for the sodium salts of Omeprazole and neutral 
forms in D2O, and (S)-BINOL 1.43 for use with the neutral forms of the sulfoxides.
102, 639, 693 
Both BINOL and cyclodextrins have been reported in their application for their role in the 
production of Esomeprazole, the former as a chiral ligand in the Ti-mediated S-oxidation, and 
both CDs and BINOL in resolution of enantiomers via the formation of inclusion complexes.571, 
628, 694-696  
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More recently Wenzel et al. examined 32 different compounds and assessed their use as NMR 
chiral solvating agents for the determination of enantiopurity of 16 analytes, including 
Omeprazole.697  Five compounds were found to effect full enantiodifferentiation in the 1H NMR 
of Omeprazole, these included Pirkle’s alcohol 5.10, BINOL 1.53, quinine 1.72, valine 5.21, 
and the dinitro- species 5.22, a CSA named “Whelk-O” developed within the author’s 
laboratories (Figure 5.5).  A further four compounds were reported to induced partial 
enantiodifferentiation when employed as a CSA with Omeprazole 1.1. 
 
 
Figure 5.5 
 
5.3 Chiral tartrates as CSA for ee determination in Esomeprazole  
 
We became interested in identifying alternative methods for the determination of enantiopurity 
of Esomeprazole.  Struggles to isolate and purify Esomeprazole had prevented the use of 
polarimetry.  Early results from use of chiral HPLC had led us to believe that the substrate was 
far too unstable for chromatographic analysis. However upon switching from a reverse-phase 
HPLC column to a normal-phase one we found that not to be the case.  Although satisfactory 
HPLC methods were subsequently developed for the analysis of Esomeprazole and its salts, this 
method was sensitive to the presence of other species, such as the sulfide 3.17 and sulfone 4.1, 
causing overlapping of signals which affected the accurate measurement of enantiopurity.  We 
decided to look to NMR for an alternative method for measure enantiopurity.  Preliminary 
investigations were carried out using Eu(hfc)3 and Kagan’s benzamide 5.14, however neither of 
these were found to give satisfactory NMR spectra suitable for the purpose of measuring 
enantiomeric excess.   
 
5.3.1 (S)-BINOL vs. (S,S)-DET as chiral shift agents 
 
The procedure reported by Redondo et al., for the use of (S)-BINOL 1.43 as a CSA was 
followed on a sample of Omeprazole.  A 40 mM solution of Omeprazole in CDCl3 was 
combined with 1 equivalent of (S)-BINOL and a 32 scan 1D 1H NMR spectra obtained.  The 
enantiodiscriminating effect of the CSA was evident; splitting of the proton signals was 
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observed for the pyr 6''-H and pyr methyl groups of Omeprazole ()-1.1, in accordance with the 
literature.639  Sample preparation was easy and quantification of enantiopurity was achieved 
within minutes, as opposed to hours in the case of HPLC.  The use of BINOL was however 
found to have some distinct limitations.  Changes in solution concentration and/or NMR 
experiment run time resulted in overlapping of signals in the aromatic region, limiting the 
ability to use the pyr 6''-H signals for measurement of the enantiomer ratio (Figure 5.6).   
 
 
 
Figure 5.6 
1
H NMR in CDCl3: (top) 1:1 (S)-BINOL:Omeprazole; (middle) Omeprazole only; 
(bottom) 1:1 (S,S)-DET:Omeprazole. 
 
The dual functionality of BINOL as a CSA and a chiral ligand in the asymmetric synthesis of 
Esomeprazole gave the inspiration to try (S,S)-diethyl tartrate (DET), the reagent we had 
previously employed as a chiral ligand, as a CSA.  In the discussion that follows  and  
shall both be used to describe and quantify the effects observed in the NMR spectra of a specific 
substance following complexation in solution;  refers to an observed change in the chemical 
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shift for a specific resonance of a substance and  is used to quantify the extent of induced 
magnetic nonequivalence ( = |R - S|) of specific signals pertaining to that species.
102  
 
One equivalent of (S,S)-DET in a CDCl3 solution of racemic Omeprazole gave excellent 
enantiodiscrimination (Figure 5.6).  Magnetic nonequivalence was observed in the form of 
signal splitting for nearly all protons with the exception of the benz 4- and 7-H which appeared 
broadened due to tautomerization; quantification of the induced nonequivalence for each of the 
proton signals is shown in Figure 5.7.  In contrast to when BINOL was employed as the CSA, 
none of the signals from DET were observed to overlap with those of Omeprazole, which was 
greatly preferable (Figure. 5.6). 
 
 
Figure 5.7 
 
5.3.2 Choice of NMR solvent 
 
It was found that the anisochrony between diastereomeric pairs was best observed in 
hydrophobic deuterated solvents such as DCM-d2, CDCl3, toluene-d8, and benzene-d6 (Figure 
5.8).  Due to poor substrate solubility the latter two solvents may be considered poorly suited 
for this role, however they did afford well resolved spectra with large  values observed for 
pyr 6''-H which may be beneficial for measurement of sulfoxide enantiopurity.   
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Figure 5.8 
1
H NMR spectra of Omeprazole and DET (1:1) in various solvents 
 
When hydrophilic solvents, such as CD3OD and DMSO-d6, were employed no splitting of 
resonances for Omeprazole were observed; when acetone-d6 was used only a very small 
splitting of the pyr OMe and the Me signals were seen (Table 5.1).  It is likely that such water 
miscible solvents disrupt the hydrogen bonding interactions necessary for the formation of 
diastereomeric host-guest complexes, whereas the hydrophobic solvents may assist the complex 
formation via solvophobic effects.  Conveniently the pretreatment of CDCl3 prior to use, such as 
drying with molecular sieves or passing through a plug of alumina to remove water and DCl, 
was found to be unnecessary. 
 
 
 (ppm) 
Solvent pyr 6''-H CH2 (d) CH2 (u) benz OMe pyr OMe 5''-Me 3''-Me 
benzene-d6 0.112 0.008 0.027 0.006 0.011 0.008 0.011 
toluene-d8 0.123 0.005 0.024 0.005 0.007 0.022 0.011 
DCM-d2 0.044 singlet singlet 0.004 0.012 0.009 0.025 
CDCl3 0.064 0.009 0.007 0.006 0.015 0.012 0.033 
acetone-d6 - - - - 0.004 0.006 0.016 
Table 5.5.1 (d) = downfield signal, (u) = upfield signal, refers to the position of the individual proton signals of 
the CH2 group 
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In DCM-d2, the CH2 protons of Omeprazole were seen as two singlets but for the other 
hydrophobic solvents two distinct proton environments could be seen, with different  values 
observed for each of the CH2 protons.  In benzene and toluene the sulfoxide CH2 was weak 
relative to other Omeprazole signals, these solvents did however provided excellent separation 
between the signals for the pyr 3''- and 5''-Me, in contrast to the chlorinated solvents.  In the 
spectra of samples in CDCl3 and DCM-d2, nonequivalence could be seen for the tartrate CH2 
protons ( 0.004 ppm in either solvent).  When either benzene-d6 or toluene-d8 was used a 
much larger splitting of the tartrate CH2 was seen, with the higher  resulting in a complex 
signal, shown in (Figure 5.9); no other signals of the tartrate CSA showed evidence of magnetic 
nonequivelence in any of the solvents examined.   
 
 
 
 
Figure 5.9 
1
H NMR spectra of Omeprazole and DET (1:1) in various solvents 
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5.3.3 Host-guest ratio 
 
Next we investigated how much chiral tartrate was required to achieve enantioresolution in a 
sample of racemic Omeprazole.  In addition to DET, (S,S)-diisopropyl (DIPT), and (R,R)-
dimethyl tartrate (DMT) were also examined. 
 
 
 
It was found that substoichiometric amounts of all three tartrates were sufficient to achieve 
enantiodifferentiation between the two sulfoxide enantiomers of Omeprazole.  When using a 
500 MHz spectrometer the addition of only 0.2 equivalents of DET or DIPT was sufficient to 
achieve baseline separation of the pyr 6''-H peaks of the two enantiomers.  If a lower field 
strength spectrometer i.e. 300 MHz was employed the amount of DET required to resolve the 
pyr 6''-H resonances of Omeprazole rose to one equivalent.  With the 300 MHz instrument we 
found that 0.5 equivalents of DMT was required for the total separation of the diagnostic pyr  
6''-H peaks; it may be assumed that this amount would decrease with the use of a higher 
frequency instrument.  
 
Samples of racemic Omeprazole in CDCl3 were treated with increasing amounts of DET and the 
1H NMR spectra obtained (Figure 5.10).  No information concerning the enantiodiscriminatory 
effects of DET as a CSA could be gained from the benzimidazole protons, observed between 
6.8-7.70 ppm, due to signal broadening.  With increasing amount of DET however the 
benzimidazole 4- and 7-H signals become more resolved, and a downfield field shift was 
observed for the benz 4-H, from 6.85 ppm (for Omeprazole) to 7.10 ppm in the presence of five 
equivalents of DET.  The magnetic nonequivalence induced by the addition of the CSA was 
calculated for diagnostic proton resonances and plotted against the amount of tartrate employed 
relative to Omeprazole.  With increasing amount of the tartrate applied to the substrate, an 
increase in signal separation was observed relating to a shift in the complexation equilibrium 
toward the associated species.  The effect of complexation was least observed in the methoxy 
group of the benzimidazole, with  of only 0.007 ppm after five equivalents of DET.  As this 
group appears to be the least affected this may indicate that it is the furthest away from any 
site(s) of binding in the association complex.  The benzimidazole NH proton signal was not 
observed in solutions with greater than 0.5 equivalents of tartrate added, however the 
information that may be gleaned from this observation alone is limited as the NH proton was 
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found to be highly exchangeable even in the absence of a CSA.  The CH2 signals were also not 
suitable as the resolution of these protons was found to vary quite significantly; it is thought that 
this is related to sample concentration, NMR spectrometer frequency and molecular 
aggregation.  
 
Figure 5.10 
1
H NMR spectra of omeprazole in CDCl3 in the presence of (S,S)-DET;  Top to bottom: 0 equiv 
DET,  0.4 equiv DET,  1 equiv DET, 2equiv DET and 5equiv DET. 
 
The greatest extent of signal splitting was observed in signals of the pyr 6''-H and 3''-Me 
protons.  Out of all of the proton environment around the pyridine system, these protons are in 
the closest proximity to the sulfinyl group as illustrated by the presence of cross peaks between 
these groups and the CH2 protons in the NOESY spectra of Omeprazole.  The high  values 
may indicate the involvement of nearby sulfinyl group in complexation with the CSA.  The 
pyridine 5''-Me and methoxy groups are affected very similarly by the increasing addition of the 
tartrate CSA, and are perturbed to a far lesser extent than the other signals from the pyridine 
moiety.   
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Figure 5.11  (ppm) of nonequivalent proton signals observed in spectra of Omeprazole + DET (CDCl3) 
against no. of equivalents DET 
 
The effects of adding (S,S)-DIPT and (R,R)-DMT to racemic Omeprazole were also examined 
in the same fashion (Figures 5.11 and 5.12 respectively).  The extent of splitting in the 
resonances of the substrate followed the same trend as for DET, with the pyr 6''-H protons 
affected the most, followed by the pyr 3''-Me group.  When DMT was employed no significant 
splitting of the benzimidazole OMe protons was observed; when DIPT was used no splitting of 
the pyr 5''-Me protons was found.  Interestingly, while the non equivalence observed for the pyr 
6''-H signal was distinctly affected by changing the tartrate, very little difference in  ppm 
was seen in the signals of other groups.  The use of two equivalents of tartrate to Omeprazole 
produced a nonequivalence of between  4.5 and 4.6 in the signal for pyr 3''-Me regardless of 
which tartrate was employed.  In contrast the spitting of the pyr 6''-H peak was found to increase 
from DMT < DET< DIPT ( 6.4 < 8.3 < 9.0 respectively).  This may be indicative of a 
correlation between the size of the CSA and the extent of induced nonequivalence, with the 
tartrate with the larger steric bulk giving rise to greater splitting observed for the specified peak.  
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Figure 5.12  (ppm) of nonequivalent proton signals observed in spectra of Omeprazole + DIPT (CDCl3) 
against no. of equivalents DIPT 
 
 
Figure 5.13  (ppm) of nonequivalent proton signals observed in spectra of Omeprazole + DMT (CDCl3) 
against no. of equivalents DMT 
 
In addition to the nonequivalence induced in many of the proton signals of racemic Omeprazole, 
notable changes in chemical shifts were also observed upon complexation with DET, DIPT and 
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DMT.  Table 5.2 shows the observed changes in chemical shift for the affected resonances of 
Omeprazole induced by the addition of 1 equivalent of tartrate; where peak splitting was 
induced by addition of the tartrate CSA two values are reported, one for each of the 
nonequivalent proton signals.  Complexation with DMT was found to cause the smallest change 
in the Omeprazole chemical shifts; the effects of DIPT were only marginally greater than those 
observed when DET was used.  The protons of the pyridine group of Omeprazole were all 
observed to undergo a downfield shift with addition of the tartrate CSAs.  The most significant 
deshielding was observed for the benz 7-H proton (with DET and DIPT), giving a strong 
indication that in addition to the sulfinyl group, the benzimidazole NH may also be involved in 
hydrogen bonding interactions with the tartrate CSAs.  The tartrates each had a similar shielding 
effect of the chemical shift of the CH2 protons.  
 
 
Assignment 
+ (S,S)-DET 
ppm 
+ (S,S)-DIPT  
 / ppm 
+ (R,R)-DMT 
 / ppm 
pyr 3''-Me 0.10 0.10 0.09 
 
0.12 0.13 0.11 
pyr 5''-Me 0.03 0.03 0.03 
 
0.04 0.04 
pyr OMe 0.08 0.08 0.07 
 
0.09 0.09 0.08 
benz OMe 0.03 0.03 0.03 
 
0.04 0.04 
CH2    upfield -0.04 -0.04 -0.03 
CH2    downfield -0.06 -0.06 -0.06 
benz 4-H -0.07 -0.07 0.01 
benz 5-H 0.03 0.03 0.03 
benz 7-H 0.20 0.21 0.10 
pyr 6''-H 0.03 0.04 0.03 
 
0.09 0.10 0.07 
Table 5.2 Changes in 
1
H chemical shift ( ((ppm)) of Omeprazole observed following complexation with 1 
equivalent of tartrate 
 
The effects of the tartrate CSAs on the 13C chemical shifts of Omeprazole are shown in Table 
5.3.  Carbon signals from the benzimidazole group offered limited information due to signal 
broadening and are excluded.  Signals assigned to the pyridine and the CH2 groups were seen 
further downfield when diastereomeric complexes with the CSAs were formed, with the 
exception of the pyr C2'' signal which moved upfield.  Two peaks were found for many of the 
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carbon signals ( values shown in Table 5.3) with appreciable nonequivalence observed for 
the CH2 carbon induced by the enantiodiscrimination agents.  
 
 + (S,S)-DET + (S,S)-DIPT + (R,R)-DMT 
Assignment  / ppm  / ppm  / ppm  / ppm  / ppm  / ppm 
pyr 3''-Me 0.1 0.02 0.1 0.03 0.1 0.02 
pyr 5''-Me 0.1 0.02 0.1 0.02 0.1 0.02 
pyr OMe 0.2 0.02 0.2 0.02 0.2 
CH2 0.1 and 0.3 0.23 0.1 and 0.4 0.23 0.1 and 0.3 0.18 
pyr C5'' 0.3 0.08 0.2 0.09 0.3 0.05 
pyr C3'' 0.2 0.07 0.1and 0.2 0.09 0.2 0.05 
pyr C2'' -0.3 0.04 -0.3 0.04 -0.3 0.04 
pyr C6'' 0.0 and 0.1 0.13 -0.1and 0.1 0.17 0.0 and 0.1 0.09 
pyr C4'' 0.1 0.04 0.1 0.03 0.1 0.04 
Table 5.3 Changes in 
13
C chemical shift ( ((ppm)), and signal nonequivalence ( (ppm)) of Omeprazole 
observed following complexation with one equivalent of tartrate 
 
The changes seen in the chemical shifts of the tartrate CSAs upon interaction with Omeprazole 
were minimal (Table 5.4).  For DMT no change in chemical shift was observed for the methyl 
groups.  Complexation with Omeprazole gave rise to a deshielding effect observed for the 1-H 
protons of all three tartrates; deshielding was also observed in the 13C signals of C1 and C2 for 
all tartrates.  The alkyl protons of DET and DIPT underwent an upfield shift, which may be 
attributed to magnetic anisotropy of the heteroaromatic groups of the sulfoxide.    
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Tartrate 1H Assignment 
1H  (ppm) 13C Assignment 
13C  (ppm) 
DET 4-H -0.01 C4 0.1 
 
3-H -0.01 C3 0.0 
 
1-H 0.03 C1 0.1 
   
C2 0.1 
DIPT 4-H -0.01 C4 0.0 
 
3-H -0.01 C3 -0.1 
 
1-H 0.02 C1 0.2 
   
C2 0.1 
DMT 3-H 0.00 C3 0.0 
 
1-H 0.03 C1 0.2 
   
C2 0.2 
Table 5.4 Changes in 
1
H and 
13
C chemical shift ( ((ppm)) of tartrates DET, DIPT, and DMT observed 
following complexation with one equivalent of Omeprazole. 
 
5.3.4 Determination of enantiomeric excess 
 
The efficacy of the diethyl- and dimethyl tartrates in the role of chiral shift reagents for 
enantiodetermination by NMR was assessed by comparing the results of chiral HPLC and NMR 
analysis of Esomeprazole samples across a range of % optical purities.  A range of 
sulfoxide:tartrate ratios were examine, from 0.25 equivalents of tartrate up to five equivalents, 
with CDCl3 used as the solvent.  The pyr 6''-H was used to measure to ratio of diastereomeric 
complexes formed with the chiral tartrates in solution (Figure 4.14).  The agreement between 
the two methods was found to be very good; the greatest variation between HPLC and NMR 
was found to be only 1% ee for both DET and DMT (Table 5.5). 
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Figure 5.14 
 
Tartrate CSA % ee (NMR) % ee (HPLC) 
DET (one equiv) 0 0 
 
20 20 
 
40 40 
 
53 54 
 
60 60 
 
81 81 
 
100 100 
DMT (one equiv) 0 0 
 
22 21 
 
40 41 
 
50 50 
 
62 63 
 
81 81 
 
100 100 
Table 5.5 Comparison of enantiomeric excesses determined by 
1
H NMR using tartrate based chiral shift 
reagent and by chiral HPLC 
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When (S,S)-DET or (R,R)-DMT were used as the CSA one equivalent of the tartrate was 
required to get baseline resolution of the diagnostic pyr 6''-H proton for sulfoxides across the 
whole ee range (Figure 5.15).  The resolution of nonequivalent peaks was easily improved by 
further addition of the appropriate tartrate. 
 
 
Figure 5.15  Comparison of the 
1
H NMR obtained from Esomeprazole of varying enantiopurity with the 
addition of chiral shift reagents (S,S)-DET or (R,R)-DMT  
 
As mentioned previously, the use of chiral HPLC for the determination of Esomeprazole 
enantiopurity required prior purification of the sulfoxide, either by column chromatography or 
via formation of the Na-salt 3.36.  One important advantage that was found with using NMR 
was that no prior purification was required for such analysis.  With all three tartrates it was 
possible to measure the ratio of sulfoxide enantiomers from the materials obtained from the 
extraction process of the asymmetric S-oxidation process, which typically contained other 
compounds such as the sulfide starting material and/or sulfone byproduct. 
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When using the tartrates as CSAs with the Omeprazole and Esomeprazole it was observed that a 
distinct colour change took place, with the colourless sulfoxide solutions changing to a dark 
purple over a number of hours.  This change in appearance is typically observed when 
Omeprazole undergoes degradation reactions to produce highly coloured product.  In order to 
assess if any significant degradation of the sulfoxide was taking place in the presence of the 
tartrates 1H NMR analysis was carried out on solutions containing stoichiometric amounts of 
DET and Esomeprazole, with sulfoxide enantiomeric excess of 94 and 88%.  1H NMR spectra 
obtained 24h after sample preparation showed evidence of degradation in the form of trace 
impurities now present on the base line; by comparison with the NMR spectra acquired less than 
10 min after sample preparation it was possible to estimate that for each of the two samples over 
90% of the original sulfoxide material remained after 24h.  The enantiodiscrimination of the 
tartrate CSA was still in effect with little to no change in sulfoxide % ee, suggesting that under 
these conditions the rates of decomposition are equal for both enantiomers.   
 
5.4 Contrasting enantiodiscriminatory action of CSAs: DET vs. BINOL. 
 
The effects of (S,S)-DET and (S)-BINOL on a broad range of sulfoxides were compared with 
the addition of one equivalent of either chiral shift agent to solutions of the racemic sulfoxide  
4.9-4.11 and 1.48 in CDCl3 (Table 5.6).  The two chiral shift reagents were found to have very 
different effects on the sulfoxides examined.  With DET significant splitting of peaks was only 
seen in spectra of Omeprazole and sulfoxide 4.11.  In contrast, enantiodiscrimination was 
observed for every sulfoxide with BINOL.  For Omeprazole the pyr 6''-H protons had a 
nonequivalence of  0.098 and 0.095 with (S)-BINOL and DET respectively.  The only other 
incidence of a splitting of such magnitude ( 0.077) was seen for the analogues pyr 6''-H 
proton of sulfoxide 4.12 with BINOL as the CSA. 
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   (S)-BINOL  (S,S)-DET 
Sulfoxide Assignment (ppm) (ppm)
Omeprazole ()-1.1 pyr 3''-Me  
 pyr 5''-Me  
 pyr OMe  
 benz OMe  
 CH2 (u)  
 CH2 (d)  
 pyr 6''-H  
()-4.9 benz OMea 0.011 
 CH2 (u) 0.010  
 CH2 (d) 0.022  
()-4.10 CH2 (u) 0.007  
 CH2 (d) 0.013  
()-4.11 SMe 0.018 0.008 
()-4.12 pyr 3''-Me 0.011 0.005 
 pyr 5''-Me 0.022  
 CH2 (u) 0.054  
 CH2 (d) 0.021  
 pyr 6''-H 0.077  
()-1.48 SMe 0.011  
Table 5.5.6 
a 
downfield tautomeric signal; (u) upfield CH2 proton; (d) downfield CH2 proton 
 
For sulfoxides 4.9, 4.11 and 1.48 the enantiorecognition of the CSAs was not sufficient, either 
in terms of magnitude or resolution of NMR signals, for practical measurement of % ee with 
one equivalent of either DET or BINOL.  Complexation of sulfoxides 4.10 and 4.12 with  
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(S)-BINOL resulted in well resolved splitting of the CH2 proton (Figure 5.16).  Although some 
nonequivalence was observed for analogous protons in other sulfoxide spectra only for 
sulfoxide 4.12 and 4.10 was the effect so distinct.   
 
 
 
 
 
 
BINOL and DET were found to induce contrasting nonequivalence in the pyr methyl signals of 
Omeprazole.  With DET as the CSA, a greater  was observed for the pyr 3''-Me than the 5''-
Me (0.047 and 0.019 ppm respectively).  This was reversed however when BINOL was 
employed, with observed  of 0.012 (pyr 3''-Me) and 0.028 ppm (pyr 5''-Me).  (S,S)-DET was 
also found to exert an effect upon the methoxy group protons of both the benzimidazole and the 
pyridine groups of Omeprazole; in contrast BINOL showed no significant splitting of either 
OMe signal.  It is possible that the contrasting chiral recognition displayed for Omeprazole with 
DET and BINOL arises from different modes of complexation.  Toda et al. reported that chiral 
host molecules such as BINOL worked in a similar manner to shift reagents such as Pirkles 
alcohols, with hydrogen bonding between the sulfinyl oxygen of a guest sulfoxide and the host 
alcohol (Figure 5.17).  Studies of the X-ray structure of (-)-methyl m-tolyl sulfoxide and  
(S)-BINOL showed the appropriate orientation of the naphthyl group of (BINOL) to account for 
the shielding of the methyl group observed in the NMR spectra.698  It may be assumed that 
sulfoxides such as Omeprazole interact with BINOL in a similar fashion, with the size disparity 
of the groups either side of the sulfinyl group matching those of the proposed model.  
 
 
Figure 5.17 
Figure 5.16 
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The contrasting effects of the dialkyl tartrate CSAs, in terms of the groups in which 
nonequivalence is induced and with respect to the shielding/deshielding observed in the NMR 
spectra of Omeprazole indicate that there may be additional interactions in the host-guest 
complexes.  One possibility is the involvement of the pyridyl nitrogen, in addition to the sulfinyl 
group and benzimidazole NH, in hydrogen-bonding interactions with the tartrate CSA, (Figure 
5.18).  However, given that sulfoxide 4.12 shows minimal splitting with DET it is unlikely that 
interaction with the pyridine nitrogen alone in combination with hydrogen bonding interactions 
of the sulfinyl group is responsible for the induced nonequivalence observed.    
 
 
Figure 5.18 
 
 
When the NMe derivative of Omeprazole 5.22 was treated with a tartrate based CSA no 
enantiodiscrimination was observed by NMR, highlighting the importance of the NH 
functionality in the formation of diastereomeric complexes with the tartrates such as DET.  The 
greater length of the tartrate CSAs backbone, in comparison with BINOL, may account for the 
splitting in signals observed for groups on the periphery of the sulfoxide such as the benz- and 
pyr-OMe protons. 
 
 
 
To further investigate the nature of the interactions between the tartrate CSAs and Omeprazole, 
attempts were made to grow co-crystallize Omeprazole with DMT, the only crystalline tartrate 
of the three examined.  Unfortunately this was not successful, with only the racemic sulfoxide 
obtained in crystal form, as determined by X-ray analysis.  It was interesting however that with 
the addition of one equivalent of DMT, crystallization of Omeprazole by the optimized method 
(diethyl ether anti solvent added to concentrated solution of sulfoxide in dichloromethane) gave 
the sulfoxide product in a more crystalline form than the powders typically obtained.  Future 
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optimization of the crystallization process may allow for the growth of co-crystals between 
Omeprazole or Esomeprazole and various tartrates. 
 
5.5 Conclusions and future directions 
 
(S,S)-Diethyl tartrate is a common chiral ligand in the synthesis of Esomeprazole via Ti-
mediated asymmetric oxidation; we have shown that it can have a second application in the 
quantification of enantiopurity by NMR.  (S,S)-Diethyl tartrate was shown to have excellent 
enantiorecognition towards the enantiomers of Omeprazole, but limited applicability towards 
other sulfoxides examined here.  It is likely that tartrate CSA such as DET, DIPT, and DMT 
would, however, be applicable for other analogous PPIs such as Rabeprazole 3.3 which share a 
common structural benzimidazole-pyridine framework with Omeprazole.  Although other CSAs 
such as (S)-BINOL have been reported for this specific application, the diethyl, diisopropyl, and 
dimethyl tartrates examined here are better suited as they have little or no overlap with proton 
signals of the sulfoxide substrate, enabling easier analysis of spectra, and subsequently better 
measurement of sulfoxide enantiopurity.  The 2016 paper from Wenzel et al. identified a 
number of compounds that enabled partial or total enantiodifferentiation in the 1H NMR spectra 
of Omeprazole but again these CSA give rise to numerous additional proton signals, some of 
which overlap with those of the sulfoxide under examination.   
 
The tartrates DET, DIPT, and DMT are inexpensive, non toxic and widely available in both 
their natural and unnatural enantiomeric forms.  Sample preparation for NMR analysis was 
quick and simple; the liquid tartrates DET and DIPT could be injected directly into an NMR 
tube, and if necessary the separation of the sulfoxide from the CSA could be simply achieved by 
column chromatography.  One of the only disadvantages of this method comes from the high 
viscosity of DET and DIPT, meaning that it can be difficult to use in L quantities.  However, 
the enantiodiscriminatory effects of the tartrates increase as the ratio of tartrate to sulfoxide 
increases so the only limitation to the overuse of tartrate comes from the relative intensities of 
guest/host signal peaks in the NMR spectra.  The tartrates examined here were highly suitable 
for use with sensitive substrates such as Esomeprazole.  In samples of Omeprazole and tartrate 
changes in colour were observed, from colourless to purple, which is typically associated with 
decomposition of the sulfoxide.  Analysis by NMR showed that although after 24 h some 
decomposition had occurred, there was sufficient time for collection of extensive spectroscopic 
data.  Similar issues would be expected with other shift reagents, especially those which are 
more acidic in nature such as (S)-Binol 1.43. 
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Comparison of chiral HPLC and NMR methods showed good agreement in the optical purities 
measured for a range of Esomeprazole samples.  It was also found that with the tartrate CSAs it 
was possible to measure the enantiopurity of Esomeprazole in the presence of common 
impurities such as sulfide 3.17 and sulfone 4.1, which is greatly advantageous over the chiral 
HPLC method.  Further investigation may give insight into the structural aspects of complexes 
formed between sulfoxides such as Omeprazole and the tartrates examined here.  More 
information on the stoichiometry of the sulfoxide:tartrate complex may be gained through 
investigations using the Continuous Variation Method i.e. construction of a Job plot.699, 700  It is 
possible that sulfoxides with similar heterocyclic motifs, such as imidazole rings, may also be 
suitable substrates for tartrates CSAs.  Examination of the enantiodiscrimination abilities of 
tartrates on alternative substrates may give insight into the diastereomeric complexes formed in 
solution.  The variation in spectra arising from the use of the different hydrophobic NMR 
solvents may prove useful in optimizing % ee measurement and further consideration of the 
nature of the enantiodiscriminating abilities of the tartrates examined here.  In addition, 
investigations of tartramides and alternative tartrates, such as diaryl tartrates may prove fruitful 
in terms of understanding the nature of host-guest interactions between CSAs of this type and 
sulfoxides.  Investigations may although reveal further compounds which can be used for 
enantiomeric determination of sulfoxides such as Esomeprazole (S)-1.1; the tartaric acid 
derivative 1.42 is known to resolve pyridyl sulfoxides through host-guest complexation and 
would be an interesting candidate for exploring its abilities to act as a CSA toward 
Omeprazole.105  The X-ray crystallographic structure of the complex between 1.42 and ethyl 
pyridyl sulfoxide showed hydrogen bonds between the sulfinyl group and the hydroxyl group of 
1.42, with no involvement of the pyridine heterocyclic (Figure 5.19); formation of analogous 
host:guest complexes with Omeprazole and Esomeprazole may also prove enlightening. 
 
 
Figure 5.19 
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6 Studies on the structure and reactivity of Omeprazole and 
related compounds 
 
6.1 X-ray crystallography of Omeprazole and related compounds 
 
X-ray characterization was performed for a variety of compounds in the Omeprazole family: 
Omeprazole 1.1, the sulfide Pyrmetazole 3.17, Omeprazole sulfone 4.1, the potassium salt of 
Omeprazole 3.38, and NMe Omeprazole 5.22.  In addition characterization was also performed 
on the sulfoxides 4.10-4.12.  Of these compounds only the crystal structures of Omeprazole 1.1 
and sulfoxide 4.10 have been previously deposited in the Cambridge Crystallographic Data 
Centre (CCDC), the crystal structures for the remaining compounds are thus far unreported.567, 
571, 572, 701, 702  X-ray diffraction (XRD) analysis was kindly performed by Dr Chris Pask, of the 
University of Leeds Department of Chemistry, who also assisted in the analysis of the 
crystallographic structures and packing of these compounds. 
 
 
 
6.1.1 X-ray structures of the Omeprazole family 
 
X-ray characterization for Omeprazole 1.1 
Materials suitable for XRD analysis were grown by slow evaporation from an acetone solution, 
or from addition of Et2O to a solution in CDCl3.  Crystals were obtained as colourless platelets 
which were cut down for the X-ray analysis.  Omeprazole 1.1 crystallizes in a triclinical cell and 
was solved in the P-1 space group, with one molecule in the asymmetric unit (Figure 6.1).  The 
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crystal structure obtained for Omeprazole was found to be in excellent agreement with the 
previously published data.572  Tautomeric disorder was exhibited by the compound; disorder of 
the benzimidazole ring could not be adequately modeled which is in line with the previous 
publication.567  The ratio of tautomers (derived from refinement of the site occupancy factors) 
was 15:85 5-OMe:6-OMe, matching one of the tautomeric polymorphic crystal forms of 
Omeprazole reported by Desiraju and Bhatt.567   
 
 
Figure 6.1 Crystal structure of Omeprazole 1.1.  Displacement ellipsoids are at 50% probability level and 
hydrogen atoms are omitted for clarity 
 
Assessment of the intermolecular interactions was conducted taking only the main tautomer  
(6-OMe Omeprazole) into consideration.  Omeprazole 1.1 adopts an extended form with the 
pyridine ring almost coplanar to the benzimidazole; in addition the methylsulfinyl group 
adopting a trans conformation.  In the solid state the racemic sulfoxide 1.1 forms heterochiral 
dimers, with two centrosymmetrically related molecules connected by intermolecular H-
bonding between the benzimidazole NH and the sulfinyl oxygen, with N9H…O13 and H…O13 
distances of 2.759(3) Å and 1.87(4) Å respectively (Figure 6.2).   
 
 
Figure 6.2 Heterochiral dimer formed through H-bonding between molecules of Omeprazole 1.1  
 
The dimers of Omeprazole formed through H-bonding pack together through - interactions, 
with a stacking distance of 3.647(2) Å between benzimidazole rings (Figure 6.3)   
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Figure 6.3 -Stacking interactions between dimers of Omeprazole 1.1 
 
The formation of heterochiral dimers in the solid state is consistent with the experimental 
observations made for Omeprazole, mentioned previously in chapter 4.  Omeprazole was found 
to exhibit different physical properties to the single enantiomer form Esomeprazole, with the 
racemic sulfoxide being less soluble than the optically pure isomer which can be attributed to 
the formation of stable heterochiral dimers in the solid state, with two H-bonding interactions 
between molecules.  In contrast if analogous homochiral dimers were to form, for example for 
Esomeprazole, fewer H-bonding interactions are possible due to the orientation of the sulfinyl 
groups which leads to dimers with less favourable intermolecular interactions holding them 
together (Figure 6.4). 
 
 
Figure 6.4 Heterochiral (left) and homochiral dimers (centre and right) of Omeprazole 1.1 
 
Crystallization of Omeprazole as a racemate was found to be advantageous with respect to 
enhancing the enantiopurity of Esomeprazole afforded by the titanium-mediated asymmetric 
sulfoxidation reactions.  Precipitation of racemic Omeprazole could be induced from materials 
of high sulfoxide ee (> 80% ee) with the sulfoxide remaining in solution being enhanced in ee.   
The process was achieved by addition of an antisolvent to a solution in CH2Cl2, or by stirring a 
solution in MeCN.  Using this method Esomeprazole was obtained in > 97% ee from starting 
materials of 80% ee. 
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X-ray characterization for Pyrmetazole sulfide 3.17 
Colourless crystals of Pyrmetazole 3.17 suitable for XRD were obtained by slow evaporation 
form a solution in CDCl3 over a period of several days.  This sulfide crystallized in an 
orthorhombic cell and structural solution was performed in the space group P212121 with one 
molecule in the asymmetric unit (Figure 6.5).    
 
Figure 6.5 Crystal structure of Pyrmetazole 3.17.  Displacement ellipsoids are at 50% probability level and 
hydrogen atoms are omitted for clarity 
 
Pairs of sulfide molecules are held together by H-bonding interactions between the thioether 
group and the benzimidazole NH (N9H…S12 3.371(2) Å, H...N 2.692(3) Å) and the 
benzimidazole NH and pyridyl N (N9H…N15 2.937(3) Å, H...N 2.142(4) Å) (Figure 6.6).  The 
dimers of the sulfide 3.17 form a double strand type structure along the crystallographic a axis 
(Figure 6.7). 
 
 
Figure 6.6 Intermolecular H-bonding between molecules of Pyrmetazole sulfide 3.17 
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Figure 6.7 Double strand structure formed by Pyrmetazole 3.17 
 
X-ray characterization for Omeprazole sulfone 4.1 
Crystals of the sulfone 4.1 suitable for XRD was obtained in the form of the solvate by slow 
evaporation from a solution in MeOD over a period of several days.  Crystals were obtained as 
colourless cubes which were cut down for the X-ray experiment.  Omeprazole sulfone 4.1 
crystallized in a triclinical cell and was solved in the P-1 space group, with one molecule of 
MeOD in the asymmetric unit. 
 
 
Figure 6.8 Crystal structure of the Omeprazole sulfone 4.1, obtained as the MeOD solvate.  Displacement 
ellipsoids are at 50% probability level and hydrogen atoms are omitted for clarity 
 
The solvate of the sulfone 4.1 exists as tetramers comprising of two molecules of the sulfone 
plus two solvent molecules connected through H-bonding interactions (N17H…O26 2.766(2) 
Å, H...O26 1.97(2) Å, and O26H...O13 2.746(18) Å, H...O13 2.00(3) Å) (Figure 6.8).  No 
significant - stacking is observed between the tetramers of sulfone 4.1 (Figure 6.9 and 6.10). 
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Figure 6.9 Tetramer formed between molecules of Omeprazole sulfone 4.1 and MeOD 
 
 
Figure 6.10 Packing diagram of Omeprazole sulfone 4.1as the MeOD solvate 
  
X-ray characterization for K-Omeprazole 3.38 
Colourless platelets of K-omeprazole 3.38 were obtained through addition of Et2O to a solution 
in MeOH.  The compound crystallized as a one dimensional polymeric chain with one “unit” in 
the asymmetric unit (Figure 6.11).   
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Figure 6.11 Crystal structure of the potassium salt of Omeprazole 3.38.  Displacement ellipsoids are at 50% 
probability level and hydrogen atoms are omitted for clarity 
 
Each potassium ion is bridged by the oxygen of the sulfoxide group, one MeOH molecule, and 
the N15 of the pyridyl ring to form a one dimensional chain along the crystallographic b axis 
(Figures 6.12 and 6.13) 
 
 
Figure 6.12 Crystal structure of the potassium salt of Omeprazole 3.38 showing the bridging interactions of the 
pyridine N, MeOH, and the sulfinyl group with the K atom. Displacement ellipsoids are at 50% probability 
level and hydrogen atoms are omitted for clarity. Note: not all bond to the K atoms are shown 
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Figure 6.13 Top: Series of K…O, N, K interactions forming a 1D chain along the crystallographic b axis of  
K-Omeprazole 3.38 (viewed down the a axis); Bottom: packing diagram of K-Omeprazole as viewed down the 
b axis (left) and c axis (right) 
 
Each potassium atom is eight coordinate, including the metal-metal bond, with K-K interaction 
distances of 3.9554(5) (Figure 6.13).  Two distances were measures for between the K atom and 
the 2 sulfinyl group coordinated to it, K1…O2 ( 2) 2.732(2) and 2.664(3)  No interaction 
between the metal and the benzimidazole group is found, but three interactions of the metal with 
the sulfoxide occurs via the pyridine N15 (K1…N15 2.938(3) and 2.916(3)  2) (Figure 6.14). 
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Figure 6.14 Crystal structure of the potassium salt of Omeprazole 3.38 showing three pyridine N to K atom 
interactions 
  
Although the potassium salt of Omeprazole forms a complex structure in the solid state, the fact 
that the sulfoxide crystallizes in a form other than the heterochiral dimers seen for just 
Omeprazole suggests that crystallization of this salt could be used to improve the optical yield 
of asymmetric reactions producing Esomeprazole in a process similar to that employed in this 
body of work with the formation of the Na-salt of Esomeprazole.  
 
X-ray characterization for NMe Omeprazole 5.22 
Crystals of N-methylated derivative of Omeprazole 5.22 were obtained through addition of Et2O 
to a solution in CH2Cl2.  The compound crystallized as colourless plates, in a triclinic cell and 
was solved in the P-1 space group, with one molecule in the asymmetric unit (Figure 6.15)   
This compound exhibited isomeric disorder; disorder of the benzimidazole ring could not be 
adequately models in line with the previous publications.567 Disorder in the molecule was 
observed around the position of the methoxy group on the benzimidazole ring. The minor 
isomer (8%) has been ignored in the discussion of the packing 
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Figure 6.15 Crystal structure of NMe Omeprazole 5.22.  Displacement ellipsoids are at 50% probability level 
and hydrogen atoms are omitted for clarity 
 
No intra- or intermolecular hydrogen bonding is observed, however π-π stacking is observed 
between benzimidazole rings (centroid-centroid distance 3.593 Å) (Figure 6.16). 
 
 
Figure 6.16 π-π Stacking between molecules of NMe Omeprazole 5.22  
 
As a result of the intermolecular stacking between the benzimidazole rings the molecules pack 
as head-to-toe pairs along the crystallographic a axis (Figure 6.17) 
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Figure 6.17 Packing of head-to-tail pairs along crystallographic a-axis. 
 
6.1.2 Structural analysis of the Omeprazole family 
 
 
 
Selected bond lengths for the compounds belonging to the Omeprazole family are shown in 
Table 6.1.  Sulfoxides 1.1, 3.38, and 5.22 have S-O bond distances ranging from 1.494(2) Å to 
1.506(2) Å which are consistent with the average bond length reported for sulfoxides 
(1.497(13)).703  Shorter S-O bond lengths were found for the sulfone 4.1.  The shortest C2-S 
bond was found for the sulfide 3.17 (1.744(3) Å) where as the potassium salt of Omeprazole 
3.38 and the N-methylated derivative 5.22 contained the longest bonds of this type (1.797(3) 
and 1.794(3) Å respectively).  Similar distances of the S-C8 bond were found for the sulfide 
3.17 and sulfoxide 1.1, with the shortest bond of this type featured in the sulfone 4.1.  All 
compounds were found to have a similar C8-C2'' distance (1.499(4) to 1.509(2) Å) with the 
exception of Omeprazole which was longer (1.522(4) Å).  
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 Distance / Å 
Bond 
sulfide 
3.17 
Omeprazole 1.1 Sulfone 4.1 
K-
Omeprazole 
3.38 
NMe-
Omeprazole 
5.22 
S-O - 1.506(2) 
1.4440(12) 
1.4338(11) 
1.502(3) 1.494(2) 
C2-S 1.744(3) 1.776(3) 1.7628(15) 1.797(3) 1.794(3) 
S-C8 1.800(3) 1.800(3) 1.7831(15) 1.833(4) 1.812(3) 
C8- C2'' 1.506(4) 1.522(4) 1.509(2) 1.504(5) 1.499(4) 
N1-C2 1.359(4) 1.352(4) 1.361(2) 1.336(4) 1.370(4) 
N3-C2 1.312(3) 1.322(4) 1.312(2) 1.334(4) 1.314(4) 
N1-C9 - - - - 1.456(4) 
Table 6.1 Selected bond lengths (Å) for the series of compounds belonging to the Omeprazole family 
 
 Angle / ° 
Bonds 
sulfide  
3.17 
Omeprazole 
 1.1 
Sulfone  
4.1 
K-Omeprazole 
3.38 
NMe-
Omeprazole 
5.22 
C2-S-O - 107.11(14) 
105.73(7) 
109.73(7) 
107.74(15) 107.23(14) 
O-S-C8 - 105.52(15) 
109.85(7) 
108.89(7) 
104.98(15) 107.36(14) 
O-S-O - - 118.51(7)  - 
C2-S-C8 99.62(13) 96.55(14) 103.00(7) 94.99(15) 96.82(13) 
S-C8-C2'' 109.34(34) 109.5(2) 109.97(10) 111.1(2) 107.1(2) 
N1-C2-N3 114.4(2) 115.2(3) 115.28(13) 119.6(3) 115.2(3) 
N1-C2-S 117.49(19) 125.2(2) 121.31(11) 122.2(3) 119.5(2) 
N3-C2-S 114.4(2) 119.5(3) 123.41(12) 118.1(2) 125.3(2) 
Table 6.2 Selected bond angles (°) for the series of compounds belonging to the Omeprazole family 
 
 
Similar C2-S-O bond angles were found for all compounds of this series, while the O-S-C8 
bond angle was found to range from 104.98(15)° to 109.85(7)° with the greatest angle observed 
in the sulfone 4.1 (Table 6.2).  The C2-S-C8 angles for all five compounds were smaller, 
ranging from 94.99(15)° for the K-salt 3.38 to 103.00(7)° for the sulfone 4.1.  Torsion angles 
with magnitudes ranging from 163.37(19)° to 179.76(10)° were found for this series of 
compounds for the C2-S-C8-C2'' backbone of these compounds joining the two aromatic ring 
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systems.  The pyridyl OMe group was found to be almost perpendicular to the plane of the 
adjacent ring for each of these compounds, with C7”-O-C4”-C5” torsion angles ranging from 
87.77(17)° to 96.8(3)° in magnitudes.  In contrast, for all of these compounds the OMe group of 
the benzimidazole ring system was generally found to be almost coplanar with the adjacent ring, 
with the exception of the NMe sulfoxide where the benz OMe group was at an angle of 11.5(4)° 
out of the plane of the benzimidazole ring. 
 
 Torsion Angle / ° 
Bonds 
Sulfide 
 3.17 
Omeprazole  
1.1 
Sulfone  
4.1 
K-Omeprazole 
3.38 
NMe-
Omeprazole 
5.22 
N1-C2-S-O - 49.7(3) 
5.68(14)  
-123.21(13)  
-14.2(3) 87.5(3) 
O-S-C8-C2'' - 71.5(3) 
-67.48(12) 
63.81(12)  
-53.4(3) -74.5(2) 
C2-S-C8-C2'' -169.37(19) -178.7(2) -179.76(10) -163.3(3) 175.0(2) 
N1-C2-S-C8 -165.4(2) -58.8(3) 120.96(13) 93.3(3) -161.9(2) 
N3-C2-S-C8 18.2(3) 123.8(3) -58.64(14) -87.1(3 18.7(3) 
S-C8-C2''-N1'' -12.5(3) 31.9(4) 83.19(14) 97.9(3) -80.4(3) 
C7''-O-C4''-C5'' 96.8(3) -90.2(4) -87.77(17) 96.6(4 95.2(3) 
C9-O-C6-C5 2.6(4) 177.2(3) 177.31(14) 3.6(6) - 
C9-O-C5-C6 - - - - 11.5(4) 
Table 6.3 Selected torsion angles (°) for the series of compounds belonging to the Omeprazole family 
 
Compound Dihedral angle between aromatic rings / ° 
Sulfide 3.17 11.76(10) 
Omeprazole 1.1 29.57(9) 
Omeprazole sulfone 2.99 24.61(5) 
K-Omeprazole 3.38 21.36(11) 
NMe Omeprazole 5.22 74.51(9) 
Table 6.4 Dihedral angle measure between the planes of the two aromatic rings of the compounds belonging to 
Omeprazole family 
 
The dihedral angles between the planes of the two aromatic rings of these compounds were 
measured using Olex2 (Table 6.4).704  The N-methyl sulfoxide 5.22 featured the greatest 
dihedral angle at 74.51(9)° while the smallest angle was observed for the sulfide 3.17  
(11.76(10) °).   
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6.1.3 X-ray structures of selected racemic sulfoxides 
 
X-ray characterization for benzyl p-tolyl sulfoxide 4.10 
Colourless fragments of sulfoxide 4.10 suitable for XRD were obtained through evaporation of 
a solution in CDCl3 over a period of a number of days which afforded colourless needles which 
were cut to size for the X-ray experiment.  The compound crystallized in an orthorhombic cell 
and was solved in the P212121 space group, with one molecule in the asymmetric unit (Figures 
6.18 and 6.19).  No intermolecular H-bonds or - stacking was observed in this structure and it 
was in good agreement with the structure previously reported in the literature.701 
 
 
Figure 6.18 Crystal structure of sulfoxide 4.10.  Displacement ellipsoids are at 50% probability level and 
hydrogen atoms are omitted for clarity 
 
 
Figure 6.19 Packing viewed down crystallographic a axis 
 
X-ray characterization for methyl 6(5)-OMe benzimidazole sulfoxide 4.11  
Crystals suitable for XRD were obtained through slow addition of hexane to a solution in 
EtOAc.  The sulfoxide 4.11 crystallized as colourless needles.  The compound crystallized in a 
monoclinic cell and was solved in the P21/c space group, with two molecules in the asymmetric 
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unit (Figure 6.17).  The asymmetric unit contains two crystallographically independent 
molecules, which are bound through an intermolecular hydrogen bond (NH…O 2.721(5) Å, 
H…O 1.866(5) Å). 
 
 
Figure 6.20 Crystal structure of the methyl benzimidazole sulfoxide 4.11.  Displacement ellipsoids are at 50% 
probability level and hydrogen atoms are omitted for clarity 
 
The H-bond interactions extend to form chains of molecules along the crystallographic a axis 
(Figure 6.20).  These chains then pack in an alternating fashion (Figure 6.21 and 6.22) 
 
 
Figure 6.21 Hydrogen-bond interactions leading to chains of molecules along a axis. 
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Figure 6.22 Packing arrangement of chains viewed down the crystallographic a axis. 
 
X-ray characterization for pyridyl p-tolyl sulfoxide 4.12 
Colourless fragments of sulfoxide 4.12 suitable for XRD were obtained through evaporation of 
a solution in CDCl3 over a period of a number of days which afforded colourless needles which 
were cut to size for the X-ray experiment.  The compound crystallized in a monoclinic cell and 
was solved in the P21/c space group, with one molecule in the asymmetric unit (Figure 6.23).  
Disorder of the molecule was observed around the tolyl group. Only the major component 
(70%) is shown in the figures. 
 
 
Figure 6.23 Crystal structure of the sulfoxide 4.12.  Displacement ellipsoids are at 50% probability level and 
hydrogen atoms are omitted for clarity 
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Figure 6.24 Packing of sulfoxide 4.12 viewed along the crystallographic c axis (left) and b axis (right) 
 
No classical H-bonding or - stacking was observed for this structure.  Figure 6.24 shows the 
molecules packed in layers along the crystallographic c axis and along the b axis.  
 
6.1.4 Structural analysis of racemic sulfoxides 
 
 
 
Selected bond lengths for the racemic sulfoxides 1.1 and 4.10-4.12 are reported in Table 6.5.  
Similar S-O distances were observed for each sulfoxide, from 1.490(3) Å to 1.506(4) Å.  The 
shortest C2-S distance was found for Omeprazole 1.1 (1.790(4) Å), whilst the alkyl aryl 
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sulfoxide 4.11 had a bond length of 1.784(5) Å for the S-C8 bond, which was shorter than that 
of Omeprazole or the equivalent S-C6 bond of sulfoxides 4.10 and 4.12. 
 
 
Omeprazole 
1.1 
6-OMe 
4.11 
4.10 4.12 
Bond 
Distance 
 / Å 
Distance / 
Å 
Equivalent 
bond 
Distance  
/ Å 
Equivalent 
bond 
Distance  
/ Å 
S-O 1.506(2) 1.506(4) S-O 1.4965(12) S-O 1.490(3) 
C2-S 1.776(3) 1.790(4) C5-S 1.7931(18) C5-S 1.792(3) 
S-C8 1.800(3) 1.784(5) S-C6 1.8254(17) S-C6 1.825(2) 
C8-Pyr C2'' 1.522(4) - C6-C7 1.502(2) C6-Pyr C2'' 1.506(2) 
N1-C2 1.352(4) 1.366(6) - - - - 
N3-C2 1.322(4) 1.304(6) - - - - 
Table 6.5 Selected bond lengths (Å) for the sulfoxides 4.10-4.12 and Omeprazole 1.1 
 
Selected bond angles for sulfoxides 4.10-4.12, and Omeprazole 1.1 are shown in Table 6.6.   
The angles around the sulfoxide group i.e. C2-S-O, and O-S-C8/C6 for these racemic sulfoxides 
were found to range from 105.44(14)° to 108.53(17)°, and for each sulfoxide, with the 
exception of the methyl benzimidazole sulfoxide 4.11, the C2-S-O angel is greater in magnitude  
than the  O-S-C8/C6 angle.  For each of sulfoxides the C2-S-C8 and equivalent C5-S-C6 bond 
angle is in close approximation with each other (96.55(14) to 97.5(2)°.   
 
 
Omeprazole 
1.1 
6-OMe 
 4.11 
4.10 4.12 
Bonds 
Angle 
 / ° 
Angle  
/ ° 
Equivalent 
 bond 
Angle  
/ ° 
Equivalent 
bond 
Angle  
/ ° 
C2-S-O 107.11(14) 105.76(19) C5-S-O 107.55(8) C5-S-O 108.53(17) 
O-S-C8 105.52(15) 107.5(2) O-S-C6 106.86(8) O-S-C6 105.44(14) 
C2-S-C8 96.55(14) 97.5(2) C5-S-C6 96.88(8) C5-S-C6 97.32(11) 
S-C8-C2'' 109.5(2) - S-C8-C7 110.30(11) S-C6-C2'' 109.32(13) 
N1-C2-N3 115.2(3) 114.7(4) - - - - 
N1-C2-S 125.2(2) 118.7(3) - - - - 
N3-C2-S 119.5(3) 126.5(4) - - - - 
Table 6.6 Selected bond angles (°) for the sulfoxides 4.10-4.12 and Omeprazole 1.1 
 
For the four compounds of Omeprazole 1.1 and the sulfoxides 4.10-4.12 there is great variation 
on the N1-C2-S-O for the benzimidazole sulfoxides and equivalent C4’-C5-S-O bond in the p-
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tolyl sulfoxides, ie the sulfinyl S-O and the plane of aromatic group on its left hand side as 
illustrated above (Table 6.7).  These angles range from 49.7(3)° to 171.40(13)°.  In contrast the 
torsion angles between the right hand of the sulfoxide molecules and the sulfinyl group shows 
less variation in magnitudes, with O-S-C8-C2'' and the equivalent O-S-C6-C7/C2'' torsion 
angles of  71.5(3)° to -75.79(13)°.  As found previously for Omeprazole1.1 the benzimidazole 
OMe group of sulfoxide 4.11 lies at a nearly coplanar angle to the plane of the adjacent aromatic 
ring (174.5(4)° for the angle C9-O-C6-C5) , whereas the pyridyl OMe group of sulfoxide 4.12 
sits perpendicular to the plane of the pyridine ring (82.9(2)° for the angle C7''-O-C4''-C5'') 
 
 
Omeprazole 
1.1 
6-OMe 
4.11 
4.10 4.12 
Bonds 
Torsion 
Angle / ° 
Torsion 
Angle / ° 
Equivalent 
 bonds 
Torsion 
Angle / ° 
Equivalent 
bonds 
Torsion 
Angle / ° 
N1-C2-S-O 49.7(3) 69.4(4) C4’-C5-S-O 171.40(13) C4’-C5-S-O 148.0(3) 
O-S-C8-C2'' 71.5(3) - O-S-C6-C7 -75.79(13) O-S-C6-C2'' -74.99(18) 
C2-S-C8-C2'' -178.7(2) - C5-S-C6-C7 173.47(13) C5-S-C6-C2'' 173.42(19) 
N1-C2-S-C8 -58.8(3) -180.0(4) C4-C5-S-C6 102.97(15) C4-C5-S-C6 77.9(3) 
N3-C2-S-C8 123.8(3) -0.5(5) C4’-C5-S-C6 -78.45(14) C4’-C5-S-C6 -103.0(3) 
S-C8-C2''-N1'' 31.9(4) - S-C6-C7-C8’ -102.24(16) S-C6-C2''-N1'' -73.43(18) 
C9-O-C6-C5 177.2(3) 174.5(4) - - - - 
C7''-O-C4''-C5'' -90.2(4) - - - C7''-O-C4''-C5'' 82.9(2) 
Table 6.7 Selected torsion angles (°) for the sulfoxides 4.10-4.12 and Omeprazole 1.1 
 
Using Olex2 the dihedral angles between the planes of the aromatic rings were measured for 
sulfoxides 4.12 and 4.10 (Table 6.8), with the smallest angle found for the pyridyl p-tolyl 
sulfoxide 4.12 (11.22(6)°) whilst the greatest dihedral angle was observed in Omeprazole 1.1 
(29.57(9)°). 
 
Compound Dihedral angle between aromatic rings /° 
Omeprazole 1.1 29.57(9) 
4.10 14.07(14) 
4.12 11.22(6) 
Table 6.8 Dihedral angles between the planes of the two aromatic rings of sulfoxides 1.1, 4.10 and 4.12 
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6.2 Tautomerism of Omeprazole and related compounds 
6.2.1 Prototropic exchange of Omeprazole and related species 
 
In addition the optical isomerism of sulfoxides such as Esomeprazole (S)-1.1, prototropic 
tautomerism of the benzimidazole ring system gives rise to another aspect of structural diversity 
whereby the methoxy group can be found at either the 5- or the 6- position relative to the NH of 
this heterocyclic group.567, 568    
 
 
 
Of the two tautomeric forms Omeprazole has shown to exist more commonly as the 6-OMe 
isomer in both the solid state and in solution.569, 570 Conventionally, however, Omeprazole has 
been represented in the literature as the 5-OMe tautomer, most likely as a result of a number of 
naming errors in the literature, the most notable of which is found in one of the earliest reports 
on the crystal structure of Omeprazole, which despite discussing and illustrating the sulfoxide as 
the 6-OMe form, named the molecule as the 5-OMe benzimidazole in the title of the  
paper.571, 572  For the sake of accuracy, and in keeping with the observed structures discussed in 
the previous section, Omeprazole and all related methoxy benzimidazole species have been 
depicted in this thesis as the 6-OMe tautomers.  
 
The annular tautomerism of Omeprazole is a fast process the result of which is that only 
averaged signals are observed by NMR (1H, 13C) at room temperature.705  In DMSO-d6 the 
averaged aromatic proton signals from the benzimidazole group of Omeprazole 1.1, and its 
sulfide precursor Pyrmetazole 3.17, are observed as sharp peaks with well resolved splitting 
(Figure 6.25).  In accordance with the observation of only one set of proton signals in the 
presence of two possible tautomers this indicates that the prototropic exchange is so rapid that it 
effectively results in magnetic equivalence of the 7-H proton of the 5-OMe tautomer and 4-H 
proton of the 6-OMe tautomer, and vice versa.  In contrast, broadening of the benzimidazole  
4-H and 7-H signals was observed for Omeprazole sulfone 4.1 in DMSO-d6, indicating slower 
prototropic exchange for this compound compared to the sulfide 3.17 or sulfoxide 1.1 in this 
solvent.  Similarly, when CDCl3 was employed as the NMR solvent for these compounds the 
averaged signals for benzimidazole protons of the sulfide 3.17 were sharp and well resolved 
while those of the sulfone 4.1 were broadened for the 4-H and 7-H protons; however in CDCl3 
broadening of these proton signals was also observed for Omeprazole 1.1.   
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Figure 6.25 Partial 
1
H NMR spectra of Pyrmetazole 3.17, Omeprazole 1.1, and Omeprazole sulfone 4.1 in 
DMSO-d6 or CDCl3 
 
  
Figure 6.26 Partial 
13
C NMR spectra of sulfide 3.17, Omeprazole 1.1, and sulfone 4.1 in DMSO-d6  
Using 13C NMR on sulfide 3.17, sulfoxide 1.1, and sulfone 4.1 revealed the tautomerism of 
these compounds in the form of partial or missing signals attributed to the carbons of the 
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benzimidazole ring system (Figure 6.26).  This effect was observed when either DMSO or 
CDCl3 were employed as the NMR solvent.  In contrast, all 17 carbon signals can be seen in the 
13NMR of Na-Omeprazole (Figure 6.27). 
 
 
Figure 6.27 
13
C NMR spectra of Omeprazole 1.1, and Na-Omeprazole 3.36 in DMSO-d6 
 
The 1H NMR of Omeprazole in CDCl3 was conducted at 279, 300, and 323K (Figure 6.28).  At 
low temperature the prototropic exchange was sufficiently slowed allowing for observation of 
the two tautomers of Omeprazole.  
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Figure 6.28 Partial 
1
H NMR (CDCl3) of Omeprazole 1.1 at low temperature, room temperature, and high 
temperature 
 
Integration of the benzimidazole proton signals revealed the ratio of the two tautomers to be 
70:30, although it was not possible to identify whether the 5-OMe or 6-OMe tautomer was 
present in the greatest quantity it is likely that the 6-OMe tautomer predominates.  This is due to 
the electronic effects of the methoxy group on the benzimidazole ring system, where the 
positioning of the OMe group on C6 offers greater delocalization of the methoxy lone pair 
across the imidazole ring, with the potential of further conjugation with the sulfinyl group.  In 
contrast when the methoxy group is at the 5-position there is less opportunity for delocalization 
and therefore less contribution to stability via conjugation (Scheme 6.1)    
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Scheme 6.1 Delocalization of the OMe lone pair across the benzimidazole ring system with greater resonance 
offered by having the OMe group at the 6-position, compared to having the OMe group at the 5- position 
 
Annular tautomerism was also observed in a number of other benzimidazole species 
investigated as part of these studies (Figure 6.29).  Of these compounds the sulfoxides 4.9 and 
4.11 were notable as the ratios of their tautomers were measurable in CDCl3 at room 
temperature.   
 
 
Figure 6.29 Methoxy benzimidazole species featuring annular tautomerism 
 
For the benzyl benzimidazole sulfoxide 4.9 when CDCl3 was employed as the NMR solvent the 
signals attributed to the benzimidazole NH and the OMe group were each observed as two 
peaks, one for each tautomer (Figure 6.30).  Measurement of the integrals of the OMe group, 
with peaks from the two tautomers occurring at 3.89 and 3.82 ppm gave the ratio of tautomers 
to be 37:63.  Similarly for the methyl benzimidazole sulfoxide 4.11 it was possible to measure a 
ratio of tautomers of 62:38 from the doublets occurring at 7.65 and 7.46 ppm respectively 
(Figure 6.31).  Although further characterization would be required to correctly identify which 
tautomers are responsible for these NMR signals it is to be expected that for both sulfoxide 4.9 
and 4.11 that the 6-OMe isomer be the most prevalent, as is the case for Omeprazole 1.1.   
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Figure 6.30 Partial 
1
H NMR of benzyl benzimidazole sulfoxide 4.9 in DMSO-d6 (top) and CDCl3 (bottom) 
 
 
 
Figure 6.31 Partial 
1
H NMR of methyl benzimidazole sulfoxide 4.11 in DMSO-d6 (top) and CDCl3 (bottom) 
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In contrast to the NMR spectra of Omeprazole 1.1 which showed broaden aromatic signals in 
CDCl3, sulfoxide 4.9 was found to exhibit broadening of the aromatic signals attributed to the 
benzimidazole 4-H and 7-H when DMSO-d6 was employed as the solvent, with the use of 
CDCl3 leading to spectra with sharp, well defined peaks.  For both sulfoxide 4.9 and 4.11 full 
assignment of the 13C NMR was not possible with the use of either DMSO-d6 or CDCl3 as the 
NMR solvent.  For the benzyl benzimidazole sulfoxide 4.9 the carbon signals for both tautomers 
could be seen with either solvent, however these carbon signals were very weak leading to 
difficulties in assigning their identities.  In addition neither proton spectra from using DMSO-d6 
or CDCl3 could be used for 2D NMR analysis due to broadening of the aromatic peaks with the 
former solvent, and the splitting of the NH and OMe peak due to the two tautomers present with 
the use of the latter solvent.  Similarly full assignment of the 13C NMR spectra of sulfoxide 4.11 
was not possible due to broadening of signals in 13C NMR (in the case of DMSO-d6), or due to 
the presence of observable tautomers in the 1H NMR (in the case of CDCl3), both of which 
prevented analysis by 2D NMR.  
 
6.2.2 Synthesis and characterization of derivatized Omeprazole and related 
species 
 
To further our studies on the tautomerism of species such as Omeprazole we investigated the 
synthesis of various derivatized methoxy benzimidazoles.  Using a procedure reported by Shin 
et al. for the N-methylation of benzimidazoles Omeprazole 1.1 was treated with 1,8-
diazabicyclo-[5.4.0]undec-7-ene (DBU, 1.2 equiv) and dimethyl sulfate (2.0 equiv), with the 
aim of producing the NMe sulfoxides 5.22 (Scheme 6.2).562  The reaction was unsuccessful in 
yielding the desired target, instead a complex mixture of species was found in the crude 
materials. 
 
 
Scheme 6.2 
 
Column chromatography of the crude materials isolated the pyridyl aldehyde 6.1 the 
identification of which was supported by independent synthesis of this aldehyde by oxidation of 
the pyridyl alcohol 6.2 by MnO2 (Scheme 6.3).
706  The presence of aldehyde 6.1 in the crude 
materials in addition to the isolation of materials containing only the benzimidazole ring system 
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of Omeprazole suggested degradation of the sulfoxide starting materials, effectively cleaving 
the two halves of the molecule.  
 
 
Scheme 6.3 
 
Attempted N-methylation of sulfides 3.17, 4.5, and 4.7 using this method was also unsuccessful, 
with none of the desired methylated benzimidazole species isolated.  For the derivitization of 
the benzyl benzimidazole sulfide 4.5 the isolated product was the dimethylated methyl sulfate 
salt 6.7, the structure of which was confirmed by XRD.   
 
 
 
An alternative method was found which allowed for greater success in the synthesis of  
N-methylated benzimidazole sulfides, and NMe-Omeprazole 5.22.707, 708  Omeprazole 1.1 was 
treated with aqueous NaOH followed by methyl iodide (1.0 equiv) followed by heating at 40 C 
for 1 h (Scheme 6.4).  This reaction protocol was found to be highly efficient, producing only 
the desired methylated sulfoxide 5.22, with no formation of side products or evidence of 
sulfoxide decomposition.   
 
 
Scheme 6.4 
 
The ratio of isomers produced from this reaction was found to be 50:50, with assignment of the 
proton signals for each of the 5-OMe and 6-OMe isomers possible through NOESY NMR with 
DMSO-d6 as the NMR solvent (Figure 6.32).  Through the process of preferential crystallization 
it was possible to enrich the afforded mixture of methylated sulfoxides in favour of the 6-OMe 
isomer.  To achieve this the N-methylated sulfoxides 5.22 (50:50 5-OMe:6-OMe) were 
dissolved in the minimum amount of dichloromethane followed by slow addition of diethyl 
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ether to induce precipitation which was collected via filtration.  1H NMR analysis of the solid 
material revealed a ratio of 18:82 in favour of the 6-OMe tautomer, with the use of correlation 
NMR to confirm the identity of the two tautomers. 
 
Figure 6.32 
1
H NMR of Omeprazole 1.1 (top) and N-methylated Omeprazole 5.22, obtained as a 1:1 mixture of 
5-OMe:6-OMe tautomers 
 
An alternative method for the synthesis of NMe-Omeprazole 5.22 was investigated via the 
oxidation of the methylated sulfide 6.3 (Scheme 6.5). N-methylated Pyrmetazole 6.3 was 
produced in a yield of 60% by the treatment of the sulfide 3.17 with NaOH and methyl iodide; 
following purification by column chromatography and trituration the ratio of sulfide isomers 
was 48:52 5-OMe:6-OMe, as determined by 1H NMR in DMSO-d6.  Full characterization of 
each of the 5-OMe and 6-OMe isomers was achieved with the aid of 2D correlation NMR.  
Oxidation of the N-methylated sulfide 6.3 using mCPBA gave NMe-Omeprazole 5.22 as a mix 
of 5-OMe and 6-OMe isomers in a yield of over 90% following column chromatography, with 
the ratio of isomers found by 1H NMR in DMSO-d6 to be 41:59 (5-OMe:6-OMe).  Subsequent 
recrystallization afforded the N-methylated sulfoxide in a yield of 32%; the recrystallized 
material 5.22 was found by 1H NMR to be enriched in the 6-OMe isomer with a ratio of 13:87 
5-OMe:6-OMe. 
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Scheme 6.5 
 
Of the two methods employed in the synthesis of NMe-Omeprazole 5.22 oxidation of the 
methylated sulfide was the less favourable as isolation of the derivatized sulfoxide required 
chromatography and crystallization which incurred significant loss in material, whereas 
methylation of the sulfoxide produced NMe-Omeprazole in high yield with no need for further 
purification.   
 
6.3 Selective deuteration of Na-Omeprazole and related compounds 
 
Deuterium incorporation on carbon centers has chemical relevance in a number of areas such as 
investigations of reaction mechanisms or of metabolic pathways, or in the use of deuterated 
materials as reference standards e.g. for application in mass spectrometry.709  In addition, there 
is growing interest in assessing the pharmacokinetics of deuterated pharmaceutical bioisosteres, 
which may reveal superior properties with respect to toxicity or metabolic stability, allowing for 
new opportunities to increased efficacy of drug therapies.   
During the course of our studies on Omeprazole, and related species, we encountered an 
unexpected observation in that the CH2 group of Na-Omeprazole 3.36 underwent H/D exchange 
in DMSO-d6.  Leading on from this finding the selective deuteration of the methylene group 
was investigation for a number of other compounds using 1H NMR in MeOD and D2O under a 
range of pH conditions, with the aim of gaining insight in the relative acidio-basic properties of 
compounds in question.  
6.3.1 Deuteration of Na-Omeprazole in an aprotic solvent 
 
For NMR analysis of small organic molecules DMSO-d6 is a common solvent.  Classified as a 
“dipolar aprotic solvent”, it is generally not expected that DMSO-d6 could promote deuteration 
of solute molecules due to its inherent chemical stability even under acidic or basic conditions. 
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However, during the course of these studies it was observed that on occasion the CH2 signal of 
the sodium salts of Omeprazole (-3.36 and Esomeprazole (S)- 3.36 was depleted or indeed 
absent from the 1H NMR spectra when DMSO-d6 was employed as the solvent.  This effect was 
attributed to H/D exchange of the weakly acidic methylene protons.  The selective deuteration 
of the sodium salts of Omeprazole, and related proton pump inhibitors such as Pantoprazole 3.2 
and Rabeprazole 3.3, was also observed and recently reported on by Redondo et al.709 
  
Figure 6.33 shows the 1H NMR spectra of Na-Omeprazole (-3.36, showing the methylene 
resonances of the protonated and partially deuterated species, and the absence of the CH2 
signals for the fully deuterated form of the Na-salt.  In addition, on the occasions when 1H NMR 
characterisation showed the full deuteration of the methylene protons the absences of the 
corresponding CH2 carbon signal at 59.9 ppm was also noted (Figure 6.34).  The H/D exchange 
of the methylene protons with the deuterated solvent was found to be a fast process, often taking 
no longer than the time required to prepared and run the NMR sample. 
 
 
 
Figure 6.33 
1
H NMR (DMSO-d6) spectra of the protonated, partially deuterated and fully deuterated forms of 
Na-Omeprazole (-3.36 
229 
 
 
 
Figure 6.34 
13
C NMR (DMSO-d6 ) spectra showing the absence of the CH2 carbon peak for the deuterated 
form of Na-Omeprazole (-3.36 
 
The protons of the CH2SO group are weakly acidic as the negative charge created by 
deprotonation can be stabilized via delocalization. The mechanism of this remains a matter of 
debate but it is likely to occur via the 3s and 3p orbitals of sulfur, with some contribution to 
stabilization from the electronegative effects of the oxygen atom.
710, 711
 In PPIs such as 
Omeprazole there is also the possibility of delocalization into the adjacent pyridine ring 
(Scheme 6.6).   
 
Scheme 6.6 
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The sodium salt of Omeprazole is a basic compound and it is possible that the pH of a solution 
may be sufficiently high enough to trigger the H/D exchange via removal of the methylene 
protons.  Although measurements have not been conducted in DMSO-d6, aqueous solutions of 
Na-Omeprazole (40 mM concentration) have been shown to have a pH of 10.4, which may be 
sufficient to instigate the deuteration of the sulfoxide via a small population of deprotonated 
molecules.  Alternatively, Redondo has shown that catalytic amounts of aqueous NaOH (5 L) 
in DMSO-d6 is sufficient to effect deuteration in solution; in addition it was reported that the 
deuteration process was reversible, with addition of the deuterated sample to an excess of non 
deuterated DMSO resulting in restoration of the protonated solute molecule.709 
 
In addition to the depletion of the CH2 proton signals, deuteration of Na-Omeprazole 3.36 to 
give Na-Omeprazole-d2  in DMSO-d6 was accompanied by a shift in a number of proton 
1H 
NMR signals which may be the result of long-range isotopic effects (Table 6.10).  Although 
Redondo et al. discuss this effect for the deuteration of Na-Omeprazole in MeOD or D2O they 
make no mention of it occurring in DMSO-d6. 
 
The most significant effect was observed for the pyridyl 3”-methyl group, which underwent a 
downfield shift of 35 ppb with complete deuteration of the methylene protons (Figure 6.35).  
For Na-Omeprazole-d2 the aromatic benzimidazole protons and the pyridyl 6”-H were all 
observed at higher chemical shifts (10-19  ppb) compared to the spectra of the native 
Omeprazole salt.  The changes in chemical shifts that arise following the exchange of H for D, 
as seen in the 1H NMR spectra of Na-omeprazole and Na-Omeprazole-d2, are believed to arise 
due to the resulting changes in the rotational and vibrational state of the molecule.712 
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Proton 
Na-omeprazole 
/ ppm 
Na-omeprazole-d2  
/ ppm 
 ppb in 
DMSO-d6 
Pyr 3”-Me 2.198 2.163 -35 
Pyr 5”-Me 2.210 2.213 3 
Pyr Ome 3.693 3.687 -6 
Benz Ome 3.724 3.721 -3 
CH2 downfield 4.385 - - 
CH2 upfield 4.661 - - 
Benz 5-H 6.545 6.555 10 
Benz 4-H 7.318 7.336 18 
Benz 7-H 6.979 6.998 19 
Pyr 6"-H 8.230 8.242 12 
Table 6.9 Deuterium isotope effects ( ppb) on 1H NMR chemical shift of the proton signals of Na-Omeprazole 
 
 
Figure 6.35 
1
H NMR (DMSO-d6) spectra of  Na-Omeprazole (top) and Na-Omeprazole-d2 (bottom)showing the 
differences  due to deuterium isotopic effects. Please note the scale of the X and Y axes differ between the two 
images  
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6.3.2 Deuteration of Na-Omeprazole and related compounds in protic solvents 
 
The selective deuteration of Na-Omeprazole has also been observed to occur in protic solvents 
such as D2O (Figure 6.36) and MeOD (Figure 6.37).   
 
 
Figure 6.36 
1
H NMR (D2O) of Na-omeprazole 3.36 showing partial deuteration of the CH2 group 
 
 
 
Figure 6.37 
1
H NMR (MeOD) of Na-omeprazole 3.36 showing partial deuteration and near complete of the 
CH2 group 
 
233 
 
When MeOD was employed as the NMR solvent stereoselective exchange was observed, with 
the depletion of the two doublets from the diastereotopic methylene protons occurring at 
different rates which may indicate stereoselective H/D exchange of the methylene protons in 
agreement with the reported findings of Redondo et al.709  
 
In continuation of our examination of selective deuteration in sulfoxides we looked at a variety 
of other compounds related to Na-Omeprazole, starting with Omeprazole 1.1 in the neutral, free 
base form.  NMR spectra were collected from samples across a range of pH conditions in order 
to examine the possibility of acid promoted deuteration, which may occurs via the mechanism 
shown in Scheme 6.7. 
 
 
Scheme 6.7  Proposed mechanism for acid promoted deuteration of the CH2SO group of Omeprazole 1.1 in a 
protic NMR solvent 
 
Unlike the sodium salt 3.36, Omeprazole 1.1 is insoluble in D2O; however with the addition of 
one equivalent of NaOD a fully homogenous solution was formed which produced a 1H NMR 
spectrum where the methylene signals were completely absent indicating complete H/D 
exchange.  Under acidic conditions, i.e. with the addition of one equivalent of DCl, 
decomposition/rearrangement of Omeprazole was observed, with a complex mixture of products 
shown by NMR.  In MeOD under neutral conditions the 1H NMR spectra of Omeprazole 
showed no depletion of the CH2 protons; with the addition of one equivalent of NaOD almost 
complete deuteration was observed for the methylene group.  Typically under acidic conditions 
Omeprazole was found to decompose rapidly, however it was possible through swift 
characterization to collect the characterization data for Omeprazole deuterated with DCl  
(1 equiv) prior to the commencement of rearrangement (Figure 6.38).  
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Figure 6.38  
1
H NMR spectra (MeOD) of Omeprazole 1.1 under neutral conditions (top) and with addition of 
one equiv of DCl (bottom) 
 
It was found that acidification of Omeprazole in MeOD resulted in deuteration on the pyridine 
ring, indicated by the significant changes in the chemical shifts of the pyridyl protons signals 
but not of those for the benzimidazole ring.  Coalescence of the CH2 signal gave a singlet at 
4.76 ppm with little apparent depletion of the methylene protons due to H/D exchange however 
accurate determination of this was not possible due to the proximity of the solvent peak. 
 
Pyrmetazole 3.17, the sulfide precursor to Omeprazole, was examined next (Fig 6.39).  Under 
basic and neutral conditions in MeOD no deuteration of methylene protons was observed, 
however with the addition of one or two equivalents of DCl depletion of the CH2 proton signals 
was seen.  In addition the methylene signal under these conditions was observed to have split 
into a fine doublet, with unequal depletion observed between the two peaks, possible indicating 
selective deuteration between the two protons at this position.  Interestingly when five 
equivalents of DCl were added to the sulfide integration of the signal for the methylene protons 
showed no deuteration had occurred.  It may be possible that deuteration of both the 
benzimidazole and pyridine prevents H/D exchange.  When D2O was employed as the NMR 
solvent no deuteration was observed at the methylene position Pyrmetazole 3.17 under basic or 
acidic conditions. 
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Figure 6.39 
1
H NMR (MeOD) spectra of Pyrmetazole sulfide 3.17 across a range of pH conditions; the signals 
for the CH2 are indicated by▲ 
 
 
NMR investigation of Omeprazole sulfone 4.1 under basic conditions in MeOD was not 
possible due to poor solubility of the substrate, however under neutral and acidic conditions full 
H/D exchange of the methylene group was observed (Figure 6.40).  In D2O the same result was 
found for both basic and acidic solutions of the sulfone, although poor solubility prevented 
characterization in neutral D2O. 
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Figure 6.40 
1
H NMR (MeOD) spectra of Omeprazole sulfone 4.1 under neutral and acidic conditions; no CH2 
group observed under any conditions 
 
1H NMR investigations of the benzyl benzimidazole sulfoxide 4.9 and the p-tolyl pyridyl 
sulfoxide 4.12 were also performed, using MeOD as the NMR solvent (Figures 6.41 and 6.42 
respectively).  Under basic conditions both sulfoxides were observed to have undergone 
depletion of the methylene signals.  For sulfoxide 4.9 partial H/D exchange was seen with the 
addition of one equivalent of NaOD, and near complete deuteration observed with the addition 
of an excess of base (five equiv).  Similarly full exchange of the CH2 protons was observed for 
sulfoxide 4.12 with an excess of base, and also with the stoichiometric addition of NaOD, in 
keeping with the increase acidity of the methylene protons of sulfoxide 4.12 over those of 
sulfoxide 4.9.   
237 
 
 
Figure 6.41 1H NMR (MeOD) spectra of sulfoxide 4.9 across a range of pH conditions; the signals for the CH2 
are indicated by▲ 
 
While no deuteration of the methylene group was observed under neutral or acidic conditions 
for sulfoxide 4.9, with the addition of one equivalent of DCl sulfoxide 4.12 produced an NMR 
spectrum where the resonances attributed to the CH2 protons were depleted, and had collapsed 
in upon itself, no longer appearing as the characteristic AB system (Figure 6.42).   
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Figure 6.42
1
H NMR (MeOD) spectra of sulfoxide 4.12 across a range of pH conditions; the signals for the CH2 
are indicated by▲ 
 
Similar to the observed behavior of the sulfide Pyrmetazole 3.17, when an excess of acid was 
employed no deuteration was observed for sulfoxide 4.12, this may suggest that both the 
pyridine and pyridinium salt are required to be present for exchange to take place (Scheme 6.8). 
 
 
Scheme 6.8 
 
6.4 Conclusion and Future direction 
 
The examination of the properties of Omeprazole and related compounds in this chapter has 
revealed a great diversity in the physical and chemical nature of the species produced as part of 
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this body of work.  Through the use of X-ray crystallography the solid state structures and 
intermolecular interactions of compounds including and related to Omeprazole were uncovered.  
Omeprazole itself was found to crystallize as the racemate, forming heterochiral dimers held 
together with H-bonding interactions.  The ability of Omeprazole, but not Esomeprazole, to 
form a structure of this type account for the contrasting physical properties of Omeprazole and 
Esomeprazole with respect to crystallinity and solubility.  The formation of heterochiral dimers 
of Omeprazole can also be exploited to enhance the optical purity of Esomeprazole by 
formation and removal of racemic materials from solution. In contrast to the dimers formed by 
Omeprazole 1.1, the sulfide Pyrmetazole 3.17 formed a double strand type structure with both 
the benzimidazole and pyridyl N atoms interacting with the thioether sulfur atom.  The sulfone 
of Omeprazole 4.1 was found as a tetramer, formed between two molecules of the sulfone and 
two molecules of solvent.  Although it was not possible to form crystals of the Na-salt of 
Omeprazole, the K-salt 3.38 was found to crystallizes in a complex structure, with polymeric 
chains formed from bridging interactions between the sulfinyl group, solvent molecules, the 
potassium atom, and the pyridyl nitrogen. The benzyl benzimidazole sulfoxide 4.11 was found 
to form dimers, with H-bonding interactions between the benzimidazole and sulfinyl group, 
whereas both sulfoxide 4.10 and 4.12 did not display any H-bonding interactions or - 
stacking in their solid state packing.  For completeness, it would be desirable to grow and 
analyze crystals of the benzyl benzimidazole sulfoxide 4.9 and compare and contrast the 
structure with the sulfoxides already examined.  Further studies would also endeavor to grow 
suitable crystals for XRD analysis of the single enantiomer forms of the sulfoxides and examine 
any possible differences in their solid state structure in comparison with their racemic forms.  
 
The annular tautomerism of various methoxy benzimidazole compounds, including 
Omeprazole, was investigated by 1H and 13C NMR.  For many of the substituted benzimidazole 
species featured in this thesis the spectra obtained by 1H NMR contained broadened signals in 
the aromatic region, and for 13C NMR appeared to be missing many of the signals from the 
benzimidazole group, both of these effects can be attributed to the prototropic tautomerism of 
this aromatic group. In contrast, the NMR spectra collected for the Na-salt of Omeprazole 3.36 
featured sharp proton signals and a full complement of peaks in the 13C NMR.  The benzyl 
benzimidazole sulfoxide 4.9 and the methyl benzimidazole sulfoxide 4.11 were both found to 
show evidence of their two tautomeric forms at room temperature in CDCl3, from which a 
relative ratio of tautomeric isomers could be measured.  Further characterization may allow 
identification of which tautomer is most prevalent in solution for both of these two sulfoxides. 
The effect of varying the temperature at which the NMR of Omeprazole was performed was 
examined briefly, with broad signals for the benzimidazole 4-H and 7-H seen at high 
temperature, due to rapid tautomeric exchange, whereas at low temperature the exchange was 
240 
 
slowed sufficiently to be able to observe these protons in their different environments for the 
two tautomeric isomers.  Further investigation of this matter would examine a range of NMR 
solvents in order to be able to access a wider range of temperatures to conduct the NMR 
experiments.  In addition, further characterization, including possible 2D correlation NMR 
experiments would be conducted at low temperature to assist in assigning the tautomeric signals 
to the correct isomer.  The synthesis and full NMR characterization of N-methylated 
Pyrmetazole 6.3, and N-methylated Omeprazole 5.22 was achieved.  It was found that it was 
possible to produce material enriched in the 6-OMe isomer of NMe Omeprazole 5.22 by 
antisolvent induced crystallization of a 50:50 mix of isomers.  Future studies into the annular 
tautomerism of compounds such as Omeprazole may involve computational studies such as 
molecular modeling to uncover more information about the relative energies of the tautomeric 
forms of the benzimidazole species investigated here.  
 
The selective deuteration of Na-Omeprazole and Na-Esomeprazole was unexpectedly 
encountered during the course of these studies, observed by 1H NMR as the depletion or indeed 
absences of the CH2 protons.  This effect was attributed to H/D exchange with the deuterated 
solvent, DMSO-d6, and was found to occur within minutes, within the time required for the 
NMR sample to be prepared and run.  The selective deuteration of the methylene group of  
Na-Omeprazole was also observed to occur in the protic solvents MeOD and D2O, with possible 
stereoselective H/D exchange observed in the former NMR solvent.  Both Pyrmetazole sulfide 
3.17 and Omeprazole sulfone 4.1 underwent deuteration, with H/D exchange of the sulfide 
occurring in 1 or 2 equivalents of DCl in MeOD, whereas the exchange occurred to a much 
greater extent for the more acidic methylene protons of the sulfone, with no CH2 protons 
observed for this species, due to complete deuteration, in MeOD and D2O in acidic, basic and 
neutral conditions. The benzyl benzimidazole sulfoxide 4.9 underwent H/D exchange in basic 
conditions, while the pyridyl p-tolyl sulfoxide 4.12 showed evidence of complete deuteration 
with the addition of NaOD, and partial deuteration with a stoichiometric amount of DCl.  With 
the addition of an excess of acid, both Pyrmetazole and sulfoxide 4.12 appeared resistant to H/D 
exchange, suggesting that the pyridine and pyridinium salt needs to be present for the 
mechanism of exchange to occur.  Further examination of the selective deuteration would 
investigate the time required for these transformations to occur, possibly with the use of 
substoichiometric amounts of acid and base, which may provide information on the relative 
reactivities of the methylene groups of the various compounds examined.  The reversibility of 
the H/D exchange could also be investigated.   
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7 Appendix 
 
The X-ray diffraction data for the compounds discussed in section 6.1 has been included on the 
accompanying disk.  Alternatively, for the electronic version of this thesis this data may be 
found at the end of the document.   
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8 Experimental 
8.1 General Experimental 
 
All reagents were obtained commercially and used directly without further purification, unless 
stated otherwise.  All solvents were distilled before use or obtained dry from commercial 
suppliers.  Solvents were removed under reduced pressure using a diaphragm pump with a 
Buchi rotary evaporator.  Additional traces of solvent were removed by drying under high 
vacuum at 0.25 mmHg using a rotary oil pump.  Flash silica chromatography was performed 
using silica gel (230-400 mesh) supplied by E.M. Merck.  Thin layer chromatography (TLC) 
was performed using Merck aluminium TLC sheets (silica gel 60 F254). Visualisation of the TLC 
plates was carried out using a UV lamp (245 nm) or by dipping in KMnO4 followed by 
exposure to heat.  Melting point determination was carried out on a Reichert Hot Stage 
apparatus and are reported uncorrected.  Elemental analysis was carried out using a Carlo Ebra 
1108 Elemental Analyzer.  Determination of halogen and sulfur were carried out using the 
Schoniger Oxygen Flask combustion method followed by the relevant titration for the particular 
halogen.  LCMS analysis was performed using a Bruker HCT open access system consisting of 
a Bruker HCT Ultra mass spectrometer and an Agilent Technologies 1200 series HPLC under 
acid free conditions with positive ion electrospray ionization. 
 
Nuclear magnetic resonance (NMR) spectra were recorded for 1H at 300 or 500 MHz, and 13C at 
75 or 125 MHz on a Bruker DPX300 FT spectrometer or Bruker Avance 500 spectrometer both 
of which utilize an internal deuterium lock. Coupling constants are given in Hertz (Hz).  
Chemical shifts were recorded downfield from tetramethylsilane (TMS) defined as 0 in parts per 
million (ppm) or by residual proton signals from the deuterated solvents were used as references 
[chloroform (1H 7.26 ppm, 13C 77.1 ppm), DMSO-d6 (
1H 2.50 ppm, 13C 39.5 ppm), MeOD (1H 
3.31 ppm, 13C 49.0 ppm].  When D2O was employed as the NMR solvent, the reference peak ( 
= 0) was the methyl signal of the sodium salt of 3-(trimethylsilyl)propane-1-sulfonic acid; a 
sealed capillary tube containing a solution of the reference material in D2O (2 % w/w) was 
added to each NMR tube.713  In reporting 1H and 13C NMR data the following abbreviations will 
be used; s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Proton and carbon 
assignment has been based on HMQC, HMBC, and NOESY spectra analysis where appropriate.  
Mass spectra (HRMS) was recorded in house using a Micromass GCT Premier, using electron 
impact ionisation (EI) or a Bruker Daltonics microTOF, using electron spray ionisation (ESI).  
Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer, as 
solid samples unless stated otherwise. Vibrational frequencies are reported in wavenumbers 
(cm-1).  Chiral HPLC was carried out using an Agilent 1290 Infinity employing Chiralcel AD-H 
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or OD-H columns as stated, with column dimensions of 250 mm  4.6 mm and 5 m particle 
sizes.  Solvent system, flow rate and operating temperature are stated for each chiral species 
analyzed. 
 
Single crystal X-ray diffraction data were collected on an Agilent (Rigaku) SuperNova X-ray 
diffractometer equipped with an Atlas CCD detector using monochromated Mo-Ka (λ = 0.7107 
Å) or Cu-Ka (λ = 1.5418 Å) radiation.  Samples were mounted on a nylon loop under inert oil 
and cooled to 120 K using an Oxford Cryosystem low temperature device.714  The full dataset 
was collected and processed using CrysAlisPro.715  Structural solution was achieved using direct 
methods (SHELXS) or charge-flipping methods (Superflip) and the model refined by full matrix 
least squares on F2 using SHELXL-973 interfaced through Olex2.704, 716, 717  Molecular graphics, 
editing of CIFs and construction of data tables were achieved using Olex2.  Unless otherwise 
stated, hydrogen atoms were placed using idealized geometric positions (with free rotation for 
methyl groups), allowed to move in a “riding model” along with the atoms to which they were 
attached, and refined isotropically. 
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8.2 Synthetic Protocols 
 
6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole 
(Pyrmetazole) 3.17
718
 
 
A solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) was added to a suspension of  
2-(chloromethyl)-3,5-dimethyl-4-methoxypyridine hydrochloride 3.19 (22.2 g, 100 mmol) and 
5-methoxy-1H-benzimidazole-2-thiol 3.18 (18.0 g, 100 mmol) in EtOH (100 mL).  The mixture 
was heated at reflux for 15 min then a solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) 
was added and heating continued for 3h.  The mixture was allowed to cool to rt followed by the 
addition of H2O (50 mL) and CH2Cl2 (100 mL).  The phases were separated and the aqueous 
phase extracted with CH2Cl2 (3  100 mL), the organic materials were combined, dried 
(MgSO4), filtered and the solvent removed in vacuo.  Column chromatography (eluting with 
EtOAc) gave sulfide 3.17 as a viscous gum which was triturated with Et2O to afford the title 
compound 3.17 (29.3 g, 89.0 mmol, 89%) as a colourless amorphous powder; m.p. 112.1-113.8 
C (Et2O); Rf 0.58 (5% MeOHEtOAc); 
1
H NMR (DMSO-d6, 500 MHz): 2.19 (3H, s, pyr 5-
Me), 2.27 (3H, s, pyr 3-Me), 3.71 (3H, s, pyr OMe), 3.77 (3H, s, benz OMe), 4.65 (2H, s, 
CH2), 6.76 (1H, dd, J 8.7 and 2.4, benz 5-H), 6.99 (1H, br s, benz 7-H), 7.35 (1H, d, J 8.7, benz 
4-H), 8.17 (1H, pyr 6-H), 12.45 (1H, br s, NH, exchangeable); 13C NMR (DMSO-d6, 125 
MHz):  10.9 (pyr 3-Me), 12.9 (pyr 5-Me), 36.5 (CH2), 55.4 (benz OMe), 59.8 (pyr OMe), 
96.0 (br benz C7), 110.4 (benz C5), 113.0 (br benz C4), 124.5 (pyr C3), 125.1 (pyr C5), 148.6 
(pyr C6), 148.9 (benz C2), 154.2 (pyr C2), 155.3 (benz C6), 163.4 (Pyr C4); 1H NMR 
(CDCl3 500 MHz): 2.25 (3H, s, 5-Me), 2.30 (3H, s, 3-Me), 3.76 (3H, s, pyr OMe), 3.82  
(3H, s, benz OMe), 4.38 (2H, s, CH2), 6.81 (1H, dd, J 8.7 and 2.4, benz 5-H), 7.03 (1H, br s, 
benz 7-H), 7.40 (1H, d, J 8.7, benz 4-H), 8.24 (1H, pyr 6-H); 13C NMR (CDCl3, 125 MHz):  
11.3 (pyr 3-Me), 13.4 (pyr 5-Me), 35.5 (CH2), 56.0 (benz OMe), 60.1 (pyr OMe), 97.8 (br 
benz C7), 111.2 (benz C5), 114.9 (br  benz C4), 125.5 (pyr C3), 126.2 (pyr C5), 134.4 (benz 
C3 or C7), 140.0 (benz C3 or C7), 148.5 (pyr C6), 150.7 (benz C2), 155.8 (pyr 2C), 156.0 
(benz C6), 165.1 (Pyr C4), NMR data in accordance with the literature;718 max/cm
–1 
(solid) 
3071, 2959, 1635, 1594, 1567, 1635, 1435, 1308, 1261, 1155, 1078 ; m/z (ESI) (Found MH+, 
330.1283, C17H19N3O2S requires MH 330.1271); Anal. Calcd. for C17H19N3O2S (%): C, 62.0; H, 
5.80; N, 12.8; Found: C, 61.9; H, 5.90; N, 13.0. 
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()-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-
benzimidazole ()-Omeprazole) ()-1.1576, 719, 720 
 
Saturated aqueous NaHCO3 (100 mL) was added to a solution of Pyrmetazole 3.17 (8.24 g, 25.0 
mmol) in CH2Cl2 (100 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% 
mCPBA, 5.60 g, 25.0 mmol) in CH2Cl2 (90 mL) and MeOH (10 mL) was added dropwise and 
the reaction stirred vigorously for 3h.  The reaction was quenched by addition of saturated 
aqueous Na2S2O3 (50 mL), the phases were separated and the aqueous layer extracted with 
CH2Cl2 (3  50 mL).  The combined organic extracts were washed with brine (25 mL), treated 
with charcoal and MgSO4, filtered and the volume reduced in vacuo to approximately 20 mL.  
Et2O was added slowly to induce precipitation.  The precipitate was collected by vacuum 
filtration and washed with Et2O to give the title compound ()-1.1 (6.48 g, 18.8 mmol, 75%) as 
colourless microcrystals; m.p. decomp > 135 C (CH2Cl2– Et2O) (lit. decomp > 135 C);
719 Rf 
0.46 (5% MeOHEtOAc); 1H NMR (DMSO-d6, 500 MHz):  2.16 (3H, s, pyr 3-Me), 2.18 
(3H, s, pyr 5-Me), 3.67 (3H, s, pyr OMe), 3.80 (3H, s, benz OMe), 4.69 and 4.77 (2H, AB-
system, J 13.5, CH2), 6.92 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.10 (1H, br s, benz  
7-H), 7.54 (1H, d, J 8.9, benz 4-H), 8.18 (1H, pyr 6-H), 13.42 (1H, br s, NH, exchangeable) 
NMR data in accordance with the literature;576, 720 13C NMR (DMSO-d6, 125 MHz):  11.1 (pyr 
3-Me), 12.9 (pyr 5-Me), 55.5 (benz OMe), 59.7 (pyr OMe), 60.1 (CH2), 95.6 (br benz C7), 
113.4 (br benz C5), 119.3, 125.5 (pyr C5), 126.5 (pyr C3), 136.5, 149.2 (pyr C6), 149.6 (pyr 
C2), 153.1 (benz C2), 156.6 (benz C5), 163.5 (pyr C4)  1H NMR (CDCl3 500 MHz):  2.06 
(3H, s, pyr 3-Me), 2.19 (3H, s, pyr 5-Me), 3.57 (3H, s, pyr OMe), 3.81  (3H, s, benz OMe), 
4.75 and 4.80 (2H, 2 d, J 13.7, CH2), 6.83 (1H, br s, benz 7-H), 6.91 (1H, dd, J 8.9 and 2.1, benz 
5-H), 7.61 (1H, br s, benz 4-H), 8.17 (1H, pyr 6-H), 12.64 (1H, br s, NH, exchangeable);  
13
C NMR (CDCl3, 125 MHz):  11.5 (pyr 3-Me), 13.3 (pyr 5-Me), 55.9 (benz OMe), 59.8 
(pyr OMe), 60.7 (CH2), 95.1 (benz C7), 102.0 ( benz C3 or C7), 113.5 (benz C5), 120.9 (benz 
C4), 126.3 (pyr C5), 127.0 (pyr C3), 135.6 (benz C3 or C7), 149.0 (pyr C2), 149.8 (pyr 
C6), 151.1 (benz C2), 157.9 (benz C6), 164.5 (pyr C4); max/cm
–1 
(solid): 3056, 2943, 2901, 
1626, 1585, 1509, 1401, 1310, 1154, 1074;576, 721 m/z (ESI) (Found MH+, 346.1230 
C17H19N3O3S requires MH 346.1220); Anal. Calcd. for C17H19N3O3S (%):C, 59.1; H, 5.55; N, 
12.2; Found: C, 59.4; H, 5.60; N, 12.0. 
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()-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-
benzimidazole sodium (()-Na Omeprazole) ()-3.36 
 
A solution of NaOH (0.200 g, 5.00 mmol) in H2O (0.25 mL) was added to a suspension of 
Omeprazole ()-1.1 (1.73 g, 5.00 mmol) and MeCN (10 mL) and the resulting solution stirred at 
room temperature.  After 1h the solution was concentrated to approximately half volume in 
vacuo and precipitation of the salt was induced by dropwise addition of Et2O.  The precipitate 
was collected by filtration and washed with Et2O to give the title compound ()-3.36 (1.76 g, 
4.80 mmol, 96%) as a colourless powder; m.p. > 240 C (MeCN); 1H NMR (DMSO-d6, 500 
MHz):  2.20 (3H, s, pyr 3-Me), 2.21 (3H, s, pyr 5-Me), 3.69 (3H, s, pyr OMe), 3.72 (3H, s, 
benz OMe), 4.38 and 4.66 (2H, AB-system, J 12.9, CH2, exchangeable), 6.54 (1H, dd, J 8.6 and 
2.5, benz 5-H), 6.98 (1H, d, J 2.5, benz 7-H), 7.32 (1H, J 8.6, benz 4-H), 8.23 (1H, pyr 6-H); 
13
C NMR (DMSO-d6, 125 MHz): 11.3 (3-Me), 12.9 (5-Me), 55.2 (benz OMe), 59.7 (pyr 
OMe), 59.9 (CH2), 99.5 (benz C7), 108.7 (benz C5), 117.4 (benz C4), 124.8 (pyr C5), 126.4 
(pyr C3), 141.7 (benz C3or C7), 147.1 (benz C3or C7), 149.0 (pyr C6), 152.0 (pyr C2), 
153.4 (benz 6C), 161.8 (benz C2), 163.3 (pyr C4), NMR data in accordance with that reported 
in the literature for the (S)-enantiomer of this compound;125, 628 m/z (ESI) (Found MH+, 
368.1044 C17H18N3NaO3S requires MH 368.1039).   
 
()-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-
benzimidazole potassium (()-K Omeprazole) ()-3.38623 
 
Omeprazole ()-1.1 (1.18 g, 3.40 mmol) and MeCN (20 mL) were added to a solution of KOH 
(0.190 g, 3.40 mmol) in H2O (0.19 mL) and the solution stirred at rt.  After 1h the solution was 
concentrated to approximately half volume in vacuo and precipitation of the salt induced by 
dropwise addition of Et2O.  The precipitate was collected by filtration and recrystallised from 
MeOHEt2O give the title compound ()-3.38 (0.720 g, 1.90 mmol, 56%) as a colourless 
powder; m.p. decomp > 130 C (MeOHEt2O); 
1
H NMR (DMSO-d6, 300 MHz):  2.20 (3H, s, 
pyr 3-Me), 2.21 (3H, s, pyr 5-Me), 3.69 (3H, s, pyr OMe), 3.72 (3H, s, benz OMe), 4.38 and 
4.75 (2H, 2  d, J 12.8, CH2), 6.54 (1H, dd, J 8.6 and 2.5, benz 5-H), 6.98 (1H, d, J 2.5, benz 7-
H), 7.32 (1H, J 8.6, benz 4-H), 8.23 (1H, pyr 6-H); 13C NMR (DMSO-d6, 75 MHz):  11.3 
248 
 
(3-Me), 12.9 (5-Me), 55.2 (benz OMe), 59.7 (pyr OMe), 59.9 (CH2), 99.5 (benz 7C), 108.7 
(benz 5C), 117.4 (benz 4C), 124.8 (pyr C5), 126.4 (pyr C3), 141.7 (benz C3or C7), 147.1 
(benz Cor C7), 149.0 (pyr C6), 152.0 (pyr C2), 153.4 (benz 6C), 161.8 (benz C2), 163.3 
(pyr C4NMR data in accordance with that reported in the literature for the (S)-enantiomer of 
this compound;623 m/z (ESI) (Found MH+, 368.1044 C17H18N3NaO3S requires MH 368.1039). 
 
6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole 
(Omeprazole sulfone) 4.1 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of Pyrmetazole 3.17 (3.29 g, 10.0 
mmol) in CH2Cl2 (50 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% 
mCPBA, 5.60 g, 25.0 mmol) in CH2Cl2 (45 mL) and MeOH (5 mL) was added dropwise and the 
reaction stirred vigorously for 3h.  The reaction was quenched by addition of saturated aqueous 
Na2S2O3 (50 mL).  The phases were separated and the aqueous layer extracted with CH2Cl2 (3  
25 mL), the combined organic extracts were washed with brine (20 mL), dried (MgSO4), 
filtered and the solvent removed in vacuo.  EtOAc (30 mL) was added to the crude materials 
and the insoluble N-oxide byproduct removed by filtration.  The filtrate was concentrated in 
vacuo and subjected to column chromatography (eluting with EtOAc) to afford the title 
compound (2.13 g, 5.90 mmol, 59%) as a colourless viscous gum which dried as a solid foam 
under vacuum.  m.p. 98.6-100.7 C (from CH2Cl2); Rf 0.55 (5% MeOHEtOAc); 
1
H NMR 
(DMSO-d6, 500 MHz):  2.16 (3H, s, pyr 5-Me), 2.20 (3H, s, pyr 3-Me), 3.67 (3H, s, pyr 
OMe), 3.82 (3H, s, benz OMe), 5.02 (2H, s, CH2), 7.01 (1H, dd, J 8.9 and 1.6, benz 5-H), 7.05 
(1H, br s, benz 7-H), 7.61 (1H, br s, benz 4-H), 8.04 (1H, pyr 6-H), 13.59 (1H, br s, NH 
exchangeable); 13C NMR (DMSO-d6, 125 MHz):  11.3 (pyr 3-Me), 12.9 (pyr 5-Me), 55.5 
(benz OMe), 59.7 (pyr OMe), 60.6 (CH2), 94.6, 115.0 (br, benz C5), 121.4 (br C3 or C7), 
126.2 (pyr C3), 127.7 (pyr C5), 135.7 (br C3 or C7), 146.7 (pyr C2), 149.3 (pyr C6), 
157.6 (benz C6), 163.7 (pyr C4); 1H NMR (CDCl3 500 MHz): 2.16 (3H, s, pyr 5-Me), 2.29 
(3H, s, pyr 3-Me), 3.66(3H, s, pyr OMe), 3.79 (3H, s, benz OMe), 5.00 (2H, s, CH2), 6.88 (1H, 
br s, benz 7-H),6.93 (1H, dd, J 9.0 and 2.3, benz 5-H), 7.56 (1H, br s, benz 4-H), 8.06 (1H, pyr 
6-H), 12.16 (1H, br s, NH exchangeable); 13C NMR (CDCl3, 125 MHz):  11.9 (pyr 3-Me), 
13.4 (pyr 5-Me), 55.7 (benz OMe), 60.0(pyr OMe), 60.8 (CH2), 94.2, 101.9, 115.2, 122.1, 
127.3 (pyr C5), 128.9 (pyr C3), 134.9, 137.6, 146.1(pyr C2), 149.4 (pyr C6), 158.9 (benz 
C6), 165.0 (pyr C4); m/z (ESI) (Found MH+, 362.1175 C17H19N3O4S requires MH 362.1169)   
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6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole 
 N-Oxide 4.2
635
 
 
The title compound 4.2 was isolated during the purification procedure in the synthesis of 
Omeprazole sulfone 4.1; m.p. 205.4-205.9 C (from EtOAc) (Lit. m.p. 206 - 207 C);635 1H 
NMR (DMSO-d6, 500 MHz):  2.16 (3H, s, pyr 5-Me), 2.20 (3H, s, pyr 3-Me), 3.70 (3H, s, 
pyr OMe), 3.82 (3H, s, benz OMe), 5.33 (2H, s, CH2), 7.00 (1H, d, J 9.0, benz 5-H), 7.06 (1H, 
br s, benz 7-H), 7.59 (1H, br s, benz 4-H), 8.06 (1H, pyr 6-H), 13.69 (1H, br s, NH 
exchangeable), NMR data in accordance with the literature data;635 m/z (ESI) (Found MH+, 
378.1129 C17H20N3O5S requires MH 378.1112)   
 
(S)-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-
benzimidazole ((S)-Esomeprazole) (S)-1.1
628
 
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of Pyrmetazole 3.17 (1.65 g, 5.00 mmol) 
in toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The solution was cooled to 30 
C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by addition of CHP (80% in 
cumene, 924 L, 0.76 g, 5.00 mmol).  After 1 h the reaction was quenched by addition of 
aqueous NH4OH (12.5% NH3, 10 mL) and the mixture stirred vigorously for 30 min then 
allowed to sit for 45 min.  The reaction mixture was filtered through a pad of Celite and the 
Celite pad washed with aqueous NH4OH (12.5% NH3, 3 mL) and CH2Cl2 (4 
mLThe phases of the filtrate were separated and the organic phased extracted with 
aqueous NH4OH (12.5% NH3, 3 mL).  CH2Cl2 (50 mL) was added to the combined 
aqueous extracts and AcOH added with caution until a pH of ~ 8 was achieved.  The phases 
were separated and the aqueous phase extracted with CH2Cl2 (3 mL).  The combined 
organic extracted were washed with saturated aqueous NaHCO3 (20 mL), then brine (mL), 
dried (MgSO4), filtered and the solvent removed in vacuo.  Column chromatography (eluting 
with 5% MeOH-EtOAc) gave the title compound (S)-1.1 (0.52 g, 1.50 mmol, 30%, 96% ee) as a 
colourless oil which dried as a glassy foam under vacuum; m.p. decomp > 125 C 
(MeOHEt2O); Rf 0.46 (5% MeOHEtOAc); 
1
H NMR (DMSO-d6, 300 MHz): 2.16 (3H, s, 
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Me 8), 2.19 (3H, s, Me 7), 3.68 (3H, s, pyr OMe), 3.80 (3H, s, benz OMe), 4.67 and 4.76 (2H, 
AB-system, J 13.5, CH2), 6.92 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.09 (1H, br s, benz 7-H), 7.54 
(1H, d, J 8.9, benz 4-H), 8.18 (1H, pyr 6-H), 13.41 (1H, br s, NH, exchangeable); 13C NMR 
(DMSO-d6, 75 MHz): 11.1 (pyr 3-Me), 12.9 (pyr 5-Me), 55.5 (benz OMe), 59.7 (pyr OMe), 
60.1 (CH2), 125.5 (pyr C3), 126.5 (pyr C5), 149.1 (pyr C6), 149.6 (pyr C2), 153.0 (benz 
C2), 156.6 (benz C6), 163.5 (pyr C4) not all carbon signals observed due to annular 
tautomerism of the benzimidazole system, NMR data in accordance with the literature;628  
1
H NMR (CDCl3, 300 MHz): 2.17 (3H, s, pyr 3-Me), 2.19 (3H, s, pyr 5-Me), 3.64 (3H, s, 
pyr OMe), 3.75 (3H, s, benz OMe), 4.79 (2H, s, CH2), 6.90 (1H, br s, benz 7-H), 6.97 (1H, dd, J 
8.9 and 2.1, benz 5-H), 7.49 (1H, br s, benz 4-H), 8.15 (1H, pyr 6-H); m/z (ESI) (Found MH+, 
346.1234 C17H19N3O3S requires MH 346.1220; HPLC: tR (Smajor) = 32.5 min, tR (Rminor) = 41.9 
min [Chiracel OD-H; flow rate 1.0 mL min-1; 5% EtOH hexane; 20 C] 
 
(S)-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-
benzimidazole sodium ((S)-Na Esomeprazole) (S)-3.36
125, 628
 
 
Esomeprazole (S)-1.1 (0.31 g, 0.90 mmol) and MeCN (5 mL) were added to a solution of NaOH 
(36.0 mg, 0.90 mmol) in H2O (40 L) and the solution stirred at rt for 1h.  The resulting 
precipitate was collected by filtration and washed with Et2O to give the title compound (S)-3.36 
(0.22 g, 0.60 mmol, 65%, > 99.5% ee) as a colourless powder; m.p. > 160 C (decomp) (from 
MeCNEt2O); 
1
H NMR (DMSO-d6, 300 MHz):  2.20 (3H, s, pyr 3-Me), 2.21 (3H, s, pyr 5-
Me), 3.69 (3H, s, pyr OMe), 3.72 (3H, s, benz OMe), 4.38 and 4.66 (2H, AB-system, J 12.9, 
CH2), 6.54 (1H, dd, J 8.6 and 2.5, benz 5-H), 6.98 (1H, d, J 2.5, benz 7-H), 7.32 (1H, J 8.6, 
benz 4-H), 8.23 (1H, pyr 6-H); 13C NMR (DMSO-d6, 75 MHz):  11.3 (3-Me), 12.9 (5-Me), 
55.2 (benz OMe), 59.7 (pyr OMe), 59.9 (CH2), 99.5 (benz 7C), 108.7 (benz 5C), 117.4 (benz 
4C), 124.8 (pyr C5), 126.4 (pyr C3), 141.7 (benz C3or C7), 147.1 (benz C3or C7), 149.0 
(pyr C6), 152.0 (pyr C2153.4 (benz 6C), 161.8 (benz C2), 163.3 (pyr C, NMR data in 
accordance with the literature m/z (ESI) (Found MH+, 368.1045 C17H18N3NaO3S requires 
MH 368.1039); HPLC: tR (Smajor) = 38.2 min [Chiracel OD-H; flow rate 1.0 mL min
-1; 5% 
EtOH hexane; 20 C] 
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6(5)-Methoxy-2-[(phenylmethyl)thio]-1H-benzimidazole 4.4 
 
A solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) was added to a solution of 6(5)-
methoxy-1H-benzimidazole-2-thiol 3.18 (18.0 g, 100 mmol) in EtOH  (100 mL).  Benzyl 
bromide (11.9 mL, 17.1 g, 100 mmol) was added and the reaction heated at reflux for 2h.  The 
mixture was allowed to cool to rt followed by the addition of H2O (50 mL) and CH2Cl2 (100 
mL).  The phases were separated and the aqueous phase extracted with CH2Cl2 (3  100 mL).  
The combined organic materials were washed with brine (50 mL), dried (MgSO4), filtered and 
the solvent removed in vacuo.  Recrystallization from EtOAchexane gave the title compound 
4.4 (25.3 g, 88.0 mmol, 88%) as a colourless powder; m.p. 114.2-115.3 C (from 
EtOAchexane); Rf 0.36 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 300 MHz): 3.77 (3H, s, 
OMe), 4.58 (2H, s, CH2), 6.80 (1H, dd, J 8.7 and 2.4, benz 5-H), 7.02 (1H, d, J 2.4, benz 7-H), 
7.21-7.32 (3H, m, phenyl 12-H and 11/11-H), 7.39 (1H, d, J 8.7, benz 4-H), 7.41-7.46 (2H, m, 
phenyl 10/10-H), 12.47 (1H, br s, NH, exchangeable); 13C NMR (DMSO-d6, 125 MHz):  35.6 
(CH2), 55.5 (OMe), 96.9 (benz C7), 111.0 (benz C5), 114.7 (benz C4), 127.3 (phenyl C12), 
128.5 (phenyl C10/10), 128.8 (phenyl C11/11), 133.8 (C3 or C7), 137.6 (phenyl C9), 139.1 
(C3 or C7), 148.5 (benz C2), 155.6 (benz C6); max/cm
–1
 (solid) 3059, 2951, 2628, 1633, 1451, 
1433, 1401, 1159, 1030, 987; m/z (ESI) (Found MH+, 271.0905 C15H14N2OS requires MH 
271.0900); Anal. Calcd. for C15H14N2OS (%): C, 66.6; H, 5.20; N, 10.4; Found: C, 66.5; H, 
5.20; N, 10.4; 
 
1-Methyl-4-[(phenylmethyl)thio]-benzene 4.5
722, 723
 
 
A solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) was added to a solution of 4-
methylbenzene-1-thiol 4.6 (12.4 g, 100 mmol) in EtOH (100 mL).  Benzyl bromide (11.9 mL, 
17.1 g, 100 mmol) was added and the reaction heated at reflux for 2h.  The mixture was allowed 
to cool to rt followed by the addition of H2O (25 mL) and CH2Cl2 (20 mL).  The phases were 
separated and the aqueous phase extracted with CH2Cl2 (3  20 mL).  The combined organic 
materials were washed with brine (50 mL), dried (MgSO4), filtered and the solvent removed in 
vacuo.  Column chromatography (eluting with hexane) followed by recrystallization from 
aqueous EtOH  gave the title compound 4.5 (19.3 g, 90.0 mmol, 90%) as a colourless crystalline 
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solid; m.p. 39.7-41.5 C (aq EtOH ) (lit. 45-46 C from Pet. Ether 60-80);723 Rf 0.90 (50% 
EtOAchexane); 1H NMR (DMSO-d6, 500 MHz):  2.24 (3H, s, tol Me), 4.17 (2H, s, CH2), 
7.09 (2H, d, J 8.2, H-3/3), 7.23 (2H, d, J 8.2, H-4/4), 7.20-7.25 (1H, m, phenyl H-10), 7.26-
7.30 (2H, m, phenyl H-9/9), 7.30-7.34 (2H, m, phenyl H-8/813C NMR (DMSO-d6, 125 
MHz):  20.5 (tol Me), 37.4 (CH2), 126.9 (phenyl C10), 128.2 (phenyl  C9/9), 128.7 (phenyl 
C8/8), 129.1(tol C4/4), 129.5 (tol C3/3), 132.3 (tol C5), 135.5 (tol C2), 137.7 (phenyl  C7); 1H 
NMR (CDCl3, 300 MHz): 2.21 (3H, s, tol Me), 3.98 (2H, s, CH2), 6.97 (2H, d, J 9.0, tolyl), 
7.11-7.23 (7H, m, phenyl and tolyl); 13C NMR (CDCl3, 75 MHz): 21.2 (tol Me), 39.9 (CH2), 
128.2, 128.5, 129.0, 129.7, 130.8, 132.6, 136.7, 137.9, NMR data in accordance with the 
literature.722 
 
6(5)-Methoxy-2-methylthio-1H-benzimidazole 4.7
562, 724
 
 
A solution of NaOH (2.00g, 50.0 mmol) in H2O (50 mL) was added to a suspension of 6(5)-
methoxy-1H-benzimidazole-2-thiol 3.18 (9.00 g, 50.0 mmol) in MeOH (50 mL).  The solution 
was cooled to 0 C and MeI (3.11 mL, 7.10 g, 50.0 mmol) was added dropwise.  The reaction 
mixture was stirred at room temperature for 2 h and then concentrated to approximately half 
volume in vacuo.  Saturated aqueous NaHCO3 (30 mL) was added and the suspensions stirred at 
0 C for 2 h.  The crude sulfide was collected by filtration, washed with H2O (2 50mL) and 
dried in vacuo.  Recrystallization from CHCl3hexane gave the title compound 4.7 (6.70 g, 35.0 
mmol, 70%) as colourless needles; m.p. 141.8-143.1 C (from CHCl3hexane) (lit.  
125-128 C from aq EtOH); Rf 0.54 (EtOAc); 
1
H NMR (DMSO-d6, 300 MHz):  2.67 (3H, s, 
SMe), 3.76 (3H, s, benz OMe), 6.74 (1H, dd, J 8.7 and 2.4, benz 5-H), 6.96 (1H, d, J 2.4 benz  
7-H), 7.33 (1H, d, J 8.7, benz 4-H), 12.38 (1H, br s, benz-NH, exchangeable); 13C NMR 
(DMSO-d6, 75 MHz):  13.9 (SMe), 55.4 (benz OMe), 97.1 (benz C7), 110.0 (benz C5), 114.4 
(benz C4), 134.8 (benz C3 or C7), 140.0 (benz C3 or C7), 150.4 (benz C2), 155.1 (benz C6), 
NMR data in accordance with the literature;724 max/cm
–1
(solid) 3046, 2997, 2951, 2929, 2878, 
2827, 1633, 1594, 1388, 1265, 1153, 1030; m/z (ESI) (Found MH+, 195.0588 C9H10N2OS 
requires MH 195.0587); Anal. Calcd. for C9H10N2OS (%): C, 55.7; H, 5.20; N, 14.4; Found: C, 
55.6; H, 5.25; N, 14.7.  
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4-Methoxy-3,5-dimethyl-2-{[(4-methylphenyl)sulfanyl]methylpyridine 4.8 
 
A solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) was added to a suspension of  
2-(chloromethyl)-3,5-dimethyl-4-methoxypyridine hydrochloride 3.19 (22.2 g, 100 mmol) and 
p-tolyl thiol 4.6  (12.4 g, 100 mmol) in EtOH (100 mL) and the mixture heated at reflux for 15 
min.  A solution of NaOH (4.00 g, 100 mmol) in H2O (20 mL) was added and heating continued 
for 3h.  The mixture was allowed to cool to rt followed by the addition of H2O (20 mL) and 
CH2Cl2 (500 mL).  The phases were separated and the aqueous phase extracted with CH2Cl2 (3 
 200 mL), the organic materials were combined, dried (MgSO4), filtered and the solvent 
removed in vacuo.  Column chromatography (eluting with 0-15% EtOAchexane) followed by 
recrystallization from hexane gave the title compound 4.8 (22.2 g, 81.1 mmol, 81%) as a 
colourless crystalline solid; m.p. 48.5-49.7 C (hexane); Rf 0.60 (EtOAc); 
1
H NMR (DMSO-d6, 
500 MHz):  2.16 (3H, s, 5-Me), 2.20 (3H, s, 3-Me), 2.25 (3H, s, tol Me), 3.69 (3H, s, pyr 
OMe), 4.24 (2H, s, CH2), (2H, d, J 8.1, tol 3/3-)7.28 (2H, d, J 8.1, tol 4/4-) 8.12 (1H, 
s, pyr 6-H); 13C NMR (DMSO-d6, 125 MHz): 10.9 (pyr 3-Me), 12.8 (pyr 5-Me), 20.5 (tol 
Me), 38.5 (CH2), 59.6 (pyr OMe), 124.6 (pyr C3), 124.8 pyr C5),129.3 (tol C4/4, 129.5 (tol 
C3/3132.6 (tol C5), 135.5 (tol C2), 148.5 (pyr C6, 155.1 (pyr C2), 163.4 (Pyr C4; m/z 
(ESI) (Found MH+, 296.1083 C16H19NOS requires MH 296.1080); Found: C, 70.1; H, 7.00; N, 
5.1; S, 11.7; C16H19NOS requires C, 70.3; H, 7.00; N, 5.1; S, 11.5% 
 
()-6(5)-Methoxy-2-[(phenylmethyl)sulfinyl]-1H-benzimidazole 4.9 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of sulfide 4.4 (6.76 g, 25.0 mmol) 
in CH2Cl2 (50 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% mCPBA, 5.60 
g, 25.0 mmol) in CH2Cl2 (45 mL) and MeOH (5 mL) was added dropwise and the reaction 
stirred vigorously for 3.5h.  The reaction was quenched by addition of saturated aqueous 
Na2S2O3 (50 mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  
50 mL).  The combined organic extracts were washed with brine (25 mL), dried (MgSO4), 
filtered and the solvent remove in vacuo. Column chromatography (eluting with 1:1 
EtOAcCH2Cl2) followed by recrystallization from EtOAchexane gave the title compound 
()-4.9 (5.57 g, 19.5 mmol, 78%) as colourless needles; m.p. 136.3-137.5 C (from 
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EtOAchexane); Rf 0.42 (EtOAc); 
1
H NMR (DMSO-d6, 300 MHz):  3.80 (3H, s, benz OMe), 
4.48 and 4.67 (2H, AB-system, J 12.8, CH2), 6.92 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.07 (1H, 
br s, benz 7-H), 7.11-7.22 (2H, m, phenyl-H), 7.23-7.35 (3H, m, phenyl-H),7.54 (1H, s, J 8.9, 
benz 4-H), 13.26 (1H, br s, NH exchangeable); 
13
C NMR (DMSO-d6, 75 MHz) mixture of two 
tautomers:  55.5 (OMe), 59.5 (CH2), 94.6 (br, benz C7), 101.5 br, 112.9 (br, benz C5), 114.3 
br, 120.4 (br, benz C4), 128.2, 128.4 (phenyl), 129.9, 130.4 (phenyl), 136.4 br, 137.6 br, 144.1 
br, 151.9 br, 153.3 br, 156.0 br, 156.9 br, extra carbon signals observed due to annular 
tautomerism of the benzimidazole system; 1H NMR (CDCl3, 500 MHz) mixture of tautomers 
A:B in a ratio of 37:63: 3.82 and 3.89 (3H, s, OMe, tautomers B and A respectively), 4.30 and 
4.52 (2H, AB-system , J 13.2, CH2), 6.77-7.75 (8H, m, phenyl and benz H), 11.43 and 11.5 (1H, 
br s, NH, exchangeable,  tautomers A and B respectively); max/cm
–1
(solid) 2996, 2919, 1629, 
1405, 1206, 1153, 1050, 1025; m/z (ESI) (Found MH+, 287.0853 C15H14N2O2S requires MH 
287.0849); Anal. Calcd. for C15H14N2O2S (%): C, 63.0; H, 4.95; N, 9.8; Found: C, 62.8; H, 
4.90; N, 9.6.  
 
()-1-Methyl-4-[(phenylmethyl)sulfinyl]-benzene 4.10725 
 
Saturated aqueous NaHCO3 (60 mL) was added to a solution of sulfide 4.5 (6.83 g, 25.0 mmol) 
in CH2Cl2 (100 mL) and the mixture cooled to 0 C.  A solution of mCPBA (70% mCPBA, 6.16 
g, 25 mmol) in CH2Cl2 (100 mL) and MeOH (10 mL) was added dropwise and the reaction 
stirred vigorously for 1h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 
(50 mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  
The combined organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and 
the solvent remove in vacuo.  Column chromatography (eluting with 50-100% EtOAc-hexane) 
followed by recrystallization from CHCl3hexane gave the title compound ()-4.10 (5.21 g, 
22.6 mmol, 91%) as a colourless needles. m.p. 134.2-135.7 C (CHCl3hexane) (lit  
139-140 C);725 Rf 0.36 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 500 MHz):  2.36 (3H, s, 
tol Me), 4.04 and 4.20 (2H, AB-system, J 12.7, CH2), 7.07-7.13 (2H, m, phenyl 8/8-H ), 7.24-
7.30 (3H, m, phenyl 9/9-H and 10-H), 7.32 (2H, d, J 8.4, tol 3/3-H), 7.41 (2H, d, J 8.4, tol 4/4-
H); 13C NMR (DMSO-d6, 125 MHz):  20.9 (tol Me), 61.8 (CH2), 124.3 (C4/4), 127.7 (phenyl 
C10), 128.1 (phenyl C9/9), 129.4 (tol C3/3), 130.3 (phenyl C8/8), 130.5 (phenyl C7), 140.3 
(tol C5), 140.7 (tol C2); 1H NMR (CDCl3, 300 MHz):  2.40 (3H, s, tol Me), 4.03 (2H, AB-
system J 12.5, CH2), 7.00 (2H, dd, J 7.4 and 1.8, tolyl), 7.19-7.37 (7H, m, tolyl and phenyl), 
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NMR data in accordance with the literature data;725 m/z (ESI) (Found MH+ 231.0842, C14H14OS 
requires MH 231.0838). 
 
()-6(5)-Methoxy-2-(methylsulfinyl)-1H-Benzimidazole 4.11562 
 
Saturated aqueous NaHCO3 (60 mL) was added to a solution of sulfide 4.7 (7.77 g, 40.0 mmol) 
in CH2Cl2 (60 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% mCPBA, 9.20 
g, 40 mmol) in CH2Cl2 (96 mL) and MeOH (4 mL) was added dropwise and the reaction stirred 
vigorously for 3h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 (50 
mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  The 
combined organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and the 
solvent remove in vacuo.  Column chromatography (eluting with 1:1 EtOAchexane) followed 
by recrystallization from EtOAchexane gave the title compound ()-4.11 (5.85 g, 27.8 mmol, 
70%) as a colourless powder; m.p. 97.6-98.9 C (from EtOAchexane); Rf 0.14 (50% 
EtOAchexane); 1H NMR (DMSO-d6, 300 MHz):  (3H, s, SMe), 3.80 (3H, s, benz 
OMe), 6.93 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.11 (1H, br s, benz 7-H), 7.56 (1H, br d, J 8.9, 
benz 4-H), (13.42 (1H, br s, NH exchangeable); 13C NMR (DMSO-d6, 75 MHz):  40.3 (SMe), 
55.5 (benz OMe), 95.3 (br, benz C7) 113.5 (benz C5), 120.0 (br, benz C4) 136.3 br, 154.2, 
156.7, not all carbon signals observed due to annular tautomerism of the benzimidazole system; 
1
H NMR (CDCl3, 300 MHz) mixture of tautomers A:B in a ratio of 38:62:  (3H, s, SMe), 
3.86 (3H, s, benz OMe), 6.98 (m, benz 5-H and benz 7-H tautomer B), 7.11 (br s, benz 7-H, 
tautomer A), 7.46 and 7.65 (1H, 2 d, J 8.8, benz 4-H, tautomers B and A respectively), 12.01 
(1H, br s, NH exchangeable), NMR data in accordance with the literature;562 max/cm
–1
(solid) 
2966, 2884, 2769, 2591, 1621, 14.3, 1302, 1202, 1153, 1011; m/z (ESI) (Found MH+, 211.0535 
C9H10N2O2S requires MH 211.0535); Anal. Calcd. for C9H10N2O2S (%): C, 51.4; H, 4.80; N, 
13.3; Found: C, 54.4; H, 4.80; N, 13.3. 
 
()-4-Methoxy-3,5-dimethyl-2-{[(4-methylphenyl)sulfinyl]methyl}pyridine 4.12 
 
Saturated aqueous NaHCO3 (60 mL) was added to a solution of sulfide 4.8 (6.83 g, 25.0 mmol) 
in CH2Cl2 (100 mL) and the mixture cooled to 0 C.  A solution of mCPBA (70% mCPBA, 6.16 
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g, 25 mmol) in CH2Cl2 (100 mL) and MeOH (10 mL) was added dropwise and the reaction 
stirred vigorously for 1h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 
(50 mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  
The combined organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and 
the solvent remove in vacuo.  Column chromatography (eluting with EtOAc) followed by 
recrystallization from CH2Cl2hexane gave the title compound ()-4.12 (6.93 g, 24.0 mmol, 
96%) as a colourless needles; m.p. 90.3-91.9 C (CH2Cl2hexane); Rf 0.14 ( EtOAc); 
1
H NMR 
(DMSO-d6, 500 MHz):  
 2.02 (3H, s, 3-Me), 2.19 (3H, s, 5-Me), 2.36 (3H, s, tol Me), 3.66 
(3H, s, pyr OMe), 4.17 and 4.36 (2H, AB-system, J 12.8, CH2), (2H, d, J 8.2, tol 3/3-), 
7.44 (2H, d, J 8.3, tol 4/4-), 8.20 (1H, s, pyr 6-H); 13C NMR (DMSO-d6, 125 MHz):  11.1 
(pyr 3-Me), 12.9 (pyr 5-Me), 20.9 (tol Me), 59.6 (pyr OMe), 62.8 (CH2), 124.1 (tol C4/4, 
125.2 (pyr C5), 126.5 (pyr C3), 129.6 (tol C3/3), 141.0 (tol C2), 141.1 (tol C5), 149.0 (pyr 
C6, 150.1 (Pyr C2), 163.4 (Pyr C4); m/z (ESI) (Found MH+, 290.1219 C16H19NO2S 
requires MH 296.1209); Anal. Calcd. for C16H19NO2S (%): C, 66.4; H, 6.60; N, 4.8; Found: C, 
66.2; H, 6.90; N, 4.7.  
 
()-1-Methyl-4-(methylsulfinyl)-benzene 1.48720 
 
Saturated aqueous NaHCO3 (60 mL) was added to a solution of p-tolyl sulfide (6.72 mL, 6.92 g, 
50.0 mmol) was dissolved in CH2Cl2 (75 mL) and the mixture cooled to 0 C.  A solution of 
mCPBA (70% mCPBA, 12.3 g, 50.0 mmol) in CH2Cl2 (75 mL) and MeOH (5 mL) was added 
dropwise and the reaction stirred vigorously for 2.5h.  The reaction was quenched by addition of 
saturated aqueous Na2S2O3 (50 mL), the phases were separated and the aqueous layer extracted 
with CH2Cl2 (3  25 mL).  The combined organic extracts were washed with brine (15 mL), 
dried (MgSO4), filtered and the solvent remove in vacuo.  Column chromatography (eluting 
with 30-100% EtOAchexane) gave a colourless oil which was triturated with cold hexane to 
afford the title compound ()-1.48 (7.05 g, 46.0 mmol, 91%) as a colourless waxy solid; m.p. 
39.0-40.2 C (hexane) (lit. 39.0-40.0)720; Rf 0.08 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 
500 MHz):  2.36 (3H, s, tol Me), 2.69 (3H, s, Me), 7.37 (2H, d, J 8.1, tol 3/3-), 7.57 (2H, d, J 
8.3, tol 4/4-); 13C NMR (DMSO-d6, 75 MHz):  20.8 (tol Me), 43.3 (SMe), 123.5 (tol C4/4), 
129.7 (tol C3/3), 140.5 (tol C2), 143.2 (tol C5); 1H NMR (CDCl3 300 MHz): 
 2.41 (3H, s, tol 
Me), 2.70 (3H, s, Me), 7.33 (2H, d, J 8.1, tol 3/3-), 7.54 (2H, d, J 8.3, tol 4/4-), NMR data 
in accordance with the literature;720 m/z (ESI) (Found MH+, 155.0524 C8H10OS requires MH 
155.0525). 
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6(5)-Methoxy-2-[(phenylmethyl)sulfonyl]-1H-benzimidazole 4.13 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of sulfide 4.4 (1.08 g, 4.0 mmol) 
in CH2Cl2 (50 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% mCPBA, 2.24 
g, 10.0 mmol) in CH2Cl2 (40 mL) was added dropwise and the reaction stirred vigorously for 
3h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 (50 mL), the phases 
separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  The combined organic 
extracts were washed with brine (25 mL), dried (MgSO4), filtered and the solvent remove in 
vacuo. Purification by column chromatography (eluting with 50% EtOAchexane) gave the title 
compound 4.13 (0.95 g, 3.20 mmol, 79%) as a colourless powder; m.p. 219.7-220.2 C (from 
EtOAchexane); Rf. 0.40 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 500 MHz):  3.81 (3H, 
s, OMe), 4.94 (2H, s, CH2), 7.02 (1H, dd, J 8.9 and 1.9, benz 5-H), 7.06 (1H, br s, benz 7-H), 
7.18-7.37 (5H, m, phenyl ), 7.39 (1H, d, J 8.7, benz 4-H), 7.41-7.46 (2H, m, phenyl 10/10-H), 
12.47 (1H, br s, NH, exchangeable); 13C NMR (DMSO-d6, 75 MHz):  55.5 (OMe), 60.0 (CH2), 
94.9 br, 115.2 (br, benz 5-H), 120.9 br, 127.4 br, 128.4 (phenyl), 128.7 (phenyl), 131.0 (phenyl), 
135.8 br, 146.6 br, 154.3 br, 157.6 (br benz), not all carbon signals observed due to annular 
tautomerism of the benzimidazole system; m/z (ESI) (Found MH+, 303.0804 C15H14N2O3S 
requires MH 303.0798. 
 
1-Methyl-4-[(phenylmethyl)sulfonyl]-benzene 4.14
726
 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of sulfide 4.5 (1.07g, 5.0 mmol) in 
CH2Cl2 (20 mL) and the mixture cooled to 0 C.  A solution of mCPBA (70% mCPBA, 2.71 g, 
11.1 mmol) in CH2Cl2 (40 mL) was added dropwise and the reaction stirred vigorously for 3h.  
The reaction was quenched by addition of saturated aqueous Na2S2O3 (30 mL), the phases were 
separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  The combined organic 
extracts were washed with brine (25 mL), dried (MgSO4), filtered and the solvent remove in 
vacuo.  Purification by column chromatography (eluting with 40% EtOAchexane) followed by 
recrystallization from CHCl3hexane gave the title compound 4.14 (0.48 g, 2.77 mmol, 40%) as 
colourless needles; m.p. 139.3-140.6 C (CHCl3hexane) (lit. 144.0 C from ether);
726 Rf 0.22 
(40% EtOAchexane); 1H NMR (DMSO-d6, 500 MHz): 2.38 (3H, s, tol Me), 4.62 (2H, s, 
CH2), 7.12-7.18 (2H, m, phenyl 8/8-H ), 7.25-7.33 (3H, m, phenyl 9/9-H and 10-H), 7.37 (2H, 
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d, J 8.4, tol H-3/3-H), 7.59 (2H, d, J 8.4, tol H-4/4-H); 13C NMR (DMSO-d6, 125 MHz): 
21.0 (tol Me), 60.8 (CH2), 128.0 (tol C4/4), 128.2 (phenyl C9/9), 128.2 (phenyl C10), 128.8 
(phenyl C7), 129.5 (tol C3/3), 130.9 (phenyl C8/8), 135.6 (tol C2), 144.2 (tol C5); 1H NMR 
(CDCl3 300 MHz): 
  
2.33 (3H, s, tol Me). 4.21 (2H, s, CH2), 7.01 (2H, dd J 7.8 and 1.2, tolyl), 
7.11-7.28 (5H, m, phenyl), 7.42 (2H, dd J 7.8, tolyl), NMR data in accordance with the 
literature;726 m/z (ESI) (Found MH+ 247.0787, C14H14O2S requires 247.0787); 
 
6(5)-Methoxy-2-(methylsulfonyl)-1H-benzimidazole 4.15 
 
Saturated aqueous NaHCO3 (20 mL) was added to a solution of sulfide 4.7 (2.91 g, 15.0 mmol) 
in CH2Cl2 (20 mL) and the mixture cooled to 0 C.  A solution of mCPBA (70% mCPBA, 9.25 
g, 37.5 mmol) in CH2Cl2 (38 mL) and MeOH (2 mL) was added dropwise and the reaction 
stirred vigorously for 3h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 
(30 mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  
The combined organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and 
the solvent remove in vacuo.  Purification by column chromatography (eluting with 5% 
MeOHtOAc) followed by recrystallization from EtOAchexane gave the title compound 
4.15 (5.85 g, 27.8 mmol, 70%) as a colourless powder; m.p. 131.6-134.2 C (from 
EtOAchexane); Rf 0.22 (5% MeOHtOAc) 
1
H NMR (DMSO-d6, 300 MHz:  3.46 (3H, s, 
Me), 3.82 (3H, s, OMe), 7.01 (1H, dd, J 8.9 and 2.3, benz 5-H), 7.10 (1H, br s, benz 7-H), 7.62 
(1H, d, J 8.9, benz 4-H), 13.75 (1H, br s, benz-NH); 13C NMR (DMSO-d6, 75 MHz):  42.6 
(SMe) 55.6 (OMe), 96.6 (br, benz C7), 115.5, (benz C5), 119.2 (br, benz), 137.3 (br, benz), 
148.3 (benz), 157.5 (benz), not all carbon signals observed due to annular tautomerism of the 
benzimidazole system; m/z (ESI) (Found MH+, 227.0491 C9H10N2O3S requires MH 227.0485); 
Anal. Calcd. for C9H10N2O3S (%): C, 47.8; H, 4.45; N, 12.4; Found: C, 47.8; H, 4.50; N, 12.7. 
 
4-Methoxy-3,5-dimethyl-2-([(4-methylphenyl)sulfonyl]methyl)pyridine 4.16 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of sulfide 4.8 (1.37g, 5.00 mmol) 
in CH2Cl2 (20 mL) and the mixture cooled to 0 C.  A solution of mCPBA (70% mCPBA, 2.71 
g, 11.1 mmol) in CH2Cl2 (40 mL) was added dropwise and the reaction stirred vigorously for 
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3h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 (30 mL), the phases 
were separated and the aqueous layer extracted with CH2Cl2 (3  50 mL).  The combined 
organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and the solvent 
remove in vacuo.  Purification by column chromatography (eluting with 80-100% 
EtOAchexane) gave the title compound 4.16 (0.84 g, 2.77 mmol, 55%) as a colourless 
platelets; m.p. 89.7-91.4 C (CHCl3-hexane); Rf 0.40 ( EtOAc); 
1
H NMR (DMSO-d6, 500 
MHz):  2.12 (3H, s, 3-Me), 2.17 (3H, s, 5-Me), 2.38 (3H, s, tol Me), 3.67 (3H, s, pyr OMe), 
4.71 (2H, s, CH2), 7.37 (2H, d, J 8.1, tol 3/3-H), 7.56 (2H, d, J 8.1, tol 4/4-H), 8.08 (1H, s, pyr 
6-H); 13C NMR (DMSO-d6, 125 MHz):  11.3 (pyr 3-Me), 12.9 (pyr 5-Me), 21.0 (tol), 59.7 
(pyr OMe), 61.5 (CH2),125.9 (pyr C5), 127.5 (pyr C3), 128.0 tol C4/4, 129.6 (tol C3/3), 
136.4 (tol C5), 144.3 (tol C2), 147.6 (Pyr C2), 149.0  (pyr C6), 163.6 (pyr C4); m/z (ESI) 
(Found MH+, 306.1170 C16H19NO3S requires MH 306.1158). 
 
1-Methyl-4-(methylsulfonyl)-benzene 4.17
720
 
 
Saturated aqueous NaHCO3 (50 mL) was added to a solution of p-tolyl sulfide (0.67 mL, 0.69 g, 
5.00 mmol) dissolved in CH2Cl2 and the mixture cooled to 0C. A solution of mCPBA (70% 
mCPBA, 2.71 g, 11.1 mmol) in CH2Cl2 (40 mL) was added dropwise and the reaction stirred 
vigorously for 3h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 (25 
mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  20 mL).  The 
combined organic extracts were washed with brine (25 mL), dried (MgSO4), filtered and the 
solvent remove in vacuo.  Purification by column chromatography (eluting with 50-100% 
EtOAchexane) followed by recrystallization from aqueous EtOH gave the title compound 4.17 
(0.48 g, 2.77 mmol, 40%) as colourless platelets; m.p. 82.3-82.9 C (aq EtOH ) (lit. 82.0-
85.0);720 Rf 0.67 (EtOAc); 
1
H NMR (DMSO-d6, 500 MHz): 
 2.40 (3H, s, tol Me), 3.17 (3H, s, 
Me), 7.44 (2H, d, J 8.4, tol 3/3-), 7.81 (2H, d, J 8.4, tol 4/4-); 13C NMR (DMSO-d6, 125 
MHz):  20.8 (tol Me), 43.7 (SMe), 126.9 (tol C4/4), 129.8 (tol C3/3), 138.1 (tol C2), 144.00 
(tol C5); (CDCl3 300 MHz): 
 2.44 (3H, s, tol Me), 3.02 (3H, s, Me), 7.35 (2H, d, J 8.1, tol 
3/3-), 7.81(2H, d, J 8.3, tol 4/4-); 1H NMR (CDCl, 300 MHz): 2.38 (3H, s, tol Me), 2.96 
(3H, s, SMe), 7.29 (2H, d, J 8.2, tolyl), 7.75 (2H, d, J 8.2, tolyl); 13C NMR (CDCl3, 75 MHz):  
21.6 (tol Me), 44.6 (SMe), 127.4 (tolyl), 130.0 (tolyl), 137.8 (tolyl), 144.8 (tolyl)  NMR data in 
accordance with the Lit. data720 
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(S)-6(5)-Methoxy-2-[(phenylmethyl)sulfinyl]-1H-benzimidazole (S)-4.9   
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of sulfide 4.4 (1.35 g, 5.00 mmol) in 
toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The reaction mixture was cooled 
to 30 C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by CHP (80% in cumene, 
924 L, 0.76 g, 5.00 mmol).  The reaction mixture was stirred at 30C and followed by TLC.  
After 4 h no sulfide starting material was observed by TLC and the reaction was quenched by 
addition of aqueous NH4OH (12.5% NH3, 10 mL).  The mixture was stirred vigorously for 30 
min then allowed to sit for 45 min.  The reaction mixture was filtered through a pad of Celite 
and theCelite pad washed with aqueous NH4OH (12.5% NH3, 3 mL) and CH2Cl2 (4 
mLThe phases of the filtrate were separated and the organic phased extracted with 
aqueous NH4OH (12.5% NH3, 3 mL).  CH2Cl2 (50 mL) was added to the combined 
aqueous extracts and AcOH added with caution until a pH of ~ 8 was achieved.  The phases 
were separated and the aqueous phase extracted with CH2Cl2 (3 mL).  The combined 
organic extracted were washed with saturated aqueous NaHCO3 (20 mL), then brine (mL), 
dried (MgSO4), filtered and the solvent removed in vacuo.  Column chromatography (eluting 
with 50% EtOAcCH2Cl2) gave the title compound (S)-4.9 (0.29 g, 0.85 mmol, 17%, 95% ee) 
as a colourless gum; Rf 0.42 (EtOAc); 
1
H NMR (DMSO-d6, 300 MHz): 3.80 (3H, s, benz 
OMe), 4.48 and 4.67 (2H, AB-system, J 12.8, CH2), 6.92 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.07 
(1H, br s, benz 7-H), 7.11-7.22 (2H, m, phenyl-H), 7.23-7.35 (3H, m, phenyl-H), 7.54 (1H, s, J 
8.9, benz 4-H), 13.26 (1H, br s, NH exchangeable); 13C NMR (DMSO-d6, 75 MHz):  55.5 
(OMe), 59.5 (CH2), 128.1, 128.4 (phenyl), 129.9, 130.4 (phenyl), not all carbon signals 
observed due to annular tautomerism of the benzimidazole system; m/z (ESI) (Found MH+, 
368.1045 C17H18N3NaO3S requires MH 368.1039); HPLC: tR (Rminor) = 55.7 min, tR (Smajor) = 
61.9 min, [Chiracel OD-H; flow rate 1.0 mL min-1; 5% IPAhexane; 20 C] 
 
(S)-1-Methyl-4-[(phenylmethyl)sulfinyl]-benzene (S)-4.10
449
 
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of sulfide 4.5 (1.07 g, 5.00 mmol) in 
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toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The reaction mixture was cooled 
to 30 C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by CHP (80% in cumene, 
924 L, 0.76 g, 5.00 mmol).  After 2 h stirring at 30C the reaction was quenched by addition of 
H2O (10 mL).  The mixture was stirred vigorously for 30 min then allowed to sit for 45 min.  
The reaction mixture was filtered through a pad of Celite and the Celite pad washed with H2O 
(2 mL) and CH2Cl2 (4 mLThe phases of the filtrate were separated and the aqueous 
phase extracted with CH2Cl2 (3 mL).  The combined organic extracted were washed with 
brine (mL), dried (MgSO4), filtered and the solvent removed in vacuo.  Column 
chromatography (eluting with 0-50% EtOAchexane) gave the title compound (S)-4.10 (0.46 g, 
40%, 16% ee) as colourless crystalline solid.  Recrystallization from CH2Cl2hexane afforded 
the sulfoxide (S)-4.10 as colourless needles (0.28 g, 1.2 mmol, 24%, 19% ee); m.p. 133.7-135.0 
C (CHCl3hexane) (lit. 165.3.7-165.80 C);
449 Rf 0.36 (50% EtOAchexane); 
1
H NMR 
(DMSO-d6, 300 MHz): 2.36 (3H, s, tol Me), 4.04 and 4.20 (2H, 2  d, J 12.7 CH2), 7.07-7.13 
(2H, m, phenyl 8/8-H ), 7.24-7.30 (3H, m, phenyl 9/9-H and 10-H), 7.32 (2H, d, J 8.4, tol 3/3-
H), 7.41 (2H, d, J 8.4, tol 4/4-H); 13C NMR (DMSO-d6, 75 MHz):  20.9 (tol Me), 61.8 (CH2), 
124.3 (C4/4), 127.7 (phenyl C10), 128.1 (phenyl C9/9), 129.4 (tol C3/3), 130.3 (phenyl 
C8/8), 130.5 (phenyl C7), 140.3 (tol C5), 140.7 (tol C2), NMR data not comparable to the 
literature due to the use of a different solvent (CDCl3)
449
 but is comparable to the data 
previously described here for the racemic sulfoxide; m/z (ESI) (Found MH+ 231.0842, 
C14H14OS requires MH 231.0838); HPLC: tR (Rminor) = 25.0 min), (Smajor) tR = 30.6 min, 
[Chiracel OD-H; flow rate 1.0 mL min-1; 5% IPAhexane; 20 C] 
 
(S)-6(5)-Methoxy-2-(methylsulfinyl)-1H-benzimidazole (S)-4.11
623
 
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of sulfide 4.7 (1.35 g, 5.00 mmol) in 
toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The reaction mixture was cooled 
to 30 C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by CHP (80% in cumene, 
924 L, 0.76 g, 5.00 mmol).  After 4 h stirring at 30 C the reaction was quenched by addition 
of aqueous NH4OH (12.5% NH3, 10 mL).  The mixture was stirred vigorously for 30 min then 
allowed to sit for 45 min.  The reaction mixture was filtered through a pad of Celite and the 
Celite pad washed with aqueous NH4OH (12.5% NH3, 3 mL) and CH2Cl2 (4 
mLThe phases of the filtrate were separated and the organic phased extracted with 
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aqueous NH4OH (12.5% NH3, 3 mL).  CH2Cl2 (50 mL) was added to the combined 
aqueous extracts and AcOH added with caution until a pH of ~ 8 was achieved.  The phases 
were separated and the aqueous phase extracted with CH2Cl2 (3 mL).  The combined 
organic extracted were washed with saturated aqueous NaHCO3 (20 mL), then brine (mL), 
dried (MgSO4), filtered and the solvent removed in vacuo.  Column chromatography (eluting 
with 50% EtOAcCH2Cl2) gave the title compound 4.11 (0.63 g, 30.0 mmol, 60%, 95% ee) as a 
colourless gum; Rf 0.14 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 300 MHz):  (3H, s, 
SMe), 3.80 (3H, s, benz OMe), 6.92 (1H, dd, J 8.9 and 2.3, benz 5-H), 7.10 (1H, br s, J 2.3, 
benz 7-H), 7.55 (1H, d, J 8.9, benz 4-H), (13.36 (1H, br s, NH exchangeable); 13C NMR 
(DMSO-d6, 75 MHz):  40.2 (SMe), 55.5 (benz OMe), 113.4 (benz ), 154.2 (benz), 156.7(benz), 
not all carbon signals observed due to annular tautomerism of the benzimidazole system, NMR 
data not comparable to the literature due to the use of a different solvent (MeOD)623 but is 
comparable to the data previously described here for the racemic sulfoxide  
()-4.11; m/z (ESI) (Found MH+, 211.0534 C9H10N2O2S requires MH 211.0535); HPLC: tR 
(Rminor) = 55.7 min, tR (Smajor) = 61.9 min, [Chiracel AD-H; flow rate 0.5 mL min
-1; 5% 
IPAhexane; 20 C] 
 
(S)-4-Methoxy-3,5-dimethyl-2-([(4-methylphenyl)sulfinyl]methyl)pyridine (S)-4.12 
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of sulfide 4.8 (1.37 g, 5.00 mmol) in 
toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The reaction mixture was cooled 
to 30 C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by CHP (80% in cumene, 
924 L, 0.76 g, 5.00 mmol).  After 2 h stirring at 30C the reaction was quenched by addition of 
H2O (10 mL).  The mixture was stirred vigorously for 30 min then allowed to sit for 45 min.  
The reaction mixture was filtered through a pad of Celite and the Celite pad washed with H2O 
(2  50 mL) and CH2Cl2 (4 mLThe phases of the filtrate were separated and the aqueous 
phase extracted with CH2Cl2 (3 mL).  The combined organic extracts were washed with 
brine (mL), dried (MgSO4), filtered, and the solvent removed in vacuo.  Column 
chromatography (eluting with 0-2.5% MeOHEtOAc) gave the title compound (S)-4.12 (0.87 g, 
30.0 mmol, 60%, 20% ee) as colourless crystalline solid.  Recrystallization from 
CH2Cl2hexane afforded the sulfoxide (S)-4.12 as colourless needles (0.58 g, 40%, 27% ee); 
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m.p. 90.3-91.9 C (CH2Cl2hexane); Rf 0.14 ( EtOAc); 
1
H NMR (DMSO-d6, 300 MHz): 
   
2.02 (3H, s, 3-Me), 2.19 (3H, s, 5-Me), 2.36 (3H, s, tol Me), 3.66 (3H, s, pyr OMe), 4.17 and 
4.36 (2H, AB-system, J 12.8, CH2), (2H, d, J 8.2, tol 3/3-), 7.44 (2H, d, J 8.3, tol 4/4-) 
8.20 (1H, s, pyr 6-H); 13C NMR (DMSO-d6, 125 MHz):  11.1 (pyr 3-Me), 12.9 (pyr 5-
Me), 20.9 (tol Me), 59.6 (pyr OMe), 62.8 (CH2), 124.1 (tol C4/4, 125.2 (pyr C5), 126.5 (pyr 
C3), 129.6 (tol C3/3), 141.0 (tol C2), 141.1 (tol C5), 149.0 (pyr C6, 150.1 (Pyr C2163.4 
(Pyr C4m/z (ESI) (Found MH+, 290.1211 C16H19NO2S requires MH 296.1209); HPLC: tR 
(Smajor) = 24.6 min, tR (Rminor) = 30.3 min, [Chiracel OD-H; flow rate 1.0 mL min
-1; 5% 
IPAhexane; 20 C] 
 
(S)-1-Methyl-4-(methylsulfinyl)-benzene (S)-1.48
153, 727
 
 
Ti(OiPr)4 (444 L, 0.43 g, 1.50 mmol), (S,S)-DET (513 L, 0.62 g, 3.00 mmol) and H2O (9.0 
L, 9.01 mg, 0.50 mmol) were added to a suspension of p-tolyl sulfide (1.07 g, 5.00 mmol) in 
toluene (7.5 mL) and the mixture heated at 54 C for 50 min.  The reaction mixture was cooled 
to 30 C and DIPEA (261 L, 0.19 g, 1.5 mmol) was added, followed by CHP (80% in cumene, 
924 L, 0.76 g, 5.00 mmol).  After 2 h stirring at 30 C the reaction was quenched by addition 
of H2O (10 mL).  The mixture was stirred vigorously for 30 min then allowed to sit for 45 min.  
The reaction mixture was filtered through a pad of Celite and the Celite pad washed with H2O 
(2  50 mL) and CH2Cl2 (4 mLThe phases of the filtrate were separated and the aqueous 
phase extracted with CH2Cl2 (3 mL).  The combined organic extracted were washed with 
brine (mL), dried (MgSO4), filtered and the solvent removed in vacuo.  Column 
chromatography (eluting with 50-100% EtOAchexane) gave the title compound (S)-1.48 (0.49 
g, 3.15 mmol, 63%, 6% ee) as colourless waxy solid; m.p. 40.2-41.2 C (hexane) (lit. 74.5-
75.5);727 Rf 0.08 (50% EtOAchexane); 
1
H NMR (DMSO-d6, 300 MHz):  2.36 (3H, s, tol Me), 
2.69 (3H, s, SMe), 7.37 (2H, d, J 8.1, tol 3/3-), 7.57 (2H, d, J 8.3, tol 4/4-); 13C NMR 
(DMSO-d6, 125 MHz):  20.8 (tol Me), 43.3 (SMe), 123.5 (tol C4/4), 129.7 (tol C3/3), 140.5 
(tol C2), 143.2 (tol C5) NMR data not comparable to the literature due to the use of a different 
solvent (CDCl3)
153 but is comparable to the data previously described here for the racemic 
sulfoxide; m/z (ESI) (Found MH+, 155.0524 C8H10OS requires MH 155.0525); HPLC: tR 
(Rminor) = 26.5 min, (Smajor) tR = 29.4 min [Chiracel OD-H; flow rate 0.5 mL min
1; 5% EtOH 
hexane; 20 C] 
 
264 
 
4-Methoxy-3,5-dimethylpyridine-2-carboxaldehyde 6.1
706
 
 
To a stirred solution of 3,5-dimethyl-2-hydroxymethyl-4-methoxypyridine (0.330 g, 2.00 mmol) 
in CHCl3 (25 mL)  was added activated MnO2 (2.65 g, 30 mmol, 15 equiv).  The resulting 
mixture was stirred at rt for 19 h and then was filtered through a pad of Celite and the pad 
washed with CHCl3 (3  15 mL).  The organic materials were combined and the the solvent 
removed in vacuo to give the title compound 6.1 (0.282 g, 1.70 mmol, 85%) as a yellow oil; Rf 
0.48 (50% EtOAchexane); 1H NMR (CDCl3, 500 MHz):  2.35 (3H, s, pyr 5-Me), 2.56 (3H, 
s, pyr 3-Me), 3.81 (3H, s, pyr OMe),  8.45 (1H, s, pyr 6-H), 10.13 (1H, s, 7-H); 13C NMR 
(CDCl3, 125MHz): 10.5 (pyr 3-Me), 13.8 (pyr 5-Me), 60.1 (pyr OMe), 129.3 (pyr C3), 130.5 
(pyr C5), 150.2 (pyr C2), 150.4 (pyr C6), 164.8 (pyr C4), 195.0 (C7) NMR data in accordance 
with the literature data.706 
 
6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1-methyl-1H-
benzimidazole (NMe Pyrmetazole) 6.3 
 
Pyrmetazole 3.17 (6.56 g. 20.0 mmol) was suspended in a solution of NaOH (0.80 g, 20 mmol) 
in H2O (0.8 mL).  MeI (1.2 mL, 2.69 g 20 mmol) was added whereupon the mixture became 
homogenous, and the mixture stirred at 40 C for 1 h.  The reaction mixture was allowed to cool 
to rt and then diluted with H2O (10 mL) and CHCl3 (10 mL).  The phases were separated and 
the aqueous layer extracted with CHCl3 (3  10 mL).  The combined organic materials were 
washed with brine (20 mL), dried (MgSO4), filtered, and the solvent removed in vacuo.  
Column chromatography (eluting with 0.0-2.5 % MeOHCHCl3) followed by trituation with 
Et2O gave the title product 6.3 as a colourless amorphous powder (4.09 g, 12.0 mmol, 60%) as 
mixture of tautomers in the ratio of 48:52 5-OMe:6-OMe; m.p. 105.2-106.9 C (from Et2O); Rf 
0.22 (CHCl3); 
1
H NMR (DMSO-d6, 500 MHz): 5-OMe isomer: 2.19 (3H, s, pyr 5- Me), 2.26 
(3H, s, pyr 3-Me), 3.62 (3H, s, NMe), 3.72 (3H, s, pyr OMe), 3.78 (3H, s, benz OMe), 4.68 
(2H, s, CH2), 6.82 (1H, dd, J 8.7 and 2.4, benz 6-H), 7.14 (1H, d, J 2.4, benz 4-H), 7.34 (1H, d, 
J 8.7, benz 7-H), 8.17 (1H, s, pyr 6-H); 6-OMe isomer: 2.19 (3H, s, pyr 5-Me), 2.25 (3H, s, 
pyr 3-Me), 3.62 (3H, s, NMe), 3.71 (3H, s, pyr OMe), 3.81 (3H, s, benz OMe), 4.64 (2H, s, 
CH2), 6.78 (1H, dd, J 8.7 and 2.4, benz 5-H), 7.06 (1H, d, J 2.4, benz 7-H), 7.45 (1H, d, J 8.7, 
benz 4-H), 8.17 (1H, s, pyr 6-H); 13C NMR (DMSO-d6, 125 MHz): 5-OMe isomer: 10.8 (pyr 
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3-Me), 12.9 (pyr 5-Me), 29.9 (NMe), 37.3 (CH2), 55.6 (benz 6-OMe), 59.8 (pyr OMe), 93.5 
(benz C7), 110.7 (benz C5), 118.1 (benz C4), 124.5 (pyr C3), 125.1 (pyr C5), 137.3 (benz C), 
143.6 (benz C), 148.7 (pyr C6), 149.5 (benz C2), 153.9 (pyr C2), 155.6 (benz C6), 163.4 (pyr 
C4); 6-OMe isomer:10.8 (pyr 3-Me), 12.9 (pyr 5-Me), 29.8 (NMe), 37.2 (CH2), 55.4 
(benz 5-OMe), 59.8 (pyr OMe), 100.8 (benz C4), 109.7 (benz C7), 110.4 (benz C6), 124.5 (pyr 
C3), 125.1 (pyr C5), 131.3 (benz C), 143.6 (benz C), 148.7 (pyr C6), 151.1 (benz C2), 153.9 
(pyr C2),  155.4 (benz C5), 163.4 (pyr C4); m/z (ESI) (Found MH+, 344.1441. C18H21N3O2S 
requires MH 344.1427) 
 
()-6(5)-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-methyl-1H-
benzimidazole (()-NMe Omeprazole) 5.22562, 708 
 
Method A: methylation of Omeprazole 1.1562, 708 
Omeprazole ()-1.1 (10.4 g. 30.0 mmol) was suspended in a solution of NaOH (1.20 g, 30 
mmol) in H2O (5 mL) and MeCN 5 mL.  MeI (1.87 mL, 4.26 g 30 mmol) was added and the 
mixture stirred at 40 C for 1 h.  The reaction mixture was allowed to cool to rt and then diluted 
with H2O (20 mL) and CHCl3 (20 mL).  The phases were separated and the aqueous layer 
extracted with CHCl3 (3  30 mL).  The combined organic materials were washed with brine (20 
mL), dried (MgSO4), filtered, and the solvent removed in vacuo to give the title compound 5.22 
as a 50:50 mixture of 5-OMe:6-OMe tautomers (10.3 g, 28.7 mmol, 93%) as a colourless 
viscous gum that dried as a glassy foam under vacuum.  No further purification was required. 
m.p. 112.8-114.2 C (Et2O); Rf 0.32 (5% MeOHEtOAc); 
1
H NMR (DMSO-d6, 500 MHz): 
two isomers 5-OMe:6-OMe 5-OMe isomer:  2.16 (3H, s, pyr 5-Me), 2.18 (3H, s, pyr Me), 
3.66 (3H, s, pyr Me), 3.80 (3H, s, benz  OMe), 3.91 (3H, s, NMe), 4.84 and 4.94  (2H, 2d, J 
13.8, CH2), 7.02 (1H, dd, J 8.9 and 2.4, benz 6-H), 7.25 (1H, d, J 2.4, benz 4-H), 7.56 (1H, d, J 
8.9, benz 7-H), 8.11 (1H, s, pyr 6-H); 6-OMe isomer:  2.16 (3H, s, pyr 5-Me), 2.18 (3H, s, 
pyr 3-Me), 3.66 (3H, s, pyr OMe), 3.85 (3H, s, benz OMe), 3.93 (3H, s, NMe), 4.82 and 4.94  
(2H, 2d, J 13.7, CH2), 6.93 (1H, dd, J 8.9 and 2.4, benz 5-H), 7.21 (1H, d, J 2.4, benz 7-H), 
7.61 (1H, d, J 8.9, benz 4-H), 8.12 (1H, s, pyr 6-H); 13C NMR (DMSO-d6, 125 MHz): 5-OMe 
isomer:  11.0 (pyr 3-Me), 12.8 (pyr 5-Me), 30.4 (NMe), 55.5 (benz 5-OMe), 58.4 (CH2), 
59.7 (pyr OMe), 101.7 (benz C4), 111.4 (benz C7), 114.7 (benz C6), 125.4 (pyr C3), 126.1 
(pyr C5), 130.9 (benz C3 or C7), 142.3(benz C3 or C7), 148.9 (pyr C6), 150.1 (pyr C2), 
152.5 (benz C2), 156.3 (benz C5), 163.3 (pyr C4); 6-OMe isomer:  11.0 (pyr 3-Me), 12.8 
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(pyr 5-Me), 30.4 (NMe), 55.7 (benz 6-OMe), 58.4 (CH2), 59.7 (pyr OMe), 93.4 (benz C7), 
113.4 (benz C5), 120.8 (benz 4H), 125.4 (pyr C3), 126.1 (pyr C5), 135.9 (benz C3 or C7), 
137.1 (benz C3 or C7), 148.9 (pyr C6), 150.1 (pyr C2), 151.4 (benz C2), 157.3 (benz C6), 
163.3 (pyr C4); 1H NMR (CDCl3, 500 MHz): mixture of tautomers A:B ratio 50:50:  2.20 
(3H, s, pyr 5”-Me), 2.26 and 2.27 (3H, s, pyr 3”-Me), 3.68 and 3.69 (3H, s), 3.85 and 3.86 (3H, 
s), 3.93 and 3.94 (3H, s), 4.93 (2 H, m, CH2), tautomer A: 6.78 (d, J 2.4), 6.96 (dd, J 8.9 and 
2.4), 7.66 (d, J 8.9), tautomer B: 7.02 (1H, dd, J 8.9 and 2.4), 7.25 (d, J 2.4), 7.28 (d, J 8.9), 
8.11 (1H s, pyr 6”-H) NMR data in accordance with the literature;562 m/z (ESI) (Found MH+, 
360.1384 C18H21N3O3S requires MH 360.1376) 
 
Method B: oxidation of NMe Pyrmetazole 6.3 
Saturated aqueous NaHCO3 (10 mL) was added to a solution of NMe Pyrmetazole 6.3 (0.69 g, 
2.00 mmol) in CH2Cl2 (10 mL) and the mixture cooled to 0 C.  A solution of mCPBA (75% 
mCPBA, 0.46 g, 2.00 mmol) in CH2Cl2 (90 mL) was added dropwise and the reaction stirred 
vigorously for 2h.  The reaction was quenched by addition of saturated aqueous Na2S2O3 (20 
mL), the phases were separated and the aqueous layer extracted with CH2Cl2 (3  10 mL).  The 
combined organic extracts were washed with brine (10 mL), dried with MgSO4, filtered and the 
solvent removed in vacuo.  Column chromatography (eluting with 2.5-5.0 % MeOHEtOAc)  
gave the title compound (5.22 as a mixture of tautomers in the ratio of 41:59 5-OMe:6-OMe.  
Recrystallization was achieved by addition of the minimum amount of CH2Cl2 followed by 
dropwise addition of Et2O to induce precipitation.  The precipitate was collected by vacuum 
filtration and washed with Et2O to give the title compound ()-5.22 as colourless microcrystals 
(0.24 g, 0.66 mmol, 32%) as mixture of tautomers in the ratio of 13:87 5-OMe:6-OMe.  NMR 
characterization data as stated above.  
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8.3 NMR studies 
 
1
H NMR studies of the catalyst components (chapter 4) 
 
1H NMR studies were conducted using NMR tubes that had been dried under vacuum for 24h.  
Glassware in which sample were prepared were dried in an oven for 24h; prior to use they were 
stoppered and removed from the oven and allowed to cool.  CDCl3 was dried using 4Å 
molecular sieves and was passed through a plug of alumina immediately prior to use.  All 
solutions were filtered through a plug of cotton wool prior to NMR analysis.  Although samples 
were not prepared under strictly anhydrous conditions, exposure to environmental moisture was 
minimized by preparation under a blanket of nitrogen and rapid analysis in addition to the use of 
dried glassware and Parafilm sealed NMR tubes.  
 
NMR studies of the catalyst components: Ti(O
i
Pr)4 + Pyrmetazole sulfide 3.17 (section 
4.7.1) 
 
Pyrmetazole sulfide 3.17 (32.9 mg, 0.10 mmol) was dissolved in CDCl3 (0.75 mL) which had 
been passed through alumina to remove residual water.  The solution was transferred to the 
NMR tube and Ti(OiPr)4 was added according to the quantities given in Table 8.1.  The tubes 
were sealed using Parafilm and the contents mixed for 30 s.  Characterization by 1H NMR was 
performed within 10 min of preparation for each sample.   
 
Ti(O
i
Pr)4 / equiv Ti(O
i
Pr)4 / mmol Ti(O
i
Pr)4 / L 
0.2 0.02 5.9 
0.4 0.04 11.8 
0.6 0.06 17.8 
0.8 0.08 23.7 
1.0 0.1 29.6 
Table 8.1 Volumes of Ti(O
i
Pr)4 employed in sample preparation for NMR studies on the interaction of sulfide 
3.17 and Ti(O
i
Pr)4 
 
NMR studies of the catalyst components: Ti(O
i
Pr)4 concentration studies (section 4.7.2.1) 
 
Solutions of Ti(O
i
Pr)4 in CDCl3 and Tol-d8 were prepared in accordance with the quantities 
given in Table 8.2 using 0.75 mL of solvent.  The tubes were sealed using Parafilm and the 
contents mixed for 30 s.  Characterization by 1H NMR was performed within 10 min of 
preparation for each sample.   
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[Ti(O
i
Pr)4 ] / mol L
-1
 Ti(O
i
Pr)4 / mmol Ti(O
i
Pr)4 / L 
0.30 0.23 66.6 
0.25 0.19 55.5 
0.20 0.15 44.4 
0.15 0.11 33.3 
0.10 0.08 22.2 
0.05 0.04 11.1 
0.025 0.02 5.6 
0.01 0.01 2.2 
Table 8.2 Volumes of Ti(O
i
Pr)4 employed in sample preparation for NMR studies on the effects of 
concentration 
 
NMR studies of the catalyst components: Ti(O
i
Pr)4 + DET + H2O (section 4.7.3) 
 
Ti(OiPr)4: DET:H2O = 1:2:0 
Ti(OiPr)4 (29.6 L, 0.1 mmol) and  DET (34.3 L, 0.2 mmol) were added to CDCl3 (1.0 mL) in 
an NMR tube.  The tube was sealed using Parafilm and the contents mixed for 30 s.  
Characterization by 
1
H NMR was performed within 10 min of preparation 
 
Ti(OiPr)4: DET:H2O = 1:2:1 
Ti(OiPr)4 (59.2 L, 0.2 mmol),  DET (68.5 L, 0.4 mmol), and H2O (3.6 L, 0.2 mmol) were 
added to CDCl3 (2.0 mL); the solution was thoroughly mixed and 1.0 mL removed for analysis.  
The tube was sealed using Parafilm and the contents mixed for 30 s.  Characterization by 1H 
NMR was performed within 10 min of preparation 
 
Ti(OiPr)4: DET:H2O = 1:4:0 
Ti(OiPr)4 (29.6 L, 0.1 mmol) and  DET (68.5 L, 0.4 mmol) were added to CDCl3 (1.0 mL) in 
an NMR tube.  The tube was sealed using Parafilm and the contents mixed for 30 s.  
Characterization by 1H NMR was performed within 10 min of preparation 
 
Ti(OiPr)4: DET:H2O = 3:6:1 
Ti(OiPr)4 (88.8 L, 0.3 mmol),  DET (102.8 L, 0.6 mmol), and H2O (1.8 L, 0.1 mmol) were 
added to CDCl3 (3.0 mL); the solution was thoroughly mixed and 1.0 mL removed for analysis.  
The tube was sealed using Parafilm and the contents mixed for 30 s.  Characterization by 1H 
NMR was performed within 10 min of preparation 
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Evaluation of chiral tartrates for use as chiral shift reagents (chapter 5) 
 
(S)-BINOL vs. (S,S)-DET as chiral shift reagents (section 5.3.1) 
(S)-BINOL (11.4 mg, 0.04 mmol) was added to a solution of Omeprazole ()-1.1 (13.8 mg, 0.04 
mmol) in CDCl3 (0.75 mL).  The solution was mixed and passed through a plug of cotton wool 
into an NMR tube.  Characterization by 1H NMR was performed within 10 min of preparation 
 
(S,S)-DET (8.24 mg, 6.8 L, 0.04 mmol) was added to a solution of Omeprazole ()-1.1 (13.8 
mg, 0.04 mmol) in CDCl3 (0.75 mL).  The solution was mixed and passed through a plug of 
cotton wool into an NMR tube.  Characterization by 1H NMR was performed within 10 min of 
preparation 
 
Choice of NMR solvent (section 5.3.2) 
Solutions of Omeprazole ()-1.1 (17.3 mg, 0.05 mmol) and (S,S)-DET (10.3 mg, 8.6 L, 0.05 
mmol) were prepared in 0.75 mL in the following solvents: acetone-d6, benzene-d6, CDCl3, 
DCM-d2, D2O, DMSO-d6, MeOD, and Tol-d8.  The solutions were mixed and passed through a 
plug of cotton wool into an NMR tube.   
 
Host-guest ratio (section 5.3.3) 
Solutions of Omeprazole ()-1.1 (34.5 mg, 0.1 mmol) and (S,S)-DET or (S,S)-DIPT were 
prepared in CDCl3 (1.0 mL) according to the quantities of the tartrates given in Table 8.3.  The 
solutions were mixed and passed through a plug of cotton wool into an NMR tube. 
 
equiv of tartrate (S,S)-DET /  mL (S,S)-DIPT  /  L 
0.2 3.4 - 
0.4 6.8 8.4 
0.6 10.3 -  
0.8 13.7 -  
1.0 17.1 21.0 
2.0 34.2 41.9 
5.0 85.6 104.9 
Table 8.3 Quantities of DET or DIPT employed in order to investigate the Host-guest ratios 
 
(R,R)-DMT was added to solution of Omeprazole ()-1.1 (34.5 mg, 0.1 mmol) according to the 
quantities given in Table 8.4.  The solutions were mixed and passed through a plug of cotton 
wool into an NMR tube. 
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equiv of tartrate (R,R)-DMT / mg 
0.25 4.45 
0.50 8.91 
0.75 13.36 
1.00 17.81 
2.00 35.63 
Table 8.4 Quantities of DMT employed in order to investigate the Host-guest ratios 
 
Determination of enantiomeric excess (section 5.3.4) 
(S,S)-DET as the chiral shift reagent 
Samples of Esomeprazole (S)-1.1 of varying % ee were prepared by mixing the appropriate 
amounts of racemic Omeprazole with Esomeprazole of high optical purity (> 99.5% ee, 
obtained through neutralization of the Na-salt of Esomeprazole).  Solutions were prepared using 
103.6 mg (0.3 mmol) of the sulfoxide mixtures in 0.8 mL of CDCl3. 0.1 mL of each solution 
was removed for analysis by HPLC; chiral HPLC showed these mixtures to have enantiomeric 
purities of 0, 20, 40, 54, 60, 81, and > 99.5% ee.  (S,S)-DET was added to the remainder of the 
sulfoxide solutions according to the quantities given in Table 8.5 
 
equiv of tartrate (S,S)-DET /  L 
0.25 11.2 
0.50 22.5 
0.75 33.7 
1.00 44.9 
2.00 89.8 
5.00 224.6 
Table 8.5 Quantities of DET used with solutions of Esomeprazole of varying ee to compare with ee 
determination performed by chiral HPLC 
 
(R,R)-DMT as the chiral shift reagent 
Samples of Esomeprazole (S)-1.1 of varying % ee were prepared by mixing the appropriate 
amounts of racemic Omeprazole with Esomeprazole of high optical purity (> 99.5% ee, 
obtained through neutralization of the Na-salt of Esomeprazole); chiral HPLC showed these 
mixtures to have enantiomeric purities of 0, 21, 41, 50, 63, 81, and > 99.5% ee.  Solutions were 
prepared using 69.1 mg (0.20 mmol) of the sulfoxide mixtures in 0.7 mL of CDCl3.  (R,R)-DMT 
was added to the sulfoxide solutions according to the quantities given in Table 8.6 
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equiv of tartrate (R,R)-DMT  /  mg 
0.25 8.91 
0.50 17.81 
0.75 26.72 
1.00 35.63 
2.00 71.26 
Table 8.6 Quantities of DMT used with solutions of Esomeprazole of varying ee to compare with ee 
determination performed by chiral HPLC 
 
Selective deuteration of Omeprazole and related compounds (chapter 6) 
 
Deuteration of Na-Omeprazole in aprotic, and protic solvents (section 6.3.1 and 6.3.2) 
Solutions of Na-Omeprazole 3.36 were typically prepared using 40.0 mg of the Omeprazole salt 
dissolved in 0.75 mL of DMSO-d6, MeOD, or D2O.  All solutions for NMR analysis were mixed 
thoroughly and passed through a plug of cotton wool to remove any solid material.   
 
Deuteration of Omeprazole and related compounds in protic solvents (section 6.3.2) 
Solutions were prepared using 0.2 mmol of each of the following compounds suspended or 
dissolved in 0.8 mL of D2O or MeOD: Omeprazole 1.1 (69.1 mg), Pyrmetazole sulfide 3.17 
(65.9 mg), Omeprazole sulfone 4.1 (72.3 mg), sulfoxide 4.9 (57.3 mg), and sulfoxide 4.12 (57.9 
mg).  NaOD (14.24 M in D2O) or DCl (11.68 M in D2O) was added in accordance with the 
quantities given in Table 8.7.  All solutions for NMR analysis were mixed thoroughly and 
passed through a plug of cotton wool to remove any solid material.   
 
equiv mmol DCl /L NaOD /L
0 0.0 0.0 0.0 
1 0.20 17.1 14.00 
2 0.40 34.2 28.1 
3 0.60 51.4 42.1 
4 0.80 68.5 56.2 
5 1.00 85.6 70.2 
Table 8.7 Quantities of DCl or NaOD added to Omeprazole 1.1 in D2O or MeOD to prepared samples for 
1
H 
NMR analysis across a range of pH condition 
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1.1 XRD data for Omeprazole 1.1 
 
Table 1 Crystal data and structure refinement for JS04_07_Cu. 
Identification code JS04_07_Cu 
Empirical formula C17H19N3O3S 
Formula weight 345.41 
Temperature/K 99.8(6) 
Crystal system triclinic 
Space group P-1 
a/Å 9.6371(5) 
b/Å 10.1691(6) 
c/Å 10.4608(6) 
α/° 90.477(5) 
β/° 112.162(5) 
γ/° 115.682(6) 
Volume/Å
3
 837.30(8) 
Z 2 
ρcalcmg/mm
3
 1.370 
m/mm
-1
 1.897 
F(000) 364.0 
Crystal size/mm
3
 0.17 × 0.08 × 0.06 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 9.32 to 133.14° 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -12 ≤ l ≤ 12 
Reflections collected 12305 
Independent reflections 2860 [Rint = 0.0584, Rsigma = 0.0457] 
Data/restraints/parameters 2860/0/245 
Goodness-of-fit on F
2
 1.058 
Final R indexes [I>=2σ (I)] R1 = 0.0523, wR2 = 0.1336 
Final R indexes [all data] R1 = 0.0734, wR2 = 0.1506 
Largest diff. peak/hole / e Å
-3
 0.36/-0.38 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS04_07_Cu. Ueq is defined as 1/3 of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1A 13675(4) 4596(4) 6504(5) 54.9(11) 
O2A 13404(3) 5739(3) 6995(3) 49.8(7) 
C3 11821(4) 5322(4) 6879(4) 58.7(10) 
C4 11635(4) 6461(4) 7432(4) 58.1(9) 
C5 10119(4) 6227(4) 7403(4) 59.0(9) 
C6 8737(4) 4791(3) 6789(3) 52.6(8) 
C7 8926(3) 3666(3) 6224(3) 51.5(8) 
C8 10474(3) 3865(4) 6243(3) 53.3(8) 
N9 7334(3) 2429(3) 5660(3) 49.2(7) 
C10 6307(3) 2878(3) 5902(3) 51.4(8) 
N11 7067(3) 4271(3) 6591(3) 56.1(7) 
S12 4107.5(9) 1735.8(8) 5429.5(9) 50.8(3) 
O13 3912(2) 322(2) 5960(2) 50.9(6) 
C14 3481(4) 1263(4) 3566(3) 52.5(8) 
C15 1567(3) 273(3) 2821(3) 43.9(7) 
N16 676(3) 534(3) 3411(3) 49.9(7) 
C17 -1019(4) -253(4) 2766(4) 56.0(9) 
C18 -1896(3) -1310(4) 1522(4) 51.9(8) 
C19 -934(3) -1582(3) 949(3) 46.2(7) 
C20 849(3) -797(3) 1605(3) 44.1(7) 
C21 -3820(4) -2097(5) 802(5) 79.6(13) 
O22 -1728(3) -2596(2) -303(2) 55.3(6) 
C23 -2077(5) -4081(4) -110(4) 70.5(11) 
C24 1889(4) -1116(4) 993(4) 60.1(9) 
C1B 13490(20) 8570(20) 8450(30) 63(7) 
O2B 13466(13) 7326(13) 7771(13) 38(3) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS04_07_Cu. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1A 36.4(17) 42.6(19) 75(3) 10.5(19) 17.6(18) 14.5(15) 
O2A 24.6(11) 40.4(13) 63.7(18) 5.7(11) 9.3(11) 6.2(9) 
C3 28.7(14) 65(2) 49(2) 21.6(17) 3.6(14) 5.3(14) 
C4 40.9(16) 42.7(17) 49(2) 1.1(15) 2.0(14) -0.3(13) 
C5 37.7(16) 49.0(18) 47(2) -0.7(15) 2.8(14) -2.4(13) 
C6 39.0(15) 45.9(17) 38(2) -2.8(14) 6.3(14) -0.4(13) 
C7 30.6(14) 50.3(17) 38.7(19) 8.6(14) 5.9(13) -2.7(13) 
C8 32.2(14) 52.5(17) 46(2) 11.8(15) 7.5(13) 3.7(13) 
N9 32.0(12) 44.0(14) 39.5(16) -3.3(12) 9.2(11) -3.5(11) 
C10 30.8(14) 50.8(17) 36.5(19) -7.5(14) 7.8(13) -4.9(12) 
N11 37.0(13) 50.9(15) 42.0(17) -8.1(12) 9.5(12) -4.7(11) 
S12 31.4(4) 47.4(4) 43.5(5) -8.5(3) 12.1(3) -3.1(3) 
O13 32.4(10) 51.2(12) 48.6(14) 1.8(10) 17.4(9) 2.6(9) 
C14 31.9(14) 50.6(17) 43(2) -1.9(14) 12.5(13) -4.4(12) 
C15 30.9(13) 38.9(14) 39.3(18) 2.3(13) 11.8(12) 0.2(11) 
N16 34.9(12) 43.9(13) 48.4(17) -1.6(12) 13.6(12) 3.4(10) 
C17 35.4(15) 60.7(19) 57(2) 6.8(17) 18.2(15) 11.2(14) 
C18 29.3(14) 53.6(17) 45(2) 6.4(15) 9.5(13) 2.1(12) 
C19 32.5(13) 42.3(15) 36.1(18) 3.9(13) 8.7(12) -0.4(12) 
C20 32.4(13) 40.6(15) 35.4(17) 4.5(13) 10.4(12) 0.8(11) 
C21 31.3(16) 100(3) 68(3) 7(2) 13.0(17) 5.1(17) 
O22 38.9(10) 50.8(12) 36.4(13) 0.1(10) 7.8(9) -5.1(9) 
C23 70(2) 49.2(19) 47(2) -5.8(16) 15.8(18) -2.0(16) 
C24 40.3(16) 71(2) 40(2) -5.2(16) 14.2(14) 5.0(15) 
C1B 23(9) 40(11) 90(20) -5(11) 16(10) -5(8) 
O2B 26(6) 47(7) 32(8) 5(5) 13(5) 10(5) 
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Table 4 Bond Lengths for JS04_07_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
C1A O2A 1.427(4)   S12 C14 1.800(3) 
O2A C3 1.349(4)   C14 C15 1.522(4) 
C3 C4 1.398(5)   C15 N16 1.335(4) 
C3 C8 1.410(4)   C15 C20 1.394(4) 
C4 C5 1.362(5)   N16 C17 1.338(4) 
C5 C6 1.404(4)   C17 C18 1.386(5) 
C6 C7 1.394(5)   C18 C19 1.391(5) 
C6 N11 1.387(4)   C18 C21 1.515(4) 
C7 C8 1.408(5)   C19 C20 1.405(4) 
C7 N9 1.384(3)   C19 O22 1.380(4) 
N9 C10 1.352(4)   C20 C24 1.511(4) 
C10 N11 1.322(4)   O22 C23 1.432(4) 
C10 S12 1.776(3)   C1B O2B 1.43(3) 
S12 O13 1.506(2)         
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Table 5 Bond Angles for JS04_07_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 O2A C1A 116.2(3)   O13 S12 C10 107.11(14) 
O2A C3 C4 114.2(3)   O13 S12 C14 105.52(15) 
O2A C3 C8 122.6(4)   C15 C14 S12 109.5(2) 
C4 C3 C8 123.2(3)   N16 C15 C14 115.0(3) 
C5 C4 C3 121.7(3)   N16 C15 C20 124.3(2) 
C4 C5 C6 117.4(4)   C20 C15 C14 120.7(3) 
C7 C6 C5 120.6(3)   C15 N16 C17 117.7(3) 
N11 C6 C5 129.0(3)   N16 C17 C18 123.9(3) 
N11 C6 C7 110.3(3)   C17 C18 C19 117.1(3) 
C6 C7 C8 123.6(3)   C17 C18 C21 121.1(3) 
N9 C7 C6 106.0(3)   C19 C18 C21 121.7(3) 
N9 C7 C8 130.4(3)   C18 C19 C20 120.8(3) 
C7 C8 C3 113.5(3)   O22 C19 C18 120.1(2) 
C10 N9 C7 105.2(3)   O22 C19 C20 119.1(3) 
N9 C10 S12 125.2(2)   C15 C20 C19 116.1(3) 
N11 C10 N9 115.2(3)   C15 C20 C24 123.3(2) 
N11 C10 S12 119.5(3)   C19 C20 C24 120.6(3) 
C10 N11 C6 103.2(3)   C19 O22 C23 113.1(2) 
C10 S12 C14 96.55(14)           
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Table 6 Torsion Angles for JS04_07_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
C1A O2A C3 C4 177.2(3)   N11 C10 S12 O13 -127.8(3) 
C1A O2A C3 C8 -3.3(5)   N11 C10 S12 C14 123.8(3) 
O2A C3 C4 C5 -179.8(3)   S12 C10 N11 C6 179.2(2) 
O2A C3 C8 C7 -179.7(3)   S12 C14 C15 N16 31.9(4) 
C3 C4 C5 C6 -0.2(5)   S12 C14 C15 C20 -149.0(3) 
C4 C3 C8 C7 -0.2(5)   O13 S12 C14 C15 71.5(3) 
C4 C5 C6 C7 -0.6(5)   C14 C15 N16 C17 176.9(3) 
C4 C5 C6 N11 -178.1(3)   C14 C15 C20 C19 -175.9(3) 
C5 C6 C7 C8 1.0(5)   C14 C15 C20 C24 3.7(5) 
C5 C6 C7 N9 -177.6(3)   C15 N16 C17 C18 -0.4(5) 
C5 C6 N11 C10 176.6(4)   N16 C15 C20 C19 3.1(5) 
C6 C7 C8 C3 -0.6(5)   N16 C15 C20 C24 -177.3(3) 
C6 C7 N9 C10 0.5(4)   N16 C17 C18 C19 1.9(5) 
C7 C6 N11 C10 -1.1(4)   N16 C17 C18 C21 -176.4(3) 
C7 N9 C10 N11 -1.3(4)   C17 C18 C19 C20 -0.8(5) 
C7 N9 C10 S12 -178.9(2)   C17 C18 C19 O22 -178.5(3) 
C8 C3 C4 C5 0.6(5)   C18 C19 C20 C15 -1.5(4) 
C8 C7 N9 C10 -178.0(3)   C18 C19 C20 C24 178.9(3) 
N9 C7 C8 C3 177.7(3)   C18 C19 O22 C23 -90.2(4) 
N9 C10 N11 C6 1.5(4)   C20 C15 N16 C17 -2.2(5) 
N9 C10 S12 O13 49.7(3)   C20 C19 O22 C23 92.1(3) 
N9 C10 S12 C14 -58.8(3)   C21 C18 C19 C20 177.4(3) 
C10 S12 C14 C15 -178.7(2)   C21 C18 C19 O22 -0.3(5) 
N11 C6 C7 C8 179.0(3)   O22 C19 C20 C15 176.3(3) 
N11 C6 C7 N9 0.3(4)   O22 C19 C20 C24 -3.3(4) 
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS04_07_Cu. 
 
Atom x y z U(eq) 
H1AA 12993 4242 5507 82 
H1AB 13361 3786 6980 82 
H1AC 14853 4991 6696 82 
H4 12570 7402 7830 70 
H5 10005 6989 7775 71 
H8 10596 3108 5872 64 
H9 7100(40) 1550(40) 5200(40) 46(9) 
H14A 3802 2165 3192 63 
H14B 4057 744 3401 63 
H17 -1646 -81 3176 67 
H21A -4244 -3116 906 119 
H21B -4189 -2065 -182 119 
H21C -4245 -1608 1225 119 
H23A -2586 -4729 -1009 106 
H23B -2844 -4425 335 106 
H23C -1037 -4086 476 106 
H24A 2729 -195 928 90 
H24B 1158 -1741 69 90 
H24C 2442 -1615 1592 90 
H1BA 12445 8597 7929 94 
H1BB 14425 9477 8475 94 
H1BC 13618 8472 9392 94 
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Table 8 Atomic Occupancy for JS04_07_Cu. 
Atom Occupancy   Atom Occupancy   Atom Occupancy 
C1A 0.848(4)   H1AA 0.848(4)   H1AB 0.848(4) 
H1AC 0.848(4)   O2A 0.848(4)   C1B 0.152(4) 
H1BA 0.152(4)   H1BB 0.152(4)   H1BC 0.152(4) 
O2B 0.152(4)           
 
 
A10 
 
1.2 XRD data for Pyrmetazole sulfide 3.17 
 
Table 1 Crystal data and structure refinement for JS04_68C_Mo. 
Identification code JS04_68C_Mo 
Empirical formula C17H19N3O2S 
Formula weight 329.41 
Temperature/K 119.99(10) 
Crystal system orthorhombic 
Space group P212121 
a/Å 6.8937(5) 
b/Å 13.9553(12) 
c/Å 16.8423(15) 
α/° 90.00 
β/° 90.00 
γ/° 90.00 
Volume/Å
3
 1620.3(2) 
Z 4 
ρcalcg/cm
3
 1.350 
μ/mm-1 0.213 
F(000) 696.0 
Crystal size/mm
3
 0.35 × 0.08 × 0.07 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.32 to 52.72 
Index ranges -7 ≤ h ≤ 8, -15 ≤ k ≤ 17, -21 ≤ l ≤ 19 
Reflections collected 7430 
Independent reflections 3241 [Rint = 0.0670, Rsigma = 0.0894] 
Data/restraints/parameters 3241/0/212 
Goodness-of-fit on F
2
 1.032 
Final R indexes [I>=2σ (I)] R1 = 0.0530, wR2 = 0.1126 
Final R indexes [all data] R1 = 0.0637, wR2 = 0.1190 
Largest diff. peak/hole / e Å
-3
 0.56/-0.26 
Flack parameter 0.02(11) 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS04_68C_Mo. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 -18855(5) 1500(3) 83(2) 37.6(9) 
O2 -17621(3) 762.7(17) 381.1(13) 32.0(6) 
C3 -15950(4) 570(2) -37.0(18) 22.8(7) 
C4 -14849(4) -190(2) 253.1(17) 23.0(7) 
C5 -13175(4) -416(2) -167.9(17) 18.2(6) 
C6 -12624(4) 70(2) -863.3(17) 18.5(6) 
C7 -13738(4) 840(2) -1119.4(17) 21.8(6) 
C8 -15402(4) 1089(2) -708.5(18) 24.5(7) 
N9 -11792(3) -1116.9(17) -63.5(14) 19.4(5) 
C10 -10525(4) -1031.2(19) -677.2(17) 19.1(6) 
N11 -10929(3) -333.7(16) -1172.7(14) 20.0(5) 
S12 -8666.3(12) -1875.6(5) -743.6(5) 27.5(2) 
C13 -7113(4) -1280(2) -1446.8(16) 18.1(6) 
C14 -5560(4) -1964(2) -1720.1(16) 17.8(6) 
N15 -5365(3) -2780.0(17) -1301.9(13) 18.2(5) 
C16 -3963(4) -3386(2) -1520.0(16) 20.4(6) 
C17 -2728(4) -3253(2) -2160.6(16) 18.0(6) 
C18 -3002(4) -2404(2) -2593.1(16) 19.5(6) 
C19 -4411(4) -1740.5(19) -2378.9(15) 16.7(6) 
C20 -1196(5) -3969(2) -2375.9(18) 25.9(7) 
O21 -1929(3) -2254.6(15) -3272.4(12) 25.5(5) 
C22 -108(5) -1821(3) -3133(2) 35.3(8) 
C23 -4684(5) -822(2) -2832.0(17) 24.0(7) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS04_68C_Mo. The 
Anisotropic displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 24.6(16) 47(2) 41.5(19) -2.1(16) -0.4(17) 19.8(18) 
O2 28.3(12) 38.7(13) 29.0(12) 5.2(10) 2.4(10) 9.7(12) 
C3 15.3(15) 28.0(16) 25.0(15) -12.3(13) 0.4(13) 2.3(14) 
C4 20.3(15) 29.7(17) 19.1(15) 1.1(12) -1.7(13) 0.6(14) 
C5 15.7(14) 18.8(15) 20.1(15) -0.7(12) -3.3(12) 1.1(13) 
C6 15.7(14) 20.0(14) 19.9(15) 0.5(12) -1.1(12) -2.0(12) 
C7 18.0(14) 20.1(14) 27.3(15) 2.7(12) 0.0(14) 1.8(14) 
C8 24.1(16) 19.7(14) 29.5(16) 0.1(14) -6.0(15) 4.2(13) 
N9 14.9(12) 23.6(13) 19.7(12) 7.6(10) 0.8(10) 0.2(11) 
C10 15.7(14) 21.1(14) 20.7(14) 3.5(13) 3.4(13) 0.8(12) 
N11 18.7(13) 17.6(12) 23.6(13) 3.5(10) 3.9(11) 2.5(11) 
S12 21.1(4) 25.3(4) 36.0(4) 12.5(4) 10.1(4) 8.5(4) 
C13 17.7(14) 17.1(14) 19.6(14) 2.1(11) 3.2(12) 0.6(13) 
C14 18.0(14) 20.2(14) 15.0(13) -2.4(12) -2.9(12) -0.1(13) 
N15 18.9(13) 20.4(12) 15.4(11) 0.1(10) -0.3(10) 2.4(11) 
C16 21.4(15) 21.0(14) 18.7(14) 1.6(11) 0.2(13) 0.3(13) 
C17 17.7(14) 17.3(14) 19.0(14) -4.3(12) -1.2(12) 0.5(13) 
C18 17.4(14) 25.1(15) 16.0(14) -2.0(12) 2.6(12) -7.5(14) 
C19 21.7(14) 16.6(13) 11.8(13) -0.1(11) -2.6(11) -2.6(13) 
C20 24.2(16) 24.1(15) 29.3(16) -2.6(13) 6.0(15) 2.0(15) 
O21 25.5(12) 30.9(11) 20.0(11) -1.1(9) 6.6(9) -4(1) 
C22 26.2(17) 42(2) 37.1(19) 3.7(16) 4.1(15) -9.2(19) 
C23 27.4(17) 22.6(15) 22.1(15) 5.9(13) 1.3(14) 2.3(15) 
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Table 4 Bond Lengths for JS04_68C_Mo. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 O2 1.427(4)   S12 C13 1.800(3) 
O2 C3 1.377(3)   C13 C14 1.506(4) 
C3 C4 1.393(4)   C14 N15 1.346(4) 
C3 C8 1.395(4)   C14 C19 1.399(4) 
C4 C5 1.391(4)   N15 C16 1.335(4) 
C5 C6 1.406(4)   C16 C17 1.387(4) 
C5 N9 1.377(3)   C17 C18 1.404(4) 
C6 C7 1.389(4)   C17 C20 1.498(4) 
C6 N11 1.398(4)   C18 C19 1.390(4) 
C7 C8 1.384(4)   C18 O21 1.378(3) 
N9 C10 1.359(4)   C19 C23 1.503(4) 
C10 N11 1.312(3)   O21 C22 1.414(4) 
C10 S12 1.744(3)         
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Table 5 Bond Angles for JS04_68C_Mo. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 O2 C1 117.4(2)   C10 S12 C13 99.62(13) 
O2 C3 C4 115.2(3)   C14 C13 S12 109.34(19) 
O2 C3 C8 122.7(3)   N15 C14 C13 116.6(2) 
C4 C3 C8 122.2(3)   N15 C14 C19 123.2(3) 
C5 C4 C3 116.5(3)   C19 C14 C13 120.2(2) 
C4 C5 C6 122.6(3)   C16 N15 C14 117.6(2) 
N9 C5 C4 132.1(3)   N15 C16 C17 125.0(3) 
N9 C5 C6 105.2(2)   C16 C17 C18 115.7(2) 
C7 C6 C5 118.9(3)   C16 C17 C20 122.2(2) 
C7 C6 N11 131.1(3)   C18 C17 C20 122.2(2) 
N11 C6 C5 110.0(2)   C19 C18 C17 121.5(2) 
C8 C7 C6 119.8(3)   O21 C18 C17 119.1(3) 
C7 C8 C3 120.0(3)   O21 C18 C19 119.3(2) 
C10 N9 C5 106.6(2)   C14 C19 C23 121.5(3) 
N9 C10 S12 117.49(19)   C18 C19 C14 117.0(2) 
N11 C10 N9 114.4(2)   C18 C19 C23 121.6(3) 
N11 C10 S12 128.1(2)   C18 O21 C22 113.8(2) 
C10 N11 C6 103.9(2)           
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Table 6 Torsion Angles for JS04_68C_Mo. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 O2 C3 C4 -176.7(3)   N11 C10 S12 C13 18.2(3) 
C1 O2 C3 C8 2.6(4)   S12 C10 N11 C6 175.8(2) 
O2 C3 C4 C5 178.5(2)   S12 C13 C14 N15 -12.5(3) 
O2 C3 C8 C7 -177.8(3)   S12 C13 C14 C19 167.3(2) 
C3 C4 C5 C6 -1.7(4)   C13 C14 N15 C16 -178.2(2) 
C3 C4 C5 N9 -178.7(3)   C13 C14 C19 C18 179.7(2) 
C4 C3 C8 C7 1.4(4)   C13 C14 C19 C23 -0.1(4) 
C4 C5 C6 C7 3.4(4)   C14 N15 C16 C17 -2.1(4) 
C4 C5 C6 N11 -177.7(3)   N15 C14 C19 C18 -0.6(4) 
C4 C5 N9 C10 177.1(3)   N15 C14 C19 C23 179.7(3) 
C5 C6 C7 C8 -2.6(4)   N15 C16 C17 C18 0.8(4) 
C5 C6 N11 C10 0.4(3)   N15 C16 C17 C20 -179.4(3) 
C5 N9 C10 N11 0.7(3)   C16 C17 C18 C19 0.8(4) 
C5 N9 C10 S12 -176.20(19)   C16 C17 C18 O21 -175.2(2) 
C6 C5 N9 C10 -0.4(3)   C17 C18 C19 C14 -0.8(4) 
C6 C7 C8 C3 0.3(4)   C17 C18 C19 C23 178.9(3) 
C7 C6 N11 C10 179.1(3)   C17 C18 O21 C22 -87.1(3) 
C8 C3 C4 C5 -0.8(4)   C19 C14 N15 C16 2.0(4) 
N9 C5 C6 C7 -178.9(2)   C19 C18 O21 C22 96.8(3) 
N9 C5 C6 N11 0.0(3)   C20 C17 C18 C19 -179.1(2) 
N9 C10 N11 C6 -0.7(3)   C20 C17 C18 O21 5.0(4) 
N9 C10 S12 C13 -165.4(2)   O21 C18 C19 C14 175.1(2) 
C10 S12 C13 C14 -169.37(19)   O21 C18 C19 C23 -5.2(4) 
N11 C6 C7 C8 178.8(3)             
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS04_68C_Mo. 
Atom x y z U(eq) 
H1A -19312 1326 -436 56 
H1B -18142 2090 51 56 
H1C -19942 1581 433 56 
H4 -15214 -528 705 28 
H7 -13366 1187 -1566 26 
H8 -16155 1602 -880 29 
H9 -11740 -1528 316 23 
H13A -7870 -1065 -1898 22 
H13B -6521 -724 -1201 22 
H16 -3803 -3939 -1219 24 
H20A 42 -3747 -2191 39 
H20B -1157 -4045 -2942 39 
H20C -1491 -4574 -2133 39 
H22A 545 -1722 -3629 53 
H22B 663 -2230 -2801 53 
H22C -296 -1215 -2873 53 
H23A -5943 -819 -3075 36 
H23B -3705 -772 -3235 36 
H23C -4577 -289 -2475 36 
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1.3 XRD data for Omeprazole sulfone 4.1 
 
Table 1 Crystal data and structure refinement for JS02_99_Cu. 
Identification code JS02_99_Cu 
Empirical formula C18H23N3O5S 
Formula weight 393.45 
Temperature/K 100.0(4) 
Crystal system triclinic 
Space group P-1 
a/Å 8.9134(4) 
b/Å 10.1893(5) 
c/Å 11.0478(6) 
α/° 94.295(4) 
β/° 110.952(5) 
γ/° 91.060(4) 
Volume/Å
3
 933.30(8) 
Z 2 
ρcalcmg/mm
3
 1.400 
m/mm
-1
 1.852 
F(000) 416.0 
Crystal size/mm
3
 0.17 × 0.16 × 0.11 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 8.6 to 133.04° 
Index ranges -10 ≤ h ≤ 10, -12 ≤ k ≤ 9, -13 ≤ l ≤ 13 
Reflections collected 6452 
Independent reflections 3189 [Rint = 0.0178, Rsigma = 0.0203] 
Data/restraints/parameters 3189/0/257 
Goodness-of-fit on F
2
 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0325, wR2 = 0.0839 
Final R indexes [all data] R1 = 0.0344, wR2 = 0.0854 
Largest diff. peak/hole / e Å
-3
 0.45/-0.32 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS02_99_Cu. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 339(2) 10671.5(17) 13577.6(16) 24.1(4) 
O2 -907.1(14) 9781.6(12) 12717.3(11) 25.7(3) 
C3 -586.9(19) 9086.5(16) 11744.5(15) 18.2(3) 
C4 834.7(18) 9220.5(15) 11524.2(15) 17.2(3) 
C5 960.0(17) 8375.7(15) 10507.4(14) 14.8(3) 
C6 -261.5(18) 7450.5(15) 9744.3(14) 15.8(3) 
C7 -1709.8(18) 7359.2(16) 9975.0(15) 18.3(3) 
C8 -1851.9(18) 8181.4(16) 10966.9(15) 19.3(3) 
N9 2191.0(16) 8232.2(13) 10047.1(12) 15.2(3) 
C10 1663.6(18) 7259.7(15) 9056.7(14) 15.1(3) 
N11 215.2(15) 6750.7(13) 8825.8(12) 16.8(3) 
S12 2876.4(4) 6736.7(4) 8171.8(3) 14.88(12) 
O13 4415.4(13) 7435.1(11) 8817.5(11) 20.8(3) 
O14 2043.8(14) 6868.1(11) 6814.2(10) 22.1(3) 
C15 3059.6(18) 5029.1(15) 8420.0(14) 15.1(3) 
C16 4085.9(18) 4418.6(15) 7720.4(14) 14.5(3) 
N17 5676.0(15) 4580.1(13) 8376.9(12) 15.8(3) 
C18 6658.2(18) 4076.3(15) 7809.0(15) 16.9(3) 
C19 6140.3(19) 3383.1(15) 6585.8(15) 17.2(3) 
C20 4480.7(19) 3206.2(15) 5942.4(14) 15.9(3) 
C21 3405.0(18) 3737.8(15) 6486.2(14) 15.6(3) 
C22 7318(2) 2857.8(18) 6007.3(16) 25.3(4) 
C23 3710(2) 3119.6(18) 3658.5(15) 25.1(4) 
O24 3888.3(14) 2423.4(11) 4781.8(10) 19.7(2) 
C25 1611.0(19) 3552.3(17) 5791.4(15) 22.1(4) 
O26 5205.1(17) 10082.6(14) 8525.3(14) 36.6(3) 
C27 4516(2) 10074.0(19) 7146.2(18) 30.4(4) 
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 Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS02_99_Cu. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 27.8(9) 21.9(9) 21.6(8) -5.8(6) 9.1(7) 0.3(7) 
O2 25.9(6) 27.7(7) 25.1(6) -9.4(5) 13.7(5) -3.2(5) 
C3 22.0(8) 18.6(8) 15.5(7) 0.9(6) 8.5(6) 2.9(6) 
C4 17.2(7) 15.7(8) 17.0(7) -0.2(6) 4.6(6) -1.2(6) 
C5 14.4(7) 14.8(7) 15.6(7) 3.8(6) 5.5(6) 1.6(6) 
C6 17.3(7) 16.0(8) 13.9(7) 2.7(6) 5.0(6) 0.5(6) 
C7 15.5(7) 20.5(8) 17.8(8) 0.0(6) 5.3(6) -3.1(6) 
C8 15.5(7) 23.7(9) 20.8(8) 2.8(6) 8.8(6) -0.6(6) 
N9 13.5(6) 15.3(7) 16.4(6) -0.3(5) 5.3(5) -2.2(5) 
C10 16.9(7) 15.3(8) 14.0(7) 0.8(6) 7.0(6) 1.4(6) 
N11 16.7(6) 18.3(7) 15.7(6) 0.1(5) 6.5(5) -0.5(5) 
S12 16.14(19) 15.3(2) 15.01(19) 0.44(13) 8.04(15) -0.04(14) 
O13 18.8(6) 18.2(6) 27.7(6) -1.9(4) 12.2(5) -3.2(4) 
O14 28.1(6) 24.4(6) 16.7(6) 4.7(4) 10.8(5) 5.9(5) 
C15 16.4(7) 15.5(8) 13.2(7) 0.5(5) 5.5(6) -1.0(6) 
C16 17.6(7) 13.3(7) 13.2(7) 2.8(5) 6.1(6) 0.2(6) 
N17 17.4(6) 16.4(7) 13.4(6) 2.4(5) 5.1(5) 0.5(5) 
C18 16.0(7) 18.5(8) 16.4(7) 4.8(6) 5.3(6) 2.3(6) 
C19 22.4(8) 15.9(8) 15.9(7) 6.2(6) 9.2(6) 4.3(6) 
C20 25.0(8) 11.1(7) 12.2(7) 1.4(5) 7.3(6) 0.1(6) 
C21 18.8(8) 13.1(8) 14.8(7) 1.8(6) 6.0(6) -1.6(6) 
C22 26.7(9) 32(1) 20.6(8) 5.1(7) 11.8(7) 10.0(7) 
C23 32.4(9) 28.2(9) 13.6(8) 2.5(6) 7.0(7) -1.6(7) 
O24 30.3(6) 16.2(6) 12.9(5) -1.4(4) 8.8(5) -0.4(5) 
C25 19.6(8) 26.0(9) 18.7(8) -5.8(6) 6.1(6) -3.7(7) 
O26 36.9(7) 26.3(7) 36.3(7) 4.0(6) 1.3(6) -12.5(6) 
C27 30.6(9) 28(1) 34.1(10) 2.6(8) 13.5(8) 0.6(8) 
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Table 4 Bond Lengths for JS02_99_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 O2 1.427(2)   S12 O14 1.4338(11) 
O2 C3 1.3605(19)   S12 C15 1.7831(15) 
C3 C4 1.379(2)   C15 C16 1.509(2) 
C3 C8 1.418(2)   C16 N17 1.342(2) 
C4 C5 1.401(2)   C16 C21 1.400(2) 
C5 C6 1.404(2)   N17 C18 1.336(2) 
C5 N9 1.3704(19)   C18 C19 1.392(2) 
C6 C7 1.405(2)   C19 C20 1.395(2) 
C6 N11 1.389(2)   C19 C22 1.499(2) 
C7 C8 1.373(2)   C20 C21 1.399(2) 
N9 C10 1.361(2)   C20 O24 1.3806(18) 
C10 N11 1.312(2)   C21 C25 1.507(2) 
C10 S12 1.7628(15)   C23 O24 1.4364(19) 
S12 O13 1.4440(12)   O26 C27 1.424(2) 
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Table 5 Bond Angles for JS02_99_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 O2 C1 117.08(13)   O13 S12 C15 109.85(7) 
O2 C3 C4 124.10(15)   O14 S12 C10 109.73(7) 
O2 C3 C8 113.83(14)   O14 S12 O13 118.51(7) 
C4 C3 C8 122.06(14)   O14 S12 C15 108.89(7) 
C3 C4 C5 115.49(14)   C16 C15 S12 109.97(10) 
C4 C5 C6 123.44(14)   N17 C16 C15 114.67(13) 
N9 C5 C4 130.75(14)   N17 C16 C21 123.63(14) 
N9 C5 C6 105.81(13)   C21 C16 C15 121.69(13) 
C5 C6 C7 119.65(14)   C18 N17 C16 117.90(13) 
N11 C6 C5 110.23(13)   N17 C18 C19 124.29(14) 
N11 C6 C7 130.11(14)   C18 C19 C20 116.36(14) 
C8 C7 C6 117.60(14)   C18 C19 C22 121.18(15) 
C7 C8 C3 121.73(14)   C20 C19 C22 122.46(14) 
C10 N9 C5 105.50(13)   C19 C20 C21 121.40(14) 
N9 C10 S12 121.31(11)   O24 C20 C19 119.24(13) 
N11 C10 N9 115.28(13)   O24 C20 C21 119.24(14) 
N11 C10 S12 123.41(12)   C16 C21 C25 122.07(14) 
C10 N11 C6 103.18(12)   C20 C21 C16 116.38(14) 
C10 S12 C15 103.00(7)   C20 C21 C25 121.53(14) 
O13 S12 C10 105.73(7)   C20 O24 C23 113.81(12) 
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Table 6 Torsion Angles for JS02_99_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
C1 O2 C3 C4 -2.0(2)   N11 C10 S12 O14 57.19(15) 
C1 O2 C3 C8 177.31(14)   N11 C10 S12 C15 -58.64(14) 
O2 C3 C4 C5 177.39(14)   S12 C10 N11 C6 179.74(11) 
O2 C3 C8 C7 -177.27(15)   S12 C15 C16 N17 83.19(14) 
C3 C4 C5 C6 0.3(2)   S12 C15 C16 C21 -97.03(15) 
C3 C4 C5 N9 -178.83(15)   O13 S12 C15 C16 -67.48(12) 
C4 C3 C8 C7 2.0(2)   O14 S12 C15 C16 63.81(12) 
C4 C5 C6 C7 1.1(2)   C15 C16 N17 C18 -179.31(13) 
C4 C5 C6 N11 -179.43(14)   C15 C16 C21 C20 -179.47(13) 
C4 C5 N9 C10 179.42(16)   C15 C16 C21 C25 -1.1(2) 
C5 C6 C7 C8 -1.0(2)   C16 N17 C18 C19 -0.7(2) 
C5 C6 N11 C10 0.01(16)   N17 C16 C21 C20 0.3(2) 
C5 N9 C10 N11 -0.19(18)   N17 C16 C21 C25 178.68(15) 
C5 N9 C10 S12 -179.82(11)   N17 C18 C19 C20 -0.8(2) 
C6 C5 N9 C10 0.18(16)   N17 C18 C19 C22 179.41(14) 
C6 C7 C8 C3 -0.5(2)   C18 C19 C20 C21 2.0(2) 
C7 C6 N11 C10 179.39(16)   C18 C19 C20 O24 -173.99(13) 
C8 C3 C4 C5 -1.8(2)   C19 C20 C21 C16 -1.8(2) 
N9 C5 C6 C7 -179.57(14)   C19 C20 C21 C25 179.79(15) 
N9 C5 C6 N11 -0.12(16)   C19 C20 O24 C23 -87.77(17) 
N9 C10 N11 C6 0.11(17)   C21 C16 N17 C18 0.9(2) 
N9 C10 S12 O13 5.68(14)   C21 C20 O24 C23 96.12(17) 
N9 C10 S12 O14 -123.21(13)   C22 C19 C20 C21 -178.16(14) 
N9 C10 S12 C15 120.96(13)   C22 C19 C20 O24 5.8(2) 
C10 S12 C15 C16 -179.76(10)   O24 C20 C21 C16 174.21(13) 
N11 C6 C7 C8 179.70(15)   O24 C20 C21 C25 -4.2(2) 
N11 C10 S12 O13 -173.92(13)             
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS02_99_Cu. 
 
Atom x y z U(eq) 
H1A 599 11325 13092 36 
H1B 1276 10193 13996 36 
H1C -21 11095 14224 36 
H4 1655 9831 12017 21 
H7 -2542 6763 9474 22 
H8 -2803 8144 11133 23 
H15A 3545 4925 9343 18 
H15B 2002 4585 8095 18 
H18 7760 4197 8261 20 
H22A 7340 3388 5330 38 
H22B 6999 1964 5650 38 
H22C 8370 2885 6671 38 
H23A 3438 2502 2903 38 
H23B 4702 3593 3782 38 
H23C 2870 3729 3539 38 
H25A 1195 2885 6172 33 
H25B 1379 3287 4888 33 
H25C 1116 4367 5871 33 
H27A 3929 9250 6787 46 
H27B 5354 10184 6803 46 
H27C 3799 10782 6919 46 
H9 3070(20) 8660(20) 10335(19) 19(5) 
H26 5100(30) 9300(30) 8770(30) 58(8) 
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1.4 XRD data for K-Omeprazole 3.38 
 
Table 1 Crystal data and structure refinement for JS04_20_Cu_a. 
Identification code JS04_20_Cu_a 
Empirical formula C19H26KN3O5S 
Formula weight 447.59 
Temperature/K 99.9(6) 
Crystal system monoclinic 
Space group P21 
a/Å 10.7149(5) 
b/Å 7.3404(3) 
c/Å 13.7741(5) 
α/° 90.00 
β/° 98.193(4) 
γ/° 90.00 
Volume/Å
3
 1072.30(7) 
Z 2 
ρcalcmg/mm
3
 1.386 
m/mm
-1
 3.382 
F(000) 472.0 
Crystal size/mm
3
 0.14 × 0.05 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 6.48 to 133.16° 
Index ranges -9 ≤ h ≤ 12, -7 ≤ k ≤ 8, -16 ≤ l ≤ 16 
Reflections collected 4086 
Independent reflections 2845 [Rint = 0.0375, Rsigma = 0.0632] 
Data/restraints/parameters 2845/3/280 
Goodness-of-fit on F
2
 1.025 
Final R indexes [I>=2σ (I)] R1 = 0.0360, wR2 = 0.0803 
Final R indexes [all data] R1 = 0.0422, wR2 = 0.0837 
Largest diff. peak/hole / e Å
-3
 0.31/-0.29 
Flack parameter 0.031(13) 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS04_20_Cu_a. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
K1 4304.9(6) 1518.9(10) 4933.0(5) 16.00(17) 
O2 3486(2) 4972(3) 5229.6(18) 17.9(5) 
S3 2190.8(8) 5468.1(11) 5439.6(6) 14.94(19) 
C4 1242(3) 5997(4) 4291(2) 14.7(7) 
N5 -5(3) 6084(4) 4266(2) 16.0(6) 
C6 -395(3) 6522(5) 3290(2) 15.3(7) 
C7 682(3) 6620(5) 2806(2) 16.7(7) 
N8 1745(3) 6292(4) 3471(2) 16.7(6) 
C9 -1604(3) 6811(5) 2780(2) 17.7(7) 
C10 -1715(4) 7187(5) 1793(3) 19.5(8) 
C11 -635(4) 7252(5) 1305(3) 19.6(8) 
C12 562(4) 7003(5) 1790(3) 19.8(8) 
O13 -924(3) 7599(4) 306.5(18) 27.7(6) 
C14 101(4) 7587(7) -245(3) 31.7(10) 
N15 4476(3) 8670(4) 6444(2) 16.0(6) 
C16 5459(4) 8893(5) 7146(3) 18.5(8) 
C17 5439(4) 8506(5) 8142(3) 19.9(8) 
C18 4290(3) 7889(5) 8383(2) 17.7(8) 
C19 3245(3) 7621(5) 7679(2) 16.1(7) 
C20 3384(4) 8047(5) 6702(3) 15.9(7) 
C21 6585(4) 8756(6) 8888(3) 28.7(9) 
O22 4230(3) 7446(4) 9354.5(17) 23.0(6) 
C23 3744(4) 8903(6) 9891(3) 31.8(10) 
C24 2008(3) 6962(5) 7943(3) 19.0(8) 
C25 2326(3) 7835(5) 5867(3) 16.4(7) 
O26 1772(2) 1486(4) 4474.4(17) 21.8(5) 
C27 1219(3) 1440(6) 3474(3) 25.3(8) 
O28 6035(3) 3320(4) 6314.6(19) 20.8(6) 
C29 5718(4) 3758(6) 7250(3) 25.5(9) 
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 Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS04_20_Cu_a. The 
Anisotropic displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
K1 14.3(4) 16.9(4) 16.8(3) 0.4(3) 2.0(2) 0.8(3) 
O2 10.4(12) 20.3(14) 22.1(12) -3.9(10) -1.0(9) 1.7(10) 
S3 13.3(4) 16.5(4) 14.4(4) 0.4(4) 0.0(3) -0.4(3) 
C4 14.2(18) 15.4(18) 13.7(16) 0.2(12) -1.4(12) -1.8(13) 
N5 14.3(15) 16.2(16) 17.2(14) -0.3(11) 0.9(11) -1.9(11) 
C6 16.2(17) 12.5(15) 16.4(16) 0.7(15) -0.3(12) -1.5(17) 
C7 19.5(18) 12.8(16) 17.9(16) -1.7(15) 3.0(12) -0.4(16) 
N8 15.1(15) 18.4(15) 16.6(14) -0.2(13) 1.8(10) -1.4(13) 
C9 14.9(18) 19.0(19) 19.1(17) -1.5(14) 1.7(13) -1.1(15) 
C10 14.9(19) 22(2) 20.5(18) -0.4(14) -1.0(13) 0.5(14) 
C11 25(2) 18.4(18) 14.9(17) -1.5(14) 2.2(14) 0.1(15) 
C12 21(2) 24(2) 14.8(17) -2.8(13) 4.3(14) 1.4(15) 
O13 25.3(15) 43.5(16) 13.6(13) 5.1(12) 0.3(10) 4.4(13) 
C14 29(2) 48(3) 19(2) 8.8(19) 6.0(16) 3(2) 
N15 17.8(16) 14.3(14) 15.9(15) -2.0(12) 3.1(12) -1.4(12) 
C16 16(2) 16.5(18) 23.5(19) 1.8(15) 5.9(15) 1.4(15) 
C17 20(2) 16.9(17) 20.9(19) -2.1(15) -1.9(15) 4.2(15) 
C18 24(2) 18.1(18) 10.5(16) 0.4(13) 1.2(13) 2.7(15) 
C19 21.3(19) 12.3(16) 14.9(16) -0.3(14) 2.7(13) 2.3(15) 
C20 18.5(19) 12.8(17) 15.8(18) -0.4(13) 0.6(14) 0.6(14) 
C21 28(2) 30(2) 26(2) 0.9(17) -3.1(16) -2.7(19) 
O22 28.9(15) 25.7(13) 13.9(13) 3.6(11) 1.3(10) 2.0(12) 
C23 45(3) 32(2) 18.5(19) -5.9(17) 6.1(17) 1(2) 
C24 21(2) 17.5(19) 19.2(18) 1.5(14) 4.4(14) -2.1(14) 
C25 14.4(18) 16.4(18) 18.1(17) 2.5(14) 1.6(13) -0.3(14) 
O26 14.9(13) 30.3(13) 20.3(12) 4.7(13) 3.0(9) -1.5(13) 
C27 25(2) 29(2) 21.0(18) -1.8(19) 1.5(13) 1(2) 
O28 19.9(15) 25.4(14) 16.7(13) -0.9(10) 1.1(10) 3.1(11) 
C29 33(2) 27(2) 17.7(18) -0.9(16) 7.4(16) 4.8(18) 
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 Table 4 Bond Lengths for JS04_20_Cu_a. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
K1 K1
1
 3.9554(5)   C10 C11 1.420(5) 
K1 K1
2
 3.9554(5)   C11 C12 1.372(5) 
K1 O2 2.732(2)   C11 O13 1.389(4) 
K1 O2
2
 2.664(3)   O13 C14 1.422(5) 
K1 N15
3
 2.938(3)   N15 K1
4
 2.938(3) 
K1 N15
2
 2.916(3)   N15 K1
1
 2.916(3) 
K1 C16
2
 3.392(4)   N15 C16 1.334(5) 
K1 O26 2.697(2)   N15 C20 1.350(5) 
K1 O28
2
 2.902(3)   C16 K1
1
 3.392(4) 
K1 O28 2.793(3)   C16 C17 1.404(5) 
O2 K1
1
 2.664(3)   C17 C18 1.395(5) 
O2 S3 1.502(3)   C17 C21 1.496(5) 
S3 C4 1.797(3)   C18 C19 1.387(5) 
S3 C25 1.833(4)   C18 O22 1.388(4) 
C4 N5 1.334(4)   C19 C20 1.409(5) 
C4 N8 1.336(4)   C19 C24 1.503(5) 
N5 C6 1.388(4)   C20 C25 1.504(5) 
C6 C7 1.414(4)   O22 C23 1.439(5) 
C6 C9 1.399(5)   O26 C27 1.421(4) 
C7 N8 1.378(4)   O28 K1
1
 2.902(3) 
C7 C12 1.416(5)   O28 C29 1.415(4) 
C9 C10 1.376(5)         
1
1-X,1/2+Y,1-Z; 
2
1-X,-1/2+Y,1-Z; 
3
+X,-1+Y,+Z; 
4
+X,1+Y,+Z 
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Table 5 Bond Angles for JS04_20_Cu_a. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
K1
1
 K1 K1
2
 136.22(4)   O2 S3 C4 107.74(15) 
O2 K1 K1
1
 168.74(6)   O2 S3 C25 104.98(15) 
O2
1
 K1 K1
1
 43.53(5)   C4 S3 C25 94.99(15) 
O2
1
 K1 K1
2
 93.79(6)   N5 C4 S3 118.1(2) 
O2 K1 K1
2
 42.19(5)   N5 C4 N8 119.6(3) 
O2
1
 K1 O2 135.76(7)   N8 C4 S3 122.2(3) 
O2 K1 N15
3
 122.91(8)   C4 N5 C6 101.4(3) 
O2
1
 K1 N15
3
 77.85(8)   N5 C6 C7 108.4(3) 
O2
1
 K1 N15
1
 71.96(8)   N5 C6 C9 130.6(3) 
O2 K1 N15
1
 77.18(8)   C9 C6 C7 121.0(3) 
O2 K1 C16
1
 73.38(8)   C6 C7 C12 120.7(3) 
O2
1
 K1 C16
1
 88.50(9)   N8 C7 C6 109.4(3) 
O2
1
 K1 O26 148.54(9)   N8 C7 C12 129.9(3) 
O2
1
 K1 O28
1
 69.11(8)   C4 N8 C7 101.2(3) 
O2 K1 O28 69.83(7)   C10 C9 C6 118.0(3) 
O2 K1 O28
1
 145.42(8)   C9 C10 C11 120.9(3) 
O2
1
 K1 O28 75.37(8)   C12 C11 C10 122.3(3) 
N15
3
 K1 K1
1
 47.26(6)   C12 C11 O13 124.6(3) 
N15
3
 K1 K1
2
 129.96(6)   O13 C11 C10 113.1(3) 
N15
1
 K1 K1
1
 109.40(7)   C11 C12 C7 117.0(3) 
N15
1
 K1 K1
2
 47.73(6)   C11 O13 C14 116.6(3) 
N15
1
 K1 N15
3
 149.07(5)   K1
2
 N15 K1
4
 85.01(8) 
N15
1
 K1 C16
1
 22.84(9)   C16 N15 K1
4
 112.9(2) 
N15
3
 K1 C16
1
 163.56(9)   C16 N15 K1
2
 99.1(2) 
C16
1
 K1 K1
1
 116.30(7)   C16 N15 C20 118.3(3) 
C16
1
 K1 K1
2
 59.33(7)   C20 N15 K1
2
 118.2(2) 
O26 K1 K1
2
 112.27(7)   C20 N15 K1
4
 117.3(2) 
O26 K1 K1
1
 111.24(7)   N15 C16 K1
2
 58.09(19) 
O26 K1 O2 73.11(9)   N15 C16 C17 124.3(4) 
O26 K1 N15
1
 112.42(8)   C17 C16 K1
2
 137.2(3) 
O26 K1 N15
3
 96.83(9)   C16 C17 C21 121.4(4) 
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O26 K1 C16
1
 90.03(9)   C18 C17 C16 115.7(3) 
O26 K1 O28
1
 79.44(9)   C18 C17 C21 122.8(3) 
O26 K1 O28 135.38(9)   C19 C18 C17 122.1(3) 
O28
1
 K1 K1
1
 44.89(5)   C19 C18 O22 119.8(3) 
O28 K1 K1
1
 101.44(6)   O22 C18 C17 118.0(3) 
O28 K1 K1
2
 47.15(6)   C18 C19 C20 116.8(3) 
O28
1
 K1 K1
2
 142.48(6)   C18 C19 C24 121.9(3) 
O28 K1 N15
1
 82.63(8)   C20 C19 C24 121.3(3) 
O28 K1 N15
3
 83.44(8)   N15 C20 C19 122.7(3) 
O28
1
 K1 N15
3
 80.42(8)   N15 C20 C25 114.9(3) 
O28
1
 K1 N15
1
 94.76(8)   C19 C20 C25 122.4(3) 
O28 K1 C16
1
 102.11(9)   C18 O22 C23 113.1(3) 
O28
1
 K1 C16
1
 86.21(8)   C20 C25 S3 111.1(2) 
O28 K1 O28
1
 143.29(7)   C27 O26 K1 119.6(2) 
K1
2
 O2 K1 94.28(8)   K1 O28 K1
2
 87.96(7) 
S3 O2 K1
2
 140.29(14)   C29 O28 K1
2
 109.2(2) 
S3 O2 K1 125.38(13)   C29 O28 K1 120.4(2) 
1
1-X,-1/2+Y,1-Z; 
2
1-X,1/2+Y,1-Z; 
3
+X,-1+Y,+Z; 
4
+X,1+Y,+Z 
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Table 6 Torsion Angles for JS04_20_Cu_a. 
 
A B C D Angle/˚   A B C D Angle/˚ 
K1
1
 K1 O2 K1
2
 87.9(3)   C12 C11 O13 C14 3.6(6) 
K1
2
 K1 O2 S3 -178.0(2)   O13 C11 C12 C7 -178.5(3) 
K1
1
 K1 O2 S3 -90.1(3)   N15
1
 K1 O2 K1
2
 -39.09(8) 
K1
1
 K1 O26 C27 -86.2(3)   N15
4
 K1 O2 K1
2
 115.15(9) 
K1
2
 K1 O26 C27 88.8(3)   N15
1
 K1 O2 S3 142.90(17) 
K1
1
 K1 O28 K1
2
 144.78(5)   N15
4
 K1 O2 S3 -62.86(18) 
K1
2
 K1 O28 C29 111.2(3)   N15
1
 K1 O26 C27 36.9(3) 
K1
1
 K1 O28 C29 -104.1(2)   N15
4
 K1 O26 C27 -132.8(3) 
K1 O2 S3 C4 -93.37(17)   N15
1
 K1 O28 K1
2
 36.39(8) 
K1
2
 O2 S3 C4 89.7(2)   N15
4
 K1 O28 K1
2
 -171.30(8) 
K1
2
 O2 S3 C25 -10.6(2)   N15
1
 K1 O28 C29 147.5(3) 
K1 O2 S3 C25 166.25(16)   N15
4
 K1 O28 C29 -60.1(2) 
K1
3
 N15 C16 K1
2
 -88.38(16)   N15 C16 C17 C18 -1.4(5) 
K1
2
 N15 C16 C17 -128.5(3)   N15 C16 C17 C21 178.8(4) 
K1
3
 N15 C16 C17 143.1(3)   N15 C20 C25 S3 97.9(3) 
K1
2
 N15 C20 C19 119.4(3)   C16
1
 K1 O2 K1
2
 -62.39(9) 
K1
3
 N15 C20 C19 -141.1(3)   C16
1
 K1 O2 S3 119.60(17) 
K1
2
 N15 C20 C25 -60.4(3)   C16
1
 K1 O26 C27 32.2(3) 
K1
3
 N15 C20 C25 39.1(4)   C16
1
 K1 O28 K1
2
 24.40(10) 
K1
2
 C16 C17 C18 -79.6(5)   C16
1
 K1 O28 C29 135.6(2) 
K1
2
 C16 C17 C21 100.7(4)   C16 N15 C20 C19 -0.2(5) 
O2
1
 K1 O2 K1
2
 7.38(5)   C16 N15 C20 C25 -180.0(3) 
O2
1
 K1 O2 S3 -170.63(17)   C16 C17 C18 C19 1.9(5) 
O2 K1 O26 C27 104.8(3)   C16 C17 C18 O22 178.5(3) 
O2
1
 K1 O26 C27 -55.0(4)   C17 C18 C19 C20 -1.6(5) 
O2 K1 O28 K1
2
 -42.62(7)   C17 C18 C19 C24 -179.8(3) 
O2
1
 K1 O28 K1
2
 109.59(8)   C17 C18 O22 C23 96.6(4) 
O2
1
 K1 O28 C29 -139.2(3)   C18 C19 C20 N15 0.7(5) 
O2 K1 O28 C29 68.5(2)   C18 C19 C20 C25 -179.6(3) 
O2 S3 C4 N5 165.4(2)   C19 C18 O22 C23 -86.8(4) 
O2 S3 C4 N8 -14.2(3)   C19 C20 C25 S3 -81.9(4) 
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O2 S3 C25 C20 -53.4(3)   C20 N15 C16 K1
2
 129.1(3) 
S3 C4 N5 C6 179.5(2)   C20 N15 C16 C17 0.6(5) 
S3 C4 N8 C7 179.6(3)   C21 C17 C18 C19 -178.3(4) 
C4 S3 C25 C20 -163.3(3)   C21 C17 C18 O22 -1.8(5) 
C4 N5 C6 C7 1.3(4)   O22 C18 C19 C20 -178.1(3) 
C4 N5 C6 C9 179.9(4)   O22 C18 C19 C24 3.7(5) 
N5 C4 N8 C7 -0.1(4)   C24 C19 C20 N15 178.9(3) 
N5 C6 C7 N8 -1.5(4)   C24 C19 C20 C25 -1.3(5) 
N5 C6 C7 C12 178.4(3)   C25 S3 C4 N5 -87.1(3) 
N5 C6 C9 C10 -178.3(4)   C25 S3 C4 N8 93.3(3) 
C6 C7 N8 C4 0.9(4)   O26 K1 O2 K1
2
 -157.63(9) 
C6 C7 C12 C11 -0.7(5)   O26 K1 O2 S3 24.36(15) 
C6 C9 C10 C11 0.9(5)   O26 K1 O28 K1
2
 -78.22(12) 
C7 C6 C9 C10 0.2(6)   O26 K1 O28 C29 32.9(3) 
N8 C4 N5 C6 -0.8(4)   O28 K1 O2 K1
2
 47.67(7) 
N8 C7 C12 C11 179.2(4)   O28
1
 K1 O2 K1
2
 -118.71(13) 
C9 C6 C7 N8 179.7(3)   O28 K1 O2 S3 -130.35(17) 
C9 C6 C7 C12 -0.3(6)   O28
1
 K1 O2 S3 63.3(2) 
C9 C10 C11 C12 -2.0(6)   O28
1
 K1 O26 C27 -53.9(3) 
C9 C10 C11 O13 178.3(3)   O28 K1 O26 C27 139.6(3) 
C10 C11 C12 C7 1.8(5)   O28
1
 K1 O28 K1
2
 124.46(12) 
C10 C11 O13 C14 -176.7(4)   O28
1
 K1 O28 C29 -124.4(2) 
C12 C7 N8 C4 -179.0(4)             
1
1-X,-1/2+Y,1-Z; 
2
1-X,1/2+Y,1-Z; 
3
+X,1+Y,+Z; 
4
+X,-1+Y,+Z 
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS04_20_Cu_a. 
 
Atom x y z U(eq) 
H9 -2312 6751 3099 21 
H10 -2508 7401 1441 23 
H12 1265 7082 1466 24 
H14A -209 7804 -924 47 
H14B 514 6424 -177 47 
H14C 690 8525 -7 47 
H16 6150(40) 9280(50) 6970(30) 8(9) 
H21A 7273 9172 8569 43 
H21B 6806 7616 9209 43 
H21C 6413 9641 9365 43 
H23A 3655 8488 10539 48 
H23B 2937 9276 9558 48 
H23C 4316 9915 9936 48 
H24A 2134 6496 8601 29 
H24B 1681 6014 7498 29 
H24C 1420 7956 7898 29 
H25A 2478 8620 5330 20 
H25B 1540 8208 6079 20 
H26 1160(30) 1340(80) 4850(30) 41(13) 
H27A 1860 1197 3069 38 
H27B 832 2594 3295 38 
H27C 593 497 3381 38 
H28 6700(30) 2550(60) 6400(40) 44(15) 
H29A 4988 4531 7175 38 
H29B 6412 4380 7627 38 
H29C 5539 2659 7582 38 
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1.5 XRD data for NMe Omeprazole 5.22 
 
Table 1 Crystal data and structure refinement for JS_NMeOmep_Cu. 
Identification code JS_NMeOmep_Cu 
Empirical formula C18H21N3O3S 
Formula weight 359.44 
Temperature/K 120.00(10) 
Crystal system triclinic 
Space group P-1 
a/Å 7.6932(5) 
b/Å 9.8933(6) 
c/Å 12.3472(8) 
α/° 95.341(5) 
β/° 107.606(6) 
γ/° 103.055(6) 
Volume/Å
3
 859.30(10) 
Z 2 
ρcalcg/cm
3
 1.389 
μ/mm-1 1.870 
F(000) 380.0 
Crystal size/mm
3
 0.17 × 0.12 × 0.06 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.62 to 134.14 
Index ranges -9 ≤ h ≤ 9, -8 ≤ k ≤ 11, -14 ≤ l ≤ 14 
Reflections collected 5898 
Independent reflections 2971 [Rint = 0.0546, Rsigma = 0.0778] 
Data/restraints/parameters 2971/0/239 
Goodness-of-fit on F
2
 1.066 
Final R indexes [I>=2σ (I)] R1 = 0.0531, wR2 = 0.1213 
Final R indexes [all data] R1 = 0.0737, wR2 = 0.1373 
Largest diff. peak/hole / e Å
-3
 0.31/-0.32 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS_NMeOmep_Cu. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
S13 686.5(11) 7813.2(8) 2440.1(6) 24.0(2) 
O23 908(3) 6915(2) 7019.9(18) 29.5(5) 
O2A 5331(4) 13518(2) -151.9(19) 28.7(5) 
O14 2153(4) 7071(2) 2941(2) 33.3(6) 
N11 1350(4) 8534(3) 482(2) 22.7(5) 
N21 -2013(4) 8038(3) 3979(2) 24.9(6) 
N9 2575(4) 10329(3) 2007(2) 23.7(5) 
C17 968(4) 8051(3) 5387(2) 21.2(6) 
C16 -115(4) 8391(3) 4362(2) 21.6(6) 
C18 -60(5) 7280(3) 5993(2) 23.9(7) 
C10 1615(4) 9003(3) 1615(2) 22.0(6) 
C6 2259(4) 9667(3) 108(3) 22.9(6) 
C20 -2927(5) 7340(3) 4606(3) 27.2(7) 
C15 779(4) 9143(3) 3585(2) 22.9(6) 
C19 -2019(5) 6926(3) 5625(3) 25.6(7) 
C5 3007(4) 10765(3) 1058(3) 23.1(6) 
C7 2490(5) 9817(3) -955(3) 27.9(7) 
C4 4053(4) 12074(3) 960(3) 26.2(7) 
C8 3489(4) 11115(3) -1050(3) 27.4(7) 
C12 372(5) 7135(3) -201(3) 27.3(7) 
C22 3092(4) 8523(3) 5823(3) 29.5(7) 
C25 -3111(5) 6177(4) 6321(3) 34.2(8) 
C3 4279(5) 12231(3) -99(3) 28.8(7) 
C1A 5326(5) 13803(4) -1273(3) 28.4(8) 
C24 1387(5) 5615(3) 6864(3) 36.0(8) 
O2B 4310(40) 11750(30) -1660(20) 27(6) 
C1B 5020(50) 13120(40) -1820(30) 21(7) 
  
A35 
 
 Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS_NMeOmep_Cu. The 
Anisotropic displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
S13 30.5(4) 19.4(4) 25.8(4) 4.3(3) 14.5(3) 6.7(3) 
O23 42.2(14) 23.5(11) 23.8(11) 4.9(9) 11(1) 10.3(10) 
O2A 36.3(14) 26.1(13) 26.2(12) 4.8(10) 16.7(11) 4.5(10) 
O14 45.2(15) 32.0(13) 36.9(12) 14.4(10) 22.5(11) 22.5(11) 
N11 26.1(14) 23.2(13) 21.8(12) 5.3(10) 10(1) 9.0(11) 
N21 23.5(14) 26.1(14) 26.3(13) 2.2(11) 9.7(11) 7.8(11) 
N9 25.6(14) 21.9(13) 25.7(12) 4.7(10) 11.2(11) 6.8(11) 
C17 26.0(16) 13.7(14) 23.9(14) 0.7(11) 11.3(12) 2.2(11) 
C16 25.6(16) 17.8(15) 23.9(14) 0.3(11) 12.2(12) 6.5(12) 
C18 37.1(18) 15.9(15) 21.1(14) 1.0(11) 13.0(13) 8.2(13) 
C10 23.6(15) 22.3(15) 22.2(14) 3.3(12) 10.4(12) 6.8(12) 
C6 21.1(16) 25.4(16) 26.9(15) 8.3(12) 9.3(12) 12.0(13) 
C20 28.0(17) 23.0(16) 31.8(16) 0.6(13) 14.2(14) 5.2(13) 
C15 27.4(16) 18.8(15) 24.7(14) 4.5(12) 11.0(13) 7.2(12) 
C19 33.6(18) 14.7(14) 32.2(16) -1.0(12) 19.0(14) 4.7(13) 
C5 22.1(16) 23.8(16) 28.0(15) 7.4(12) 11.2(13) 9.9(12) 
C7 31.4(18) 33.2(18) 26.9(15) 8.7(13) 13.4(14) 18.0(14) 
C4 22.4(16) 26.4(16) 30.8(16) 4.1(13) 9.7(13) 7.4(13) 
C8 29.4(17) 33.6(18) 27.6(15) 10.5(14) 14.8(14) 15.4(14) 
C12 31.7(18) 25.1(16) 24.3(15) 2.4(12) 7.9(13) 8.3(13) 
C22 26.9(17) 31.1(18) 29.7(16) 5.8(13) 7.9(13) 7.8(14) 
C25 39(2) 31.2(18) 38.1(18) 6.0(14) 22.3(16) 7.0(15) 
C3 24.0(16) 29.9(17) 42.7(18) 17.5(15) 17.8(15) 13.1(13) 
C1A 37(2) 23.9(18) 31.9(18) 9.3(16) 21.0(16) 7.8(15) 
C24 41(2) 21.7(16) 44.2(19) 9.6(15) 12.0(16) 7.8(15) 
  
  
A36 
 
Table 4 Bond Lengths for JS_NMeOmep_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
S13 O14 1.494(2)   C17 C16 1.406(4) 
S13 C10 1.794(3)   C17 C18 1.399(4) 
S13 C15 1.812(3)   C17 C22 1.502(4) 
O23 C18 1.389(4)   C16 C15 1.499(4) 
O23 C24 1.428(4)   C18 C19 1.385(5) 
O2A C3 1.365(4)   C6 C5 1.400(4) 
O2A C1A 1.437(4)   C6 C7 1.393(4) 
N11 C10 1.370(4)   C20 C19 1.390(5) 
N11 C6 1.377(4)   C19 C25 1.506(4) 
N11 C12 1.456(4)   C5 C4 1.398(4) 
N21 C16 1.341(4)   C7 C8 1.376(5) 
N21 C20 1.334(4)   C4 C3 1.388(4) 
N9 C10 1.314(4)   C8 C3 1.411(5) 
N9 C5 1.392(4)   O2B C1B 1.39(5) 
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Table 5 Bond Angles for JS_NMeOmep_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
O14 S13 C10 107.23(14)   N9 C10 S13 125.3(2) 
O14 S13 C15 107.36(14)   N9 C10 N11 115.2(3) 
C10 S13 C15 96.82(13)   N11 C6 C5 105.6(2) 
C18 O23 C24 113.4(2)   N11 C6 C7 131.6(3) 
C3 O2A C1A 117.3(3)   C7 C6 C5 122.8(3) 
C10 N11 C6 105.4(2)   N21 C20 C19 123.5(3) 
C10 N11 C12 128.7(3)   C16 C15 S13 107.1(2) 
C6 N11 C12 125.9(2)   C18 C19 C20 116.9(3) 
C20 N21 C16 118.5(3)   C18 C19 C25 121.5(3) 
C10 N9 C5 103.0(2)   C20 C19 C25 121.6(3) 
C16 C17 C22 122.1(3)   N9 C5 C6 110.9(3) 
C18 C17 C16 115.8(3)   N9 C5 C4 129.4(3) 
C18 C17 C22 122.1(3)   C4 C5 C6 119.7(3) 
N21 C16 C17 123.4(3)   C8 C7 C6 117.2(3) 
N21 C16 C15 114.5(3)   C3 C4 C5 117.7(3) 
C17 C16 C15 122.0(3)   C7 C8 C3 120.9(3) 
O23 C18 C17 119.3(3)   O2A C3 C4 115.9(3) 
C19 C18 O23 118.9(3)   O2A C3 C8 122.5(3) 
C19 C18 C17 121.8(3)   C4 C3 C8 121.6(3) 
N11 C10 S13 119.5(2)           
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Table 6 Torsion Angles for JS_NMeOmep_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
O23 C18 C19 C20 178.6(2)   C6 C5 C4 C3 1.0(4) 
O23 C18 C19 C25 0.9(4)   C6 C7 C8 C3 1.5(4) 
O14 S13 C10 N11 87.5(3)   C20 N21 C16 C17 0.8(4) 
O14 S13 C10 N9 -91.9(3)   C20 N21 C16 C15 178.7(3) 
O14 S13 C15 C16 -74.5(2)   C15 S13 C10 N11 -161.9(2) 
N11 C6 C5 N9 0.0(3)   C15 S13 C10 N9 18.7(3) 
N11 C6 C5 C4 179.0(3)   C5 N9 C10 S13 178.4(2) 
N11 C6 C7 C8 179.8(3)   C5 N9 C10 N11 -1.0(3) 
N21 C16 C15 S13 -80.4(3)   C5 C6 C7 C8 -0.6(4) 
N21 C20 C19 C18 0.5(4)   C5 C4 C3 O2A -179.1(3) 
N21 C20 C19 C25 178.2(3)   C5 C4 C3 C8 -0.1(5) 
N9 C5 C4 C3 179.8(3)   C7 C6 C5 N9 -179.7(3) 
C17 C16 C15 S13 97.5(3)   C7 C6 C5 C4 -0.7(4) 
C17 C18 C19 C20 1.6(4)   C7 C8 C3 O2A 177.7(3) 
C17 C18 C19 C25 -176.1(3)   C7 C8 C3 C4 -1.2(5) 
C16 N21 C20 C19 -1.7(4)   C12 N11 C10 S13 0.0(4) 
C16 C17 C18 O23 -179.4(2)   C12 N11 C10 N9 179.5(3) 
C16 C17 C18 C19 -2.4(4)   C12 N11 C6 C5 -179.1(3) 
C18 C17 C16 N21 1.2(4)   C12 N11 C6 C7 0.6(5) 
C18 C17 C16 C15 -176.6(3)   C22 C17 C16 N21 -176.9(3) 
C10 S13 C15 C16 175.0(2)   C22 C17 C16 C15 5.3(4) 
C10 N11 C6 C5 -0.6(3)   C22 C17 C18 O23 -1.2(4) 
C10 N11 C6 C7 179.1(3)   C22 C17 C18 C19 175.7(3) 
C10 N9 C5 C6 0.6(3)   C1A O2A C3 C4 -169.5(3) 
C10 N9 C5 C4 -178.3(3)   C1A O2A C3 C8 11.5(4) 
C6 N11 C10 S13 -178.4(2)   C24 O23 C18 C17 -87.7(3) 
C6 N11 C10 N9 1.0(3)   C24 O23 C18 C19 95.2(3) 
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS_NMeOmep_Cu. 
 
Atom x y z U(eq) 
H20 -4242 7119 4347 33 
H15A 2082 9657 4012 27 
H15B 95 9805 3267 27 
H7 1990 9070 -1573 33 
H4 4580 12814 1584 31 
H8 3645 11260 -1752 33 
H12A 1270 6707 -388 41 
H12B -555 7212 -899 41 
H12C -245 6565 234 41 
H22A 3569 8113 5276 44 
H22B 3562 8225 6549 44 
H22C 3504 9531 5924 44 
H25A -2753 5323 6462 51 
H25B -4442 5954 5902 51 
H25C -2832 6775 7044 51 
H1AA 4044 13631 -1776 43 
H1AB 5941 13200 -1583 43 
H1AC 5989 14770 -1208 43 
H24A 260 4878 6448 54 
H24B 1975 5390 7604 54 
H24C 2249 5702 6435 54 
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Table 8 Atomic Occupancy for JS_NMeOmep_Cu. 
 
Atom Occupancy   Atom Occupancy   Atom Occupancy 
O2A 0.92   C1A 0.92   H1AA 0.92 
H1AB 0.92   H1AC 0.92   O2B 0.08 
C1B 0.08           
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1.6 XRD data for Benzyl p-tolyl sulfoxide 4.10 
 
Table 1 Crystal data and structure refinement for JS03_91_Cu. 
Identification code JS03_91_Cu 
Empirical formula C14H14OS 
Formula weight 230.31 
Temperature/K 99.9(5) 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.66476(12) 
b/Å 11.6755(2) 
c/Å 17.5269(4) 
α/° 90.00 
β/° 90.00 
γ/° 90.00 
Volume/Å
3
 1159.21(4) 
Z 4 
ρcalcmg/mm
3
 1.320 
m/mm
-1
 2.257 
F(000) 488.0 
Crystal size/mm
3
 0.27 × 0.13 × 0.09 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 9.1 to 133.2° 
Index ranges -6 ≤ h ≤ 6, -13 ≤ k ≤ 13, -20 ≤ l ≤ 20 
Reflections collected 10499 
Independent reflections 2053 [Rint = 0.0286, Rsigma = 0.0187] 
Data/restraints/parameters 2053/0/146 
Goodness-of-fit on F
2
 1.088 
Final R indexes [I>=2σ (I)] R1 = 0.0254, wR2 = 0.0621 
Final R indexes [all data] R1 = 0.0267, wR2 = 0.0631 
Largest diff. peak/hole / e Å
-3
 0.16/-0.23 
Flack parameter -0.012(16) 
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Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS03_91_Cu. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 -4563(4) 2400.7(15) -3501.6(11) 27.1(4) 
C2 -3815(3) 1596.7(14) -4128(1) 19.3(4) 
C3 -1666(3) 1015.8(14) -4100.8(9) 20.7(4) 
C4 -1000(3) 276.9(14) -4683(1) 20.2(4) 
C5 -2494(3) 116.4(15) -5297.6(10) 17.8(4) 
C6 -4636(3) 695.7(15) -5343.5(10) 19.3(4) 
C7 -5274(3) 1429.1(14) -4757.2(10) 19.7(4) 
S8 -1658.4(7) -822.3(3) -6060.9(2) 18.93(11) 
O9 841(2) -1182.1(11) -5923.8(7) 25.4(3) 
C10 -3527(3) -2026.5(14) -5784.6(9) 19.6(4) 
C11 -3441(3) -2946.9(14) -6382.9(9) 18.0(3) 
C12 -1522(3) -3687.6(14) -6442.4(10) 19.4(3) 
C13 -1466(3) -4525.0(14) -7002.1(10) 21.2(4) 
C14 -3336(3) -4647.5(14) -7505.9(10) 22.1(4) 
C15 -5261(3) -3913.7(14) -7449.7(10) 22.0(4) 
C16 -5313(3) -3065.8(14) -6898.1(10) 20.2(4) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS03_91_Cu. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 29.8(10) 23.4(9) 28(1) -4.4(8) -1.6(9) -1.8(8) 
C2 20.9(9) 16.5(8) 20.6(9) 2.5(6) 3.2(7) -4.7(7) 
C3 18.9(8) 22.4(8) 20.9(9) 3.2(6) -5.5(7) -5.2(7) 
C4 15.2(9) 19.7(8) 25.6(9) 5.2(7) 0.0(7) 0.8(7) 
C5 17.0(8) 16.4(8) 20.1(9) 2.5(7) 0.4(7) -2.3(6) 
C6 16.1(8) 22.0(9) 19.8(8) 0.2(7) -3.6(7) -1.1(7) 
C7 14.5(8) 18.8(8) 25.8(10) 3.2(7) 0.3(7) 0.6(7) 
S8 16.6(2) 19.52(19) 20.6(2) 0.82(17) 3.08(17) 0.28(17) 
O9 15.2(6) 26.2(6) 34.7(8) -4.3(5) 5.1(5) 1.3(5) 
C10 16.7(8) 21.4(8) 20.7(8) 2.6(7) 4.3(7) -2.9(8) 
C11 16.3(8) 19.0(8) 18.6(8) 4.1(6) 3.3(7) -0.9(7) 
C12 17.1(8) 22.5(8) 18.4(8) 5.3(6) 0.4(8) 0.6(8) 
C13 21.1(8) 17.2(8) 25.2(9) 5.8(6) 3.1(8) 3.3(7) 
C14 27.4(9) 17.8(8) 21.0(9) 1.2(7) 2.6(9) -2.2(8) 
C15 20.0(9) 23.5(9) 22.5(9) 1.4(7) -2.3(7) -2.0(7) 
C16 16.8(9) 18.8(8) 25.0(9) 4.3(7) 0.9(7) 0.6(7) 
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Table 4 Bond Lengths for JS03_91_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.505(2)   S8 C10 1.8254(17) 
C2 C3 1.394(2)   C10 C11 1.502(2) 
C2 C7 1.392(2)   C11 C12 1.393(2) 
C3 C4 1.389(3)   C11 C16 1.400(2) 
C4 C5 1.383(2)   C12 C13 1.385(2) 
C5 C6 1.391(2)   C13 C14 1.387(3) 
C5 S8 1.7931(18)   C14 C15 1.390(3) 
C6 C7 1.386(2)   C15 C16 1.384(2) 
S8 O9 1.4965(12)         
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Table 5 Bond Angles for JS03_91_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 C2 C1 121.61(16)   O9 S8 C5 107.55(8) 
C7 C2 C1 119.88(16)   O9 S8 C10 106.86(8) 
C7 C2 C3 118.51(16)   C11 C10 S8 110.30(11) 
C4 C3 C2 120.94(16)   C12 C11 C10 121.46(16) 
C5 C4 C3 119.37(16)   C12 C11 C16 118.79(16) 
C4 C5 C6 120.87(16)   C16 C11 C10 119.76(16) 
C4 C5 S8 120.16(13)   C13 C12 C11 120.60(17) 
C6 C5 S8 118.96(13)   C12 C13 C14 120.41(17) 
C7 C6 C5 119.02(16)   C13 C14 C15 119.38(16) 
C6 C7 C2 121.29(16)   C16 C15 C14 120.47(17) 
C5 S8 C10 96.88(8)   C15 C16 C11 120.35(16) 
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Table 6 Torsion Angles for JS03_91_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C3 C4 -179.99(16)   C7 C2 C3 C4 -0.7(2) 
C1 C2 C7 C6 179.94(16)   S8 C5 C6 C7 -179.44(13) 
C2 C3 C4 C5 0.0(2)   S8 C10 C11 C12 77.35(18) 
C3 C2 C7 C6 0.6(2)   S8 C10 C11 C16 -102.24(16) 
C3 C4 C5 C6 0.8(2)   O9 S8 C10 C11 -75.79(13) 
C3 C4 C5 S8 179.36(13)   C10 C11 C12 C13 -179.46(15) 
C4 C5 C6 C7 -0.9(2)   C10 C11 C16 C15 -179.68(16) 
C4 C5 S8 O9 -7.18(16)   C11 C12 C13 C14 -0.8(2) 
C4 C5 S8 C10 102.97(15)   C12 C11 C16 C15 0.7(2) 
C5 C6 C7 C2 0.2(2)   C12 C13 C14 C15 0.7(2) 
C5 S8 C10 C11 173.47(13)   C13 C14 C15 C16 0.2(2) 
C6 C5 S8 O9 171.40(13)   C14 C15 C16 C11 -0.9(3) 
C6 C5 S8 C10 -78.45(14)   C16 C11 C12 C13 0.1(2) 
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS03_91_Cu. 
 
Atom x y z U(eq) 
H1A -3556 2297 -3066 41 
H1B -6167 2241 -3361 41 
H1C -4442 3177 -3678 41 
H3 -664 1125 -3687 25 
H4 438 -106 -4660 24 
H6 -5624 592 -5762 23 
H7 -6706 1817 -4785 24 
H10A -2991 -2334 -5301 24 
H10B -5141 -1766 -5721 24 
H12 -267 -3619 -6103 23 
H13 -165 -5008 -7040 25 
H14 -3303 -5215 -7878 26 
H15 -6523 -3993 -7785 26 
H16 -6599 -2572 -6870 24 
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1.8 XRD data for Methyl 6(5)-OMe benzimidazole sulfoxide 4.11 
 
Table 1 Crystal data and structure refinement for JS03_82_Cu. 
Identification code JS03_82_Cu 
Empirical formula C9H10N2O2S 
Formula weight 210.25 
Temperature/K 120.00(12) 
Crystal system monoclinic 
Space group P21/c 
a/Å 8.0080(3) 
b/Å 14.5693(6) 
c/Å 16.4409(4) 
α/° 90.00 
β/° 95.840(3) 
γ/° 90.00 
Volume/Å
3
 1908.20(11) 
Z 8 
ρcalcg/cm
3
 1.464 
μ/mm-1 2.826 
F(000) 880.0 
Crystal size/mm
3
 0.25 × 0.05 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.12 to 134.16 
Index ranges -9 ≤ h ≤ 9, -15 ≤ k ≤ 17, -19 ≤ l ≤ 19 
Reflections collected 6999 
Independent reflections 3410 [Rint = 0.0892, Rsigma = 0.1038] 
Data/restraints/parameters 3410/0/257 
Goodness-of-fit on F
2
 0.989 
Final R indexes [I>=2σ (I)] R1 = 0.0663, wR2 = 0.1536 
Final R indexes [all data] R1 = 0.1027, wR2 = 0.1849 
Largest diff. peak/hole / e Å
-3
 0.63/-0.50 
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 Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS03_82_Cu. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 -2347(5) 10002(4) 1023(3) 41.7(11) 
O2 -1067(4) 10548(2) 730.7(18) 40.3(8) 
C3 453(5) 10584(3) 1196(2) 32.9(9) 
C4 757(5) 10204(3) 1961(2) 32.7(9) 
C5 2378(5) 10336(3) 2355(2) 31.2(9) 
C6 3634(5) 10816(3) 2001(2) 32.6(9) 
C7 3291(5) 11177(3) 1215(3) 37.5(10) 
C8 1700(6) 11074(3) 823(3) 36.2(10) 
N9 3087(4) 10079(3) 3120(2) 35.1(8) 
C10 4698(5) 10400(3) 3183(2) 34.8(10) 
N11 5106(5) 10835(3) 2539(2) 35.4(8) 
S12 6017.3(14) 10202.8(8) 4111.7(6) 36.7(3) 
O13 6361(4) 9186(2) 4136.7(16) 37.9(7) 
C14 7851(6) 10759(4) 3822(3) 43.8(11) 
C15 2611(5) 8440(3) 944(2) 35.9(10) 
O16 3862(4) 7896(2) 622.4(16) 36.0(7) 
C17 5382(5) 7826(3) 1091(2) 27.4(8) 
C18 5715(5) 8198(3) 1859(2) 26.9(8) 
C19 7321(5) 8041(3) 2252(2) 25.2(8) 
C20 8551(5) 7542(3) 1893(2) 30.3(9) 
C21 8166(5) 7167(3) 1117(2) 35(1) 
C22 6606(5) 7309(3) 722(2) 31.9(9) 
N23 8048(4) 8303(3) 3012.8(18) 29.2(8) 
C24 9647(5) 7959(3) 3071(2) 31.4(9) 
N25 10020(4) 7501(3) 2429.5(19) 33.4(8) 
S26 10954.4(13) 8088.6(8) 4013.0(5) 34.5(3) 
O27 11215(3) 9101(2) 4138.4(16) 35.4(7) 
C28 12817(5) 7624(4) 3666(3) 41.2(11) 
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 Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS03_82_Cu. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 28(2) 46(3) 52(2) 10(2) 9.6(17) 1(2) 
O2 29.8(15) 38(2) 54.1(16) 15.4(14) 11.5(12) 6.5(14) 
C3 27(2) 26(3) 47(2) 1.9(18) 9.5(16) 5.6(18) 
C4 31(2) 24(2) 46(2) 5.3(17) 17.3(16) 4.8(18) 
C5 34(2) 21(2) 40.6(19) 2.2(16) 13.2(16) 4.0(18) 
C6 34(2) 21(2) 44.7(19) -1.7(17) 15.0(16) -2.1(18) 
C7 36(2) 32(3) 47(2) 1.9(19) 16.0(18) -2.4(19) 
C8 40(2) 26(3) 44(2) 9.3(18) 13.1(17) 5(2) 
N9 38.4(19) 29(2) 39.9(16) 1.4(15) 12.5(14) -1.2(17) 
C10 38(2) 26(3) 41.4(19) -4.9(17) 8.7(16) 2.7(19) 
N11 39(2) 28(2) 40.6(16) -1.2(15) 9.8(14) -0.1(17) 
S12 43.5(6) 32.8(7) 35.2(5) -3.0(4) 10.6(4) 1.0(5) 
O13 42.1(17) 31.4(19) 41.8(14) 3.1(13) 11.1(12) 1.0(15) 
C14 45(3) 41(3) 45(2) 0(2) 1.5(18) -12(2) 
C15 24.3(19) 40(3) 42.7(19) -4.4(19) -1.8(15) 8.2(19) 
O16 28.1(14) 40(2) 38.1(13) -7.1(13) -4.3(11) 4.1(14) 
C17 22.0(18) 26(2) 33.9(17) 0.2(15) 0.4(14) -0.5(17) 
C18 24.0(18) 25(2) 31.8(16) 0.1(15) 4.5(13) -6.6(17) 
C19 25.5(18) 17(2) 33.3(16) 0.8(15) 4.8(14) -3.9(16) 
C20 25.9(19) 27(2) 37.8(18) 5.6(17) 2.7(15) 0.8(18) 
C21 35(2) 31(3) 39.3(18) -3.3(17) 5.1(16) 7.5(19) 
C22 35(2) 28(3) 32.2(17) -2.5(16) 2.4(15) 3.9(19) 
N23 26.3(16) 30(2) 31.2(14) 0.4(14) 1.8(12) -0.7(15) 
C24 28(2) 28(2) 37.9(18) 8.4(17) 1.2(15) -3.1(18) 
N25 27.3(16) 35(2) 36.2(16) 3.4(15) -3.2(13) 0.8(16) 
S26 32.1(5) 38.4(7) 32.2(4) 5.6(4) -1.5(3) -4.1(5) 
O27 30.1(15) 36(2) 40.0(13) -3.5(12) 1.5(11) -3.8(13) 
C28 33(2) 39(3) 48(2) 3(2) -9.2(18) 3(2) 
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 Table 4 Bond Lengths for JS03_82_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 O2 1.419(5)   C15 O16 1.421(5) 
O2 C3 1.371(5)   O16 C17 1.376(5) 
C3 C4 1.373(6)   C17 C18 1.376(5) 
C3 C8 1.416(6)   C17 C22 1.421(6) 
C4 C5 1.404(6)   C18 C19 1.398(5) 
C5 C6 1.399(6)   C19 C20 1.402(6) 
C5 N9 1.378(5)   C19 N23 1.378(5) 
C6 C7 1.397(6)   C20 C21 1.394(6) 
C6 N11 1.400(6)   C20 N25 1.397(5) 
C7 C8 1.376(6)   C21 C22 1.364(6) 
N9 C10 1.366(6)   N23 C24 1.369(5) 
C10 N11 1.304(6)   C24 N25 1.308(6) 
C10 S12 1.790(4)   C24 S26 1.789(4) 
S12 O13 1.506(4)   S26 O27 1.501(3) 
S12 C14 1.784(5)   S26 C28 1.783(5) 
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Table 5 Bond Angles for JS03_82_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 O2 C1 117.6(3)   C17 O16 C15 116.7(3) 
O2 C3 C4 124.1(4)   O16 C17 C22 114.2(3) 
O2 C3 C8 113.8(4)   C18 C17 O16 124.2(4) 
C4 C3 C8 122.2(4)   C18 C17 C22 121.6(4) 
C3 C4 C5 115.9(4)   C17 C18 C19 116.3(4) 
C6 C5 C4 123.1(4)   C18 C19 C20 122.9(3) 
N9 C5 C4 131.3(4)   N23 C19 C18 131.1(4) 
N9 C5 C6 105.5(4)   N23 C19 C20 106.0(3) 
C5 C6 N11 110.1(4)   C21 C20 C19 119.2(4) 
C7 C6 C5 119.4(4)   C21 C20 N25 130.9(4) 
C7 C6 N11 130.6(4)   N25 C20 C19 109.8(3) 
C8 C7 C6 118.5(4)   C22 C21 C20 118.9(4) 
C7 C8 C3 120.9(4)   C21 C22 C17 121.1(4) 
C10 N9 C5 105.9(4)   C24 N23 C19 105.5(3) 
N9 C10 S12 118.7(3)   N23 C24 S26 118.9(3) 
N11 C10 N9 114.7(4)   N25 C24 N23 114.8(3) 
N11 C10 S12 126.5(4)   N25 C24 S26 126.2(3) 
C10 N11 C6 103.7(4)   C24 N25 C20 103.9(3) 
O13 S12 C10 105.76(19)   O27 S26 C24 106.46(18) 
O13 S12 C14 107.5(2)   O27 S26 C28 107.9(2) 
C14 S12 C10 97.5(2)   C28 S26 C24 96.8(2) 
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Table 6 Torsion Angles for JS03_82_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
C1 O2 C3 C4 -6.9(6)   C15 O16 C17 C18 4.2(6) 
C1 O2 C3 C8 174.5(4)   C15 O16 C17 C22 -177.3(4) 
O2 C3 C4 C5 -178.0(4)   O16 C17 C18 C19 178.7(4) 
O2 C3 C8 C7 179.6(4)   O16 C17 C22 C21 -179.0(4) 
C3 C4 C5 C6 -0.6(6)   C17 C18 C19 C20 0.6(6) 
C3 C4 C5 N9 177.8(4)   C17 C18 C19 N23 -179.3(4) 
C4 C3 C8 C7 0.9(7)   C18 C17 C22 C21 -0.4(7) 
C4 C5 C6 C7 -0.8(7)   C18 C19 C20 C21 -1.2(6) 
C4 C5 C6 N11 179.9(4)   C18 C19 C20 N25 179.9(4) 
C4 C5 N9 C10 -179.2(4)   C18 C19 N23 C24 -179.8(4) 
C5 C6 C7 C8 2.2(7)   C19 C20 C21 C22 1.0(7) 
C5 C6 N11 C10 -1.2(5)   C19 C20 N25 C24 0.0(5) 
C5 N9 C10 N11 -0.2(5)   C19 N23 C24 N25 -0.3(5) 
C5 N9 C10 S12 179.4(3)   C19 N23 C24 S26 -175.6(3) 
C6 C5 N9 C10 -0.6(5)   C20 C19 N23 C24 0.3(4) 
C6 C7 C8 C3 -2.3(7)   C20 C21 C22 C17 -0.2(7) 
C7 C6 N11 C10 179.5(5)   C21 C20 N25 C24 -178.7(5) 
C8 C3 C4 C5 0.5(7)   C22 C17 C18 C19 0.2(6) 
N9 C5 C6 C7 -179.5(4)   N23 C19 C20 C21 178.7(4) 
N9 C5 C6 N11 1.2(5)   N23 C19 C20 N25 -0.2(5) 
N9 C10 N11 C6 0.9(5)   N23 C24 N25 C20 0.2(5) 
N9 C10 S12 O13 69.4(4)   N23 C24 S26 O27 -63.8(4) 
N9 C10 S12 C14 -180.0(4)   N23 C24 S26 C28 -174.8(4) 
N11 C6 C7 C8 -178.6(4)   N25 C20 C21 C22 179.6(4) 
N11 C10 S12 O13 -111.1(4)   N25 C24 S26 O27 121.5(4) 
N11 C10 S12 C14 -0.5(5)   N25 C24 S26 C28 10.5(4) 
S12 C10 N11 C6 -178.6(3)   S26 C24 N25 C20 175.0(3) 
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Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters 
(Å
2
×10
3
) for JS03_82_Cu. 
 
Atom x y z U(eq) 
H1A -3324 10012 632 63 
H1B -2628 10243 1535 63 
H1C -1956 9382 1098 63 
H4 -61 9878 2203 39 
H7 4119 11480 961 45 
H8 1440 11329 308 43 
H9 2613 9778 3484 42 
H14A 8106 10527 3303 66 
H14B 8778 10640 4226 66 
H14C 7656 11408 3783 66 
H15A 1627 8460 559 54 
H15B 3030 9052 1043 54 
H15C 2332 8177 1448 54 
H18 4916 8536 2104 32 
H21 8959 6826 872 42 
H22 6340 7064 203 38 
H23 7593 8616 3375 35 
H28A 12638 6990 3525 62 
H28B 13725 7675 4092 62 
H28C 13089 7958 3194 62 
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1.9 XRD data for Pyridyl p-tolyl sulfoxide 4.12 
 
Table 1 Crystal data and structure refinement for JS03_90_Cu. 
Identification code JS03_90_Cu 
Empirical formula C16H19NO2S 
Formula weight 289.38 
Temperature/K 100.0(5) 
Crystal system monoclinic 
Space group P21/c 
a/Å 20.2700(6) 
b/Å 4.89800(15) 
c/Å 15.8506(5) 
α/° 90.00 
β/° 108.354(3) 
γ/° 90.00 
Volume/Å
3
 1493.63(8) 
Z 4 
ρcalcmg/mm
3
 1.287 
m/mm
-1
 1.929 
F(000) 616.0 
Crystal size/mm
3
 0.24 × 0.14 × 0.07 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection 9.2 to 134.08° 
Index ranges -24 ≤ h ≤ 23, -5 ≤ k ≤ 5, -18 ≤ l ≤ 18 
Reflections collected 11126 
Independent reflections 2654 [Rint = 0.0387, Rsigma = 0.0280] 
Data/restraints/parameters 2654/9/233 
Goodness-of-fit on F
2
 1.060 
Final R indexes [I>=2σ (I)] R1 = 0.0445, wR2 = 0.1069 
Final R indexes [all data] R1 = 0.0540, wR2 = 0.1136 
Largest diff. peak/hole / e Å
-3
 0.22/-0.24 
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Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS03_90_Cu. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1A 362.1(19) 8136(9) 9324(2) 49.6(9) 
C1B 536(5) 7080(20) 9583(7) 59(3) 
C2A 782(3) 6878(18) 8784(3) 39(2) 
C2B 809(10) 6510(30) 8792(9) 50(6) 
C3A 704(3) 7795(14) 7941(4) 42.6(17) 
C3B 671(8) 8140(30) 8034(9) 47(5) 
C4A 1076(2) 6649(10) 7424(2) 35.1(8) 
C4B 974(6) 7521(17) 7384(5) 39(3) 
C5A 1532.0(15) 4543(7) 7779(3) 29.1(6) 
C5B 1425(4) 5306(16) 7495(4) 27(2) 
C6A 1619.2(16) 3576(7) 8630(3) 42.0(8) 
C6B 1548(4) 3643(13) 8240(5) 34(2) 
C7A 1241(2) 4800(9) 9121(3) 45.3(10) 
C7B 1252(6) 4282(19) 8898(5) 45(3) 
S8A 2015.0(3) 2972.0(14) 7137.7(5) 35.9(3) 
S8B 1782.1(7) 4537(3) 6624.8(11) 31.5(6) 
O9A 1590.4(12) 3085(7) 6180.9(17) 54.8(7) 
O9B 1826(3) 1521(11) 6567(4) 42.8(13) 
C10 2670.7(9) 5637(4) 7283.2(12) 34.4(4) 
C11 3217.1(9) 4699(4) 6887.7(12) 32.0(4) 
C12 3267.8(9) 5742(4) 6090.5(12) 32.5(4) 
C13 3813.9(9) 4744(4) 5816.6(12) 34.5(4) 
C14 4269.5(10) 2784(4) 6296.7(13) 39.9(5) 
C15 4153.2(11) 1873(5) 7066.8(15) 47.0(5) 
N16 3646.2(8) 2790(4) 7367.4(11) 42.7(4) 
C17 2766.9(11) 7815(4) 5549.4(14) 45.9(5) 
O18 3911.8(7) 5832(3) 5058.4(9) 46.2(4) 
C19 3630.8(13) 4191(6) 4283.3(14) 61.9(7) 
C20 4861.7(11) 1646(5) 6016.4(16) 53.3(6) 
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Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for JS03_90_Cu. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1A 41.9(18) 72(3) 46(2) -18(2) 30.2(16) -4.6(19) 
C2A 24(2) 59(3) 40(3) -26.4(19) 17.6(15) -15.1(16) 
C3A 30(2) 51(3) 52(3) -8(2) 20.3(17) 8.0(15) 
C4A 34(2) 42(2) 31.9(17) 0.6(14) 14.9(12) -1.0(18) 
C5A 28.1(14) 29.1(16) 34.4(18) -0.4(15) 16.0(13) -0.8(12) 
C6A 36.8(16) 50(2) 38(2) 8.3(15) 11.0(16) 4.5(13) 
C7A 40(2) 70(3) 29.0(17) -5(2) 15.8(15) -22.1(18) 
S8A 35.6(4) 31.1(4) 48.5(5) -7.5(4) 24.0(3) -0.5(3) 
S8B 30.7(8) 36.6(11) 29.9(10) -2.3(7) 13.4(6) 2.7(6) 
O9A 41.1(13) 82(2) 44.6(15) -34.2(16) 18.0(11) -8.3(14) 
O9B 45(3) 37(3) 54(3) -16(3) 26(2) -6(2) 
C10 34.8(9) 37.6(10) 36.1(10) -7.7(8) 19.0(8) -2.8(8) 
C11 30.0(9) 36.6(10) 33.5(9) -6.7(8) 16.0(7) -2.5(7) 
C12 35.5(9) 32.1(10) 33.4(9) -6.4(7) 15.7(7) -5.3(7) 
C13 37.9(10) 39.1(10) 33.0(9) -9.6(8) 20.2(8) -11.4(8) 
C14 34.9(10) 47.7(12) 43.2(11) -10.0(9) 21.2(8) -2.5(9) 
C15 38.9(11) 58.7(14) 49.5(12) 7.4(10) 22.4(9) 14.6(10) 
N16 37.7(9) 57.2(11) 39.7(9) 4.6(8) 21.3(7) 8.2(8) 
C17 50.0(12) 45.9(12) 47.7(12) 6.9(9) 23.7(10) 5.2(10) 
O18 52.4(8) 59.3(9) 35.8(7) -7.2(7) 26.7(6) -14.4(7) 
C19 60.0(14) 93(2) 36.3(12) -16.0(12) 20.8(10) -11.7(14) 
C20 42.4(12) 65.6(15) 63.6(14) -10.1(12) 33.3(11) 2.9(11) 
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Table 4 Bond Lengths for JS03_90_Cu. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
C1A C2A 1.516(5)   S8A O9A 1.490(3) 
C1B C2B 1.547(11)   S8A C10 1.825(2) 
C2A C3A 1.370(5)   S8B O9B 1.484(5) 
C2A C7A 1.368(7)   S8B C10 1.855(2) 
C2B C3B 1.3927(17)   C10 C11 1.506(2) 
C2B C7B 1.3901(10)   C11 C12 1.397(2) 
C3A C4A 1.394(6)   C11 N16 1.339(2) 
C3B C4B 1.3901(10)   C12 C13 1.398(2) 
C4A C5A 1.381(5)   C12 C17 1.500(3) 
C4B C5B 1.3926(17)   C13 C14 1.382(3) 
C5A C6A 1.386(5)   C13 O18 1.385(2) 
C5A S8A 1.792(3)   C14 C15 1.388(3) 
C5B C6B 1.3898(10)   C14 C20 1.512(3) 
C5B S8B 1.789(5)   C15 N16 1.339(2) 
C6A C7A 1.390(6)   O18 C19 1.428(3) 
C6B C7B 1.3934(17)         
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Table 5 Bond Angles for JS03_90_Cu. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3A C2A C1A 120.2(6)   O9A S8A C10 105.44(14) 
C7A C2A C1A 121.0(4)   C5B S8B C10 93.6(3) 
C7A C2A C3A 118.8(4)   O9B S8B C5B 107.7(3) 
C3B C2B C1B 124.8(8)   O9B S8B C10 104.9(2) 
C7B C2B C1B 115.1(8)   S8A C10 S8B 35.06(6) 
C7B C2B C3B 120.01(10)   C11 C10 S8A 109.32(13) 
C2A C3A C4A 121.5(5)   C11 C10 S8B 112.85(13) 
C4B C3B C2B 120.01(10)   C12 C11 C10 122.57(17) 
C5A C4A C3A 118.5(3)   N16 C11 C10 114.09(16) 
C3B C4B C5B 119.97(10)   N16 C11 C12 123.34(16) 
C4A C5A C6A 121.0(2)   C11 C12 C13 116.36(18) 
C4A C5A S8A 120.3(3)   C11 C12 C17 122.39(16) 
C6A C5A S8A 118.7(3)   C13 C12 C17 121.25(17) 
C4B C5B S8B 118.3(5)   C14 C13 C12 121.93(17) 
C6B C5B C4B 120.00(10)   C14 C13 O18 119.46(16) 
C6B C5B S8B 121.5(5)   O18 C13 C12 118.58(18) 
C5A C6A C7A 118.3(3)   C13 C14 C15 116.00(17) 
C5B C6B C7B 119.97(10)   C13 C14 C20 123.29(18) 
C2A C7A C6A 121.9(3)   C15 C14 C20 120.7(2) 
C2B C7B C6B 119.95(10)   N16 C15 C14 124.6(2) 
C5A S8A C10 97.32(11)   C11 N16 C15 117.79(17) 
O9A S8A C5A 108.53(17)   C13 O18 C19 113.73(17) 
  
  
A60 
 
Table 6 Torsion Angles for JS03_90_Cu. 
 
A B C D Angle/˚   A B C D Angle/˚ 
C1A C2A C3A C4A -179.0(6)   S8A C5A C6A C7A -179.8(3) 
C1A C2A C7A C6A 178.5(5)   S8A C10 C11 C12 106.63(18) 
C1B C2B C3B C4B 176.5(17)   S8A C10 C11 N16 -73.43(18) 
C1B C2B C7B C6B -177.8(13)   S8B C5B C6B C7B -179.0(7) 
C2A C3A C4A C5A -0.1(9)   S8B C10 C11 C12 69.1(2) 
C2B C3B C4B C5B -1(3)   S8B C10 C11 N16 -110.92(17) 
C3A C2A C7A C6A -0.9(10)   O9A S8A C10 S8B 27.53(13) 
C3A C4A C5A C6A 0.2(6)   O9A S8A C10 C11 -74.99(18) 
C3A C4A C5A S8A 179.3(4)   O9B S8B C10 S8A -35.2(2) 
C3B C2B C7B C6B -1(3)   O9B S8B C10 C11 56.2(3) 
C3B C4B C5B C6B 2.7(18)   C10 C11 C12 C13 178.08(16) 
C3B C4B C5B S8B 178.2(11)   C10 C11 C12 C17 -2.1(3) 
C4A C5A C6A C7A -0.7(5)   C10 C11 N16 C15 -179.10(18) 
C4A C5A S8A O9A -31.1(3)   C11 C12 C13 C14 1.5(3) 
C4A C5A S8A C10 77.9(3)   C11 C12 C13 O18 -176.21(15) 
C4B C5B C6B C7B -3.7(14)   C12 C11 N16 C15 0.8(3) 
C4B C5B S8B O9B -143.4(8)   C12 C13 C14 C15 -0.1(3) 
C4B C5B S8B C10 109.8(8)   C12 C13 C14 C20 179.56(19) 
C5A C6A C7A C2A 1.1(7)   C12 C13 O18 C19 -99.4(2) 
C5A S8A C10 S8B -84.07(18)   C13 C14 C15 N16 -1.0(3) 
C5A S8A C10 C11 173.42(19)   C14 C13 O18 C19 82.9(2) 
C5B C6B C7B C2B 2.9(19)   C14 C15 N16 C11 0.7(3) 
C5B S8B C10 S8A 74.2(3)   N16 C11 C12 C13 -1.9(3) 
C5B S8B C10 C11 165.6(3)   N16 C11 C12 C17 177.99(18) 
C6A C5A S8A O9A 148.0(3)   C17 C12 C13 C14 -178.38(18) 
C6A C5A S8A C10 -103.0(3)   C17 C12 C13 O18 4.0(3) 
C6B C5B S8B O9B 32.0(8)   O18 C13 C14 C15 177.51(18) 
C6B C5B S8B C10 -74.8(7)   O18 C13 C14 C20 -2.8(3) 
C7A C2A C3A C4A 0.4(12)   C20 C14 C15 N16 179.3(2) 
C7B C2B C3B C4B 0(3)             
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 Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement 
Parameters (Å
2
×10
3
) for JS03_90_Cu. 
 
Atom x y z U(eq) 
H1AA 349 10083 9249 74 
H1AB 574 7699 9941 74 
H1AC -103 7424 9124 74 
H1BA 694 5666 10020 88 
H1BB 37 7106 9376 88 
H1BC 707 8811 9843 88 
H3A 396 9216 7709 51 
H3B 376 9632 7964 57 
H4A 1018 7288 6853 42 
H4B 877 8589 6874 47 
H6A 1923 2146 8865 50 
H6B 1827 2104 8298 41 
H7A 1301 4189 9696 54 
H7B 1351 3218 9409 54 
H10A 2455 7300 6992 41 
H10B 2883 6021 7911 41 
H10C 2682 7613 7323 41 
H10D 2779 4917 7882 41 
H15 4448 533 7397 56 
H17A 2311 7026 5334 69 
H17B 2912 8373 5055 69 
H17C 2757 9373 5913 69 
H19A 3748 4983 3795 93 
H19B 3134 4105 4140 93 
H19C 3821 2383 4394 93 
H20A 4697 148 5615 80 
H20B 5224 1020 6531 80 
H20C 5041 3048 5725 80 
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 Table 8 Atomic Occupancy for JS03_90_Cu. 
 
Atom Occupancy   Atom Occupancy   Atom Occupancy 
C1A 0.690(2)   H1AA 0.690(2)   H1AB 0.690(2) 
H1AC 0.690(2)   C1B 0.310(2)   H1BA 0.310(2) 
H1BB 0.310(2)   H1BC 0.310(2)   C2A 0.690(2) 
C2B 0.310(2)   C3A 0.690(2)   H3A 0.690(2) 
C3B 0.310(2)   H3B 0.310(2)   C4A 0.690(2) 
H4A 0.690(2)   C4B 0.310(2)   H4B 0.310(2) 
C5A 0.690(2)   C5B 0.310(2)   C6A 0.690(2) 
H6A 0.690(2)   C6B 0.310(2)   H6B 0.310(2) 
C7A 0.690(2)   H7A 0.690(2)   C7B 0.310(2) 
H7B 0.310(2)   S8A 0.690(2)   S8B 0.310(2) 
O9A 0.690(2)   O9B 0.310(2)   H10A 0.690(2) 
H10B 0.690(2)   H10C 0.310(2)   H10D 0.310(2) 
 
